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Review Articic
The professional status of hospital pharma-
cy in the United Kingdom is changing. The
development of clinical pharmacy, a set of
proactive roles in which pharmacists help
ensure appropriateness of drug use, is one
contributory factor. A review of the literatu-
re revealed that clinical pharmacy has pro-
fessionalised pharmacy by contributing to
the development of a body of expert and in-
determinate knowledge. It could also lead
to fragmentation of hospital pharmacy with
resulting deprofessionalisation. Other fac-
tors are important. The National Health Ser-
vice reforms, general changes in profession-
al roles and in society pose risks of depro-
fessionalisation due to increased managerial
power. encroachment by new professions
and patient empowerment. They also offer
opportunities for further professionalisation
by the development of new roles. We con-
clude that clinical pharmacy is the most im-
portant factor influencing the changing pro-
fessional status of pharmacists; it is tile
principal means for pharmacists to expand
their territory and increase their professio-
nal status.
Key words: Clinical Pharmacy; Great Britain;
Hospital phannacy; Pharmacists, hospital; Pro-
fcSs!oII Review
Introduction
Pharmacy developed as a profession in the
United Kingdom (UK) in tle 19th Century.
Initially, almost all pharmacists worked in
their own or other pharmacists' shops. Ho-
wcver, the newly-founded voluntary hospi-
tals began to employ them in the second
half of the 19th Centurv Few pharmacists
were attracted to a hospital career until the
middle of this century due to poor pay and
working conditions. Improvements in both
of these h.ive enhanced tile status and appe-
al of hospital pharmacy as has the growing
oerception of the potential contribution
which nospital pharmacists can make to pa-
tient tare 11]. In tho 1970s ,id 1980s, the
würk of hospital pharmdcass expanded to
eicenlpas' a new set of roles, collectively
known as "clinical pharmac y services". Cl-
nical pharmacy is seen b y some authors as
ha iii promoted tlit. prtihssIonalisatioI1 of
phai::acv 12,31. Since it development hits
COiflk .2d with SiginIIt...flt changes in thc
Naioial Health Scr'it (NIIS) aild in tnc
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status of health professions in general. the
relative effect of clinical pharmacy on the
professional status of hospital pharmacy
nierits examination.
The aims of this paper are to outline the de-
velopment of clinical pharmacy in UK hos-
pitals, to consider published evidence of
professionalising and de-professionalising
forces on UK hospital pharmacy, and to de-
fine actions that we think the profession
should consider if it wishes to further pro-
fessionalise. Following a brief description of
pharmacy within the theories of profes-
sions, the article focuses on hospital phar-
macy, considering the effects on professio-
nal status of clinical pharmacy and other
forces, such as the NHS reforms, changing
professionals roles and patient empower-
ment.
The development of clinical
pharmacy in the United
Kingdom
In the UK, clinical pharmacy first develop-
ed in the hospital sector. Although clinical
pharmacy has several definitions (4-91, a re-
cent suggestion that it is "about the optimal
use of drugs, ensuring that those reaching the
patient arc safe, effective, offer value for money
and quality of life" ItO] adequately reflects its
current meaning in the UK. It originated
from a service known as "ard pharmacy"
which had evolved in response to concerns
about the safe use of drugs in hospitals in
the l9bOs. Errors 'ere reported in the pro-
cess leading to the administration of drugs
to patients in hospitals Ill]. It was suggest-
ed that these could be due to the number
and ambiguity of prescriptions fli], tran-
scriptiort of prescriptions by nurses (121, the
increased number of drugs on the market
and the increased complexity of prescribing
(131. The introduction of patient-specific
drug charts (14.15] improved the situation
[15,16]. Deployment of pharmacists to the
ards to provide a drug supply service was
also thought neces-arv and was associated
with a reduction in the ipcidence of discrep-
ancies between prescribed and administer-
ed drug therapy $371. Nurses and doctors
frequentl y consulted with the ward phar-
macit about niedcines and their u'-e 1171
thereby incteasiag tlie status of the ward
phat maust. Ward pharmac y was comnien-
det 1w the Department ol I Iealth in 1974
I thi
After its inception in the late 1960s, the
ward pharmacy service gradually expanded
and several new services were initiated, in-
cluding drug information and therapeutic
drug monitoring. These new, proactive roles
were termed clinical pharmacy services.
Their provision was endorsed by the UK
Department of Health in 1988 as a means of
increasing the cost-effective use of medi-
cines and enhancing patient care (71. Hospi-
tal pharmacists appear to have taken on
these new clinical roles willingly since clini-
cal pharmacy is now available in most UK
Ni-IS hospitals and most UK Schools of
Pharmacy provide post-graduate courses in
the subject. Hospital pharmacy has become
more appealing, salaries have increased [19]
and the career is viewed as attractive by
new graduates.
Pharmacy as a profession -
Theoretical aspects
Several theories have been advanced to ex-
plain the features that distinguish occupa-
tions from professions. Most include lists of
characteristics which an occupational group
must possess to be a profession, such as a
tradition of service to the individual, a tech-
nical knowledge base, an altruistic nature
[20], monopoly powers [21], specialized
training and education, formal examina-
tions of competence of members, and the
presence of a professional organisation and
a code of conduct (22]. These theories have
been criticised. Most present professions in
a utopian light [211 and reflect the profes-
sion's view of themselves. The y presume
that "true" professions, exhibiting these
characteristics to varying degrees, actually
exist (or have existed in the past). None re-
cognise that, in practice, the behaviour of
professionals frequently is at odds with pro-
fessional traits. Most are based on analyses
of a few professions hence are not applica-
ble to the majority of professions (231.
Pharmacy
 i not well-described by these
theories becau'e it is not considered to have
a duty to individual patients and there are
doubts regarding pharmacy's knowledge
base (241 It has been claimed that the
knowledge that professions possess should
be largel indeterminate to maintain a soci-
al distance between professional and client
and to as'ure '-tatus and respect for the pro-
Ies'. ion 121 The assertion has been macic
that pharm.K .. knob led . base is too pie-
-
-
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cisc and systematic to be indeterminate 1241.
The theories also justify professional status
on the basis of professions' importance to
the structure of society 1261. Pharmacy, ho-
wever, does not currently appear to com-
mand such status perhaps because society
perceives pharmacists' work as being less
prestigious than that carried out by other
groups such as doctors.
A more recently developed theory better
explains the position of pharmacy in the hi-
erarchy of professions. "Occupational con-
trol" [23], proposes that pharmacy the less
professionalised occupation, is dominated
by the more professionalised occupation of
medicine [241. It suggests that the medical
profession dominates or limits pharmacy
since the doctor retains control over the
drug treatment of patients; pharmacists
supply medicines on the doctor's orders
hence do not have full autonomy over their
area of practice [24,27].
Although this theory explains many of
the characteristics that prevented pharmacy
attaining full professional status under the
previously described theories, it has a num-
ber of limitations. It does not allow for the
division of pharmacy into several branches
whose practitioners behave in different
ways nor for changes in practice over time
within these branches. In the UK, pharmacy
consists of two main branches, community
and hospital pharmacy. Community phar-
macists are seIf-eniploved or employees of
retail pharmav companies. They work
from shops where, in additicn to the dis-
pensing and sale of pharmaceuticals, a wide
variety of commercial products are sold.
Community pharmacy is recognisably diffe-
rent from hospital pharmacy in the UK.
Currently community pharmacy is primari-
l y involvcd in the supply of pre-packaged
medicines and the provision of advice on
drug use to patients, although it has recent-
ly acquired new roles such as the provision
of pharmaceutical advice to nursing and re-
sidential homes and the supniv of mcdiii-
ncs which were formerl y prcscrinton -onl
In contrast, hospital pharmac y ha aiqul-
red numerous additional roles, cii as the
provision ol advice to health proJessional'
and the control of di ug use. I-or th.' present,
at kast, the greater de'ciopmen! ot ch'ucai
pharmacy in the hc.spttal sector ii'1IieS Se-
pat ate ct,ncideration of the ba'.is and extent
ol hosp;tal plar; . ." p:c It '.ion,.l '.tats
The net effect i! c!!tiIca pham'. ad oth-
t'r lactors, suh as the NI-IS chanti, is an
alteration in hospital pharmacy's status
from that of a group occupationally limited
by doctors.
Influences on the professional
status of hospital pharmacy
Clinical pharmacy has been viewed as a
professionalising force in hospital pharma-
cy [2). The acquisition of new roles has in-
creased the prestige of hospital pharmacists'
work, their power within the hospital struc-
ture and their professional status. These
changes have had important effects on the
power balance between professions. Other
changes, which are outlined here and dis-
cussed in detail in subsequent paragraphs,
have also been significant.
In the UK, the NHS has undergone suc-
cessi'e radical changes with implications
for the professions. it is likely that the most
recent NHS changes will have the greatest
effects on professional power. In addition,
notable changes in society and in the posi-
tion of professionals in society have taken
place in recent decades. Technological ad-
vances, increased consumer power and the
increasing emphasis on knowledge have
modified the power and status of profes-
sions and raised the threat of deprofessiona-
lisation (a reduction in professional status
and power). This ma)' occur as a consequ-
ence of increasing bureaucracy and the ex-
ertion of greater external control on profes-
sions, the growth in knowledge necessita-
ting specialisation and the resultant frag-
mentation of a profession, or the develop-
ment of new professions that will try to en-
croach upon the territory of older profes-
sions [28]. In contrast, there is a view that
in.reased knowledge is not a threat to pro-
fess:ons but that technical knowledge is in-
creasing in importance as a means of con-
trolling and managing social and political
matters and will stimulate professionalisa-
tion !2'1. These conflicting opinions remain
'e re'olved.
The effect of clinical pharmacy
Berore the introduction of ward pharmacy,
l-vital pharmaiists mainly manufactured,
prs.ured and dcpensed drugs (II. The on-
gtnal purpose ot ward pharmacy, to provide
a ph.rmaci'.t on the ards to initiate the
dr.z upplv proics, did not aim to profes-
sio:'aie htpi1al ph.trmai since the rcla-
tin-.hip het een dottor'.. and pharmacists
365
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regarding the prescribing of drugs remai-
ned unchanged; doctor-s still prescribed and
pharmacists supplied on their command.
Nevertheless, changes were being initiated.
Claims that pharmacists could provide a
consultancy service at the point of prescri-
bing [151 were being substantiated since
ward pharmacists were providing doctors
and nurses with advice on medicines and
their use (171. Reports began to emerge of
hospital pharmacists intervening to have
patients' medications changed to more ap-
propriate choices (30-321. Recent studies
have corroborated this 133-351. Currently,
hospital doctors still prescribe but pharma-
cists assist in the choice of drug regimen
thereby establishing partnership with the
doctor in the provision of patient drug the-
rapy. Ward pharmacy gave hospital phar-
macists access to patient-specific informa-
tion enabling them to use their indetermina-
te knowledge to advise doctors on drug use.
It also facilitated consultation between
pharmacists and doctors on such issues.
Thus ward pharmacy has professionalised
hospital pharmacy by decreasing its domi-
nation by the medical profession. It has en-
gendered clinical pharmacy, which has fur-
ther reduced medical control over pharma-
cists in the area of drug use.
Clinical pharmacy involves pharmacists
in roles entailing interaction with patients
and other health care professionals 141. Ser-
vices to patients include the identification of
those in need of education, counselling or
additional monitoring of their drug therapy
and the provision of the appropriate ser-
vices. These functions are performed sepa-
rately from, although in collaboration 'ith,
other health care professionals demonstra-
ting the professional traits of independence
(23] and a duty to the individual patient
(20]. Hospital pharmacists provide health
care professionals with independent advice
that is well accepted (30,33,34]. Surveys in-
dicate that other health professionals hold
those providing clinical pharmacy services
in high regard 136,371. Doctors, clinical
pharmacologists and managers have recog-
nised pharmacists' expert knowledge in the
area of drug use by including them in Drug
and Therapeutic Committees and formularv
and drug policy-making groups (38]. More
recently, hospital pharmacists have begun
to prescribe for patients within a team
tramework in cooperation with doctors 1391
and have become involved in multidis. pl
nary teams 140,411. The increased trust pla-
ced by health professionals in pharniacist
and the recognition of pharmacists' experti-
se in the area of medicine use accords with
the increase in indeterminacy of pharma-
cists' knowledge (25] and has resulted in
enhanced professional standing for hospital
pharmacy,
Explanations, other than professionalisa-
tion, may be advanced for changes in the
activities of hospital pharmacists. Activities
in the drug use and policy-making domains
might represent pharmacists seeking to con-
trol expenditure on drugs solely to preserve
their numbers and a degree of financial
autonomy since they, until recently, invari-
ably held the drug budget. An equally plau-
sible view is that the control of expenditure
on medicines has freed resources for the de-
velopment of clinical pharmacy services.
Furthermore, where pharmacy has relin-
quished control of the drug budget no evi-
dence exists that this has caused deprofes-
sionalisation.
It has been argued that the roles adopted
by hospital pharmacists were those delegat-
ed to them by doctors [24] and that clinical
pharmacy has facilitated occupational limi-
tation of pharmacy by the medical profes-
sion; this may be so. An equally plausible
explanation is that many of the tasks in
question, such as education and patient me-
dication ccunselling, were seldom provided
by doctors (271, and pharmacists merely ac-
quired these roles. It is impossible, however,
to deny opportunism in the adoption of cer-
tain roles such as therapeutic drug monito-
ring. It could also be claimed that pharma-
cists 'ill remain professionally limited un-
less they assume responsibility for prescri-
bing. This view is outdated since a prescrip-
tion is now the end product of a decision-
making process which draws on the skills of
both doctor and pharmacist, having regard
to the particular needs of the patient and to
joint pharmacy-medical drug policies, and
is rarely an autonomous decision made by
one doctor. Although the pharmacist may
not be present when ever-v piescribing deci-
sion i made, their skills are utilised via
drug policies and as a consequence ot prc-
scription review, which occurs routinely in
almost every NHS hospital in the UK 1421.
Hospital pharmacists' education has
altered radicall y
 in recent years. In response
to the demands ot clinical pharmac y practt-
cc. phannacy education N now more specia-
li-.ed and mo't Schools ol Pharmac y oiler
po-.tt aduate courses in clinical pharmacy
-
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In addition to facilitating the extension 01
clinical pharmacy services, the enhanced
level of education may be seen as a profes-
sionalising force because it increases phar-
macy's knowledge base and the indetermi-
nacy of its knowledge (20,22,251. This
knowledge base overlaps to an extent with
that of medicine but is distinct due to dif-
ferences in education and training and pro-
fessional focus.
Nevertheless, there may be some draw-
backs. As the field of clinical pharmacy
grows and clinical pharmacy knowledge ex-
pands, hospital pharmacists may specialise
in one or more areas of practice and the pro-
fession may become fragmented and depro-
fessionalised [281. It remains to be seen
whether or not this danger materialises. A
more obvious danger is that post-graduate
education and training may be severely cur-
tailed in the new market-driven NHS with
detrimental effects on professional develop-
ment [431.
The effect of the NHS Reforms and
increasing managerial control in the NHS
Recent changes in the NHS have had far-re-
aching effects on several professions [44-47]
including pharmacy "Working for Patients"
[481 and the "White Paper on Primary Care"
[49] have radically changed the wa y in
which health care is delivered in the UK.
The former has enabled hospitals and gene-
ral practitioners (GPs), respectivel y, to beco-
me independent providers and purchasers
01 health care and initiated the purchaser-
provider split; the latter has shifted the em-
phasis in the funding and provision of
health care to the primary sector. Both have
had implications for hospital pharmac not
all of which are positive.
Spiralling costs have led to a reassess-
ment of the ways in which health care is
provided. One common strategy is to redu-
ce staffing levels. A reduction in the number
of hospital pharmacists would cause a con-
traction in clinical pharmacy services rather
than reducing the ability of the pharmacy
department to provide patients with inedi-
cines. This would deprive hospital pharma-
cists of those components of pharmacy that
have contributed most to their enhanced
professional status and leave a core of tech-
nical functionc. Cost cutting may reduce in-
service education 1471 and alter pharma-
ci't'' roles with negative efiect' on prote-
sional status. Pharmacists are relativel y cx-
p'n ive and the high costs of dinica! phar
macy services, may lead to reallocation or
loss of some roles, particularly if pharna-
cists fail to demonstrate the contribution
that their services make to the provision of
cost-effective health care [501.
Any transfer of roles is threatening be-
cause it reduces professional territory [28],
hut the nature of the lost roles will determi-
ne the net effect on professional status. The
key issue is the extent to which pharmacy
retains roles that demonstrate its possession
of indeterminate knowledge. If the forfeited
roles are those that do not require the skills
and knowledge of a pharmacist, this change
will de-skill certain tasks leaving the profes-
sional standing of pharmacy unaltered. Fur-
ther professionalisation may actually be fa-
cilitated by role expansion into areas of
practice more appropriate to pharmacists'
skills and knowledge.
Tasks that, we suggest, could be delega-
ted include much routine dispensing, some
technician training, some patient counsel-
ling, almost all stock control and manage-
ment, and routine computing. Technicians
are already performing these tasks at some
hospitals [51] and, in several others, tasks
have been automated [52,53]. In contrast, if
the lost roles are those that pharmacists ap-
propriately perform, such as control of drug
use, the provision of drug information and
man of the newer clinical pharmacy roles,
deprofessionalisation may occur. Nurses
pose particular threats since they are less
e\pensive to employ and appear to be ex-
tending their roles in areas pertinent to
pharmacists. Nurses will soon be permitted
to prescribe [54,55] and are increasingly in-
volved in pain control teams and self-medi-
cation (self-administration) schemes.
The development of computer programs
that contain pharmaceutical knowledge in
areas such as drug interactions and patient
counselling [531 may also be considered a
threat. Freidson [561 argues that the ever-
present gap between available knowledge
and that which is stored on computers, and
the retention of professional control over
the nature of stored knowledge and its use,
ill prevent computer technology exerting
a deprofessionalising influence on medici-
ne A similar argument pertains to pharma-
c' Technical information on drugs and their
pharmacology can readily be stored using
intormation technology without consequent
lo of professional satus since pharmacy
ill reLiin the indeterminate knowledge,
the abilit y to Llse such codified computer in-
-
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formation to determine appropriate treat-
nient for patients. The individuality of pati-
ent's needs and their response to medicines
remain the strongest reasons why software
will not replace pharmacists.
The redistribution of resources from se-
condary to primary care as a result of the
NHS changes may offer opportunities for
hospital pharmacy to further professionali-
Se. Government concern about accelerating
expenditure on medicines in primary care
and general practitioner prescribing, illu-
strated by the recent extension of a list of
drugs not paid for by the NHS, has provid-
ed openings for hospital pharmacists to
advise Family Health Services Authorities
(FHSAs) and GPs on methods of controlling
drug expenditure and improving prescri-
bing habits, and in the creation of formula-
ties 171. Efforts to reduce hospital costs by
enabling ill patients to return home sooner
than they would have in the past and to re-
ceive complex drug treatments in the pri-
mary care sector have led to a requirement
for pharmacists to provide an input into the
care of these patients. Evidence exists that
hospital pharmacists are expanding their
activities in primary care [57]; FHSAs, for
example, are employing hospital pharma-
cists as pharmaceutical advisors. These de-
velopments also provide an opportunity for
hospital and community pharmacists to col-
laborate and use their respective skills for
the benefit of patients in moving closer to
the ideal of seamless care.
The devolution of management within
hospitals, with the creation of clinical direc-
tors responsible for their specialty's drug
budget has led to the need for pharmacists
to provide assistance with drug budget con-
trol. Previously, pharmacy held the drug
budget in most hospitals and strove to keep
expenditure to a reasonable level. The chan-
ge in budgetary control has led to pharma-
cists becoming advisors on the judicious use
of medicines (58), rather than the inspecto-
rate of the drug budget, and has provided
opportunities for role development.
Increased managerial control in the NHS
has implications for the professions and for
hospital pharmacy The expanded role of
managers in the UK NHS, consequent or.
the Griffiths Report (59), represents a
growth in bureaucracy that poses threats of
deprofessionalisation 128,601 for hospital
pharmacy as well a For other health care
professions 144,47,611. The most recent NI-IS
reform', have further 'trengtheiied manage-
rial control of the NI-IS and reduced the po-
wer of the medical profession 1621. This re-
duction in medical power seems to have
been a planned consequence of Thatcherism
in the late 1980s since the medical profes-
sion were virtually excluded from their usu-
al advisory role in NHS policy-making [621.
Hospital pharmacy appears to have escaped
the effects of increased managerial control
as vet; it is unlikely to continue to do so
1501. Hospital pharmacists may increasingly
move into hospital management and could
potentially modulate the effects of manage-
rial power on pharmacy. This advantage
may be negated, however, if pharmacists in
management positions become insensitive
to pharmacy issues and lose their identity
as pharmacists among their professional
colleagues.
Effect of general changes in professional
roles
The role of the medical profession and of
health care occupations and professions alli-
ed to medicine have altered in the 1980s.
New professions have emerged and estab-
lished professions have extended their ro-
les (24,45,47) causing competition amongst
professions and the encroachment of newer
professions upon the territory of established
ones. Hospital pharmacy will have to pro-
tect professional territory from encroach-
ment by nurses and, possibh from clinical
pharmacologists (on whose territory it is
claimed clinical pharmacists have already
encroached [27]). To further professionalise,
hospital pharmacy 'ill have to consider ta-
king on certain roles presently performed
by
 doctors and may have to compete with
nurses [63), amongst others, for these.
The increased importance of technical
knowledge in modern society as a means of
controlling and managing social and politi-
cal matters has been claimed as a professio-
nalising force [29). This conflicts with views
on the importance of indeterminate know-
ledge in maintaining professional status
1251 hut the resolution of this argument is
beyond the scope of this essa\ Nonetheless,
some implications for hospital pharmacy
'arrant mention. Since technical knowled-
ge can be acquired by education, some
para-medical occupations, many of whom
iio require their members to possess a uni-
veNltv degree, could threaten pharmacy's
terriorv An enhanced kvel of education
ma lead to demands for increased profes-
sion.il statu .. trom the iiara-ITledical occup.
-
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(ions. I'roject 2tXX (which aii1s to ensure
that by the year 2000 all British nurses will
possess a university degree) has had this ef-
fect on nursing 145]. Whilst it can be clai-
med that pharmacists, too, have augmented
their education and increased their profes-
sional status, increases in the status of other
professional groups could result in intense
competition for roles currently held by
pharmacists.
Effects of changes in society in general
Society has changed radically in the past
two decades. Rapid technological advances
have facilitated the replacement of humans
by machines in many areas of production.
Much of pharmacy's role in the production
and compounding of medicines had been
lost by the 1970s [2] but subsequent techno-
logical progress has further reduced its pro-
fessional territory Automation, in particu-
lar, has had profound effects on many as-
pects of production and delivery of medici-
nes in the hospital sector forcing pharmacy
to re-consider its professional role. Hospital
pharmacists have recently adopted new ro-
les [39,40] but the effects of automation and
other technologies on professional status
are still unclear.
The status afforded by society to health
care professions has changed [24,45,471. The
power balance between professional and
client has altered; consumers have gained
and, arguahl professions have lost power.
Patients are better educated and they have
become empowered by documents such as
'The l'atient's Charter' [64]. They no longer
defer to doctors [62] and it is claimed that
patient enipowerment has reduced the sta-
tus of medicine [65,661. Changes in the pat-
terns of morbidity
 and mortality have en-
couraged the redirection of resources from
curative to preventative medicine. This has
led to patients assuming greater responsibi-
lity for their health and having increased in-
put into decisions about their care. It is
thought that this has also reduced doctors'
powei- 167 1 . Patients, increasingl are rejec-
ting interventionist medicine in favour of a
more holistic approach and their mistrust of
doctors is increasing 147]. In addition, the
medical profession in Britain has aroused
suspicions ot protectionism and restrictive
practices. Areas of concern include profes-
sional lees charged in private practice and
control of the award of specialist status In-
crecing scrutin y of these issues nia fur-
ther redLice then status in the public's e
Although it is still untiear if a reduction
in medical power has actuall y
 taken place
in the UK, these events raise the spectre of
loss of professional power for other profes-
sions. In community pharmac the Consu-
mers Association's recent report suggesting
that the quality of advice given by commu-
nity pharmacists was poor and that propo-
sals to extend their advisory role should
take this into consideration [681 provoked
an angry and defensive response from the
profession [69,70]. Perhaps this signifies
pharmacy's fearful perception of the power
of the patient to determine professional sta-
tus. Increased consumer power could pose
threats in hospital pharmacy if the Customer
does not value the pharmacists role but it
could also provide an opportunity for role
extension, particularly in the areas of pati-
ent information and education. latrogenesis,
due to negligence in the use of medicines, is
still common [71] and patients now demand
a reduction in the risks associated with the
use of medicines. Thus there is ample op-
portunity for hospital pharmacists to ex-
pand their efforts into areas of expressed
patient need, collaborating, where appropri-
ate, with their colleagues in primary care.
Discussion
Cliniçal pharmacy is a relativel y new depar-
ture in hospital pharmacy
 It has resulted in
hospital pharmacists adopting new roles
and providing services independently of
the medical profession. Pharmacists are ac-
cepting the concept of responsibilit y
 to indi-
vidual patients and the indeterminacy of
pharmacy's knowledge base has increased.
ConsequentI medical domination of phar-
mac)' has been reduced and patients, and
other health care professions, now afford
pharmacists greater professional status. But
clinical pharmacy is a double-edged sword.
It poses hazards of fragmentation due to
specialisation. Specialisation is inevitable
hut the physical existence of sub-divisions
within hospital pharmacy
 should not threa-
ten professional status if pharmat.ists retain
a central identity.
One of the gravest problem in pharmacy
at present, we think, is the possibility that
their identit y
 is ambiguous and a core ideo-
lo' is lacking. Hospital pharmacists have
'..hown a lack of consensus regarding the ro-
k'.
 which the perform 142,571 and the grea-
ter development of clinical pharmacy in the
ho.piial sector may be emphasising intra-
-
369
64	 S M Goiter. N 0 Barber and M Mckee Profess4onallsaiuon of UK Hosp tal Pharmacy
professional differences. Arguably, until
pharmacy decides its future professional
role it will run the risk of deprofessionalisa-
tion in a competitive health service environ-
ment.
In the wider context of the NHS and soci-
ety, changes have occurred which may ser-
ve to advance or restrain pharmacy's pro-
fessionalisation. The NHS reforms have
opened up new avenues of professionalisa-
tion in primary and secondary care both in
the direct care of patients and as advisors to
other health care professionals. However,
the increase in managerial power in the
NHS, along with the emphasis on stricter
budgetary control, threaten to deprofessio-
nalise hospital pharmacy by removing the
clinical roles that have been acquired. Phar-
macists can protect their status in the face of
such challenges by examining the cost-effec-
tiveness of the services that they provide. In
addition, delegation of roles that are within
the competence of ancillary and technical
staff and automation of other suitable tasks
will help retain and develop roles requiring
pharmacists' professional input. This will
facilitate the provision of more cost-effecti-
ve hospital pharmacy services and guard
against the loss of territory to other occupa-
tional groups. Encroachment by other pro-
fessional groups will, however, remain a
hazard of changes in professional roles in
general and the growth of new professions
whose status is increasing in a knowledge-
driven society. Hospital pharmacy can fur-
ther protect itself by delineating its profes-
sional boundary and by achieving consen-
sus on its professional identity.
Finally, patient empowerment, consequ-
ent to societal changes, poses some threats
of deprofessionalisation but is more likely
to offer hospital pharmacists new roles and
an opportunity to further professionalise.
By acceptance of the patient's part in deci-
ding on their health care needs, and by see-
king to accommodate these within a profes-
sional framework, hospital pharmacy can
continue to develop. The adoption of the
concept of "pharmaceutical care" (721, whe-
re pharmacists primary duty is to the pati-
ent, is a step along this path.
Conclusion
The development of clinical pharmacy is
one of several influences on the professional
development of hospital pharmacy in the
UK. Although changes in the NHS and in
society are also important, clinical pharma-
cy remains the pre-eminent influence; it has
opened avenues of professionalisation
enabling pharmacists to respond to the
changing environment in the hospital sector
in the UK today. With careful development
of clinical pharmacy, challenges to the pro-
fessional status of hospital pharmacy can ef-
fectively be overcome.
The successful future development of cli-
nical pharmacy in hospitals requires greater
consensus, both within the profession and
within hospital pharmacy, on the essential
role of the pharmacist. The profession in ge-
neral must make difficult decisions about its
professional role and tethtory It needs to
decide which roles can be delegated and
which must be retained by pharmacists. We
have suggested some answers for hospital
pharmacy but this issue needs to be tackled
both by the profession, to establish dearly
its professional identity, and then by each of
its branches, since practice varies signifi-
cantiv between each branch of pharmacy in
the UK. Even within the UK hospital sector,
clinical pharmacy has not developed uni-
formly and there is little published evidence
of the contribution that hospital pharma-
cists make to the provision of cost-effective
health care. -Pertinent changes in the health
care envirnment also need to be taken into
account.
Although this paper concentrates on hos-
pital pharmacy in the UK, the issues discus-
sed have implications for the profession of
pharmacy in all industrialised countries. We
have indicated that there are marked diffe-
rences between hospital and community
pharmacy in the UK but these may not be
so obvious elsewhere. The development of
clinical pharmacy is, however, becoming an
issue in most developed countries. Its natu-
re may vary between countries but, as in the
UK, it provides a means for pharmacists to
change their role and their relationships
with other professionals. The issues raised
here regarding professional identity and de-
velopment will therefore merit considera-
tion when pharmacy in any country consi-
derc its professional development.
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The lohlowiiiu aie examples of letteis ot request and thanks sent to phannaists duriii postal and louis
group pre testing of the questiolmailes. All weie personally signed.
1.	 Letter of instruction for those helping with postal pre-testing.
London School of Hygiene and Tropical Medicine
(_.	 0(University of London) 	 1.
Keppel Street. London Wf1E 7HT
Tel: 071-636 8636 -Tel Direct. 071-9274e Fax: 071-436 3611
The Pharmacist,
Senior Clinical Pharmacist,
Pharmacy Department,
The Hospital,
Hospital Address,
Postcodc.
Department of Public Health and Policy
Health Services Research Unit
Date
Dear Pharmacist,
This is a draft of the questionnaire which I intend to send to Principal Clinical Pharmacists (or their
equivalent) in hospitals in England. There are separate similar questionnaires for Pharmacists in
other parts of the United Kingdom.
I would veiy much appreciate if you could take the time to:-
1. Fill in the questionnaire.
2. Time yourself - How long did it take (approx)? ....... minutes.
3. Comment on the questions with respect to wordingflanguage,
specificity, ambiguity, clarity etc. 	 -
4. Comment on the order in which the questions are asked.
5. Comment on the ease/difficulty experienced in answering the
questions
Please write your comments on this sheet and return it plus the completed questionnaire to me as
soon as possible. Thanking you in anticipation,
Yours sincerely,	 (C-i4' --i
Siobhan M Cotter MRPharmS,
Clinical Research Pharmacist.
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2.	 Letter of thanks to those helping with focus group pre-testing.
London School of Hygiene and Tropical Medicine
(Universuiy of London)
keppel Street. london WC1E 7HT	 •7uP S
Tel 071-636 8636 Tel Direct O71-9274tC Fax 071 436 3611
Department ol Public Health and Polsi.y
Health Services Research Uuiut
Ms P Pharmacist,
Senior Clinical Pharmacist,
Pharmacy Department,
The Hospital,
Hospital Address,
Postcode.	 Date
Dear Ms Pharmacist,
Thankyou for taking the time to see me on ....................at..............
I found the discussion we had veiy enlightening. Your comments were most helpful and will assist
mc in the production of the next draft of the questionnaire.
Once again, thank you for your help.
Yours sincerely,
Siobhan M Cotter MRPharmS,
ainical Research Pharmacist.
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1.	 Results of the first pre-test (focus QrOUP).
1.1.	 Participants.
Six District Pharmaceutical Officers from the North West Thames Region pre-tested the first draft of
the questionnaire.
1.2.	 Results.
1.2.1. Some interesting verbatim comments:
"1 feel threatened by some of the questions.. I'm not going to tell you we don't provide a service .. I'll
cheat..".
"I like the check list and the open part (of the questions)".
"1 couldn't answer that .. it's too complicated".
"What's a 'target patient'? .. We've got to be able to understand the questions".
"What do you mean by 'role'?.. I'd think it's my business plan".
"I think some managers won't know what HG (88)54 is.. It hasn't made any visible changes anywoy..
in my District the changes were already in place •
"(about HC(88)54) If you mean did it increase the amount of money given? or more staff? then ask
that
"What's a University Medical School Teaching Hospital?".
"I work in a Special Health Authority . .that 'S not included here".
(Regarding the question on opening hours) A pharmacy can only be open or shut.. it can't be 'easily
accessible to patients and staff' and not be open".
"Do you want to know the grades of staff visiting the wards?".
(On the question referring to the collection of adverse drug reaction data) "I've never worked in a
hospital like that.. Pharmacists don't do that".
"You haven't dealt with the provision offinancial information., or clinical training or word pharmacy
training".
1.2.2. Researchers sununary comments:
Helpful feedback was received from this group. Participants' views on clinical pharmacy were different
from those of the researcher mainly because they were managers not clinical pharmacists. Participants
got distracted by the wording of some questions, for example whether or not a hospital was a teaching
hospital or how many pharmacists worked in the pharmacy. The researcher realised, after this meeting,
that managers may be suspicious of questions inquiring about anything related to resources or workload.
In addition, certain managers reacted in a hostile manner to questions about some specialist services,
particularly if their hospital pharmacy did not provide them. The researcher assumed that these services
might be provided by a minority of hospitals. Some managers indicated that they were reluctant to
admit that they did not provide a service, even a rare, new or specialised service; they believed such an
admission would be evidence of an inferior pharmacy service and they would be tempted to lie in their
answers. This served to emphasise the importanee of allaying fears of inferiority by carefully wording
such questions. Useful insights were gained on managers' reactions to questions about clinical pharmacy
services. They misunderstood the reasons for asldng some questions, might answer hostile questions
incorrectly and refuse to answer irrelevant questions. They suggested that some questions would be
better asked of senior managers and others of clinical pharmacists.
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1.3.	 Action consequent on the pre-test.
Question wording was changed to reduce the possibility of respondents reacting in a defensive fashion.
The possibility of two questionnaires being required was considered. Subsequent pre-testing involved
persons more similar to prospective respondents.
2.	 Results of the second pre-test (postal).
2.1.	 Participants.
Three regional clinical pharmacy specialists.
2.2.	 Results.
Respondents suggested asking demographic questions at the beginning of the questionnaire to help
respondents complete later questions. The length of the questionnaire (10 pages) was considered to be
excessive. One respondent thought that a list of contents, and a note stating that the results would be
made available as soon as they were processed, should be included. Another thought that it might be
better to specify at the start of any sub-section which might not be applicable to all pharmacies "f the
services concerned are not provided please go to page X".
The wording of the questions was considered to be too complex, probably because more than one idea
was being introduced in some questions, for example the frequency of ward pharmacist visits g4 the
percentage of beds visited at each specified frequency were included in one question. One person
considered the wording "pompous and unfriendly and advised seeking advice on wording from a
sociologist.
The concept of the "percentage of beds served", which had been used extensively, was considered to be
unhelpful, beyond the scope of the information available to most respondents and a potential cause of a
poor response to these questions. The idea had been borrowed from a questionnaire investigating
clinical pharmacy services in the USA (Personal communication: Bond CL. 1989 American Society of
Hospital Pharmacy National Clinical Pharmacy Services Survey). In several questions the choice of
answers was thought to be inadequate. The large number of open questions was found to be off-putting.
Pharmacists were happier ticking boxes in closed questions than writing replies. Where the researcher
could not be certain that all possible answers were given as options, however, a closed questions that
included an open section at the end was considered to be a good idea. A range of answers for the
number of hours for which the pharmacy was open had been provided in the form of bands, for
example "6-10 hours per day". The advice was that this style would cause the loss of valuable
information without simplifying the questionnaire. Some questions were considered irrelevant, for
example "At present is a formulary (or list of preferred medicines) in use at your hospital?" It was
thought that the answer in all cases would be "yes". Conversations with pharmacists at meetings and
conferences had revealed, however, that hospitals without formularies existed.
2.3.	 Action consequent on the pre-test.
Demographic questions were moved to the beginning of the questionnaire. Several questions containing
more than one idea were expanded into two or more parts or questions. A sociologist was consulted
regarding the optimal wording of questions. The use of questions from an American questionnaire was
abandoned. Several questions containing closed and open sections were created and questions were
simplified wherever possible.
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3.	 Results of the third nrc-test (postal and focus group).
3.1.	 Participants.
Two groups were used. Six Masters of Science (MSc) in Clinical Pharmacy graduates who held senior
or middle grade clinical pharmacy posts in hospitals around London participated in a postal pre-test.
Five of these returned completed questionnaires. Eight senior clinical pharmacists from England and
Wales who held senior pharmacy management posts participated in a focus group discussion. It was felt
that these participants most closely resembled prospective respondents.
3.2.	 Results.
Broadly speaking, the comments showed a difference in managerial experience between the MSc
graduates and the senior clinical pharmacists.
Length.
Most thought that the questionnaire was too long (22 pages) and that this would adversely affect the
response rate.
Topics.
Some felt that they lacked the knowledge to answer questions relating to management and to the nature
and effect of changes over the preceeding 2-5 years. They thought that these questions might be
answered with greater ease and accuracy by a more senior manager, such as the District Pharmaceutical
Officer (or equivalent). Certain questions, particularly those regarding services provided to patients,
professionals and institutions in primary care, were felt to be difficult to answer because of the nature
of the participants' responsibilities. It seemed that certain sections of the questionnaire would have to be
omitted or the questions asked in the form of two separate questionnaires directed at different
respondents. The latter option was recommended. The first questionnaire should inquire about clinical
pharmacy services provided to primary care. It should be sent to District Pharmaceutical Officers
(DPhOs) or their equivalents in the first instance with an option of passing the questionnaire on to a
more appropriate respondent, possibly a Community Services Pharmacists, also being provided. The
second questionnaire, asking about clinical services provided in hospitals, should be sent to Principal
Clinical Pharmacists or the pharmacists responsible for clinical pharmacy services in individual
hospitals. The ensuing discussion helped allocate questions to each of these questionnaires. It was
thought that a question on the effects of The Way Forward should be asked of the DPhO (or
equivalent) since other pharmacists may not have been in post sufficiently long to know the answer. As
in previous pre-tests, some questions were considered to be irrelevant.
(3) Clarity and comprehension.
Certain questions confused participants because the wording was "too complicated". One participant
said "it reads like a politician's speech". A participant who had been involved in the Plain English
Campaign thought, however, that the wording of the questionnaire was probably at the correct level;
snot too much jargon, not too colloquial". A few questions were misinterpreted. Some participants
admitted that they did not understand a few questions. In a few instances a question was felt to include
more than one idea.
(4) Arrangement of topics in the questionnaire.
The division of the questionnaire into sections was found to be useful but the headings were thought
insufficiently prominent. Most found the sequence of topics agreeable.
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(5) Question style.
A sociologist had recommended that the tone of some questions be made friendlier and had reminded
the researcher that all hospital pharmacies may not provide the services mentioned in the questionnaire.
The questions had subsequently been rephrased to indicate that the researcher thought that certain
services may be provided only by a minority of pharmacies. This would help prevent feelings of
inadequacy among respondents and so enhance the quality (and perhaps the rate) of response. The
sociologist also suggested that a larger number of open questions inquiring about respondents' own
opinions be included. Many pre-test participants disliked open questions; they felt that they "disturbed
their train of thought" and such a style "was intrusive , "took too much time to think about and
answer ", "made the whole thing too long and "makes it look like we have to woi* hard to complete".
They felt that these types of questions might elicit a better response in an interview survey. Any open
questions retained in the postal questionnaire should placed in a separate section at the end where "we
might tiy answering them if they were on the last two pages when we know we're nearly finished".
(6) Question wording.
Use of the 24-hour clock was advised to simplify coding. Some participants thought that the use of
bands, such as 0-5; 6-10, for the numbers of staff employed would help respondents by providing
closed instead of open questions but others thought that it would cause loss of valuable information.
Some participants thought that staff numbers questions should ask for numbers of persons; others
suggested requesting Whole Time Equivalents (WTEs). Some questions were insufficiently specific to
obtain the required information whilst others were too specific, for example the term "New Drugs
Panel" had been used in one question but participants said that other committees do its work in several
hospitals. In some circumstances the questions, although clear, did not discriminate between different
levels of service provision. Questions relating to practice research and education were thought to
require greater discrimination between different levels of service provision.
3.3.	 Action consequent on the pre-test.
Two questionnaires were created, one to be sent to DPhOs and their equivalents and the other to the
pharmacist responsible for clinical pharmacy services in individual hospitals. DPhOs were given the
option of delegating completion of the questionnaire to a more informed respondent if appropriate.
Questions were omitted unless they were considered essential. Those remaining were allocated to the
two questionnaires resulting in two shorter rather than one long questionnaire. The researcher conceded
that the depth of information originally hoped for could not be obtained without compromising the
response rate. It was decided to obtain the in-depth information at interviews.
Section headings were removed. The questionnaire was no longer divided into sections since the depth
of questioning did not require it. A column at the right hand side of the page, previously intended for
use in the coding process, was removed and the space used to confine the questionnaire to fewer pages.
Various other space-saving ideas were implemented. It became a "miracle of miniaturisation". Each
question concentrated on a single topic. Where there was more than one question asked about a topic,
the question was divided into the required number of parts. Questions became mostly closed with an
open section at the end. A few open opinion questions were retained in a separate section at the end of
the questionnaire. Questionnaire wording was further simplified. Where a term or concept was likely to
be misinterpreted, for example "audit", an explanation was provided when the term was introduced.
Some questions were made less specific to prevent loss of information or omitted where there was
serious risk of inaccurate information being gathered. Others were expanded upon to elicit more
detailed and accurate information on service levels, for example the respondent was asked to list the
current research projects or the word "formal" was inserted before provision to provide a degree of
discrimination. In other cases discrimination was achieved by providing several categories of reply, for
example none, very little, a moderate amount and lots. Opening hours were requested to be completed
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according to the 24-hour clock and staff numbers were inquired about in terms of whole time
equivalents as well as in the numbers of persons employed.
4.	 Results of the fourth ore-test (postal, and individual and group discussions).
Draft four consisted of two questionnaires:
(a). Questionnaire I	 -	 to be sent to DPhOs or equivalents
(b). Questionnaire II -	 to be sent to the pharmacist responsible for clinical pharmacy
services in individual hospitals.
4.1.	 Participants.
Questionnaire I was discussed with two specialist pharmacists, a sociologist and a group of health
service researchers. Questionnaire II was sent to six hospital clinical pharmacists, three of whom held
senior positions, and discussed with a sociologist and a group of health service researchers.
4.2.	 Results.
Questionnaire I.
Questionnaire I consisted of 9 questions on 3 pages (see Appendix IV). Very few changes were
suggested; most were concerned with question wording.
Questionnaire II.
Questionnaire II consisted of 27 (England, Scotland, Wales and Special Health Authorities) or 28
(Northern Ireland) questions on 6 and 8 pages respectively (see Appendix JV). Most respondents had
few comments to make.
Scales.
A categorical scale had been used in some questions. It was thought better to define the categories.
Wording.
Some questions were considered to be ambiguous.
4.3.	 Action consequent on the pre-test.
A few questions in Questionnaires I and II were reworded and simplified. In general, the changes were
few and minor. "Lots", a term used in a categorical scale in both questionnaires was defined in
Questionnaire H as "greater than, or equal to, an average of 2 hours/week over the course of a year".
Due to perceived difficulties in estimating with accuracy the exact number of hours per week that was
devoted to any of the tasks inquired about in Questionnaire I the term were not defined there.
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Questionnaire I, inquiring about the provision of services, in Districts (and equialents), by
National Health Service hospital pharmacies to primary care.
THE CLINICAL ROLE OF THE
HOSPITAL PHARMACIST
A NATIONAL SURVEY OF NHS
HOSPITAL PHARMACY SERVICE
PROVIDERS
SERVICES PROVIDED TO PRIMARY CARE.
STRICTLY CONFIDENTIAL
Please return to:-
S M Cotter, Clinical Research Pharmacist,
Room 32a Health Services Research Unit,
The London School of Hygiene & Tropical Medicine,
Keppel Street,
London WC1 E 7HT.
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2.	 Questionnaire I continued.
The questions here ask about clinical pharmacy services provided to the primary health
care area. I am specifically interested in those services
• provided by phsxmacists seployed in the hospital sector or
• provided using hospital pharmacy resources eg. Drug Information
• provided by Comminity Services Pharmacists (or similar) who use hospital pharmacy
resources.
I ask about services such as advice, information, education etc.., provided to:-
• GP • a	 • Primary health care nurses 	 I Couliminity pharmacists 	 • patients
• other health care professionals working in primary health care
• primary health care institutions.
The questions are of the tick the box variety with an open section to enable you to answer
toe question more fully or more accurately. I also ask some general questions at the end of
the questionnaire Finally, if you wish to make any conta or clarify any answers and
there is insufficient space on the front of the page. please write on the back of the pages.
1. Pharmacists employed in th. hospital service or pharmacists employed by the health
authority way use hospital pharmacy resources to provide pharmacy service, to General
Practitioners. Please tell me if services of an advisory or educational nature are
provided by your pharmacists.
NONE VERY MODERATE LOTS
LITTLE AMOUNT
Advice to GP's on prescribing/prescribing policies 	 0	 0	 0	 0
Advice to GPB on financial aspects of drug use 	 0	 0	 0	 0
Information to GP5 on general drug-related matters	 0	 0	 0
Information service provided by the hospital 	 a	 a	 a	 0
Drug Information Department to GPs
Educational service for OP's (including trainees) 	 0	 0	 0	 0
Other services of an advisory or educational nature - Please specify..
2. Pharmacists employed in the hospital service or pharmacists employed by the health
authority may use hospital pharmacy resources to provide pharmacy services to nurses
working in the primary health care area. Please tell me if services of an advisory or
educational nature are provided by your pharmacists.
NONE VERY MODERATE LOTS
LITTLE AMOUNT
Advice to Nurses on wound care	 a	 a	 a	 0
Advice to Nurses on analgesia or on equipment used 	 a	 a	 a	 a
in Patient Controlled Analgesia (PCA)
Information to Nurses on general drug-related matters 	 0	 0	 0	 a
Information service provided by the hospital 	 a	 a	 a	 a
Drug Information Department to Nurses
Educational service for Nurses (including trainees) 	 0	 0	 0	 0
Other services of an advisory or educational nature - Please specify..
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3.	 Quctionnaire I continued.
3. Pharmacists employed in the hospital service or pharmacists employed by the health
authority may use hospital pharmacy resources to provide advice, information or other
help to patients in the coemunity or to patients in primary health care institutions.
Please tell me if your pharmacists provide any such services.
NONE VERY WLE)ERATE LOTS
LITTLE AMOUNT
Individual patient counselling for patients with 	 0	 I]	 0	 0drug-related need. eq. patient. receiving TPN,
patients on PCA
Group sessions giving patient. information on
	 0	 0	 0	 0
medication or on medication-related matters
Group sessions giving person, in the comeunity
	 0	 0	 0	 0information on medication or on health care
Other services of an advisory or educational nature - Please specify..
4. Pharmacists employed in the hospital service or pharmacists employed by the health
authority may use hospital pharmacy resources to provide pharmacy services to Comeunity
Pharmacists. Please tell me if services of an advisory or educational nature are
provided by your pharmacists.
NONE VERY MODERATE LOTS
LITTLE AI400NT
Advice to Coemunity pharmacists on analgesia or on
	 (]	 0	 0	 I]
equipment used in Patient Controlled Analgesia
Advice to Cosimanity pharmacists on Parenteral nutrition o
	 a	 0	 0
or on equipment used in parenteral nutrition
Advice about patient. with specific drug-related needs a
	 a	 0	 0
who are being discharged from hospital
Information service provided by the hospital
	 a	 a	 a	 aDrug Information Department to Coamiunity pharmacists
Educational service for Cunity pharmacist,
	 a	 a	 a	 a(including Pre-regi.tration pharmaciSts)
Other services of an advisory or educational nature - Please specify..
5. Pharmacists employed in the hospital service or pharmacists employed by the health
authority may use hospital pharmacy resources to provide pharmacy services to other
health care professional. working in the primary health care area. Please tell me if
services of an advisory or educational nature are provided by your pharmacists.
NONE VERY MODERATE LOTS
LITTLE A14OtNT
Information on general drug-related matters
	 0	 0	 0	 0
Information .ervice provided by the hospital
	 0	 0	 0	 0
Drug Information Department
Educational service for Health Care Professionals
	 0	 0	 0	 0
other than GP's, Nurse, and Coaamanity pharmacists
Other services of an advisory or educational nature - Please specify..
385
4	 Questionnaire J continued.
6. Pharmacists employed in the hospital service or pharmacists employed by the health
authority may use hoapital pharmacy resources to provide pharmacy service, to Primary
Health Care Institutions eg. Residential Homes, Hospices, Nursing Homes etc. Please tell
me if services of an advisory or educational nature are provided by your pharmacists.
NONE VERY NODERATE LOTS
LIT1LS AI400NT
Advice on wound care	 0	 0	 0	 0
Advice on sedation policies 	 0	 0	 0	 0
Advice on analgesia and equipment used	 0	 0	 0	 0
in Patient Controlled Analgesia
Information on general drug-related matters 	 0	 0	 I]	 0
Information servic, provided by the hospital 	 C]	 0	 I]	 0
Drug Information Department
Educational service for Health care personnel 	 0	 0	 0	 C]
working in these institution.
Other services of an advisory or educational nature - Please specify..
7. This question ask. about changes in pharmacy staff and resources. Please tell me:-
(a). have any new posts been funded or hs there been a shift of
resources (staff or money) as a result of HC(88)54, The Way
	 No 0	 Yes 0
Forward for Hospital Pharmaceutical. Services?
(b). have any new posts been funded or has there been a shift of
resources (staff or money) as a result of the Nuffield Report?
	 No C]	 Yes 0
8. If any of your hospitals have recently become a trust, or is in the process of applying
for trust status can you tell me if this has caused any shift in resources (staff or
money)?
Not applicable 0 Yes applicable, but No it has not caused any changes in resources 0
Yes applicable, and it has caused changes in resources 0 - Please specify these changes
9. If you have any comeents or views on the practice of clinical pharmacy which you feel
are important, please write them here.
Thank you for taking the time to complete this questionnaire. I hope you found it
interesting and worthwhile.
Siobhan Cotter, Clinical Research Pharmacist.
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5.	 Questionnaire Ii, inquiring about the provision of clinical pharmacy services in National
Health Service hospitals.
THE CLINICAL ROLE OF THE
HOSPITAL PHARMACIST
A NATIONAL SURVEY OF NHS
HOSPITAL PHARMACY SERVICE
PROVIDERS
STRICTLY CONFIDENTIAL
Please return to:-
S M Cotter, Clinical Research Pharmacist,
Room 32a Health Services Research Unit.
The London School of Hygiene & Tropical Medicine,
Keppel Street,
London WC1E 7HT.
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6.	 Questionnaire II ContiflUe(l.
For most questions you need only tick one box. Some also include a space, labelled
Otber which will enable you to answer certain questions more fully or accurately. I
have clearly indicated the few questions where more than one box may be ticked. Finally,
if you wish to make any coements or clarify any answers and there is insufficient space on
the front of the page, please feel free to write on the back of the pages.
The first few questions are about the hospital and pharmacy department. Then I ask about
• Ward pharmacy	 • Drug Information 	 S Education	 S Drug Control
• Specialist Clinical Services 	 • Clinical Trials 	 S Research & Audit
and finish of f with a few general questions. Feel free to consult with others, if
necessary, to obtain information for the answers to any of the questions.
1. Please describe your hospital using the following terms. (Tick j box in	 section).
(a) Ii it an? - BUS Trust 0 Directly-managed Unit Cl Part Trust, part Directly-managed I]
(b)Is it? - Non-teaching CI	 Medical School Teaching 1]
2. Please indicate, to the best of your knowledge, the approximate number of beds and
wards in the hospital, both on-site and off-site, to which a pharmacy service is
currently provided.
WARD TYPE	 TOTAL NO. TOTAL NO. WARD TYPE	 TOTAL NO. I TOTAL NO.
OF WARDS	 OF BEDS	 OF WARDS OF BEDS
ITU/CCU	 Long-stay Psychiatric &
Mentalhandicap wards	 __________ __________
Day-care & 5	 Other Long-stay wards
day/week wards __________ __________ ________________________
Acute wards	 Other wards
3(a). Are pharmacy services provided by your pharmacy
to units of the hospital which ar. off-site?
(b). Are pharmacy services provided by
your pharmacy to other BUS hospitals?
No 0	 Ye. CI
No 0	 Yes 0
4. Please indicate the official pharmacy opening hours (using 24 hour clock times) on:-
Monday - Friday inclusive 	 to	 Saturday	 to ......
Bank & official holidays	 to	 Sunday	 to ......
5. Thia question asks about your pharmacists. Please tell me...
(a)how many pharmacists are employed in your pharmacy? . . .persons equivalent to . . .WTE's
(b)for how many of your pharmacists is their highest qualification a:-
PhD	 MPhil	 USc	 Post-graduate Diploma .....
(C) how many of your pharmacists are clinical s pecialists? eg. oncology specialist.(Clinical Specialist - pharmacist who spends 50% of their time on that work)
6. Please tell me if an out-of-hours pharmacy service is provided?
No El	 Yes, by pharmacists on-call from home 0 	 Yes, a Residency service CI
7. I would like to find out how pharmacy fit. into the overall hospital management
structure. Please indicate who the head of the pharmacy department reports to?
A member of the hospital board 0	 A clinical director 0	 A service manager El
The Unit General Manager 	 I]	 Another - Who?..................................
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7	 Questionnaire II con(inueil.
8. Please tell me who holds the drug budget? (YOU may need to tick more than one box).
The bead of the pharmacy department	 0	 The Unit General Manager 	 0
Held at Clinical Directorate/Care Group level 0	 Another - Who? ....................
9. Please tell me how many pharmacists routinely work on the wards? . . .peraons .. .WrEs
10(a) Would you say that patient medication charts of acute
in-patients are routinel y monitored in your hospital?	 No 0	 Yes 9
(b) If yea,
(i) where is this usually done?	 On the ward 0	 Ia the pharmacy 0
(ii)for the majority of patients roughly how frequently is this routine monitoring of
inpatient medication charts carried out? on:-
Monday-Friday: Twice daily 0 Daily 0 Not done 0 Other - specify..............
W/E & Holidays: Twice daily 0 Daily 0 Not done 0 Other - specify..............
11. Please tell me, do one or more of your pharmacists routinely accompany doctors on
ward rounds (or case conferences) AND contribute to decisions on drug therapy?
No, never 0	 Yes, but Only specialist pharmacists 0
Yes, many of our pharmacists do this 0	 Yea, all our pharmacists do this 	 0
12. Are medication charts of long-stay in-patients routinely monitored in your hospital?
No 0	 Yes, for the majority of patients this is done weekly or more frequently 0
Yea, for the majority of patients this is done less frequently than weekly 0
13(a). Some hospitals have an on-site Drug Information (DI) service. Please tell me if
an on-site Drug Information service is available at your hospital?
No 0 (b). From where is DI obtained? 	 Local hospital 0	 Region I]
Other - describe..
Yes 0 (c). How many pharmacists are designated to work in DI? 	 .. .persona . ..WTE's
14. The amount and type of information that pharmacy departments provide varies widely.
Please tell ins if one or more of your pharmacists provide information in any of the
following categories. (You may need to tick iiore than one box).
Compilation of clinical information on drug use	 0
Compilation of financial information on drug use 	 0
Clinical information for formulation of prescribing policies	 0
Clinical information for formulary decisions	 0
Clinical information for evaluation of new products	 0
Information for production of educational bulletins used by hospital staff 	 0
Information for the production of educational bulletins used by health care 0
professionals outside the hospital
Information for the production of material used in patient education 	 U
Other information - please specify...
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8.	 Qucstioiiiiaire II continued.
15(a). Please tell me if your pharmacy routinely off era formal professional
educational activities for your pharmacy staff	 No I] Yea 0
(b). If yea, do any of these activities lead to a formal qualification? 	 No 0
Yea, a Diploma 0	 Yes, an MSc. (1	 Other - please specify.....................
(C). If education j5 provided, please describe the	 in which it is provided and how
much of each activity is done. Throughout this questionnaire, "lots means
^ 2 hours/week, averaged over the course of a year
MOER y	 MODERATE LOTS
LITTLE AMOUNT
Group teaching on the clinical use of drugs	 0	 0	 El	 El
Clinical skills training	 0	 (]	 0	 0
In-house clinical training course	 0	 0	 El	 0
Use of peer review eq. ward pharmacy meetings	 El	 El	 0	 El
Group learning where peer review is not used	 El	 0	 El	 El
eq. journal clubs
By routine dissemination of printed or other	 0	 0	 0	 1]
learning materialOther - please specify
0	 El	 El	 El
El	 El	 El	 El
16. One or more of your pharmacists may routinely provide formal educational activitiesfor other health cars professionals in the hospital (including off-site units). If
so, please indicate how much of the activity i. done. VERY MODERATE
LITTLE AMOUNT
Group teaching for nursing staff (including students) 0	 0	 0	 0
Group teaching for medical staff	 El	 El	 0	 El
Group teaching for medical students 	 El	 0	 El	 0
Group teaching for other health care professionals	 0	 El	 El	 0
Other - please specify
o	 o	 0	 0
0	 El	 0	 0
17(a). Please tell me if there is a Drug and Therapeutics comnittee(or equivalent) in your hospital at present?	 No El	 Yes El
(b). If yes, how many pharmacists normally attend the meetings?
18(a). At present is a formulary (or equivalent) in use in your hospital? 	 No 0 Yes El
(b). If yes, in the case of a request for a non-formulary drug for an individual
patient in what percentage of cases would the drug be supplied?
0% 0	 25% 0	 50% 0	 75% 0	 100% El
(c). Please tell me who is usually consulted when deciding whether or not the drug is
supplied. (More than one box may be ticked).
No one	 0	 Ward pharmacist	 0	 consultant/senior doctor El
Prescriber El	 A senior pharmacist 0	 Ward sister/senior nurse 0
The Drug & Therapeutics comeittee (or equivalent) 0
Other - please specify............................................................
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9.	 Questionnaire II COfltiIlue(1.
19(a). Please tell me if there are clinical directoratea/care groups
(or their equivalent) in your hospital at present. 	 No 0	 Yes 0
(b). If yes, is advice/information on prescribing
regularly given to any of them?	 No 0	 Yea 0
(C). If yea -
(i)Is the advice/information provided to them by:- 	 One pharmacist only El
Specific pharmacists for individual (or combinations of) directorates/care groups 0
Other - please specify............................................................
(ii)Does this involve a meeting with: A Clinical Director 0 A Businees manager 0
Another - Who?...........................
20. Some pharmacies way have the resources to provide some special clinical services.
(a).If your pharmacy provides any of the service, listed here to some or all wards (ie.
to in-patient, or day-patients), please indicate the nature of the service provided.
SERVICE	 NO SERVICE SUPPLY SERVICE ADVICE ON PART OF
PROVIDED	 ONLY	 REQUEST A TEAM
TPN/Nutrition	 13	 I]	 0	 0
Cytotoxics	 El	 0	 El	 13
Central Intravenous Additives 	 13	 0	 0	 El
Patient Controlled Analgesia 	 0	 0	 13	 0
(b).If your pharmacy provides any extra help to doctors or health care professionals,
caring for in-patients or day-patients, in the following areas please indicate the
mature of this extra help.
EELP/ADVYCE	 ROUTINE SPECIAL
5KRVICE	 ONLY ON REQUEST	 SERVICE I'VAILABI.E
TOM	 fl	 0	 13
Pain control	 El	 El	 0
Infection control 	 0	 13	 13
Anticoagulation control 	 0	 El	 0
Woundcare	 El	 0	 0
(c).If one or more of your pharmacists provide some of the following services routinely
please tell me which services are provided, the patient categories served
(eq. In-patient) and the 	 of patients served (eg. geriatric patients). (This
question is continued overleaf).
Formal drug	 No [3	 Yes [3 for: In-patient. 13 Day-patients I] Out-patients 0
history-taking
For what types of patients?
Formal self-	 No El
medication schemes
For what types of patients?
Formal patient	 No 0
counselling
For what types of patients?
Yes 0 for: In-patient. El Day-patients El Out-patients 0
Yes 0 for: In-patient. I] Day-patients El Out-patients 0
Formal group sessions No 0	 Ye. I] for: In-patients 0 Day-patients 0 Out-patients El
educating patients
about drugs/health care
For what types of patients?
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10.	 Questionnaire II continued.
CSI4 Yellow Card 	 No I]	 Yea 0 for: In-patients U Day-patients [1 Out-patients [3
APR Monitoring Schese
If yes, does pharmacy ensure CSM form is given to the doctor 0 CSM form is filled in 0
Other formal APR	 No C]	 Yes C] for: In-patients CI Day-patients 0 Out-patients I]
onitoring in addition
to the CSM achese
For what types of patients?
(d). Other clinical services which are provided routinely by your pharmacy to in-patients
and day-patients - please describe
(e). Other clinical services which are provided routinely by your pharmacy to
out-patients - please describe
21. Some pharmacies may contributes to research by helping with clinical trials.
(a).Please tell me if one or ore of your pharmacists play a role
in clinical trials which are carried out in the hospital? 	 No 0	 Yes 0
(b).If yes, please indicate the roles commonly performed by pharmacy. (Tick as many boxes
a. necessary).
Other roles - please specify..
22. A few pharmacy departments have the resources to carry out research. Please tell me
(a).if one or more of your pharmacy staff are actively
involved in pharmacy practice research 	 No 0	 Yes 0
(b).If yes, for how many of the staff involved is the research registered for a:-
MPhil	 PhD	 Part of an )4Sc 	 Part of a Diploma
(C). Please list the practice research projects which are currently being undertaken
(continuing on the back of this sheet if necessary).
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II.	 Questionnaire II continued.
23. Hospitals are becoming increasingly involved in audit. However, there is little
information on how many hospital pharmacies are routinely involved in medical or
clinical audit. In this questionnaire the following definition of audit is used:
Audit = the systematic, critical analysis of the quality of care involving setting
and monitoring standards and changing practice.
(a)Please tell me if one or emre of your pharmacy staff routinely
provide information for, or otherwise assist in, medical audit? 	 No 0	 Yes El
(Medical audit - audit of the practices of doctors).
(b)If yea, please describe their contribution? (Lots"
is 2 hours/week, averaged over a year). 	 NONE y	 MODERATE LOTS
LITTLE AMOUNT
El	 0	 0	 0
0	 0	 0	 0
0	 0	 0	 0
0	 0	 0	 0
Provision of financial information on drug use
Provision of information on problems encountered
in the drug use process eg. prescribing errors
Provision of information and assistance in setting
prescribing policies
Provision of feedback on adherenc. to the agreed
prescribing policies
Other roles in medical audit - please describe....
o	 a
o	 0
El	 0
NOD	 es0
0	 0
El	 El
0	 0
24(a). Please tell me if your pharmacy staff are routinely involved in
clinical audit of the pharmacy department. (Clinical audit is
audit of the practices of health care professionals)
(b). If yes, please specify these audits.
25(a). Please tell me if your pharmacy staff are routinely
involved in clinical audit of other departments.	 NoD	 yesD
(b). If yes, please specify these audits.
26. This question asks about changes in pharmacy staff and resources. Please tell me:-
(a).have any new posts been funded or has there been a shift of resources
(staff or money) towards clinical services as a result of HC(88)54,
The Way Forward for Hospital Pharmaceutical Services? 	 No El	 Yes El
(b).have any new posts been funded or has there been a shift of resources (staff/money)
towards clinical services as a result of the Nuf field Report?
	 No El	 Yes El
27. If you have any Coasnents or views on the practice of clinical pharmacy which you feel
are important, please write them here.
Thank you for taking the time to complete this questionnaire. I hope you found it
interesting and worthwhile. 	 Siobhan Cotter, Clinical Research Pharmacist.
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1 he following are examples of covering and totlow-up Ieuers and a form selit to questionnaire
iespondents. All letters were peisonally signed.
Covering letter sent to District Pharmaceutical Officers and their equivalents. "District" was
replaced by "Authority" or "Board" where appropriate.
London School of Hygiene and Tropical Medicine
(University of London)
Keppel Street. London WC1E 7HT
Tel: 071-6368636 . Tel Direct: 071-927Z*O Fax 071-436 3611
Department of Public Health and Policy
The District Pharmaceutical Officer, 	 Health Services Research Unit
District Health Authority Offices.	 Date
Dear Pharmacist,
I am a pharmacist researching the present and future clinical roles of the hospital pharmacist. In this
three year study, which is funded by the Department of Health and co-supervised by Dr. Nicholas
Barber (School of Pharmacy, London) and Dr. Martin McKee (The London School of Hygiene &
Tropical Medicine), I will investigate
o the dinical roles which hospital pharmacists have adopted
o the clinical roles which you and others in the hospital service value and wish to maintain
o novel clinical roles
o methods of quality assurance in clinical pharmacy.
The results of this national study into dinical pharmacy practice in the hospital sector will influence
future policy decisions. In addition to providing valuable base line data on our profession's present
contribution to patient care, the acceptability of clinical pharmacy amongst other hospital
professionals will be evaluated and areas of future role development identified.
The enclosed questionnaire, which asks about pharmacy services to the priniazy health care sector,
forms the first part of this study. It has been sent to all District Pharmacists in England and Chief
Pharmaceutical Officers n Scotland, Wales and Northern Ireland. I know that titles and
responsibilities are rapidly altering at present and you may feel, after glancing through the
questionnaire, that some member of your staff may be more directly involved in these areas of
service provision. If so, please feel free to pass the questionnaire on to the most appropriate
respondent in your opinion. If you decide to complete it yourself please set aside enough time for
the purpose (pilot studies show this to be approximately 10 minutes). I assure you that
of any person or hospital be disclosed.
The results of this study will take some months to analyze but will be published in the pharmacy
press as soon as possible.
I will be sending the next questionnaire, asking about pharmacy services within hospitals, to the
principal Clinical Pharmacist (or pharmacist responsible for dinical services) in each hospital which
provides a comprehensive pharmacy service. I hope you will provide me with their
• Name	 • Title	 and • Hospital address.
I have enclosed a separate slip of paper for this purpose.
I have just moved from the pharmacy service to do this research and I understand the enormous
demands being made on your time especially in the present state of change in the NHS. However I
think that now, more than ever, we need to demonstrate the contribution which we can make to
enhanced patient care. I hope you think this research is of importance to our professional
development and will find time to complete this questionnaire. Thanking you in advance for your
cooperation - and for the time I know it will take to complete the questionnaire.
Yours sincerely,
/tr
Siobhan M Cotter MRPharmS
Clinical Research Pharmacist.
PS.	 If you require any further information please do not hesitate to call me on 071-927 2460 or
write to mc.
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2.	 Form sent to District l'harmaceutical Officers and their equivalents requesting nanies and
addresses of respondents for Questionnaire 11.
Please complete this form and retuni it to me in the addressed envelope provided.
Please fill in the name, title and hospital address of the Princi pal Clinical Pharmacist or
pharmacist responsible for clinical services in each hospital which provides a comprehensive
pharmacy service Ic. hospitals which have an on-site pharmacy having pharmacists among its staff
during normal rking hours and where advice on drugs is available in addition to a drug Supply
service.
NAME
TITLE
HOSPITAL
ADDRESS
NAME
TITLE
HOSPITAL
ADDRESS
NAME
TITLE
HOSPITAL
ADDRESS
NAME
TITLE
HOSPITAL
ADDRESS
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3.	 Form sent to District Pharmaceutical Officers and their equivalents requesting names and
addresses of respondents for Questionnaire II continued.
NAME	 -.
TITLE
HOSPITAL
ADDRESS
NAME
TITLE
HOSPITAL
ADDRESS
NAME
TITLE	 V
HOSPITAL
ADDRESS
NAME
TITLE
HOSPITAL
ADDRESS
S Cotter, Clinical Research Pharmacist,
Room 32a, Health Services Research Unit,
The London School of Hygiene & Tropical Mcdicine,
Keppel Street, London WCIE 7HT.
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Follo-up letter sent to District Pharmaceutical Officers and (heir equialents. "District" as
replaced by "Authorit3' or "Board" here appropriate.
London School of Hygiene and Tropical Medicine
(University of London)
Keppel Street. London WC1E 7HT
Tel: 071-636 8636 Tel Direct: 071-9272fj2 . Fax: 071-436 3611
Department of Public Health and Policy
The Pharmacist,	 Health Services Research Unit
District Pharmaceutical Officer,
District Health Authority Offices,
Address,
Postcode.	 Date
Dear Pharmacist,
About a month ago I sent you a short questionnaire about your clinical pharmacy service to primary
health care. 1 do not appear to have received a reply from you as yet so I hope you do not mind me
contacting you again.
In case you did not receive the questionnaire, I have endosed another copy.
If you have already posted the questionnaire to me, please disregard this reminder and aecept my
apologies for adding to your post tray!
If you have received the questionnaire but have not yet had time to fill it in, I hope you can find the
10 minutes or so which it takes to do this in the near future. We need a high response rate to make
the results relevant and generalisable across the United Kingdom.
I recognise that this is a busy time for you but the results of this study will be of fundamental
importance to hospital pharmacists in these changing times. The information gathered will influence
future policy decisions and provide valuable data on our profession's present contribution to patient
care.
If you have any questions about the survey or the project as a whole, or if I can help clarify anything
with regard to the survey, please do not hesitate to contact me.
Yours sincerely,
/1D6
Siobhan M Cotter MRPharmS
Clinical Research Pharmacist.
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5.	 Co ering letter sent to respondents to Questionnaire II (usually the Principal Clinical
Pharmacist).
London School of Hygiene and Tropical Medicine	 94
(Unuvers,ty of London)	
r \
Keppel Street. London WC1E 7HT	 o PAY
Tel: 071-636 8636- Tel Direct: O71-927.4.4O- Fax: 071-436 3611
Department of Public Health and Policy
The Pharmacist, 	 Health Services Research Unit
Pnncipal Clinical Pharmacist,
The Pharmacy,
The Hospital,
Hospital Address,
Postcode.	 Date
Dear Pharmacist,
I am a pharmacist who has just moved from the hospital pharmacy service to carry out research on
our role in that setting. I understand the enormous demands being made on your time but I think,
that now more than ever, we need to spell out exactly what hospital pharmacists do to enhance
patient care. At present, remarkably little is known about the huge variation in hospital pharmacy
practice across the country and the way in which this is linked to differences in the size, type and
history of the hospitaL From the results of this study I hope to demonstrate the vast contribution
which we can make to the present and future care of patients.
The enclosed questionnaire forms the first part of a three year study which is being funded by the
Department of Health and carried out in collaboration with Dr. Nicholas Barber (School of
Pharmacy, London) and Dr. Martin McKee (The London School of Hygiene & Tropical Medicine).
However, the detailed information which you provide will remain strictly confidential to me. At no
stage will the identities of any person or hospital be disclosed.
The results of this national study will influence future policy decisions. In addition to collecting
valuable baseline data on our profession's contribution to patient care, this research will evaluate the
acceptability of clinical pharmacy among other hospital professionals and pinpoint areas of future
role development. The results of this questionnaire may take many months to analyze but will be
published in the pharmacy press as soon as possible.
The questionnaire may look fearsome! However, it mainly consists of "tick the box" style questions
with a few open questions. I have induded a short guide to the questionnaire at the start which I
hope will be of assistance to you. It is important that you set aside enough time to fill it in; pilot
studies have shown this to be 25 - 35 minutes. Thanking you in advance for your cooperation - and
for the time I know it will take you to complete the questionnaire.
Yours sincerely,
Siobhan M Cotter MRPharmS
Clinical Research Pharmacist.
PS.	 If you require any further information please do not hesitate to call me (at 071-927 2460) or
write to me.
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6.	 F'olIo'-up letter sent to respon(leflts to Questionnaire II. "District" was replaced li
"Authorit3" or "Board' here appropriate.
London School of Hygiene and Tropical Medicine	 0
(University of London)
Keppel Sireet. London WC1E 7HT
	 Ub
Tel: 071-636 8636 -Tel Direct: 071-927.i4t) Fax: 071-436 3611
Department of Public Health and Policy
Health Services Research Unit
The Pharmacist,
Principal Clinical Pharmacist,
The Pharmacy,
The Hospital,
Hospital Address
Postcode.
Dear Pharmacist,
About six weeks ago I sent you a questionnaire about dinical pharmacy services in your hospital. I
do not appear to have received a reply from you as yet so I hope you do not mind me contacting you
again.
In case you did not receive the questionnaire, I have enclosed another copy.
If you have already posted the questionnaire to me, please disregard this reminder and accept my
apologies for adding to your post tray!
If you have received the questionnaire but have not yet had time to fill it in, I hope you can find the
half hour or so which it takes to do this in the near future. We need a high response rate to make
the results relevant and gcneralisable across the United Kingdom.
Your colleagues at district level have already answered a questionnaire on clinical pharmacy services
to the primaiy health care sector. So far, 88% of these questionnaires have been returned; I am
delighted with their support and enthusiasm. We now need your contribution to complete the
picture at both local and national level.
I recognise that this is a busy time for you but the results of this study will be of fundamental
importance topi pharmacists in these changing times. The information gathered will influence
future policy decisions and provide valuable data on our profession's present contribution to patient
care.
If you have any questions about the survey or the project as a whole, or if! can help clari1, anything
with regard to the survey, please do not hesitate to contact me.
Yours sincerely,
Siobhan M Cotter MRPharmS
Clinical Research Pharmacist.
Date
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I	 Code Book for Questionnaire I.
CODING FRAME FOR QUESTIONNAIRE 1
QUESTION	 FIELD CODES TO USE FOR ANSWERS
NUMBER
	
NAME
District Insert the questionnaire number-top right
corner of questionnaire
0
Q FIELD
NO NAME
CPA
GPB
GPc
GPO
GPE
2 NURSEA
NURSEB
NURSEC
NURSED
NURSEE
3 PATIENTA
PAIl ENTB
PATIENTC
4 CPA
CPB
CPc
CPD
CPE
CPF
£ PHCPA
PHCPB
PHCPC
6 PHCIA
PHCIB
PHCIC
PHCID
PHCIE
PHCIF
CODES TO USE FOR ANSWERS
NONE VERY MODERATE LOTS THAT PART WHOLE
LITTLE AMOUNT
	 OF ThE	 QUESTION
QUESTION	 LEFT
LEFT BLANK BLANK
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
1	 2	 3	 4	 0	 enter
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2	 Code Book For Questionnaire J continued.
Q FIELD	 CODES TO USE FOR ANSWERS
NO NAME
YES	 NO	 NOT ANSWERED
7 HCRES	 1	 2	 enter
NUFF	 1	 2	 enter
NOT	 YES APPLICABLE YES APPLICABLE	 NOT
APPLICABLE BUT NO Cl-lANGE
	
AND YES CHANGE ANSWERED
8 TRUSTA	 1	 2
	
3	 enter
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3	 Code Book for Quc(ionnaire II.
Code Book for Que8tionnaire II
0.	 SEE ¶LOP OP FORM
Ql(a).	 HOSMAN&G NHS Trust	 (1)
Directly-managed Unit	 (2)
Part Trust, part Directly-managed (3)
Becoming Trust 4/92 	 (4)
Not answered	 (0)
Ql(b)	 HOSTEACH Non-teaching	 (1)
Medical School Teaching 	 (2)
Postgrad teaching	 (3)
Speciality teaching	 (4)
Not answered	 (0)
WARD TYPE	 TOTAL NO. TOTAL NO. WARD TYPE	 TOTAL NO. TOTAL No.
OF WARDS OF BEDS	 OF WARDS OF BEDS
ITU/CCU	 (NO)	 (NO)	 Long-stay Psychiatric B (NO)	 (NO)
__________ Mental handicap wards
Day-care & 5	 (NO)	 (NO)	 Other Long-stay wards 	 (NO)	 (NO)
day/week wards	 __________ ________________________
Acute wards	 (NO)	 (NO)	 Other wards	 (NO)	 (NO)
Bed & Ward blanks	 (0)
Bed or Ward blank	 ward = 99	 bed - 9999
Whole question unanswered	 (0)
Q3(a).	 OFFSITE No	 (1)
	Yes	 (2)
Whole question (a) unanswered (0)
Q3(b).	 OTHRHOSP No	 (1)
	Yes	 (2)
Whole question (b) unanswered	 (0)
Q4. Monday - Friday inclusive 	 HRSWK (hrs)
Saturday	 BRSSAT (hrs)
Bank & official holidays 	 HRSHOL(hrs) (excluding stat days)
Sunday	 HRSSUN (hrs)
Any blanks	 (0)
Whole question unanswered 	 (99.99)
Q5(a)	 PHARMNO
PHARMWTE
Any blanks
Q5(b)	 PhD
MPhi 1
MSc
Post-graduate Diploma
Any blanks
Whol, question 5(b) unanswered
Q5(c)	 PIL?RMSPN
Any blanks
Whole question 5 unanswered
(NUMBER) persona
(NUMBER) wrs
(99)
(NO)
(NO)
(NO)
(NO)
(0)
(99)
(NUMBER)
(0)
(99 for 5(c))
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Q6. OUTOFURS No	 (1)
Yee by pharmacists on-call from home 	 (2)
Ye., a Residency service (3)
Yes, by District-wide on call from home (4)
ye., by District-wide Residency service (5)
Whole question unanswered 	 (0)
Q7. Member of the hospital board 	 (1 = Blank; 2 Tick)
Clinical director	 (1 = Blank; 2 =	 Tick)
A service manager	 (1 - Blank; 2 - 	 Tick)
Unit General Manager	 (1 = Blank; 2 Tick)
Another - Code. (ENTERED IN ANY OF MAMAGOT1 2):
CAPO/DPhO/DPS	 - ( 1)
Principal pharm at other hospital = ( 2)
Dir, of operation.	 - ( 3)
Trust Dir, of services 	 - ( 4)
Chief Executive	 - ( 5)
Director of Standard.	 - ( 6)
Chief Pharmacist .t acute unit	 - (7)
principal Phar.. o.'lty Service. - ( 8)
Medical director	 - ( 9)
Dir. Pharmacy Service.	 - ( 10)
Business Manager	 - ( 11)
speciality .anaqament team	 (12)
Acute unit General Manager 	 - ( 13)
Hospital Manager	 (14)
Unit Pharmacy Manager	 - ( 15)
chair of clinical directorate.	 - ( 16)
Other' blank	 - ( 0)
Q8. The head of th. pharmacy department	 DRUGPHAR (1	 Blank; 2 Tick)
The Unit G.n.ral Manager 	 DRUGU((	 (1	 - Blank; 2 - Tick)
Held at Clinical Directorate level	 DRUGCD	 (1	 - Blank; 2 = Tick)
Another (CODES CAN BE ENTERED IN 1NT OF DRUGOT1 & 2)2
CAPO/DPhO/DPS	 - ( 1)
Principal. phar.. at other hospital - ( 2)
Individual consultant. 	 - ( 3)
Drug & Therapeutic. comeittee	 - ( 4)
Trust Board	 - ( 5)
Ward Nurse Manager 	 (6)
Medical Director 	 - ( 7)
Dir, of Pharmacy Service.	 - ( 8)
Departmental Manager	 - ( 9)
Unit Pharmacy Manager	 - ( 10)
Clinical Co-ordinator	 - ( 11)
Acute Service. Manager	 - ( 12)
Medical Executive Comaittee	 - ( 13)
Chair Pharmaceutical Sub-cittee - ( 14)
"Other' blank	 (0)
Q9. WDPHARMN	 (NUMBER) persons
WDPHARI(W	 (NUMBER) WrE.
Any blanks	 (99/99.99)
Whole question unanswered	 (99 + 99.99)
QlO(a) INPTCHTN No	 (1)
Yes	 (2)
Yes by technicians	 (3)
Some	 (5)
Any blanks	 (0)
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Ql0(b)(i)	 If yes, LOCMONIT	 On the ward	 (1)
In the pharmacy	 (2)
Both
	 (3)
Some wards, on ward	 (4)
lOb(i) unanswered when answer to 10 (a) was YES 	 (0)
lOb ( i) unanswered when answer to 10 (a) was NO	 (9)
lOb (1) unanswered as well as 10(a) 	 (0)
lOb ( i) answered when 10(a) = NO 	 (8)
lOb ( i) answered when 10(a) • UNANSWERED 	 (7)
lOb(i) WARD when answer to Question 9 was ZERO	 (11)
Q10(b)(ii) FREQMTWK	 Twice daily	 (2)
Daily	 (1)
Not done	 (0)
Other codes:	 Once/Twice per week 	 = ( 3)
Alternate days	 = ( 4)
3 times per week	 - ( 5)
Weekly	 - ( 6)
Pm when sent to pharmacy	 = ( 7)
Monthly on ward, daily in pharmacy = ( 8)
Not applicable	 - ( 40)
2-3 times per week	 - ( 10)
2 times per week	 - ( 11)
Use two codes separated by a decimal point if > 1 type of service frequency
lOb(ii) unanswered when answer to 10(a) was NO 	 (9)
lOb(ii) unanswered as well as 10(a) and/or lob(i)	 (99.99)
lO(bii) unanswered when lOb(i) answered 	 (99.99)
lOb(ii) answered when 10(a) - NO
	 (19)
lOb(ii) answered when 10(a) - UNANSWERED 	 (17)
Q10(b)(ii) FREQMTWE	 Twice daily	 (2)
Daily	 (1)
Not done	 (0)
Other codes:	 Daily-on take/emergency wards o ly - (3)
Daily-key wards	 - (4)
Monthly on ward	 - (5)
Daily Saturday Only	 - (6)
Pm when sent to pharmacy	 - (7)
Use two codes separated by a decimal point if > 1 type of service frequency
lOb(ii) unanswered when answer to 10(a) was NO 	 (9)
lOb(ii) unanswered as well as 10(a) and/or lOb(i) 	 (99.99)
10(bii) unanswered when lOb(i) answered 	 (99.99)
lOb(ii) answered when 10(a) = NO 	 (18)
lOb(ii) answered when 10(a) - UNANSWERED 	 (17)
Qll. WDROUND	 No, never	 (1)
Yes, but only specialist pharmacists 	 (2)
Yes, many of our pharmacists do this 	 (3)
Yes, all our pharmacists do this 	 (4)
Yes, many of our more experienced 	 (5)
Yes, Diploma/NSc students do this 	 (6)
Yes, Diploma/MSc students & specialists (7)
Whole question unanswered 	 (0)
11 answered YES but 9 - ZERO 	 (11)
Q12. LSCHTMNT No	 (1)
Yea, for the majority weekly or more frequently
	 (2)
Yes, for the majority less frequently than weekly
	 (3)
Whol, question unanswered
	 (0)
Question not applicable (see Q2) and answered NO
	 (4.1)
Question not applicable (see Q2) and answered Yea
	 (4.2 or 4.3)
Question not applicable (see Q2) and unanswered
	 (4.0)
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Blank -(1) Tick=(2)
Blank -(1) Tick-(2)
Blank -(1) Tick-(2)
Blank -(1) Tick-(2)
Blank -(1) Tick-(2)
Blank (l) Tick.(2)
Blank -(1) Tick-(2)
6	 Code Book for Questionnaire II continued.
Q13(a)
Q13(b)
DRUGINFO No	 (1) but if 13(c) >0 change to (8)
Yes	 (2)
Unanswered but 13(c) >0	 (7)
Unanswered & 13(b)/(c) also	 (0)
NODILOC1 Local hospital	 (1)
Region	 (2)
Both	 (3)
NODILOC2	 Other-codes:
Joint service-2 Districts-at other hospital 	 - ( 4)
District service	 - ( 5)
Use Industry-Own hospital handle query 	 - ( 6)
Use within dept. sources and handle query 	 - ( 7)
Use the service from another district 	 - ( 8)
Regional DI in the district	 - ( 10)
13(b) Unanswered but 13(a) answered NO	 (0)
13(b) Unanswered but 13(a) answered YES	 (9)
13(b) Unanswered but 13(a) unanswered	 ( 0)
13(b) answered but 13(a) unanswered (prefix 7 on 13(b) codes)
13(b) answered but 13(a) - YES 	 (prefix 8 on 13(b) codes)
13(b) NODILOC1 OR 2 blank	 (0)
013(c) PHAR}IDIN
13(c) Unanswered but 13(a) YES
13(c) Unanswered but 13(a) NO
13(c) Unanswered but 13(a) unanswered
All 3 parts unanswered
(NUMBER) persons
(NUMBER) wrss
(99/99.99)
(0)
(99/99.99)
(99199.99 for part 13(c))
Q14.
Compilation of clinical information on drug use
Compilation of financial information on drug use
Clinical information for formulation of
prescribing policies
Clinical information for formulary decisions
Clinical information for evaluation of new products
Information for production of educational
bulletins used by hospital staff
Information for the production of educational
bulletins for health professionals outside hospital
Information for the production of material used
in patient education 	 Blank -(1) Iick-(2)
Other codes in DIOTR1-5	 Info to public on travel medication. 	 - ( 1
Other codes blank
Whole question unanswered
info for use in hospital staff education - (2)
info for use in outside presentations 	
- ( 3)
info to risk management team - ( 4)
info to other hospitals re own specialty - ( 5)
Info for specialty palliative care team = (6)
Info on benzodiazepine withdrawal 	 - (7)
Info for medical audit meetings 	 - ( 8)
Info on kinetics	
- ( 10)
- (0)
- (0)
Ql5(a) Professional education No	 (1)
Ye.	 (2)
Question unanswered	 (0)
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Q15(b).	 If yes, formal qualification?
Other codes-enter in QUALOT1-2
Other" codes blank
15(b) unanswered when answer to 15(a) was ye.
15(b) unanswered when 15(a) unanswered
15(b) unanswered when answer to 15(a) Wa. No
15(b) answered when answer to 15(a) was No
15(b)answered when 15(a) unanswered
Q]5(c). way it i provided and how much done.
Group teaching on the clinical use of drugs
Clinical skills training
In-house clinical training course
Use of peer review eg. ward pharmacy meetings
Group learning where peer review is not used
eg. journal clubs
By routine diseemination of printed or other
Any of the codes under other can be entered in PHMEDOT1-5
Enter code of education type plus how much done eq 10.3
Other 1 -Clinical Pharmacy appraisal on wards 1:1
Other 2 -Drug Company videos & other drug Co. stuff
Other 3 -Individual tutorials
Other 4 -Quizzes
Other S -Case studies/presentations
Other 6 -Consultant talks
Other 9 -Grand round attendance
Other 10-Training to meet needs
Other 11-Tutoring for clinical projects
Other 12-Evening clinical pharmacy meetings
Other 13-Peer review using data on quality
Other 14-Technician training
Other 15-University modules for Diplocna/MSc
Other 16-District organised courses
Other 17-Video meetings
Other 18-Block release on secondsent
Other 19-Regional cascade training
Other 20-Management training
Other 21-tutorials
Other 22-Practice meetings
Other 23-Ward rounds with a pharmacist
Other 24-Project presentations
Other 25-Regional clinical pharmacy course
Other 26-Consultant ward rounds
Other 27-Pre-reg seminars
other codes blank
All 15(c) unanswered when answer to 15(a) was Yes
Some 15(c) unanswered when answer to 15(a) was Yes
All 15(c) unanswered when 15(a) unanswered
Some 15(c) unanswered when 15(a) unanswered
15(c)unanswered when answer to 15(a) was No
15(c) answered when answer to 15(a) was No
15(c) answered when 15(a) unanswered
Tick -(2)
Tick (2)
Tick -(2)
- (1)
- (2)
- (3)
- (4)
- (5)
- (6)
- (7)
- (8)
- (0)
(0)
(0)
(9)
(prefix 8 on 15(b) codes)
(prefix 7 on 15(b) codes)
	
?28! !!	 MODERATE
LIrrLE	 ?.MOUNT
1	 2	 3	 4
1	 2	 3	 4
1	 2	 3	 4
1	 2	 3	 4
1	 2	 3	 4
1	 2
	 3	 4
1	 2
	
3	 4
1	 2
	 3	 4
1	 2
	 3	 4
1
	
2
	
3	 4
1	 2
	 3	 4
1
	 2
	 3	 4
1	 2
	 3	 4
1	 2
	 3	 4
1	 2
	
3	 4
1	 2
	 3	 4
1	 2
	 3	 4
1	 2	 3	 4
1	 2
	
3	 4
1	 2
	 3	 4
1	 2
	
3	 4
1	 2	 3	 4
1	 2
	 3	 4
1	 2
	 3	 4
1	 2
	 3	 4
1	 2
	 3	 4
1	 2
	 3	 4
1	 2	 3	 4
1	 2	 3	 4
1	 2	 3	 4
(0)
(0)
(0)
(0)
(0)
(9)
(Use prefix 8)
(Use prefix 7)
No	 Blank -(1)
yes, a Diploma	 Blank -(1)
Yes, an NBC.	 Blank -(1)
MPh ii
N Management Cert
BTec
DM1
MBA
MPharm
o(S
PharmD
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2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4(0)(0)
8	 Code Book for Questionnaire II continued.
Q16. Education for health care professionals in the hospital
NONE
Group teaching for nursing staff (including students)
	 1
Group teaching for medical staff	 1
Group teaching for medical students 	 1
Group teaching for other health care professionals 	 1
Any of the codes under other can be entered in HCPEDOT1-5
Enter as code of activity plus how much done eq. 10.3
Other 1 -Diploma in Nursing P2000 teaching	 1
Other 2 -Education at grand rounds & audit 	 1
Other 3 -Pharmacy undergrad. teaching in din, pharmacy 1
Other 4 -Clin Pharmacy Dip at university 	 1
Other 5 Physiotherapists	 1
Other 6 0Th	 1
Other 7 Cossaunity NH team 	 1
Other 8 Cosisunity midwives	 1
Other 9 Opticians	 1
Other 10 Practice nurses 	 1
Other 11 Care staff	 1
Other 12 GP5	 1
Other 13 Radiographers 	 1
Other 14 Residential/Nursing home staff
	 1
Other 15 Social workers	 1
Other 16 Mother & baby teachers	 1
Other 17 Paramedics	 1
Other 18 District nurses 	 1
Other 19 School nurses
	 1
Other 20 Health visitors
	 1
Other 21 Psychologists	 1
Other 22 Cosinunity pharmacists	 1
Other 23 Clinical resource groups 	 1
Other 24 Chiropodiste	 1
Other 25 ODAS	 1
Other 26 Porters - medical gas	 1
Other 27 Drug counsellors	 1
Other 28 Dental assistants 	 1
Other 29 .S	 1
Other 30 Medical secretaries	 1
Other 31 ECG teche 	 1
Other 32 Managers 	 1
Other 33 Radiotherapy students 	 1
Other 34 Ambulance staff 	 1
Other 35 Speech therapists 	 1
Other 36 Dieticians	 1
Other 37 Public -resuscitation training
	 1
Other 38 Vaccination clinic staff
	 1
"Other codes blank
All of 16 unanswered
!X MODERATE LOTS
LITTLE AnOUrr
2	 3	 4
2	 3	 4
2	 3	 4
2	 3	 4
Q17(a).	 Drug & Therapeutics comeittee
	 No	 (1)
Yes	 (2)
District D&T
	 (3)
17(a) Unanswered but 17(b) answered more than ZERO
	 (7)
17(a) answered NO but 17(b) answered more than ZERO
	 (8)
17(a) and 17(b) unanswered	 (0)
Ql7(b).	 PHARI4DTN	 (NUNBER)
17b >0 but lie answer is NO
17b >0 but ha unanswered
17b unanswered but 17a is NO
17b unanswered but 17a ja unanswered too
17b unanswered but 17a answered YES
(ha answer becomes 8)(ha answer becomes 7)(0)
(99/99.99)
(99/99.99)
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Q18(a). FORIfULARY	 No	 (1)
Yes	 (2)
Antibiotics only	 (3)
Question unanswered	 (0)
Q18(b). NONFORML	 0% (1)	 25% (2)	 50% (3)	 75% (4)	 100% (5)
18b answered but iSa answer is NO	 (Prefix 8 on answers to 18(b))
18b answered but 18a unanswered	 (Prefix 7 on answers to 18(b))
l8b unanswered but 18a is NO 	 (9)
18b unanswered but 18a is unanswered/YES	 (0)
018(c).	 No one	 Blank - ( 1) Tick = ( 2)
Ward pharmacist	 Blank - (1) Tick - ( 2)
Consultant/senior doctor	 Blank - (1) Tick - ( 2)
Prescriber	 Blank (1) Tick = ( 2)
A senior pharmacist	 Blank - (1) Tick - ( 2)
Ward sister/senior nurse
	 Blank - (1) Tick - ( 2)
The Drug B Therapeutics coomittee Blank - ( 1) Tick - ( 2)
Other codes-enter in CONSOT1-3	 Pormulary group/pharmacist 	 - ( 1)
Patient	 - ( 2)
Consultant microbiologist 	 - ( 3)
DPhO/CAPO/DPS	 - ( 4)
CPU	 - ( 5)
Clinical Director	 - ( 6)
UGN	 -(7)
Chair of D&T Coomittee 	 - ( 8)
Pharmacy Stores	 - ( 10)
- (0)
(Prefix 8 on 18c codes)
(Prefix 7 on 18c codes)
(9)
(0)
(0)
"Other" codes blank
18c answered but 18a answer is No
18c answered but l8a unanswered
18c unanswered but iSa is NO or 18(b) is 100%
18c unanswered but l8aJb is unanswered/YES
Whole question unanswered
Q19(a).	 CDIRECT	 No	 (1)
Yes	 (2)
19a Unanswered (0)
019(b).	 ADVICECD	 No	 (1)
Yes	 (2)
19b Unanswered when 19a was unanswered too 	 (0)
19b Unanswered when l9a was YES 	 (0)
19b Unanswered when 19a waS NO	 (9)
19b answered when 19a was NO	 (Prefix 8 on 19b codes)
19b answered when 19a was Unanswered 	 (Prefix 7 on 19b codes)
Ql9(c)(i) WHOADVC1
One pharmacist only	 (1)
Specific ph. for individual/combinations of directoratos/caro groups
	 (2)
Both	 (3)
"Other" codes (enter in WHQADVC 1-two codes split by a decimal point)
All Ward Pharmacists	 -(4)	 DXC
DPhO/CAPO/DPS	 "(6)	 Formulary Pharmacist	 -(7)
Chief Pharmacist	 -(8)	 Technician	 -(10)
No specific pharmacist .(ll) 	 Clinical services manager
	 .(12)
Drug economy pharmacist (l3)	 Snr. ph tech services 	 .(14)
D&T coamiittee	 (l5)	 DIC B ward Pharmacist	 -(16)
DPhO, DXC B Porisulary Ph=(l7) 	 Chief & Purchasing Ph
	
-(18)
din Srv Mgr & Drug economy Ph 	 -(19)
din Ph 5 Pcy Kgr	 .(20)	 DTC & Specific Ph
	
e(21)
Chief & Clin Ph	 -(22)	 din Pormulary B DI Ph
	
(23)
dim & Purchasing Ph	 -(24)	 Two pharmacists	 -(25)
Dir Ph & din economist "(26) 	 DUE Ph at other hospital	 -(27)
Other" codes blank
	 - ( 0)
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NONE
(1)
(1)
(1)
(1)
(1)
HELP/ADVICE
ONLY ON REQUEST
(2)
(2)
(2)
(2)
(2)
ROUTINE SPECIAL
SERVICE AVAILABLE
(3)
(3)
(3)
(3)
(3)
(4)
(0)
(8)
(0)
another ticked in a section
10	 Code Book for Questionnaire II continued.
19c(i) Unanswered when 19a/b was unanswered too 	 (0)
19c(i) Unanswered when 19a/b was No 	 (9)
19c(i) Unanswered when l9a/b was YES 	 (0)
19c(i) answered when 19a/b was NO	 (Prefix 8 on 19c(i) codes)
19c(j) answered when 19a/b was Unanewered 	 (Prefix 7 on 19c(i) codes)
Q19c(ii)	 HOWADVCD A Clinical Director 	 Blank - (1) Tick - ( 2)
IIOWADVBN A Business Manager	 Blank = (1) Tick = ( 2)
Other-codes enter in HOWADOT1-2
Comeittee for each care group
Pm. meetings with ?
Ward managers
Directorate managers
Medical staff/consultants in directorate
Send information only
All consultants
At medical audit meeting
Send written information regularly
Meeting with chair of D&T comeittee
Drug policies group meeting
Director of pharmaceutical services
Management accountant
At audit meeting
Team
Nurse manager & Clinical Director
Finance manager
Clinical care manager
Via clinical meetings
"Other codes blank
19c (ii) Unanswered when 19a/b was unanswered too
l9c(ii) Unanswered when l9a/b was NO
19c(ii) Unanswered when 39a/b was YES
19c(ii) answered when 19a was NO	 (Prefix
19c (ii) answered when 19a was Unanswered 	 (Prefix
-(1)
-(2)
-(3)
-(4)
-(5)
-(6)
-(7)
-(8)
-(10)
-(11)
-(12)
-(13)
-(14)
-(15)
-(16)
-(17)
=(18)
-(19)
-(20)
- (0)
(0)
(9)
(0)
on 19c(ii) codes)
on 19c(ii) codes)
NO SERVICE SUPPLY SERVICE ADVICE ON PART OF
PROVIDED	 ONLY	 REQUEST A TEAM
(1)	 (2)	 (3)	 (4)
(1)	 (2)	 (3)	 (4)
(1)	 (2)	 (3)	 (4)
(1)	 (2)	 (3)	 (4)
(5)
(7)
(6)
(10)
(0)
A another ticked in a section 	 (8)
(0)
Q20(a) SERVICE
YPE/Nutrition 1
Cytotoxics 1
Central Intravenous Additives 1
Patient Controlled Analgesia 1
Box 2 & 3 ticked - code
Box 2 & 4 ticked - code
Box 3 & 4 ticked - code
Box 2. 3 & 4 ticked - code
Any sub-section unanswered
Any question wher, both box 1
Whole question unanswered
Q20 (b)
SERVICE
TDM
Pain control
Infection control
Anticoagulation control
Wound care
Box 2 & 3 ticked - code
Any sub-section unanswered
Any question where both box 1 &
Whole question unanswered
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Q20c(1)	 HSTRYA	 No	 (1)
Yes	 (2)
Unanswered (0)
In-patients	 Blank = (1) Tick (2)
Day-patients	 Blank - (1) Tick = ( 2)
Out-patients	 Blank (1) Tick - ( 2)
This part unanswered when the first part unanswered/YES 	 (0)
This part unanswered when the third part answered 	 (0)
This part unanswered when th. first part answered NO 	 (9)
This part answered when the first part unanswered 	 (Prefix 7 on these answers)
This part answered when the first part answered NO 	 (Prefix 8 on these answers)
Patient type-RSTRYPT1-5 Radiology/oncology hostel patients	 -(1)
ophthalmology	 -(2)
short stay surgical 	 -(3)
urology	 -(4)
Anticoagulated patients	 -(5)
Haematology	 -(6)
on request-problem psychiatric patients 	 -(7)
all patients	 -(8)
Rheumatology	
- ( 10)
Neurology	 -(11)
All elderly	 -(12)
Specific elderly patients	 ..(13)
Cardiac	 -(14)
Rehabilitation	 -(15)
Psychiatric	 (16)
Renal	 -(17)
Specific/difficult patients	 -(18)
Respiratory	 -(19)
Acute patients	 -(20)
Long-stay/ Mental Handicap 	 ..(21)
Terminal Car.	 -(22)
Surgical 0/A
	
-(23)
cystitis	 (24)
Self-medicating	 -(25)
Pain clinic	 -(26)
Obstetric (27)
All this part unanswered when first part unanswered/YES or second part answered (0)
Some this part unanswered when first part unanswered/YES or second part answered (0)
This part unanswered when the first part answered NO (9) answered (Prefix 8 on these)
This part answered when the first /second part unanswered	 (Prefix 7 on these)
All three parts unanswered 	 (0)
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Q20c(2)	 SLFMDA	 No	 (1)
Yea	 (2)
Unanswered (0)
In-patients	 Blank - (1) Tick - (2)
Day-patients	 Blank = (1) Tick (2)
Out-patients	 Blank (1) Tick (2)
This part unanswered when the first part unanswered/YES	 (0)
	This part unanswered when the third part answered 	 (0)
This part unanswered when the first part answered 	 No	 (9)
	
This part answered when the first part unanswered	 (Prefix 7 on these answers)
This part answered when the first part answered wo (Prefix 8 on these answers)
Patient type-SLFMDPT1-5 Geriatric 	 -(1)
Psychiatric
Inhaler technique	 -(3)
Rheumatology	 -(4)
Rehabilitation	 =(5)
Medical patients	 -(6)
Haematology/transplant 	 -(7)
Assisted ventilation patients	 -(8)
Cardiac patients	 -(10)
Compliance aids pm 	 -(11)
Short stay surgical 	 -(12)
Respiratory	 -(13)
Acute patients	 (14)
Orthopaedic patients 	 (15)
Paediatric	 .(16)
Elective surgery	 (17)
Specific problem patients 	 -(18)
Specific long-stay patients 	 -(19)
Neurology	 -(20)
Oncology	 =(21)
Post-operative patients 	 -(22)
Maternity	 -(23)
Some medical patients	 -(24)
All patients	 -(25)
Some surgical patients 	 -(26)
TURP patients	 -(27)
Palliative care patients 	 -(28)
GP patients	 -(29)
Pain clinic	 .(30)
Long-stay mentally handicapped	 -(31)
Long stay patients 	 -(32)
Opthalaology	 -(33)
Dermatological	 (34)
Renal	 .(35)
Young disabled	 -(36)
Respite care	 -(37)
Geriatric rehab	 (38)
Urology	 ..(39)
Heart transplant	 -(40)
cystitis .(41)
All this part unanswered when first part unanswered/YES or second part answered (0)
Some this part unanswered when first part unanswered/YES or second part answered (0)
This part unanswered when the first part answered NO (9) answered (Prefix 8 on these)
This part answered when the first /second part unanswered	 (Prefix 7 on these)
All three parts unanswered	 (0)
413
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Q20c(3)	 PTCSL1t	 No	 (1)
	
es	 (2)
Unanswered (0)
In-patients	 Blank (1) Tick - ( 2)
Day-patients	 Blank = (1) Tick (2)
Out-patients	 Blank - (1) Tick (2)
This part unanswered when the first part unanswered/YES 	 (0)
This part unanswered when the third part answered
	 (0)
This part unanswered when the first part answered NO	 (9)
This part answered when the first part unanswered	 (Prefix 7 on these answers)
This part answered when the first part answered NO (Prefix 8 on these answers)
Patient type-PTCSLPT1-.5
 Anticoagulated patients	
-(1)
Rheumatology patients
	
.( 2)All patients	
-(3)
Geriatric patients
Pre-discharge, on request
	
-(5)
Cardiology patients	
-(6)
Inhaler technique	
-(7)
Self-medication scheme patients
	 = ( 8)
Obstetric patients	
-(10)
Ely	
- ( 11)
Selected problem patients	
-(12)
Parents of neonates	
-(13)
Respiratory patients
	 (l4)
Medical patients 	 (15)
Psychiatric patients	
-(16)
TPN patients	
-(17)
Surgical patients	
-(18)
On request	
-(19)
Patients on poiy drug therapy 	
-(20)
ENT patients	 (21)
Ophthalmology patients
	
-(22)
PCA patients	
.(23)
Inhaler technique, on request
	
-(24)
Diabetics	
.(25)
Renal patients	
-(26)
Haematology patients
	
-(27)
Rehabilitation patients
	
-(28)
All out patients	
-(29)
All discharged patients	
-(30)
Oncology patients
	
-(31)
Palliative care patients	
-(32)
BP unit	
-(33)
Dermatology	
-(34)
Infertility	
-(35)
Acute discharges	
-(36)
Nebuliser therapy
	
..(37)
Poet MI	
-(38)
Neurology	
.(39)
Gynae	
-(40)
Orthopaedics	
.(41)
On new medicines 	
-(42)
Asthmatics	
.(43)
Asthma clinic
	 (44)
Cystic fthroeis ..(45)
All this part unanswered when first part unanswered/YES or second part answered (0)
Some this part unanswered when first part unanswered/YES or second part answered (0)
This part unanswered when the first part answered NO (9) answered (Prefix 8 on these)
This part answered when the first /second part unanswered
	 (Prefix 7 on these)
All three parts unanswered 	 (0)
414
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Q20c(4)	 PTEDA	 NO	 (1)
yes	 (2)
Unanswered (0)
In-patients	 Blank - (1) Tick - ( 2)
Day-patients	 Blank (1) Tick (2)
out-patients	 Blank (1) Tick (2)
This part unanswered when the first part unanswered/YES 	 (0)
This part unanswered when the third part answered	 (0)
This part unanswered when the first part answered No	 (9)
This part answered when the first part unanswered 	 (Prefix 7 on these answers)
This part answered when the first part answered NO (Prefix 8 on these answers)
Patient type-PTEDPT1-5 Respiratory patients	 -(1)
Rheumatology patients	 - ( 2)
Post MI patients (in rehabilitation) 	 -(3)
Geriatric patients
Cardiology patients	 -(5)
Psychiatric patients
oncology patients
	
(7)
Stroke patients
Cystic fibrosis patients 	 (l0)
Breast cancer patients	 (12)
Cardiac surgery patients	 -(13)
Patients on nebuliser therapy 	 ..(14)
Neurology patients 	 .(15)
Diabetics	 -(16)
Psychiatric	 .(17)
Renal	 (18)
Transplant -(19)
All this part unanswered when first part unanswered/YES or second part answered (0)
Some thi. part unanswered when first part unanswered/YES or second part answered (0)
This part unanswered when the first part answered NO (9) answered (Prefix 8 on these)
This part answered when the first /.econd part unanswered 	 (Prefix 7 on these)
All three part. unanswered	 (0)
Q20c(5)	 CSIIA	 No	 (1)
yes	 (2)
Unanswered (0)
In-patienta	 Blank - (1) Tick - ( 2)
Day-patients	 Blank - (1) Tick - ( 2)
out-patients	 Blank - (1) Tick - ( 2)
This part unanswered when the first part unanswered/YES
	
(0)
	
This part unanswered when the third part answered	 (0)
Thi. part unanswered when the first part answered 	 NO	 (9)
	
This part answered when the first part unanswered 	 (Prefix 7 on these answers)
Thi. part answered when the first part answered NO (Prefix 8 on these answers)
CSMDR	 Blank - ( 1) Tick - ( 2)
CSMFIL	 Blank = ( 1) Tick - ( 2)
This part unanswered when the first part unanswered/YES 	 (0)
This part unanswered when the first part answered NO 	 (9)
Thi, part unanswered when third part answered 	 (0)
This part answered when first part unanswered (Prefix 7 on answers to this part)
This part answered when first part answered NO (Prefix 8 on answers to this part)
415
= (0)
etc prior to admin.
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Q20c(6)	 ADRA	 No	 (1)
Yes	 (2)
Unanswered (0)
	
In-patients	 Blank . (1) Tick (2)
	
Day-patients	 Blank - (1) Tick = (2)
	
Out-patients	 Blank - (1) Tick - (2)
This part unanswered when the first part unanswered/YES 	 (0)
This part unanswered when the third part answered	 (0)
This part unanswered when the first part answered NO 	 (9)
This part answered when the first part unanswered 	 (Prefix 7 on these answers)
This part answered when the first part answered NO	 (Prefix 8 on these answers)
Patient type-ADRPT1-5 All, patients 	 = ( 1)
Geriatric patients	 -(2)
Medical patients	 -(3)
Surgical patients	 -(4)
Psychiatric patients	 -(5)
Ophthalmology patients	 -(6)
Haesatology	 -(7)
ADR to desferrioxamine	 -(8)
NIV	 -(10)
Oncology (11)
All this part unanswered when first part unanswered/YES or second part answered (0)
Some this part unanswered when first part unanswered/YES or second part answered (0)
This part unanswered when the first part answered NO (9) answered (Prefix 8 on these)
This part answered when the first /aecond part unanswered 	 (Prefix 7 on these)
All three parts unanswered	 (0)
Q20(d). OTRCSIN1-5 Section unanswered
Counselling pm
Patient information leaflets as part of shared care
Individualised patient information leaflets
Abnormal U&E ' s picked out by daily computer search
Compliance card., on discharge
Borne nebuliser advice
Inhaler counselling
Radiopharmaceutical supply
Extemporaneous dispensing
Wound care advice
Education for diabetics
Counselling for those receiving cytos -Expected ADE5
Discharge counselling
CIVA service for problem drugs
Education for AIDS patients
Audit of prescribing on request
Prescribing in past assessed for impact for some patient.
Patient medication profiles
Lithium therapy monitoring & TDM
Special packaging of drugs for some patients
Pintiemetic control
Mother & baby education
Advice on drug withdrawal
Advice on IV fluid therapy
Counselling & education for cystic fibrosis patients
Attend multidisciplinary meetings
Palliative care
Revision of prescription prior to review by doctor
Relatives group discussions, on request
DIC
P.ntibiotic monitoring
Discharge counselling - on request
Camouflage service (skin)
Satellite service to specific units
Advice on choice of dressings, disposable S their use
Home nebuliser counselling & training
StandardiBed heparin and IV insulin services
-(1)
-(2)
-(3)
-(4)
-(5)
-(6)
-(7)
-(8)
-(9)
-(10)
-(11)
=(12)
-(13)
-(14)
-(15)
-(16)
-(17)
-(18)
-(19)
-(20)
-(21)
-(22)
-(23)
-(24)
.(25)
-(26)
-(27)
=(28)
-(29)
-(30)
-(31)
-(32)
-(33)
-(34)
-(35)
-(36)
-(37)
416
-(1)
-(2)
-(3)
-(4)
-(5)
-(6)
-(7)
-(8)
-(9)
-(10)
-(11)
-(12)
-(13)
-(14)
-(15)
-(16)
-(17)
-(18)
-(19)
-(20)
-(21)
-(22)
-(23)
-(24)
-(25)
-(26)
-(27)
-(28)
-(29)
-(31)
= (0)
IV antibiotics
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Q20(e). OTRCOUT1-5	 Whole question (e) unanswered
Patient information leaflets as part of shared care
TDM report. for OP
MTX syringe pre-packs for OP's
Aseptically prepared products for outpatients
Outpatient inhaler counselling clinic
Informal counselling
Patient information leaflets
Teaching cystic fibrosis patients how to prepare & use
Education for diabetics
Answer DI phone queries
Dispensing at specific intervals for certain patients
Counselling for specific out patients
All out patients counselled
Talks to relatives support groups
Talks to national interest groups
Rome dialysis
Education for mother & baby
Drug withdrawal
Counselling for dermatology patients
Counselling and education for cystic fibrosis patients
Medication histories
Formal participation in asthma clinics
Warfarin clinic
Telephone hotline for rheumatology patients
Service to needle exchange
Fertility clinic
Cytotoxic Infusion pumps
Education for relatives/carers
Lipid clinic team member
Advice to community patients
Home TPN
Q21(a) LINTRL	 No	 (1)
(2)
Unanswered (0)
Q21(b)
Blank - (1) Tick - ( 2)
No tick. in all column A/B but not both & 21(a) Unanswered
No ticks in all of column A/B and 21(a) answered YES
No tick, in all of column A/B but 21(a) answered NO
Ticks in column A/B but 21(a) unanswered	 - (prefix
Ticks in column A/B but 21(a) answered NO 	 - (prefix
(code 1 for blanks)
- (0)
- (9)
7 on answers to 21b)
8 on answers to 21b)
COLU A
	
CoLUMN B
ROLE (IN-HOUSE TRIALS)
	
ROLE (DRUG COMPANY TRIALS)
INTRL1
	
DCTRL1
IHTBL2
	
DCTRL2
IHTRL3
	
DCTRL3
IHTRL4
	
DCTRL4
IHTRLS
	
DCTRLS
IHTRL6
	
DCTRL6
IHTRL7
	
DCTRL7
IRTRL8
	
DCTRL8
IHTRL9
	
DCTRL9
IRTBL1O
	
DCTRLIO
IHTRL1 1
	
DCTRL1 1
417
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IHTRLOT1-5	 Ethics assessment	 (1)
Representative of pharmacy on ethics committee	 -(2)
Assist with blood level monitoring 	 -(3)
Provide specific counselling 	 -(4)
Assess feasibility in practice 	 (5)
Other section blank but at least one box ticked in column A(0)
DCTRLOT1-5	 Representative of pharmacy on ethics committee
	 (1)
Assistance with blood level monitoring 	 -(2)
Specific counselling for patients
Assesa feasthility in practice
Other section blank but at least one box ticked in column A- (0)
Q22(a) PRRES	 No	 (1)
Yes	 (2)
Both	 (3)
22a NO but 22b/c answered 	 (8 for 22a)
22a Unanswered but 22b/c answered (7 for 22a)
All 22 Unanswered	 (0)
Q22(b)	 PhD (NO)	 MPhil	 (NO)
MSc (NO)	 Post-graduate Diploma (NO)
Tick taken as ONE unless reason to believe otherwise
Any blanks	 (0)
22b Unanswered when 22a was unanswered too 	 (99)
22b Unanswered when 22a was NO 	 (0)
22b Unanswered when 22a was YES 	 (99)
22b answered when 22a was NO
	 (8 as answer to 22a)
22b answered when 22a was Unanswered 	 (7 as answer to 22a)
Q22(c)	 NPROJECT (NtJXBR OF PROJECTS)
22c Unanswered when 22a/b unanswered too
22c Unanswered when 22a was NO
22c Unanswered when 22a was YES
22c answered when 22a was NO
22c answered when 22a was Unanswered
(99)
(0)
(99)
(8 as answer to 22a)
(7 as answer to 22a)
418
PHARMMA	 No
Yes
Both 23a & 23b Unanswered
Both 23a & 23b ticked
23b answered when 23a was NO
23b answered, 23a Unanswered
Q23 (a)
Q23(b)
Provision of financial information on drug use
Provision of information on problems encountered
in the drug use process eq. prescribing errors
Provision of information and assistance in setting
prescribing policies
Provision of feedback on adherence to the agreed
prescribing policies
18	 Code Book for Questionnaire II continued.
(1)
(2)
(0)
(8)(8 as answer to 23a)
(7 as answer to 23a)
NONE VERY MODERATE Lors
LITTLE	 AMOUNT(1)	 (2)	 (3)	 (4)(1)	 (2)	 (3)	 (4)
(1)	 (2)	 (3)	 (4)
(1)	 (2)	 (3)	 (4)
OTHRM 1-5 Use prefix of other type , decimal point and how much done eq. 10.3
DUR	
-(1)
Audit of prescribing	
-(2)
Prescription writing audited 	
-(3)
Grand round presentations 	
-(4)
Audit of discharge prescriptions
	
-(5)
Assessment of medical audit undertaken by the doctors
	 (6)
Evaluation of antibiotic prescribing 	
-(7)
Evaluation of antiemetic	
-(8)
Presentations at consultant audit meetings
	
-(10)
Joint research projects on audit
	
-(11)
Review of discharge letters 	
.(l2)
Review of anticoagulant charts
	 .(13)
Chose audit topic	
-(14)
Part of working party on prescribing process
	 (15)
TPN	
-(16)
Suggest audit topic.
	
.(17)
Data gathering for specific projects
	
-(18)
Evaluation of impact of new therapies
	
-(19)
Prediction of future needs
	
-(20)
Forinulary	
-(21)
Pm medicines	 =(22)
Intervention monitoring fed back into
	
-(23)
Agreeing topics
	
-(24)
Prescribing of depot neuroleptics
	
-(25)
Therapy for dangerous/acute psychosis
	
-(26)
Of care group equipment 	
-(28)
To develop specialist formulary
	
-(30)
Other blank but at least one box ticked in question 23(b)
	 (0)
23b Unanswered when 23a unanswered too
	 (0)
23b unanswered when 23a NO
	 (9)
23b unanswered when 23a YES
	 (0)
23b answered when 23a NO
	 (8 as answer to 23a)
23b answered when 23a Unanswered
	 (7 for 23a)
Q24(a) PHARI(CAA No
Yes
Both
24b answered when 24a was NO
24b answered when 24a was Unanswered
Both 24a & 24b Unanswered
(1)
(2)
(8)
(8 as answer to 24a)
(7 as answer to 24a)
(0)
419
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-(1)(2)(3)
-(4)
-(5)
-'6)
-(7)
-(8)
-(10)
-(11)
-(12)
-(13)
-(14)
-(15)
-(16)
-(17)
-(18)
specifics (19)
-(20)
-(21)
-(22)
-(23)
-(24)
-(25)
-(26)
-(27)(28)
-(29)
-(30)
-(31)
-(32)
-(33)
-(34)
-(35)
-(36)
-(37)
ts	
-(38)
-(39)
-(40)
-(41)
-(42)
-(43)
-(44)
-(45)
-(46)
-(47)
-(48)
-(49)
-(50)
-(51)
-(52)
-(53)
-(54)
t	 -(55)
-(56)(57)
-(58)
-(59)
-(60)(0)(9)(0)
as answer to
24b answered when 24a was Unanswered
	 (7 as answer to
24(b) NOCAA].-10
Clinical pharmacy interventions in patients
Time involvement/clinical pharmacist/specialty
01 queries / user group
Time on DI queries / user group
Number & % Dispensing errors
Number items dispensed/time period
Mistakes
Time spent trouble shooting
Workload figures
Dispensary
QC
TPN service
Cytotoxics service
Preparation & Packaging of medicines
OPD waiting time
Occasionally, ward pharmacy
Dispensary interventions study
Mentions RPhO's standards, Pta. charter or local contract but no
All parts of pharmacy audited against standards
Peer review of interventions
peer review of interventions against standards
Costings
DI audit
Pain management
TTh waiting time
Response time in dispensing chemotherapy
Response time in dispensary
Customer satisfaction/care satisfaction surveys
Short audits in specific areas, examples given
Residency
Short audits in specific areas, no examples given
Clinical/ward pharmacy
Medication errors
Stock checks
Via collaborative care plans
Specific audits by region
Regionally/district organised meeting every month to discuss aud
Regularity of ward pharmacy visits
Quantifying interventions
Information flow in pharmacy department
Prescription errors
TDM service
Pormulary management
Protocol-setting
Activity-outcome monitoring
QARx
CIVAs
Tech top up
1-2/year clinical pharmacy surveys
Audit of all pharmacy activities
Request for information
Re-usa of patients medicines on discharge
Warfarmn clinic
Annual audit of each pharmacy department by District QA pharmaci
Safety policy
Legal requirements for registration
Aseptic dispensing unit
TQM
Time response
24b Unanswered when 24a unanswered too
24b Unanswered when 24a was NO
24b Unanswered when 24a was YES
flAb.	 ..S...... flA	 .. 24a)
24a)
420
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Q25(a) PHARNCAB No	 (1)
Yea	 (2)
Both	 (8)
25b answered when 25a was NO	 (8 as answer to 25a)
25b answered when 25a was Unanswered 	 (7 as answer to 25a)
Both 25a & 25b Unanswered	 (0)
Q25(b) NOCAB1-10
Audit of surgical department
Audit of other departments using RPhO. Standards 	 -(2)
Audit of laxative policy
Pathology
Antibiotic audit 	 -(5)
Dietetics	 (6)
Physiotherapy	 (7)
Occupational therapy
Chiropody	 -(10)
Obstetric & Gynaecology	 -(11)
Paediatrics	 -(12)
Use of on-call service/supply service 	 -(13)
Patient outcomes at EMI day hospital 	 -(14)
Haematology unit-Use of Hic)uian lines 	 -(15)
Use of EPO in renal patients 	 -(16)
CCU activity audit 	 -(17)
Medical chart audit 	 -(18)
ResuscitatiOn	 -(19)
Medicines in elderly 	 -(20)
Audits of other hospitals with reports to CAPO on pharmaceutical auppliea(21)
Audits of other hospitals with reports to Nurse Manager on supply 	 -(22)
Each pharmacist involved in audits in their own specialty 	 -(23)
General medicine 	 -(24)
Geriatrics	 -(25)
scsu	 (26)
Dermatology	 -(27)
Anaesthetic.	 -(28)
General surgery	 -(29)
Multidisciplinary quality audit 	 -(30)
Nurse telephone requests quality monitoring 	 -(31)
rru	 -(32)
Inhaler technique	 - ( 33)
Use of heparin	 -(34)
Use of antacids	 (35)
Of wards in units 	 -(36)
Of hospitals supplied by us 	 (37)
Preparation of IVa on the ward 	 -(38)
Antibiotic prophylaxis for surgery 	 -(39)
Aminoglycoside therapy in bacteraemia 	 -(40)
DUR of antidepressant. in continuing care 	 -(41)
Unit transplant audit 	 -(42)
Unit orthopaedic audit 	 -(43)
25b Unanswered when 25a unanswered too 	 (0)
25b Unanswered when 25a was 140	 (9)
25b Unanswered when 25a was YES 	 (0)
25b answered when 25a was NO 	 (8 as answer to 25a)
25b answered when 25a was Unanswered 	 (7 as answer to 25a)
Q26(a) TITEWAYF No	 (1)
Yes	 (2)
Unanswered	 (0)
Not applicable as answer 	 (3)
Doat know	 (4)
Q26(b) NUFFIELD No	 (1)
Yes	 (2)
Unanswered	 (0)
Not applicable as answer 	 (3)
Dont know	 (4)
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422
I	 lntervie topics - District Pharmacist (or equivalent).
The Clinical Role of the Hospital Pharmacist -
Interview Survey
District pharmacist (or equivalent)
A. General information about the hospital and interviewee
Hospital
Interviewee's name
Professional group/post	 (District pharmacist)
No. years at hospital
Time of interview (day/month/time)
B. Topics:
1. Views on pharmacy services Contribution to health care,
hospital, patient care, your
professional development,
pharmacy's professional
development, resources.
2. Views on the future of hospital clinical pharmacy in general.
Challenges, opportunities, action required, facilitating factors,
barriers.
3. What are our greatest strengths and weaknesses as a
profession.
423
2	 Interview topics - Chief Pharmacist.
The Clinical Role of the Hospital Pharmacist -
Interview Survey
Chief pharmacist
A. General information about the hospital and interviewee
Hospital
Interviewee's name
Professional grouplpost	 (Chief pharmacist)
No. years at hospital
Time of interview (day/month/time)
B. Topics:
1. Views on pharmacy services - Generally, new services (stimulus
for), discontinued services (reasons), contribution (to
directorate, hospital, patient care, your professional
development, pharmacy's professional development, resources).
2. Professional relationships & conflicts - Social, professional
(with management and health professionals), status, conflicts
(cause, action to reduce them), involvement at hospital leveL
3. Services contribution to patient care - Process vs outcome,
present, future, gap, hospital vs PHC.
4. Views on hospital pharmacy in general . Challenges,
opportunities, action required, facilitating factors, barriers.
5. Future developments- which valued, not wanted, are opinions
sought, new NHS, clinical directorate structure.
424
3	 Interview topics - Clinical Seric Pharmacist (Manager).
The Clinical Role of the Hospital Pharmacist -
Interview Survey
Clinical Services Pharmacist
A. General information about the hospital and interviewee
Hospital
Interviewee's name
Professional group/post	 (Clinical services pharmacist)
No. years at hospital
Time of interview (day/month/time)
B. Topics:
1. Views on pharmacy services - Generally, new services (stimulus
for), discontinued services (reasons), contribution (to
directorate, hospital, patient care, your professional
development, pharmacy's professional development, resources).
2. Professional relationships & conflicts - Social, professional,
status, conflicts (cause, action to reduce them).
3. Services contribution to patient care - Process vs outcome,
present, future, gap.
4. Views on hospital pharmacy in general - Challenges,
opportunities, action required, facilitating factors, barriers.
5. Future developments - which valued, not wanted, are opinions
sought, new NTIS, clinical directorate structure.
425
4	 Interview topics - Community Services l'harivacist (or equivalent).
The Clinical Role of the Hospital Pharmacist -
Interview Survey
Community Services Pharmacist
A. General information about the hospital and interviewee
Hospital
Interviewee's name
Professional group/post	 (Community services pharmacist)
No. years at hospital
Time of interview (day/month/time)
B. Topics:
1. Views on pharmacy services to PHC- Generally, new services
(stimulus for), discontinued services (reasons), contribution (to
directorate, hospital, patient care, your professional
development, pharmacy's professional development, resources).
2. Professional relationships & conflicts- Social, professional,
status, conflicts (cause, action to reduce them).
3. Services contribution to patient care - Process vs outcome,
present, future, gap.
4. Views on hospital pharmacy in general - Challenges,
opportunities, action required, facilitating factors, barriers.
5. Future developments - which valued, not wanted, are opinions
sought, effect of NHS reforms.
426
5	 Jnter%'ies topics - Directorate Pharmacist.
The Clinical Role of the Hospital Pharmacist -
Interview Survey
Directorate Pharmacist
A	 General information about the hospital and interviewee
Hospital
Interviewee's name
Professional group/post	 (Directorate pharmacist)
No. years at hospital
Time of interview (day/month/time)
B.	 Topics:
1. Views on pharmacy services in directorate structure - Stimulus
for development, contribution (to directorate, hospital, patient
care, your professional development, pharmacy's professional
development, resources).
2. Professional relationships & conflicts - Social, professional,
part of directorate team or pharmacy, conflicts (cause, action
to reduce them).
3. Your contribution to patient care - Process vs outcome,
present, future, gap.
4. Views on hospital pharmacy in general - Challenges,
opportunities, action required, facilitating factors, barriers.
5. Future developments - which valued, not wanted, are opinions
sought, new NHS, clinical directorate structure.
427
6	 In(ervic topics - Ward other Pharmacist.
The Clinical Role of the Hospital Pharmacist -
Interview Survey
Ward or other pharmacist
A. General information about the hos pital and interviewee
Hospital
Interviewee's name
Professional group/post
No. years at hospital
Time of interview (day/month/time)
B. Topics:
1. Views on pharmacy services- Usefulness, professional
satisfaction, contribution to patient care, contribution to your
(and pharmacy's) professional development.
2. Professional relationships & conflicts - Social, professional,
conflicts (cause, action to reduce them).
3. Your contribution to patient care - Process vs outcome,
present, future, gap.
4. Views on hospital pharmacy in general - Challenges,
opportunities, action required, facilitating factors, barriers.
5. Future developments - which valued, not wanted, are opinions
sought, new NHS.
428
7	 Interview topics - Consultant Doctor/Clinical Director/Cu nical [harrnacologist.
The Clinical Role of the Hospital Pharmacist -
Interview Survey
Consultant/Clinical Director or Pharmacologist
A. General information about the hos pital and interviewee
Hospital
Interviewee's name
Professional group/post
No. years at hospital
Time of interview (day/month/time)
B. Topics:
1. Relationship with pharmacy. Interaction with, contribution to
and conflicts with medical management.
2. Views on pharmacy services - Present services (usefulness etc.)
clinical directorates, policies, necessary changes.
3. Services contribution to patient care . Present, future, gap.
4. Professional relations- conflicts/co-operation, team
membership, future.
5. Needs in pharmacy. Challenges, opportunities, action
required, facilitating factors, barriers.
6. Future developments . which valued, not wanted, are opinions
sought, new NHS, (clinical directorate structure).
429
8	 Interview topics - Non-consultant Doctor.
The Clinical Role of the Hospital Pharmacist -
Interview Survey
Non-Consultant Doctor
A. Ceneral information about the hos pital and interviewee
Hospital
Interviewee's name
Professional group/post
No. years at hospital
Time of interview (day/month/time)
B. Topics:
1. Relationship with pharmacy - Interaction with, contribution to
and conflicts with medical management.
2. Views on pharmacy services - Present services (usefulness etc.)
clinical directorates, policies, necessary changes.
3. Views on pharmacist you meet most often - contribution,
interaction (conflicts/co-operation).
4. Services contribution to patient care - Present, future, gap.
5. Needs in pharmacy - Challenges, opportunities, action
required, facilitating factors, barriers.
6. Future developments - which valued, not wanted, are opinions
sought.
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9	 Interview topics - Nurse (senior or junior).
The Clinical Role of the Hospital Pharmacist -
Interview Survey
Nurse
A. Genera! information about the hospital and interviewee
Hospital
Interviewee's name
Professional group/post
No. years at hospital
Time of interview (day/month/time)
B. Topics:
1. Relationship with pharmacy - Interaction with, contribution to
and conflicts with nursing management.
2. Views on pharmacy services - Present services (usefulness etc.)
clinical directorates, policies, necessary changes.
3. Views on pharmacist you meet most often. Understanding of
key issues in patient care, contribution, interaction
(conflicts/co-operation).
4. Services contribution to patient care - Present, future, gap.
5. Needs in pharmacy. Challenges, opportunities, action
required, facilitating factors, barriers.
6. Future developments - which valued, not wanted, are opinions
sought, new NHS.
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JO	 Jnterview topics - Hospital Directorate Manager.
The Clinical Role of the Hospital Pharmacist -
Interview Survey
Manager
A.	 General information about the hospital and interviewee
Hospital
Interviewee's name
Professional group/post
No. years at hospital
Time of interview (day/month/time)
Topics:
1. Relationship with pharmacy- Interaction with, contribution to
and conflicts with management.
2. Views on pharmacy services- Developments, new NHS, clinical
directorates, PHC, Patients' Charter.
3. Services contribution to patient care - Present, future, gap.
4. Needs in pharmacy - Challenges, opportunities, action
required, facilitating factors, barriers.
5.	 Future developments.
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The following are examples of letters sent to interview sites (requesting patticipation. lnk)niilng
interviewees of the study. arrangin g interviews and thanking parikipaiits). All were personally signed.
1.	 Introductory letter sent to the Chief Pharmacist at interview sites.
London School of Hygiene and Tropical Medicine
(University of London)
Keppel Street, Inndon WCIE 7HT
Tel 071 636 8636 Tel Dureci 071 9272U0 Fax 071 436 3611
UepI t,ui,r,iI (ui (uLitu(. i1L.,llh dud I'olity
The Chief Pharmacist,	 Hedlilu Services Research Unit
The Pharmacy.
The Hospital,
Hospital Address,
Poatcode.	 Date
Re: Visit by Siobhan Cotter to [The Hospital].
Dear Chief Pharmacist,
Thank you for agreeing to assist in this study and have me visit your hospital on the [Date]. This
letter is just to confirm what we discussed in our recent telephone conversation and to give you a
better idea of what the study involves.
I am visiting a selected number of hospital pharmacies throughout the United Kingdom to study
innovative clinical pharmacy services. This is part of a larger three year study on the clinical role of
the hospital pharmacist in the UK. In earlier parts of this research I have conducted a questionnaire
survey of clinical pharmacy service provision in UK NHS hospitals. I now want to look towards the
future and consider the prospective role of hospital dinical pharmacy and its potential contribution
to health care.
Just a bit of background about myself - I was a hospital clinical pharmacist but now am a PhD
student in the Health Services Research Unit at the London School of Hygiene & Tropical Medicine.
Although I am funded by N.W. Thames Regional Health Authority and the Enterprise Scheme
(Department of Health), this is independent work. I am supervised by Dr Martin McKee, a public
health physician based at the School of Hygiene, and advised by Professor Nick Barber from the
School of Pharmacy, Brunswick Square.
As I mentioned on the telephone, the study involves a 2 - 3day visit to your hospital, during which I
hope to speak with pharmacy and non-pharmacy stafL I would like to obtain an interview with
yourself and with the [Name - District Pharmaceutical Officer or equivalent] since both of you have
the most influence on pharmacy service development in [Hospital]. These interviews are likely to take
about an hour and I would appreciate you setting this time aside, at a time convenient to you, during
the visit. (I will contact [The District Pharmacist or equivalent] to arrange a suitable interview time.)
As you can see, this visit will involve a number of pre-arranged interviews with some time for more
informal contact with staff. I would vely much appreciate your help in selecting the pharmacists,
doctors, nurses and managers that I should interview. You will have a much better idea of which
consultants, non-consultant doctors and senior nurses frequently interact with pharmacy and know of
the benefits of your clinical services. I hope that you can give mc the names of a few that I should
contact. Whilst I am happy to arrange the interviews myself, I would welcome your help if you feel
that it would be advantageous. I also need to speak with a few clinical directors, the non-pharmacy
manager with whom you have most contact, the pharmacist responsible for dinical pharmacy services
and the pharmacist with most links with primary care. Once again I am hoping for some names so
that I can go on to organise the interview times.
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2.	 Introductory letter sent to the Chief Pharmacist at interie' sites continued.
Needless to say, complete confidentiality will be maintained througiout. The source of the
information collected will never be idcntifiable and information will not be linked to [Name of
Hospital]. This study will, however, help me create a statement about the future role of the clinical
pharmacist in the UK and will, I hope, prove valuable to the profession in these changing times.
I hope that you can help inc idcntifij those to whom I should speak during my visit so that I can
begin to arrange the interview times as soon as possible. If you need to speak with me or to obtain
further details, I can be contacted at 071-927 2460 and at the address above.
I look forward to hearing from you and thank you for your agreement to participate in the study.
Yours sincerely
/ htfl 4
 /Z
Siobhan Cotter.
Research Fellow.
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3.	 Confirmatory letter sent to intervietees.
London School of Hygiene and Tropical Medicine
(University of London)
Keppel Street. London WC1E 7HT
Tel: 071-6368636 Tel Direct. 071-9272(t.LU . Fax: 071-436 3611
	
' 3Ni
Department of Public Health and Policy
Dr Physician,
	 Health Services Research Unit
Consultant Physician,
Department,
Hospital,
Hospital Address,
Postcode.	 Date.
Re: Arranged interview with Siobhan Cotter on (Date] at [Time] in (Place].
Dear Dr Physician,
Thank you for agreeing be interviewed on [Date] as part of this study into the future role of hospital
pharmacy in the United Kingdom. I appreciate you setting aside the time fur this in what must be a
veiy busy schedule. This letter confirms what we discussed in our recent telephone conversation and
will give you a better idea of what the study involves.
The attached letter provides more detailed information about this study. At [Hospital), I will be
interviewing a variety of pharmacy and non-pharmacy staff over a period of three days to consider
the present and prospective role of hospital pharmacy in the provision of health care. As I
mentioned on the telephone, the interviews will take 30-45 minutes and will consist of broad-based
questions to obtain your views on pharmacy services. Needless to say, complete confidentiality will
be maintained throughout. The source of the information collected will never be identifiable and
information will not be linked to your hospitaL
Once again, thank you for agreeing to assist in this study. I look forward to meeting with you on
pate]. In the meantime, if you need to speak with me or to obtain further details, I can be
contacted at 071-927 2460 and at the address above.
Yours sincerely,
Siobhan Cotter,
Research Fellow.
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4.	 Letter of information sent to sites and medicall y-qualified interviewees.
London School of Hygiene and Tropical Medicine
(University of London)
Keppel Street. (ondon WC1E 7HT
	 AW'
Tel: 071-636 8636 Tel Direct: 071-92724C Fax: 071-436 3611
Departmeni of Public Health and Poiicy
Health Services Research Unit
17th May 1993.
To whom it may concern,
Siobhan Cotter is a PhD student in the Health Services Research Unit at the London School
of Hygiene and Tropical Medicine. She is carrying out research into hospital pharmacy and
is funded by N.W. Thames Regional Health Authority and the Enterprise Scheme
(Department of Health). She is visiting a selected number of hospital pharmacies
throughout the United Kingdom to study innovative clinical pharmacy services as part of her
PhD. In earlier parts of this research she has carried out a questionnaire survey of clinical
pharmacy service provision in UK NHS hospitals. She now wants to consider issues
surrounding hospital pharmacy clinical services development.
The study involves a 2 . 3 day visit, during which she will speak with a number of pharmacy
and non-pharmacy staff for about 30 -45 minutes. With the help of the pharmacy Staff we
hope to identify hospital staff who can make useful contributions to the research.
Needless to say, complete confidentiality will be maintained throughout. The provider of any
Information will not be identifiable and information will not be linked to your hospital. This
study will, however, help in the creation of a statement about the future role of the hospital
pharmacist in the UK and will, we hope, prove valuable to pharmacists and others who work
in the hospital sector.
Yours sincerely,
Dr Martin McKee M.D. M.R.C.P. (Supervisor)
Senior Lecturer in Public Health Medicine
/ 
-'-
Siobhan Cotter
Research Fellow
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Letter of Information sent to sites and non-medically-qualifled i,itervievees.
London School of Hygiene and Tropical Medicine
(University of London)
	 (-.1
r
Keppel Street. London WC1E 7HT
Tel: 071-6368636 .
 Tel Direct: 071927 .2'r C - Fax: 071-436 3611
Department of Public Health and Policy
Health Services Research Unit
17th May 1993.
To whom it may concern,
Siobhan Cotter is a PhD student in the Health Services Research Unit at the London School
of Hygiene and Tropical Medicine. She is cariying out research into hospital pharmacy and
is funded by N.W. Thames Regional Health Authority and the Enterprise Scheme
(Department of Health). She is visiting a selected number of hospital pharmacies
throughout the United Kingdom to study innovative clinical pharmacy services as part of her
PhD. In earlier parts of this research she has carried out a questionnaire survey of clinical
pharmacy service provision in UK NHS hospitals. She now wants to consider issues
surrounding hospital pharmacy clinical services development
The study involves a 2 - 3 day visit, during which she will speak with a number of pharmacy
and non-pharmacy staff for about 30-45 minutes. With the help of the pharmacy staff we
hope to identify hospital staff who can make useful contributions to the research.
NeedLess to say, complete confidentiality will be maintained throughout. The provider of any
information will not be identifiable and Information will not be linked to your hospital. This
study will, however, help in the creation of a statement about the future role of the hospital
pharmacist in the UK and will, we hope, prove valuable to pharmacists and others who work
in the hospital sector.
Yours sincerely,
/742;' 7'q3<,
Dr Martin McKee (Supervisor)
Senior Lecturer in Public Health Medicine
V	 3
Siobhan Cotter
Research Fellow
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6.	 Letter of thanks sent to interviewees.
London School of Hygiene and Tropical Medicine
(University of London) --	 :—oi
Keppel Street. London WC1E 7HT
Tel- 071-636 8636 Tel Direct 071-9272ç4,c, Fax 071-436 3611
Department of Public Health and Policy
Health Services Research Unit
The interviewee,
The Hospital,
Hospital Address,
Postcode	 Date.
Dear Interviewee,
Just a note to say 'thank you' for participating in my interview study of providers and recipients of
hospital pharmacy services. The information that you provided has given mc a much clearer idea of
how hospital pharmacy presently contributes to patient care and how it might continue to do so in
the future. I am grateful for the time that you spent on the interview and for your valuable
contribution;
As I mentioned before, complete confidentiality will be maintained and providers of information Will
never be identifiable.
Thank you once again for your time and your thoughts on hospital pharmacy.
Yours sincerely,
Siobhan Cotter.
Research Fellow.
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Table 1.	 Response rate to a questionnaire inquiring about the provision of clinical
pharmacy services by hospital pharmacies in each District' in the UK NHS2 to
primary care recipients3.
Part of United Kingdom
	
Response4 - Returned/Sent (%)
England
	
165/177 (93.2)
Northern Ireland
	
3/4 (75.0)
Scotland
	
12/14 (85.7)
Wales	 8/9 (88.9)
Special Health Authorities 	 5/7 (71.4)
All UK MIS
	
193/211 (91.5)
Notes to Table 1:
1. District Health Authorities (England), Health Boards (Scotland & Northern Ireland) and Health
Authorities (Wales & Special Health Authorities);
2. United Kingdom National Health Service;
3. General practitioners, primary care nurses, community pharmacists, patients and persons in the
community, primary care health professionals (other than doctors, nurses and community
pharmacists) and primary care institutions;
4. The respondents were District Pharmaceutical Officers (England) and their equivalents in the
rest of the UK NHS.
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Table 11.	 Services used in calculating the Total Service Score'.
Provision of drug therapy monitoring for acute patients
Provision of drug therapy monitoring for long-stay patients2
Residenc?
Participation by some pharmacists in medical ward rounds
Participation in Drug and Therapeutic Committee meetings4
Application of a formulary system5
Provision of advice to clinical directorates6
Participation in infection control services7
On-site drug information centre
Provision of education for pharmacy staff
Provision of education for nurses (and student nurses)
Provision of education for doctors
Provision of education for other hospital staff8
Conduct of practice research
Contribution to medical audit9
Performance of pharmacy audit9
Participation in clinical audit9
Provision of support for clinical trials
Pharmacist involvement in total parenteral nutrition teams
Pharmacist involvement in cytotoxic chemotherapy teams
Pharmacist involvement in patient controlled analgesia teams
Provision of therapeutic drug monitoring
Provision of anticoagulation control
Provision of advice on wound care
Provision of advice on pain control
Provision of a central intravenous additive service
Patient medication history-taking (all patients)
Provision of self-medication schemes'°
Provision of patient medication counselling
Provision of patient education
Operation of the CSM ADR" monitoring scheme
Operation of an additional ADR monitoring schemed
Notes to Table 11:
1. Each service was allocated a score of 1 if provided and 0 if not;
2. Not all hospitals had long-stay patients;
3. Resident pharmacists usually provide an on-site emergency pharmacy supply and advisory
service. They work alone but may be supported and advised by pharmacy staff at home;
4. 361/414 (87.2%) of hospitals had a Drug & Therapeutics Committee;
5. 342/415 (82.4%) of hospitals bad a formulary. Application of the formulaiy meant that fewer
than 100% of requests for non-formulary products were acceded to by phannacy;
6. Clinical directorates are the resource management units within UK NHS hospitals. 279/4 14
(67.4%) of hospitals had clinical directorates;
7. Included assistance with the creation of, and provision of advice on, various infection control
policies;
8. Other than pharmacists, doctors and nurses;
9. Audit is a quality assurance activity. It may be led by, and predominantly involve, doctors
(medical audit) or pharmacists (pharmacy audit) or it may be multidisciplinary (clinical audit);
10. Also known as self-administration schemes;
11. Committee of Safety of Medicines (CSM) adverse drug reaction (ADR) monitoring scheme and
adverse drug reaction monitoring schemes in addition to the CSM scheme.
461
Table 12.	 Results of a Rasch analysis' for 33 Clinical Pharmacy Services in United Kingdom
National Health Service Hospitals2.
Service	 Raw	 Rasch	 Standard
score&	 scores'	 error'
Provision of drug therapy monitoring for acute patients 	 329	 -4.572	 0.300
Provision of support for clinical trials	 319	 -3.853	 0.228
Participation in Drug and Therapeutic Committee meetings 	 282	 -2.574 0.155
Participation by some pharmacists in medical ward rounds 	 268	 -2.261	 0.144
Application of a fonnulary system 3	256	 -2.024 0.138
Provision of drug therapy monitoring for long-stay patients2 	 255	 -2.006 0.137
Provision of education for pharmacy staff 	 244	 -1.807 0.133
Provision of education for nurses (and student nurses)	 225	 -1.492	 0.127
On-site drug information centre	 222	 -1.445 0.127
Patient medication counselling 	 211	 -1.276	 0.125
Contribution to medical audit3	181	 -0.835	 0.122
Provision of self-medication schemes 6	170	 -0.678	 0.121
Operation of the CSM ADR7 monitoring scheme	 158	 -0.507 0.122
Provision of advice to clinical directorates8	152	 -0.421	 0.122
Conduct of practice research	 147	 -0.348	 0.122
Pharmacist involvement in total parenteral nutrition teams 	 126	 -0.038	 0.125
Provision of a central intravenous additive service 	 117	 0.100	 0.127
Performance of pharmacy audit3	 96	 0.442 0.133
Provision of patient education 	 95	 0.459	 0.133
Pharmacist involvement in cytotoxic chemotherapy teams 	 83	 0.674 0.138
Provision of therapeutic drug monitoring	 75	 0.828 0.142
Provision of patient medication history-taking 	 56	 1.244	 0.157
Pharmacist involvement in patient controlled analgesia teams	 55	 1.268	 0.158
Provision of education for other hospital health professionals9	52	 1.344 0.161
Provision of advice on wound care 	 52	 1.344 0.161
Operation of an additional ADR monitoring scheme7	41	 1.654 0.176
Residency servic&° 	 37	 1.784	 0.183
Provision of advice on pain control 	 31	 2.002	 0.197
Participation in clinical audii? 	 25	 2.258	 0.215
Provision of education for doctors	 22	 2.407 0.226
Participation in infection control services"	 19	 2.575	 0.241
Provision of an anticoagulation control service	 15	 2.840 0.267
Provision of education for medical students 	 14	 2.916 0.275
Notes to Table 12:
1. Rasch analysis is described in the methods (Chapter ifi);
2. Hospital pharmacies where a pharmacist was present during normal working hours and services, in addition to thug
supply, were provided. The response rate was 89.9%;
3. 342/415 (82.4%) of hospitals had a formulary. Application of the formulary meant that fewer than 100% of requests
for non-formulary products were acceded to by pharmacy;
4. Not all hospitals had long-stay patients;
5. Audit is a quality assurance activity. It may be led by, and predominantly involve, doctors (medical audit) or
pharmacists (pharmacy audit) or it may be multidisciplinary (clinical audit);
6. Also known as self-administration schemes;
7. Committee of Safety of Medicines (CSM) adverse thug reaction (ADR) monitoring scheme and ADR monitoring
schemes in addition to the CSM scheme;
8. Resource management units in some (279/4 14, 67.4%) UK NIIS hospitals;
9. Health professionals other than pharmacists, doctors and mirses;
10. Resident pharmacists usually provide an on-site emergency pharmacy supply and advisory service. They work alone
but may be suppoited and advised by pharmacy staff at home;
11. Understood by respondents to include assistance with the creation of, and provision of advice on, various infection
control policies.
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APPENDIX XI
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This appendix contains an annotated bibliography of the evaluative literature on UK NHS hospital
clinical pharmacy servcies. The numbering of the references is consistent with that used in the
References section of the thesis. This has resulted in the appearance of artificial gaps in the following
bibliography.
19.	 Vere DW. Errors of Complex Prescribing. Lancet 1965;i:370-3.
Descriptive study:
l'his paper outlined the incidence of errors in drug administration at a London hospital. It was
probably the first needs assessment for prescription monitoring in hospital.
22.	 Hill PA and Wigmore HM. Measurement and control of drug-administration incidents. Lancet
1967;i:671-4.
Descriptive report:
This paper described the changes in error rates following the introduction of the new
prescription charts at the London Hospital. Use of a ward pharmacist and a new style drug
chart reduced error rates. It was suggested that a pharmacist should be sent to the wards to
initiate drug supply. The authors asserted that a pharmaceutical service would "provide a
consultancy service at the point of prescribing".
24.	 Sykes CH and Oakes AEM. Drug administration at the London hospital. Pharm J
1968;200: 117-8.
Descriptive report:
This paper described a new drug prescription chart brought into use at the London hospital
following multidisciplinary committee activity to reduce drug administration error. Pharmacists
went on the wards and spent 83% of their time monitoring prescriptions and 14% in
consultation and discussion with medical and nursing staff.
46. Brown AW, Barrett CW and Herxbeimer A. Hospital Pharmacy Committees in England: Their
structure, function and development. Br Med J 1975;270:323-5.
Descriptive study:
A survey of 150 (80% response rate) chief and group chief pharmacists in England found that
70 worked in hospitals with a committee that dealt with drugs and related matters. 72% of
teaching hospitals, as opposed to 30% of others, had such committees. The first committee was
set up in 1948. The numbers increased steadily until 1968 and then more rapidly. Only one
committee did not include a pharmacist and all were multidisciplinary.
47. George CF and Hands DE. Drug and Therapeutic Committees and information pharmacy
services: the United Kingdom. World Development 1983;! 1:229-36.
Descriptive study:
This paper described the origins of multidisciplinary drug and therapeutic committees (DTCs)
and the drug information service in the United Kingdom (UK). A census survey of district
health authorities and boards in the UK revealed that 198 had DTCs. These were usually
comprised of doctors, nurses and pharmacists. The average number of members was 9 (range
2-23). Data from the 150 respondents that provided DTC membership details showed that a
total of 629 consultants, 277 hospital pharmacists, 108 nurses, 91 administration personnel, 54
junior doctors and 41 general practitioners sat on committees. Their terms of reference varied
464
widely. One hundred and thirty one respondents provided details on DTC terms of reference.
These were to develop drug policy (106), achieve economy (86) and promote safety of drug
use (65), to provide information on drug costs and efficacy (31), to monitor the use of and
expenditure on drugs (30) and to provide information on new drugs (27). The savings achieved
by formularies at two sites were quoted. Formularies were also considered to be educational
tools. The development of the Wessex drug information centre (DIC) in 1976 was described. It
handled 2600 queries in 1981. Queries were received from consultants (9.3%), junior doctors
(24.7%), general practitioners (5.7%), hospital pharmacists (37%), community pharmacists
(3%), hospital nurses (11%) and community nurses (1%). The commonest topics on which
inquiries were received were drug administration (15.8%), indication/choice (15.8%), adverse
effects (14.5%), identification (11.8%) and availability/supply (10.4%). The sources of
information that were used by the DIC and its other activities in producing bulletins were
described as was the national network of pharmacy information services in Britain.
48. Middlebrook MJ. The use of hospital formularies in the UK. Br I Pharmaceutical Practice
1979;1(8):12-3,16-7, 20-25.
Descriptive study:
A survey of 42 hospitals in the UK found that many had developed (12) or were in the process
of developing (8) drug formularies, prescribing guidelines or policies for the introduction of
new drugs. Some had started this work as early as 1970. Hospitals stated that the purpose of
the formulary was cost reduction (10), education of prescribers (10), facilitation of rational
prescribing (10) and drug selection. Formularies were updated as frequently as every 3 months
but, more commonly, over longer periods. Of the 13 hospitals that provided information on
compliance with formulary recommendations, 9 said that this was in excess of 60%.
49. Ridley H. Drugs of choice: a report on drug formularies used in NHS hospitals. London:
Social Audit, 1986.
Descriptive study:
This publication provided details of the results of a telephone survey of district health
authorities (DHA) in 1985. The response rate was 83%. Seventy five (36%) had formularies
that extended to all hospitals in the DHA and covered all or most drug categories. The DHA
placed some restrictions on prescribing in 48 (23%) cases and 32 DHAs (15%) had no
formulary.
50. Calder 0, Davies IS, McNulty H and Smith JC. Drug information network in the United
Kingdom National Health Service. Am J Hosp Pharm 1981;38:663-6.
Descriptive report:
The national drug information network was described in this paper. Various government
reports that supported the provision of drug information were outlined. Specialist centres were
named and the many activities supported by the national network were described, such as the
production of bulletins, literature abstracting, the transfer of information, the education and
training of staff, and the setting up of an annual conference to exchange ideas. The sources of
information queries at the various centres were enumerated. There was a rise in the use of the
centres by doctors over the years 1976-9 and a fall in their use by hospital, but not community,
pharmacists. The variation in the types and distribution of queries between centres was
described.
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51. Foster JHS. Postgraduate education for clinical pharmacy. Proceedings of the Guild 1977;3: 1
29.
Report:
This report was a comprehensive review of the training needs in clinical pharmacy and an
effort to predict future needs based on current practice developments. The author described the
development of training programmes in the United States (USA) and in the UK and made
general recommendations for the UK, where the practice of clinical pharmacy had not
developed to the same extent as in the USA. He enumerated the available courses in the UK
which comprised nine MSc courses in hospital or clinical pharmacy. These were mainly
university based and an interview study of recent graduates indicated general satisfaction with
the courses. Participants suggested that greater clinical involvement was needed, such as could
be provided by a clinical residency period. He concluded by stating that, at the time, the
courses that were available were inadequate to fulfil training needs. He felt that new
developments should include the use of clinical pharmacists, currently in practice, to teach
skills to participants and become role models for them. A residency programm, such as was
common in the USA, would be desirable.
52. Goldberg LA and Cullen AMS. Continuing postgraduate education/training in hospital
pharmacy. Br J Pharmaceutical Practice 1979;1(8):9-10.
Descriptive study:
This paper described the results of a questionnaire survey of Area Health Authorities and their
equivalents in the United Kingdom to ascertain attitudes towards the provision of education for
hospital pharmacists. Of the 87 questionnaires sent, 47 were returned (54%). All respondents
thought that the provision of education was essential. In total, 35 Areas provided education in
clinical pharmacy, 31 in support services and 28 in management. In 22 Areas, education was
organised at regional level and in 10 it was on an ad hoc basis. The types of education
provided included films and taped lectures in addition to more conventional methods. Some
(27) sites had links with a university and 35 had teacher practitioners jointly employed with a
university. There was general dissatisfaction with the educational services provided to hospital
pharmacists because too few pharmacists were available to teach, it was difficult to get
pharmacists on appropriate management courses, there was a lack of courses for support
services and there was a general shortage of staff. This last fctor hindered the secondment of
pharmacists to attend educational courses.
53. Davies G, Dodds L, Fleet E, Home R and Joshua A. Pharmacy practice research in the
hospitals of South East Thames regional health authority, England. mt j Pharm Pract
1993;2: 184-8.
Descriptive study:
This paper reported the results of a survey conducted within one regional health authority in
England on ongoing practice research and perceived barriers to the conduct of practice
research. Survey were sent to 22 units; 21 were returned. This represented answers provided
by 18/19 cLinical trainers. As well as completing the questionnaire, the clinical trainers had
been asked to interviews senior pharmacy managers at their unit. Seventeen interviews were
conducted. Although 15 units had a pharmacist who had successfully completed/supervised a
project in the past, only 11 had individuals with a research commitment. Managers were
seeking to fund a research pharmacist in 6 units. Details were obtained on 199 projects, 110 of
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which had been completed and 28 of which were being planned. Most projects were concerned
with drug usage (55%) and a smaller proportion with service development (33%). Research
was often undertalcen to support service development (37%) or as part of the pre-registration
requirements (23%). The majority of managers did not afford practice research a high priority
and the main barriers to its performance were lack of money (14/17 managers and 10/18
trainers) and time (16/17 managers and all trainers). Perceived solutions to the problem were
the availability of external supervisors (10/17 managers and 11/18 trainers) and assistance with
funding (9/17 managers and 12/18 trainers). The authors envisaged a change in attitude to
research consequent on the NHS changes. They also commented on the failure of researchers
to report the results of research projects and the negative consequences for further funding
applications.
54. Talbot JCC and Veitch GBA. Adverse drug reactions. Results of a national survey to discover
the extent and limitations of the hospital pharmacist's involvement. Br J Pharmaceutical
Practice 1980;2(9):6-1 1.
Descriptive study:
This paper described the results of a postal questionnaire survey of 82 Area Pharmaceutical
Officers in England and Wales and 12 Chief Administrative Pharmaceutical Officers in
Scotland. There were 84 replies (89% response rate). The number of replies was 119 due to
officers sending the questionnaire to districts and large hospitals. Most pharmacy departments
kept CSM cards (95), some distributed them to the wards (64) but few ward pharmacists
carried them (41). Pharmacists frequently, or sometimes, recommended the making of a report
to the CSM in 88 sites, were told when the CSM reports had been sent in 68 and completed
the report in 17. Forty two sites had attempted to channel CSM reports through the drug
information service but 12 said that no reports were reaching the CSM in this way and a
further 14 made comments about the lack of success in this area. Thirty sites were involved in
encouraging adverse drug reaction reporting and 17 sites were involved in monitoring patients
for ADRs. Eighty four (71%) sites would like to be more involved in ADR reporting to the
CSM and 69 (58%) in additional ADR schemes. A number of sites had plans to be more
involved but resource constraints, inadequate training, and resistance from medical staff and
from the CSM were hindering developments.
55. Sharott P. The hospital pharmaceutical service - is there a need for extended hours of service?
Proceedings of the Guild 1978;4:33-62.
Descriptive study:
The author described a survey of 16 hospital providing extended opening hours; 8 had
residency services and 6 provided a service staffed by a pharmacist on call from home. Twenty
percent of calls to pharmacists were for drug information and advice but most concerned drug
supply issues. The advantages and disadvantages of a residency service were discussed.
63.	 Parekh R and Ghee C. Evaluation of a pharmacist controlled anticoagulant clinic. Br J
Pharmaceutical Practice 1987;9:370-81.
Objective:
To assess any change in the control of patients since active pharmacy participation was
undertaken in out-patient anticoagulation clinics at a single hospital.
Methods:
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This was a prospective 6 week controlled study measuring maintenance of international
normalised ratio (INR) in the recommended range, patient recall rate and the degree of
fluctuation in INR between visits in patients allocated to two groups, one managed by a doctor
the other by a phannacist. Some patients acted as their own controls and others were matched
for drug indication, age and sex. Patients had to be treated exclusively, or for at least nine
months, by a pharmacist to qualify for inclusion in the test group although this was not adhered
to in practice.
Results:
Seventy three patients were treated by doctors and 73 by pharmacists. The only differences
found between groups were that pharmacists carried Out more INR tests and recalled patients at
more frequent intervals. This indicated that the phannacist-run service may have been more
expensive although the costs were not measured. The proportion of patients' levels that were in
the therapeutic range were similar for both services. The discussion described the benefits to
the patient, such as counselling, continuity of care, and inferred that the patient benefited more
from a pharmacist-run clinic.
Assessment of study: (strength, size of effect, generalisability)
This was a small study since the 146 patients were split among several sub-groups. The
researchers assessed output and process only, and not outcome or costs, hence this was a
partial evaluation. Benefit was defined in a very limited sense (equivalent outcome). All
benefits not taken into account and claims of some benefits (such as continuity of care) were
not proven in the article. There was potential for confounding (patient allocation) and bias
(pharmacists-gathered data) and it was difficult to assess the implications of these results. The
results are not generalisable.
65.	 Gould TH, Crosby DL, Harmer M, Lloyd SM, Lunn IN, Rees GAD, Roberts DE and
Webster JA. Policy for controlling pain after surgery; effect of sequential changes in
management. Br Med I 1992;305:1187-93.
Objective:
To observe the effects of introducing an acute pain service to the general surgical wards of a
general hospital.
Methods:
This was a seven stage study using audit of pain control practices before and after the gradual
introduction of an acute pain team. Several pain relief strategies were assessed, including
patient controlled analgesia and regional blocks. The usefulness of patient information leaflets
was assessed also. The main outcome measures were changes in the median pain (visual
analogue) scores 24 hours after surgery, on deep inspiration and on movement.
Results:
A total of 2035 patients were involved in this 9 month study. The introduction of the service
was associated with gradually decreasing pain scores.
Assessment of study: (strength, size of effect, generalisability)
This was not an evaluation of a pharmacy service. A pharmacist was, however, involved in the
routine supervision of the acute pain team.
70.	 Daly MJ and Jones S. Preliminary assessment of a computerised counselling program for
asthmatic children. Pharm J 1991;247:206-8.
Descriptive study:
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This paper described the creation and assessment of a self-operated computerised program to
counsel children about asthma and its therapy. Asthmatic children (n = 22) and adults (n = 26),
plus interested adults (n= 16), assessed the program via a questionnaire. They were asked also
to rate the modules in order of potential effectiveness in asthma counselling. Responses were
generally positive, more so amongst children than adults. Most thought it was a good idea
(81 %), easy to use (78%), was attractive and non-threatening (63%), appropriate for children
(79%) and adults (55%), and will improve inhaler technique (60%) and knowledge of asthma
(70%). Most rated the "some facts about asthma", "using a metered dose inhaler", "what is
asthma" and "quiz" as potentially being the most useful modules.
92.	 McKay AB, Hepler CD and Knapp DA. How To Evaluate Progressive Phannaceutical
Services. Bethseda: ASHP Research and Education Foundation, 1987.
Book:
This book described methods for the evaluation of pharmaceutical services.
119. Crooks J, Weir RD. Coull DC, McNab JW, Calder 0, Barnett JW and Caie HB. Evaluation of
a method of prescribing drugs in hospital and a new method of recording their administration.
Lancet 1967;i:668-71.
Descriptive report:
This paper described a new drug prescription chart brought into use following multidisciplinary
committee activity at Aberdeen.
120. Calder G and Barnett JW. The pharmacist in the ward. Pharm J 1967;198:584-7.
Descriptive report:
This paper described ward pharmacists' activities at Aberdeen and their potential benefits.
121. Baker JA. Recent developments in the pharmaceutical service at Westminster Hospital. J
Hospital Pharmacy 1967;24:400-6.
Descriptive report:
This paper described ward pharmacy activity and benefits at the Westminster Hospital,
London. It outlined the potential sources of error in drug use on the wards, the new
prescription sheet introduced at the hospital, the findings of a study on ward drug requirements
and the various changes made as a result of this study. The ward pharmacists' responsibilities
included the checking of all new treatments, the checking of drug availability, control of stock
drug availability, regular inventory checks and the provision of information. The simplification
of ordering systems allowed the nursing staff to devote more attention to drug administration.
The pharmacy also proposed becoming more involved in the education of junior doctors.
122. Wall HM, Stephens MJ and Jepson MH. The clinical pharmacist's role in geriatric units.
PharmJ 1987;239:R12.
Descriptive study:
This paper described perceptions of the need for ward pharmacist visits to geriatric unit wards.
Need was judged on the number of prescription changes in the 3 geriatric wards studied (which
received a weekly ward pharmacist visit) in comparison with the rate on an acute medical ward
(which received a daily visit). Mean weekly prescribing activity on the geriatric unit was at
least 50% of that on the acute medical ward over a 10 week period. The authors claimed that
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this indicated a need for more frequent ward pharmacy visits.
123. Pawluczyk MB. Trends in psychiatry Part 2: Monitoring patient medication in a psychiatric
hospital. Br J Pharmaceutical Practice 1988;10:434-8.
Descriptive study:
This described the problems that a ward pharmacist may encounter in prescription monitoring
in a large psychiatric hospital (prescription type, drug interactions, doses in psychiatric
therapy, other drugs, side effects).
124. Thomas RE. Discharge prescription monitoring. A role for the pharmacist. Hospital Pharmacy
Practice 1991;l:333-7.
Descriptive study:
l'his paper described a three week retrospective survey carried Out Ofl 5 wards at a single
hospital. When a pharmacist compared discharge prescriptions with the ward drug chart, 38
(51.4%) of the 74 prescriptions assessed needed the intervention of a clinical pharmacist. Forty
nine interventions would have been necessary on these prescriptions, mainly on the frequency
of dosing (29%), enteric coating (12%), drug added (10%) or drug omitted (8%).
125. Wightman ER. Medicine interactions observed in a year of ward pharmacy. J Clin Hosp
Phann 1978;3:183-8.
Descriptive study:
The author reported on the nature and number of drug interactions observed at a general1
hospital over the course of a year by ward pharmacists. They described the types of
interactions in detail, the information supplied to the prescriber and the actions of the
prescribers' that resulted from the pharmacists' interventions.
126. Jenkins D, Cairns C and Barber N. The quality of written in patient prescriptions. mt j Pharm
Pract 1993;2:176-9.
Descriptive study:
Four hundred and thirty four prescription charts (4536 items) from a stratified sample of
inpatients discharged in one year at two hospitals were examined for errors using pre-set
criteria. The proportion of errors made and their type depended on the type of the prescription.
Hence between 12-32% failed to use the approved name of the drug (depending on the
prescription type), 4-10% were illegible or ambiguous (depending on the prescription type) and
11-26% failed to specify the dose correctly (depending on the prescription type).
127. Lannigan NA. Screening for pharmaceutical care issues on a general surgical ward. Pharm J
1994;252: 134-5.
Descriptive study:
This paper described a systematic method of identifying pharmaceutical care issues on a
general surgical unit in a single hospital. Forty six percent (197) of all phannaceutical care
issues on patients admitted to the unit over 4 months could be identified from prescription data
and 53% (226) after consideration of other sources of patient data such as case notes. The main
Throughout this appendix 'general' describes a hospital that treats general types of patients rather
than a 'District General Hospital'.
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issues identified from the prescriptions were incorrect dose or frequency (9%), illegal or
ambiguous prescriptions (13%) and inappropriate therapy (16%); those from consideration of
other data were difficulties in administration (8%), potential administration, distribution,
metabolism or excretion problems requiring possible dose adjustment (7%), problems with
concurrent therapy for other conditions (16%) and failure of appropriate therapy (14%).
128. Batty R and Barber N. Prescription monitoring for ward pharmacists. Phann J 1991;247:242-
4.
This paper described a prescription monitoring method.
129. Jenkins D, Cairns C and Barber N. How do ward pharmacists spend their time? An activity
sampling study. mt j Pharm Pract 1992;1:148-51.
Descriptive study:
Twenty eight ward pharmacists were observed at two hospitals and their activities recorded
using work sampling. Multiple (n= 1985) observations were made. Prescription monitoring and
clinical monitoring accounted for 31 % and 7%, respectively, of the time spent by ward
pharmacists, travel for 21% and stock control for 12%. Data were similar at the two sites.
130. Beech EF and Barber ND. The development of a self-reporting multidimensional work
sampling measure to study ward pharmacy services in the United Kingdom. J Soc Admin
Pharm 1993;10:157-62.
Descriptive study:
This paper described the use of hand-held credit card sized bar coding technology to record
prescription monitoring activities performed by 6 pharmacists at a general hospital. Ward
pharmacists spent about 50% of their time on clinical pharmacy activities (prescription
monitoring, information gathering, prescription annotation, changes in drug therapy, patient
monitoring, and the provision of advice).
131. Ellis S. Constraints and opportunities in ward pharmacy. Br J Pharmaceutical Practice
1982;4(4)8-20.
Descriptive study:
The author described the results of a survey of activities undertaken by 10 ward pharmacists,
each servicing one ward in a different hospital in East Anglian Region. In stage one, a four
week period, the tune spent on the ward, changes in prescriptions, work arising from the
changes, discussions held and with whom, information supplied and ward activities were
recorded. In stage 2 (4 weeks, six months from stage 1) individual defined pharmaceutical
activities on the wards were timed. These activities included the reading of every prescription
sheet and noting of any required action, the annotation of new prescriptions according to
hospital policy and the checking of prescriptions for possible dose or dose form adjustments.
Detailed work activity results were presented in the article and these were used to construct a
schematic visiting commitment for a 450 bed general hospital. Although this was not an
evaluation some results were of interest to the evaluation in this thesis. During 164 visits in
stage 1 and 169 during stage 2, 60 and 43 problems, respectively, were raised by pharmacists.
There were 29 and 17 changes in prescriptions, respectively, as a result. The numbers of beds
on each ward, and their occupancy, varied but most had 20 or more beds. On average, visits
took 28 minutes in stage 1 and 45 in stage 2 but the number of contacts with patients doctors
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and nurses actually decreased from 293 to 186. The number of queries answered increased
from 80 to 89 and the number of items of unsolicited information decreased from 34 to 27.
Most contact was with nurses; house officers were the most frequent medical contact, On
average, discussions on prescriptions took 3.11 minutes to resolve and conveying information
or answering questions took 2.81 minutes. The study did not discern any significant factors that
affected the quality of ward pharmacy services or their value in improving patient care.
132. Ashley MJ and Barber A. Bar codes - an aid to prescription monitoring in hospital clinical
pharmacy. Pharm .1 1990;246:HS6-8.
Descriptive study:
This paper described the use of hand-held bar coding technology to record prescription
monitoring activities in a general hospital.
133. Cousins D and Hatoum H. The development of a computerised quality assurance system for
clinical pharmacy. mt J Pharm Pract 1991;1:86-9.
Descriptive study:
This paper described the installation and operation of a system where interventions made by
clinical pharmacists were recorded on a computerised database (QUARx - American Society of
Hospital Pharmacists) to permit analysis of their effects on the quality of care and costs. The
system was thought to have benefits for audit, management of pharmacy services and patient
care. It built on an older system at the hospital which used paper forms to record details of the
interventions in the pharmacy. Copies of these forms used to be placed in the patients' notes.
The new system has simplified and facilitated the recording of interventions. In the new
system, interventions were scored by the pharmacists that entered the data based on their
perceptions of the effects on costs and patient care. Four hundred and ninety one interventions
were recorded over 4 months. Pharmacists' advice was accepted in 93% of cases. Twenty five
percent of interventions were scored by a single pharmacist as having changed subtherapeutic
dosing (56), prevented serious toxicity (60) or were potentially life saving (5). One hundred
and six interventions reduced drug costs, 7 saved resources on monitoring, 82 had savings
attributable to complications of drug therapy and 110 reduced length of stay.
134. Kennedy K and Wind K. The development of a monitoring package for pharmacy
interventions. Hospital Pharmacy Practice 1992;2:93-100.
Descriptive study:
This paper described the use of QUARX in a general hospital. QUARx is a computensed
system that allows pharmacists to record their interventions, the outcomes of interventions and
their contribution to care.
135. Hamilton MC and Hudson SA. Patient monitoring in clinical pharmacy; A study of initial
assessment in general medical in-patients (abstract). Proceedings of the UKCPA residential
symposium. Bournemouth, 1990:11-13.
Descriptive study:
This study compared three methods of identifying patients at risk of drug related problems.
These methods were patient interview, prescription assessment or both methods used together.
It was found that none were very specific methods when sensitivity to problem detection was in
excess of 90%.
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136. Nicholls J, Batty R and Jacklin A. Junior doctor's satisfaction with the ward pharmacy service
in the Harnmersmith and Queen Charlotte's special health authority. mt j Pharm Pract
1993;3:156-9.
Descriptive study:
The views of a random (stratified by grade) sample of 43 of a total of 135 junior doctors on
ward pharmacy were sought in a face to face 10 minute taped interview. Twenty six were
interviewed. The interviewer was unknown to the doctors and did not volunteer that she was a
pharmacist. Most (85%) thought that the service was better than average and were satisfied
because of different facets of the service. Seven were satisfied because of prescription
monitoring, 9 because of the advice provided and 23 thought the service was friendly; one
doctor rated the service as worse than in other hospitals. Suggestions for improvement included
increased liaison with ward pharmacists either via ward rounds (n= 10), general liaison (n=3)
or by pharmacists introducing themselves to doctors (n=3). The study results may be biased if
doctors with negative views on the service formed the 60% that responded.
137. Baignet B. Evaluation of clinical pharmacy in a mental health unit. Pharm J 1993;250: 150-2.
Descriptive study:
This was a postal survey of junior doctors' attitudes to clinical pharmacy in a mental health
unit. The survey aimed to assess the acceptability of a number of clinical pharmacy services, to
determine if the quality of communication between medical and pharmacy staff was adequate,
to identify areas of potential service development and to identify potential weaknesses in
pharmacy's clinical or advisory services. Thirty five responses were received (65% response
rate) to a self-completed questionnaire. The respondents thought that pharmacists should be
available for consultation with medical staff (100%), advise on modifications to patients'
therapy (94%), participate in ward rounds (83%) and visit the wards weekly (75%) or daily
(25%). Pharmacists should monitor prescriptions for the correct drug name, dose and route
(91%), frequency and duration (88%), interactions (97%) and adverse reactions (94%).
Pharmacists should ensure cost effective prescribing (86%), that medical staff adhere to the
formulary (77%) and provide information on the cost of alternative therapies (97%). On
therapeutic drug monitoring, pharmacists should help select the drugs to be monitored (89%),
when to take serum levels (83%) and how to interpret results (77%). Pharmacists should
counsel patients on discharge (66%) and train other staff to do so (83%), provide drug histories
(94%), give written reports to doctors (71%) and place these in the notes (69%). They should
provide teaching seminars for student (97%) and trained (94%) nurses, and for medical staff
(80%), bulletins on new drugs (86%) and information for patients (91 %). Most (97%) thought
that they should participate in practice research. Psychiatrists often contacted the pharmacy and
most (87%) found the advice that was provided helpful. The results were similar to those of an
unpublished survey of managers carried out at the hospital two years previously. Differences
were that a lower proportion of ward managers wanted pharmacists on ward rounds (47%) and
taking medication histories (64%).
138. Stevens E. Hospital doctors perceptions of the role of the hospital pharmacist (abstract).
UKCPA Theory into Practice Symposium Bournemouth, 1990:23.
Descriptive study:
This self-completed anonymous questionnaire survey aimed to elicit hospital doctors'
perceptions of the current and extended role of the hospital pharmacist at a single hospital.
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Ninety nine questionnaires were issued to doctors of all grades; 42 were returned. Traditional
roles, such as the provision of drug information and the monitoring of prescriptions for
completeness, appropriateness and accuracy were well accepted. Clinical economy was also
well-regarded, especially by senior doctors. Less well supported, particularly by senior
doctors, were roles where there was greater patient contact such as adverse drug reaction
monitoring, advising on dosage modifications in renal/hepatic insufficiency, medication history
taking, and counselling on discharge. A role was envisaged in therapeutic drug monitoring but
none felt that the pharmacist should be involved in medical teams.
139.	 Cavell GF, Bunn RJ and Hodges M. Consultants' views on the developing role of the hospital
pharmacist. Pharm J 1987;239:100-2.
Descriptive study:
This paper reported the results of a self-completed questionnaire survey of 27 (72% response
rate) consultants' opinions on which clinical pharmacy services should be provided at a single
general hospital. All 6 consultants with a pharmacist attached to their firm responded and the
authors wished to see if their opinions differed from those of their colleagues who did not have
a pharmacists attached to their team. Sixty one percent thought that pharmacists should monitor
therapy for drug interactions; 5/6 consultants with pharmacists on their team thought that
pharmacists should definitely do this compared with 9/17 who did not have a pharmacist on
their team. Sixty nine percent thought that pharmacists had a role in the control of drug
expenditure. Only 10/23 thought that pharmacists should monitor patients drug therapy for side
effects and 5 thought that they should monitor therapy for efficacy. More in the group with
pharmacists on their teams considered these were roles for the pharmacist. Half of the
consultants with pharmacists on their teams thought that pharmacists should take medication
histories and counsel patients whereas 24% of those with no pharmacist on their teams thought
so. About 25% thought that pharmacists should reconstitute intravenous products, 35% that
they should attend ward rounds, 52% that they should provide seminars on drug therapy, 48%
that they should provide therapeutic drug monitoring and 78% that they should take part in
research. Responses to all these questions were more favourable from consultants with
pharmacists on their teams.
141).	 Haslam R. An ex2mination of the supply, prescribing, administration and recording of drugs in
some Northern Regional Health Authority hospitals (MSc thesis). Newcastle upon Tyne:
University of Newcastle upon Tyne, 1986.
Descriptive study:
This thesis reported the results of a study involving the observation of ward activity and the
administration of questionnaires on 3 wards (selected by the hospital staff) in three hospitals
over 5 consecutive clays. Among the findings were that errors were frequently made in all
aspects of drug use. Twenty (65%) nurses thought that it was the doctor's responsibility to
ensure prescriptions were written correctly whereas all 15 pharmacists thought it was the
pharmacists' responsibility. In practice, nurses said that they and senior nurses ensured that
prescriptions were written correctly (97%). Patients were rarely asked about drug side effects
by doctors (48%). Most doctors never asked about side effects despite some patients having
experienced hide effects (72%). Three quarters of nurses said that they used pharmacy often to
check dose and drug availability and they felt that doctors should use the service more. Most
doctors were happy with the pharmacy service (90%) and 42% were satisfied with the ward
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phamacy service.
141. Bentley A and Green R. Developing pharmaceutical services: the nursing view. Br J
Pharmaceutical Practice 1981;3(3):4-9.
Descriptive study:
A self-completed questionnaire survey was carried out to assess the views of nursing staff at a
single hospital on the clinical pharmacy services then provided. Questionnaires were sent to 32
wards and were completed anonymously. The response rate varied for individual questions.
Nursing staff ranked the provision of drug information very highly but the provision of
education for nurses less highly (response rate 44%) although they felt that the pharmacist
could contribute usefully to nurse education in nursing school and on the wards. Of the 48%
that responded to a question on patient counselling, most thought that the responsibility for
discharge counselling rested with nursing staff (65%) rather than pharmacy staff (35%). In
reply to a question on drug information (response rate 44%), nurses would readily contact
pharmacy staff for infonnation on names of drugs (54%), available strengths (79%), dose
(89%), storage requirements (68%), physical incompatibilities (54%), intravenous fluids
(68%), side effects (61%), contraindications (57%), drug identification (61 %), interactions
(75%) and causes of allergic reactions (79%). Most of the 45% that replied to a question on
the benefits of having pharmacists on the wards ranked the ward pharmacy service as being
important to them.
142. Stevens MJ. How nurses view the pharmacist's role. Br J Pharmaceutical Practice 1986;8:203-
7.
Descriptive study:
This paper reported the results of 52(57% response rate) self-completed questionnaires sent to
student and qualified nursing staff on 8 wards in a single general hospital. Most thought that
the supply of drug information (44/52), and costing data (30/52) was essential or important but
few thought that the attendance on consultant ward rounds was important (7/52). Sixty one
percent thought that ward pharmacy visits were important but nurses often did not seem to
understand the reasons for these visits. Drug seminars were thought to be interesting and of
value (42/52). Many nurses thought that pharmacy staff should be involved in reconstituting
injections (10) or making intravenous additions (11); fewer though that they should counsel
patients or identify adverse drug reactions (8) and none thought that they should take
medication histories.
143. Leach RH, Feetam C and Butler D. An evaluation of a ward pharmacy service. J Clin Hosp
Pharm 1981;6:173-82.
Objective:
To make an initial assessment of the value to patient care of a ward pharmacy service.
Method:
(i) This was a retrospective survey of a random sample of prescriptions from six wards in one
general hospital for prescribing errors for 3 months before and the first 3 months after the
introduction of a ward pharmacy service. Errors were defined as any of the following:
incompleteness, incorrectness or ambiguity of a prescription item or its clinically significant
incompatibility with another item. Annotations made by the ward pharmacist (in instances
where errors had been detected) were excluded. The Chi-squared test was applied on the total
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number of errors made in each phase.
(ii) A prospective survey was performed of the contribution made by three ward
pharmacists. Personal records were made of the activities carried out by three ward
pharmacists on 13 medical and 5 surgical wards over three months. Pharmacists noted any
drug related problem that they detected, their action, the result and any questions asked by
ward staff.
(iii) A questionnaire survey of medical and nursing staffs' opinions on the value of the
service was carried out. One hundred and fifty self-completed questionnaires were sent, 6 to
each of 25 wards. All registrars, house officers, sisters and staff nurses received them.
Results:
(i) Three hundred and fifteen drug charts (2000 prescriptions) were recalled in each time
period. The mean error per patient fell from 2.04 to 1.10 (46.1% reduction) and the mean
error per prescription fell from 0.3 to 0.7 (43.3% reduction). The reductions in 6 categories of
error (name, route, frequency, signature, data, other) were significant (p <0.05) but those on 3
(dose, controlled drug requirements and interactions) were not. Errors were judged by
pharmacists to be dangerous rarely but would cause confusion for nurses. Ward pharmacists
failed to detect 50% of errors.
(ii) Seventy five problems requiring pharmacist action were detected. Most prescriptions
were altered on the pharmacists' request. Fifty eight questions were asked of pharmacists
mainly by junior doctors, nurses and paramedical personnel. Most were on the following topics
- clinical use, dose, "what is.. and interactions.
(iii) There was a 46% response rate to the questionnaires with a preponderance of replies
from medical wards. According to staff nurses the most important functions of the ward
pharmacist were: endorsing prescriptions with the approved name and supplying non-stock
items, and checking that prescriptions were clear and unambiguous and that the dose was
acceptable. According to ward sisters that most important functions of the ward pharmacist
were promoting the most effective use of drugs, discussing problems of drug therapy,
endorsing prescriptions with the approved name and supplying non-stock items. According to
house officers the most important functions of the ward pharmacist were discussing problems
of drug therapy, providing drug information, checking the dose was acceptable and promoting
the safe use of drugs. According to registrars the most important functions of the ward
pharmacist were providing drug information, detecting drug interactions, checking the dose was
acceptable and promoting the safe use of drugs.
Assessment (strength, size of effect, generalisability:
The main problems with the study are related to potential bias (pharmacists self-recording and
assessing their activities with no independent assessment, low survey response rate) and
confounding (possible non-comparability of time periods). Process was assessed in phases I and
II and perceptions in the third. Output and outcome were not addressed. The size of the effect
was large (50% reduction in error) but study design problems and lack of generalisability
(single site study using three pharmacists) limit its usefulness.
144. Gately J. An evaluation of a clinical/ward pharmacy service. Does the patient benefit?
(abstract) UKCPA Residential Symposium. Bournemouth, 1988:9-10.
Descriptive study:
This described a survey of the interventions made by pharmacists in a single 715 bed hospital
and a pharmacy assessment of these for the potential risks to patients if the intervention had not
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been made. The duration of the study was unclear. Intervention rates ranged from 0.1-0.6 per
patient per visit (37 wards). Eighty one percent were pharmacist initiated. Forty eight percent
resulted in a prescription change. Fifteen percent concerned economic issues and 16% drug
choice. The mean total risk factor (scale of 0 (none)-10 (high risk)) was 2.7.
145. Forbes DR. Can ward pharmacy be cost effective? Br J Pharmaceutical Practice 1981 ;3(5):29-
33.
Objective:
To determine whether a visiting ward phannacy service could be economically justified.
Methods:
This was a prospective before/after costing survey of prescriptions dispensed to 7 surgical
wards at one general hospital. Costs included were pharmacists' time (dispensing and visiting
wards) and nurses' time (travel to and from phannacy collecting medicines).
Results:
The time taken to dispense items fell as did nursing time in visiting the pharmacy. Total
pharmacy costs rose, from £129.72 in July to £235.15 in November, but dispensing costs fell,
from £129.72 to £96.75. Nursing costs fell from £97.80 to £29.56 in this period. Patient
throughput and length of stay data, and prescription numbers, were provided but were not used
fully in the analysis.
Assessment of study: (strength, size of effect, generalisability)
This purported to be an economic analysis but inadequate data were provided on costing
methods to enable assessment of their appropriateness or accuracy, and incremental and
sensitivity analyses were absent. The study also failed to utilise workload data to enable the
reader to judge if the service was economically viable. Judgements based on the crude figures
presented may be flawed due to confounding. The researcher considered the figures in light of
the number of prescriptions dispensed. This indicated that the total cost per item prescription
rose from 41 to 63 pence. Bias due to pharmacists analysing their own service may be a
problem.
146. Wilison A. A new approach to prescription monitoring by ward pharmacists. Pharm J
1983;230:78-80.
Descriptive study:
This paper described the effect on prescription interventions of placing pharmacists on
consultant ward rounds. For every 10 medical beds in a 20 week period the time spent by
pharmacists on the ward round was 160 hours. This compared to 17 hours for ward
pharmacists who did not attend ward rounds: The number of interventions on ward rounds was
320 (compared to 31 for ward pharmacists who did not attend ward rounds) and the number of
information requests was 160 (compared to 43 for ward pharmacists who did not attend ward
rounds).
147. Fahey M, Oaldey PA and Sims K. Prescription monitoring and the oncology patient. Pharm J
1984;233:483-5.
Descriptive study:
l'his paper described the activities of a ward pharmacist on an oncology ward at one London
hospital.
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148.	 Gilles D. Prescribing review in a large mental illness hospital. Pharm J l985;235:623-4.
Descriptive study:
This paper described prescription anomalies detected by pharmacists on 41 wards in a large
mental illness hospital over a 6 and an 18 month period. Anomalies were categorised as
follows: clarification required, cancellation suggested, treatment review recommended, drug
interaction noted and drug level monitoring indicated. Medical staff acted on pharmacists'
advice in 65% of instances in the first 6 months increasing to over 95% in the 18 month
period. The number of anomalies per 6 months increased despite a reduction in inmate
population but no data were supplied to facilitate the making of comparisons over time periods.
149. Swallow RD, St C Remington H and Standing VF. Ward pharmacy: A positive contribution to
cost control? Pharm J 1985;235:722-3.
Descriptive study:
This paper described the effect on drug expenditure over 28 months and on doctors'
compliance with the formulary in one year in a single general hospital. Drug expenditure was
related to drug budget allocation. The authors suggested that the transformation of a £100,000
overspend into a £70,000 underspend (approximate) was due to creation of a hospital formulary
which was implemented via the ward pharmacy system, training of ward pharmacists,
evaluation of drug expenditure in specialties and the creation of a procedure for the
introduction of new drugs. There was high (100%) compliance with the formulary in most drug
groups. The authors provided no information on potential confounding factors.
150. Hawkey CJ, Hodgson 5, Norman A, Daneshmend TK and Garner ST. Effect of reactive
pharmacy intervention on quality of hospital prescribing. Br Med J 1990;300:986-90.
Objective:
To evaluate the medical impact of reactive pharmacy intervention.
Methods:
This was an analysis of the interventions made by 35 pharmacists at six hospitals over 28 days.
Intervention data, collected prospectively from prescription monitoring activities, included
characterisation of pharmacists' perceptions of prescription inadequacies, outcomes, time taken
and grades of prescnbers. These interventions were analyzed for their potential for preventing
medical harm by one doctor. The hospitals represented 2530 mainly acute, 781 mental illness,
and 633 mainly care of the elderly beds.
Results:
Of the 781 interventions made (2.9% of all prescriptions), 60 were on prescriptions with major
potential for medical harm. Wrong dose (280), dose not stated (50) and prescriptions of excess
duration for antibiotics (48) were the commonest problems. The pharmacists interventions were
accepted in 639 (86%) cases; in 571 the prescription was changed leading to an appreciable
(246) or minor (231) improvement in care. Pharmacists interventions rarely saved money; 130
interventions resulted in a saving of less than 50 pence and 427 had no effect. Interventions
occupied an average of 41 minutes/pharmacist /week.
Assessment of study: (strength, size of effect, generailsabiity)
The size of the effect was relatively small although an assessment by a jury of one doctor, even
though the level of the agreement was tested with another doctor, must be open to potential
invalidity and bias. Bias due to the collection of data by pharmacists was also a possibility; no
account was taken of the effect of not having pharmacists monitoring prescriptions (lack of
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controls). Savings were calculated based on drug costs alone and other potential savings, suLh
as the avoided costs of litigation or the nursing or phannacy time saved because prescription
problems were solved in advance, were ignored. The costs of phannacists' time providing the
service were not measured.
151. Batty R and Barber N. Ward pharmacy: a foundation for prescribing audit? Quality in Health
Care 1991;1:5-9.
Descriptive study:
This survey was carried out iii one English region (31 acute hospitals with 10337 beds) over
seven days. Two hundred and ten pharmacists identified 2706 questionable prescriptions
(83%). Other pharmacy staff identified 137 whilst nurses, doctors and other health care staff
initiated a small number of inquires. The intervention rates varied depending on the hospital
and on the nature of the ward. Pharmacists advised doctors regarding prescriptions on 2095
occasions and this advice was accepted in 96% of instances; in 77% of cases the prescription
was altered. The resolution of inquires took approximately 5 minutes per prescription. This
was the largest survey of this type ever carried out in the UK.
152. Hubbard CN and Alder G. Interventions during prescription checking on ward rounds. Phann
J 1992;248:162-3.
Descriptive study:
l'his paper described the number, nature and outcome of interventions made by 6 clinical
pharmacists in a single general hospital over six weeks. Pharmacists recorded 351 interventions
(3.3% intervention rate). A senior clinical pharmacist assessed 199 (57%) of these as being of
major or moderate benefit to patients. Intervention rates varied depending on the pharmacist
and the nature of the ward. Pharmacy advice was followed in 78% of cases.
153. Maguiness JA, MacFadyen E and Coote JC. Routine discharge prescription monitoring by
clinical pharmacists. Pharm J 1992;248:294-5.
Objective:
To determine the types of intervention that are necessary before a discharge prescription can be
dispensed and to assess the impact that the clinical pharmacist can make through the routine
monitoring of discharge prescriptions.
Methods:
This was a prospective survey comparing the number and types of interventions made by
dispensary staff in a single hospital in two ten week periods before and after the institution of
ward pharmacist monitoring of discharge prescriptions.
Results:
Monitoring of discharge prescriptions by ward pharmacists reduced the proportion of
prescription queries made by dispensary staff from 21% (80/384) to 4.8% (19/394). Ward
pharmacists intervened on 21.6% of prescriptions; 34% of these interventions would probably
not have been made by dispensary staff hence the authors claimed that the use of ward
pharmacists resulted in better care for patients. Ward pharmacists interventions differed from
those made by dispensary staff and included discontinuation of unnecessary medications, re-
institution of omitted medications and improved prescribing of antibiotics. Although savings on
dispensary staff time and the expenditure in ward pharmacists time were measured crudely, the
authors claimed that an overall reduction was seen in the time used querying prescriptions
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(from 7 to 6.5 hours). Money saved on drug costs was similar in both phases (f61 versus £54).
Assessment of study: (strength, size of effect, generailsability)
The size of the effect on overall staff time was small. All costs and consequences were not
measured and bias due to self-recording may be present. Workload was comparable in the two
10 week study periods. The results are not generalisable.
154. Barber PA. Intervention monitoring project at Nottingham City Hospital. Hospital Pharmacy
Practice 1992;2:353-7.
Objective:
To demonstrate the effect of clinical pharmacy by reporting interventions made by pharmacists
and technicians at a single general hospital over 5 months.
Methods:
Interventions made by pharmacists or technicians, or as a result of other staff asking questions,
were self-recorded and subjectively scored as to their effect. The opinion of a consultant
physician was sought on a random sample of these interventions.
Results:
Of the 1585 interventions that were recorded, 62.5% were made during ward pharmacy and
33.7% in the dispensary. Pharmacy staff initiated most interventions (87.1 %). The majority of
interventions were made on dose (19%) or duration (18%) of therapy. Eight one percent of
interventions resulted in a prescription alteration (only 1.4% were rejected) although few were
thought to be life saving (0.5%) or having prevented serious toxicity (3.7%); many optimised
patient care (24.7%) or improved the standards of practice (32.8%).
Assessment of study: (strength, size of effect, generalisability)
The size of the effect was moderate. Study design problems included potential bias
(,phannacists collected intervention data and scored most of their own interventions). The use of
the doctors as assessors lent some credibility to the results but the lack of a control group
prevented comparisons with the no-pharmacist scenario. The results are not generalisable.
155. Eadon H. Assessing the quality of ward pharmacists' interventions. mt i Pharm Pract
1992; 1:145-7.
Objective:
To identify the quality of interventions made by pharmacists.
Methods:
This was a prospective survey and assessment of all interventions made by ward pharmacists at
a single hospital over one year. Their impact on patient care was assessed by a senior clinical
pharmacists using an American scoring system. Three physicians independently assessed a
random sample of 25 interventions. Pharmacist and doctor scoring agreed well.
Results:
Of the 1315 interventions that were assessed, 695 (53%) were considered to have improved
patient care and 28(2%) were thought to have had a very significant effect on outcome.
Assessment of study: (strength, size of effect, generailsability)
The size of the effect was moderate. Data collection was open to bias despite the inclusion of
all interventions (accepted and rejected). Close agreement between physician and pharmacist
assessment of 25 interventions lends credibility to the data and strengthens the assertion that
pharmacists contribute to patient care. The results are not generalisable.
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156. HaIl AD and Jackson M. Clinical pharmacy - can it be quantified. Proceedings of the Guild
1983; 16:50-6.
Descriptive study:
The authors described the results of a pilot study carried out at a single hospital. The study
compared the activities of a staff pharmacists providing a purely ward pharmacy service to
three wards over 7 months with those of a similarly-experienced pharmacist providing a fuller
service (clinical pharmacy) to six wards over the subsequent 4 months. The wards served were
different in each phase. All interventions made by these pharmacists and the result of the
interventions were self-recorded. One hundred and twenty three problems were identified by
the ward pharmacy service out of 5674 prescriptions viewed. The intervention rate varied for
the three wards from 1.5 to 3.5% (average 2%). Over the 118 days of service provision in the
initial 7 month period, 120 hours were spent on ward phannacy. Thirty seven percent of
interventions were classified by the pharmacist as having a cost benefit, 20% as having a
clinical benefit and 26% as having avoided an unnecessary hazard. Three hundred and fifteen
problems were identified from 3136 prescriptions by the clinical pharmacy service. The
intervention rate varied from 6.3 to 14.3% (average 10%) depending on the ward. Over the 64
days of service provision in the subsequent 4 month period, 300 hours were spent on clinical
pharmacy. A similar proportion of interventions were classified by the pharmacist as having
had a cost benefit (23-39% depending on the ward) in this phase but a higher proportion had a
clinical benefit (42-56% depending on the ward) and avoided an unnecessary hazard (23-38%
depending on the ward). Three quarters of interventions made during provision of clinical
pharmacy services were acknowledged by medical staff and in 58% of cases it led to a change
in prescription. The number of interventions per hour was similar for ward and clinical
services and the authors claimed that the services were equally efficient.
157. Leach RH and Leach SJ. Drug and therapeutics committees in the United Kingdom in 1992.
Pharm J 1994;253:61-3.
Descriptive study:
Senior pharmacy managers in the United Kingdom (District Pharmaceutical Officers or Chief
Administrative Pharmaceutical Officers) were surveyed by mail questionnaire to elicit
information on drug and therapeutic committee (DTC) activities, to establish benchmarks for
effectiveness and to evaluate changes induced by the National Health Service reforms. Replies
were received from 162 sites (which was thought to represent 81% of the estimated 200 DTCs
in operation). The average DTC was multidisciplinary and had 12 members (range 4-26). Most
(83%) DTCs had a GP representative and some had a Family Health Service Authority
representative, usually a medical (34%) or pharmaceutical (28%) advisor. Respondents judged
their DTC to be very effective or effective in 40% of cases. Most DTCs gave preference to
hospital needs (63%) rather than to those of primary care (38%). The DTC produced a
formulary in 156 cases. Many DTCs took an active role in formulary management by
investigating the extent of compliance with the formulary and applying peer pressure where
appropriate (n=83). In addition, those requesting the inclusion of drugs in the formulary were
asked to submit a written application for new additions (n=80), attend DTC meetings to
present their case for new additions (n=2), or both (n=12). Pharmacy sometimes (25 cases)
helped inform the process of monitoring compliance by feeding back prescribing details to the
prescribers. Although many (59%) thought that the DTC would have a role lasting for the next
10 years, some thought that several issues were now more appropriately addressed at the
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directorate level. It was also thought that whilst hospital budgets remained cash-limited there
would be few changes in the operation of DTCs to increase their involvement in priniary care
issues.
158. Josh MP, Williams A and Petrie JC. Hospital formularies in 1993; Where, why and how?
Pharm J 1994;253:63-6.
Descriptive study:
l'his study provided an overall perspective on the management of hospital formularies in the
United Kingdom. Questionnaires were sent to all hospitals containing in excess of 500 beds. A
response rate of 89% (66/74) was obtained. Sixty hospitals had a formulary and 57
implemented it. Only two were joint hospital-general practice formularies. Formulary content
varied; 17 contained costs and 40 contained prescribing information. The formulary was
overseen by a drug and therapeutics committee in most cases (42). At 33 hospitals, compliance
was compulsory for junior doctors. At 26 compliance was compulsory, and at 17 voluntary,
for junior and senior doctors. Fifty two hospitals allowed generic substitution and 15 allowed
therapeutic substitution of drugs. In 32 cases, the formulary was revised yearly. Thirty one
respondents indicated that prescribers' attitudes to the formulary were supportive and a further
24 said that prescribers were mildly supportive. Thirty two said that compliance was very good
or excellent.
159. Turner P. Local formularies and good patient care (editorial). Br Med J 1984;288:348.
Editorial:
The author claimed, based on opinion and crude costings, that formularies contributed to
economic and improved use of drugs and improved patient care.
160. Merton & Sutton Health Authority/CASPE Research. The effect on drug prescribing of
introducing a formulary and information service to clinicians. St Helier Hospital 1980-3.
London: CASPE research, King Edward's Hospital Fund, 1984.
Objectives:
To assess the effect of the introduction of a formulary on drug expenditure in a district (one
hospital).
Method:
Stockholding, drug expenditure and compliance with the formulary were measured
prospectively over three years. Pharmacists examined the effects of the formulary on 10%
samples of prescriptions.
Results:
The number of items stocked fell by 23% and the value of stocks held fell by £24,864 (1984
prices). Fonnulary compliance was 96%. The formulary did not, however, decrease overall
drug expenditure. In these calculations the authors had taken patient throughput, drug volume
and price changes into account. The reasons given for the lack of discernable effect were the
lack of implementation of, and pharmacy control over, the formulary. The formulary was
simply a list of the drugs used in the hospital and it had been created by the doctors.
Assessment (size of effect, design, generailsability):
The size of the effect was small but this may be due to poor implementation and lack of
pharmacy involvement. No data on case mix were provided hence there was potential for
confounding. The results are not generalisable.
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161. Crooks J. Drug epidemiology and clinical pharmacology: their contribution to patient care. Br
J Clin Pharmacol 1983;16:351-7.
Descriptive study:
This paper described the experience of introducing a formulary in one hospital in Aberdeen.
Drug expenditure fell by 15% on medical wards in the first year. The author suggested that the
drug information service that supported the formulary would contribute to the continuing
education of prescribers.
162. Collier J and Foster J. Management of a restricted drugs policy in hospital: The first five
years' experience. Lancet 1985;i:331-3.
Descriptive study:
This paper described the activities of the Drug and Therapeutics Committee whilst introducing
a formulary. The authors showed that, whilst national drug expenditure in UK hospitals
increased by 12% per annum in 1982-4, it increased by 9, 4 and 0% in a health district with a
prescribing list. These data did not account for changes in case mix but, because activity
remained similar in the hospital, they suggested a positive effect on the control of expenditure.
163. Baker JA, Lant AF and Sutters CA. Seventeen years experience of a voluntarily based drug
rationalisation program in hospital. Br Med J 1988;297;456-9.
Descriptive study:
This paper described the methods used in one English District, since 1970, to control rising
expenditure on medicines. Their most successful system was a fonnulary with an educational
component supported by educational bulletins plus facilitative consultation with prescnbers.
The facilitative consultations occurred on a one-to-one level for individual prescriptions and at
a more formal level using a formulary group acting in collaboration with the Drug &
Therapeutics Committee and a drugs committee. Compliance with the 700 item fonnulary, as
assessed by audit, was in excess of 99% and drug expenditure fell by £0.8-1.0 million per
annum following its introduction despite the number of prescribers and patients being treated
remaining virtually static. In practice, this meant that expenditure had stabilised compared with
rises of 10-15% per annum previous to that and an average yearly increase of 3% in other
hospitals. This study suggested that drug expenditure in a group of hospitals was successfully
controlled or decreased (after adjustment for inflation) as a result of implementation of this
system. It failed, however, to provide information on possible confounders (such as changes in
case mix).
164. Hampson J, Orme M, Bartzokas CA, Grimmer SFM and Smith J. Doctors, drugs and the
DHSS (letter) Br Med J 1984;289:l692.
Descriptive study:
Use of an antibiotic and general prescribing policy at a single general hospital in Liverpool
reduced expenditure by 2.6% in one year in contrast to normal increases of 10-15%.
Subjectively, there had been no reduction in quality of care. Savings of £9,600 on
metronidazole had financed the salary costs of a pharmacist to promote the formulary.
Compliance, as assessed by a survey of prescriptions, was 78% in the first year rising to 80%
in the next year. The policy-makers deliberately avoided choosing cheap drugs and applying the
policy in a heavy-handed way.
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165. Lewis AM and Rushworth P. The development of a drug formulary system in a non-teaching
district linked with computerised drug use reporting. Pharm J 1989;243:HS32-4.
Descriptive study:
This paper described the development of a formulary and its effectiveness in reducing the cost
per case of drugs in a district general hospital between the years 1983/4 and 1987/8. The
formulary was revised extensively in 1987, made more user friendly and enforced more
thoroughly by pharmacy staff. Compared with 1983/4, compliance increased from 64 to 83%
and drug expenditure per case (adjusted for inflation) decreased from £37.75 to £35.44. No
information was provided on case mix hence confounding remained an issue. The results,
however, suggested that the formulary had exerted a positive effect on expenditure.
166. Kopelman PG, Wiggins HK and Littlejohns DW. Practical benefits achieved by a district
diabetic prescribing policy. J Royal Coil Physicians 1989;23:248-50.
Descriptive study:
This paper described the institution of a district-wide prescribing policy for diabetics. It was
created in co-operation with general practitioners and staff at two hospitals. The authors
claimed that the policy was well-accepted. They claimed also that the care of diabetics was not
compromised as evidenced by no admissions due to the loss of diabetic control caused by
changes in therapy. No data were presented to support this statement, however. There was a
reduction in expenditure on diabetic drugs. The number of bottles of insulin purchased fell
from about 60,000 to 20,000 in each hospital and a change to a single brand reduced the price
per bottle by 25%. Savings were also made on oral hypoglysaemics (about £3,500 per annum).
The type of diagnostic reagent strips purchased changed to an increased use of blood test strips
and there was a perception, amongst diabetic nurses, that patient education had improved.
167. Sutters CA. The management of a hospital formulary. J Clin Pharm Ther 1990;15:59-76.
Descriptive study:
This study described the key features of the successful management of hospital formularies.
These included a strong, medically-led drug and therapeutics committee (DTC) with enough
resources to operate interdisciplinary policies satisfactory. This DTC should have a good
working relationship with the ethics committee and maintain an awareness of current trials. The
paper also discussed the mode of operation of DTCs, the preparation, implementation and
updating of a formulary, and its integration into pharmacy management systems. It provided
data on compliance with the Riverside East formulary. The drug savings were similar to those
presented by Baker at al (1988) for the same hospital.
168. Carvey G, Jappy B, Stewart D, Williams A, Duffus PRS, Maitland JM, Valentine MJ,
Wedderburn S, Webster J and Petrie JC. Grampian Health Board's joint drug formulary. Br
Med J 1990;301:851-2.
Descriptive study:
This paper reported on the feasibility of creating a joint hospital-general practice formulary for
ulcer healing drugs in a Scottish health board. The opinions of general practitioners and
hospital doctors on the drug that should be selected from a choice of 11 drugs coincided very
well. Although the drugs selected varied widely in price between hospital and primary care, the
authors believed that agreement on prescribing will improve care and facilitate the provision of
seamless care.
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169. Wolfson DJ. The contribution which can be made by a pharmacist in the formulation,
acceptance, monitoring and success of an area-wide antibiotics policy. Proceedings of the Guild
1982; 12:3-10.
Descriptive study:
This study described a reduction in expenditure on antibiotics, as a proportion of total drug
expenditure, from 21.6% to 16.1% as a result of the introduction of an area-wide antibiotic
policy. A survey of local doctors (44% response rate) showed that few referred to the policy
daily (2.3%) or weekly (9.1%); many felt it was some (27.3%) or a significant (11.4%)
infringement on their prescribing freedom. Only 25% felt it was helpful but 36.4% found it no
hinderance (This study is also described in Wolfson DJ and Williamson PM, 1981).
170. Petrie JC and Scott AK. Drug formularies in hospitals (editorial). Br Med J 1987;294:919-20.
Editorial:
The authors described the usefulness of formularies in helping control drug expenditure,
educating prescribers and improving the prescribing process. It referred to a survey carried out
by another investigator (Ridley H, 1986).
171. Hey R, Wareham J and Goldberg LA. An investigation into the use of the local formulary in
Stockport AHA. Br J Pharmaceutical Practice 1982;4(7):7-10.
Descriptive study:
The authors described the setting up and activities of a multidisciplinary drug and therapeutics
committee, including the creation of a formulary. A review of prescribing 6 months after the
formulary was introduced showed that over a three month period there were 256 instances of
non-formulary prescribing for in-patients. In 56 instances formulary alternatives were used but
for 203 a non-formulary drug was used, mainly because patients had been admitted on the drug
(112, 55%) or a consultant authorised its use (49, 24%). A study of out-patient prescribing
over a one week period showed that 23 (4.4%) of the 510 items that were prescribed were
non-formulary. Only one item was altered to a formulary alternative. In 17.3% of instances
there was no alternative in the formulary.
172. Hampson JP, Corkill JE, Murray A, Griffiths LR, Smith JC and Bartzokas CA. Potential
financial benefits of a local antibiotics policy. Pharm J 1988;241:660-2.
Descriptive study:
This survey calculated, retrospectively, that the potential savings in a single hospital would
have been £106,000 per annum if prescribers had adhered to the antibiotic policy. Five months
data were used to calculate this figure. The actual savings that were made were lower.
173. Lacey RW. Hospital antibiotics policy in a health district. Br Med J 1979;1:1389.
Descriptive study:
The authors claimed that the use of an antibiotic prescribing policy reduced expenditure on
antibiotics from £16,431 in 1974/5 to £10,448 (adjusted for inflation) in 1977/8. Spending on
other drugs increased from £74,331 in 1974/5 to £84,926 (adjusted for inflation) in 1977/8.
Antibiotic resistance patterns, examined in the second year, showed no problems.
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174. Cooke J, Calvert RT and Lacey RW. Antibiotic prescribing (letter). Pharm J 1984;233:707-8.
Descriptive study:
The letter referred to an abstract published in the same journal volume (page 423) that
described the development of an antibiotic prescribing policy in a single general hospital. Its
purpose was to improve the cost-effective use of antimicrobials and to reduce the incidence of
resistance. The policy was created in consultation with the drug and appliances committee,
consultants and the microbiology department. In the letter, the authors claimed that the policy
reduced expenditure on antibiotics by 15% over one year (3O,000).
175. Cooke I. Antibiotic policies. Proceedings of the Guild 1990;28: 17-27.
Descriptive study:
This paper described a strategic approach to the use of antimicrobial in a single general
hospital. Pharmacists consulted with prescnbers to create a booklet with a list of preferred
antimicrobial and information on their selection and use. Pharmacists also advised on the use of
antimicrobials and encouraged selective reporting of sensitivities. Pharmacists educated those
involved with antimicrobial use through workshops, seminars and updating sessions, and liaised
with the purchasing pharmacist regarding actual usage of these agents. A retrospective audit
revealed that the incidence of wound infections after gastro-biliary surgery decreased from 8.9
to 8.7% following the introduction of the formulary. The proportion of the drug budget spent
on antimicrobial also fell from 19.8 to 13.3% with annual savings of around £120,000.
Although the results suggested an effect, the quasi experimental nature of audit and the lack of
information on possible confounders hampered the acquisition of proof of an effect.
176. Scholfield 1K, Oberoi DK and Savage A. The development of a dermatology pharmacy
counselling service and prescribing list. Pharm J 1990;245:364-6.
Descriptive study:
This study described how the pharmacy and dermatology departments aimed to improve patient
compliance by developing a pharmacy counselling service. An list of dermatological products
was created also to rationalise stocks and reduce costs. The list became part of the district
formulary. There was a reduction in total drug expenditure on dermatological products for out-
patients from £8250 to £5400 for the same three months period in consecutive years before and
after the adoption of the list. This occurred despite an increase in the numbers of patients that
were seen in the same time period from 1720 to 2057. Patient type remained largely
comparable. Patients' satisfaction with the counselling was not assessed (Personal
communication, Scholfield 1993) and the lack of data on patient and prescribing factors leaves
the result open to potential confounding.
177. Riley MR and Cooke J. The planning, implementation and outcome of a change in intravenous
nitrate prescribing strategy. hit J Pharm Pract 1991;1:30-3.
Objective:
To describe the methods used to effect a change in intravenous nitrate prescribing at a large
general hospital.
Methods:
The costs of drugs and administration devices was measured before and after a change in
nitrate prescribing policy. The study compared actual spending with projected figures had the
policy not been implemented.
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Results:
Compared with the expected spending on nitrates (isosorbide dinitrate), a change to glyceryl
trinitrate (GTN) reduced expenditure by £24,000 in 1988/9 and £21,000 in 1989/90.
Assessment of study: (strength, size of effect, generalisability
The projections were based on the use of drugs in previous years. The size of the effect was
large. The authors assumed that prescribing would have remained unchanged without the policy
and failed to measure accurately all the costs and consequences of the change in policy. No
data were presented on issues that may have affected prescribing such as patient, physician or
other factors. No sensitivity analyses were performed. As a cost minimisation type analysis, it
was incomplete and the results are open to confounding. The results are not generalisable.
178. Goodyer LI, Fahey M and Tristram J. Audit of a laxative policy for elderly patients. mt J
Phann Pract 1992;1:238-9.
Objective:
The authors described the creation and subsequent audit of a laxative policy for elderly care
patients at a single general hospital.
Methods:
This was a prospective audit of all prescription charts on care of the elderly wards was carried
Out on a single day two weeks before and 2,4 and 8 weeks after the introduction of a laxative
prescribing policy. Differences in prescribing patterns were assessed.
Results:
Sixty four charts were reviewed in the before phase, 57 at 2 weeks, 59 at 4 weeks and 46 at
eight weeks. There was a trend, over time, towards conformity with the prescribing policy; for
some drugs this was statistically significant (lactulose, senna and co-danthrusate). Patients were
broadly comparable and the change in prescribing persisted for up to one year (Personal
conunuitication: L Goodyer, 1993).
Assessment of study: (strength, size of effect, generalisability
The size of the effect was large but the results are not generalisable. In addition, the lack of
data on patient comparability leaves the results open to confounding. The lack of outcome data
(financial or patient care) makes the study purely process orientated.
179. Patel K. A policy for rationalising laxative use and expenditure. Pharm I 1993;250:185-6.
Objective:
To report on the development of a policy to promote safe and effective prescribing of
laxatives.
Methods:
This was a prospective, before after, survey that assessed the effects of a laxative policy,
drawn up in consultation with doctors and nurses, on spending on laxatives in a single hospital.
Results:
Implementation of the laxatives policy produced savings of £11,000 in the first year. This
reduced expenditure was maintained in the second year. No adverse effects were noted.
Assessment of study: (strength, size of effect, generalisability
A large (50% reduction) effect was seen but lack of data on patient comparability and
throughput, and contamination of the results (j)olicy introduced in some wards in the before
period), make it difficult to estimate the true effect. The results are not generalisable.
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180. Morgan DJR, Sutters CA and Pugh S. Medical audit and fomulary management; a policy for
rational use for thrombolytic drugs. Postgrad Med J 1991;67:165-9.
Descriptive study:
This paper reported on the development, introduction and maintenance of a policy to promote
the rational use of thrombolytic by doctors in two hospitals in a London district. A
multidisciplinary task force suggested and implemented guidelines for the use of thrombolytics
taking current practice, and the results of a literature and drug use review, into account.
Implementation involved education of doctors and other staff via meetings and bulletins. A
retrospective audit of drug use suggested that this method ensured 100% adherence with the
policy. This 14 month study was not designed to be an evaluation but the data presented
showed that the use of streptokinase more or less mirrored the number of patients with acute
myocardial infarction and the amount of rt-PA used remained low during the study. The
authors estimated that the policy resulted in £27,000 in drug expenditure that was avoided (if
actual expenditure was compared to the use of the most expensive agent for all patients).
181. Upton DR, Taylor JK, Holmes GKT and Poston JW. Effects of withdrawal of co-danthromer
on use of laxatives in a district general hospital. Br Med J 1988;297:1446-7.
Objective:
To assess the changes in the use of laxatives following the withdrawal of co-danthromer in
1987 and the issuing of recommendations, by the drug and therapeutics committee, for
alternatives laxatives that should be used.
Methods:
This was a prospective before/after study of the amount of laxatives used in a district general
hospital. Computer issues indicated the quantity of laxatives that were used. These were
converted to defined daily doses (DDD) following consultation with colleagues. These DDDs
were related to bed occupancy using the number of occupied bed days. Use of laxatives,
expressed as the number of DDDs/100 bed days was compared for the same six months before
and after the policy change.
Results:
A 7% increase in laxative use, from 29.3 to 31.3 DDD/100 bed days, was accompanied by a
65% increase in expenditure on laxatives, from £1986 to £3274, over the 6 months.
Recommendations on prescribing were not followed. The results suggested that formulary
changes could actually increase expenditure (on laxatives) if reinforcing tactics were not used
in addition to the provision of recommendations.
Assessment of study: (strength, size of effect, generalisability)
The study was conducted at a single site so the results are not generalisable. In addition, it
suffers from potential confounding due to absence of data on case mix. Nevertheless, it is
unlikely that changes in patient case mix would have accounted for all the changes in
expenditure given that the DDDs/100 occupied beds was the measure of drug use that was
employed. It is more likely that the cause was the use of some expensive liquid preparations in
place of tablets or dietary fibre products.
182. Lewis C. Laxative prescribing before and after the implementation of treatment guidelines.
Hospital Pharmacy Practice 1991;1:341-4.
Objective:
To assess the effects of a laxative policy created jointly with doctors and nurses on laxative
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prescribing.
Methods:
A prospective before/after study of expenditure on, and prescribing of, laxatives in two
hospitals in a single district health authority. Prescribing was measured for one month before
and after implementation of the policy. Comparability and numbers of patients treated were
assessed.
Results:
Thirty seven percent of patients were prescribed laxatives before and 35% after the
introduction of the policy (65% and 58%, respectively, for geriatric patients) but the average
number of laxatives per patient decreased from 1.41 to 1.25 (1.59 to 1.38, respectively, for
geriatric patients). Prescribing practices changed in line with the policy recommendations and
expenditure was reduced from £1300 to £200 per month. Comparable numbers and types of
patients were treated before and after the study. Expenditure was decreasing before the
guidelines were implemented possibly because those involved in the creation of the guidelines
were aware of their content and altered their usage patterns as a result.
Assessment of study: (strength, size of effect, generailsability)
The effect was large but it is not known if it was sustained. Contamination was a problem as
was potential bias. The absence of data on patient outcome is a drawback. As a result, is only
possible to claim that pharmacy-initiated policies can reduce expenditure on laxatives. The
results are probably generalisable.
183. Wolfson DJ. Financial implications of a set of antibiotic policies. Pharm J 1980;224:706-7.
Descriptive study:
The article described the creation and implementation of an antibiotic prescribing policy. It was
created by pharmacy, doctors and the microbiology department, in an area containing four
hospitals. The number of antibiotics in the formulary fell by 44 on its introduction and there
was a fall of 0.4% in antibiotic expenditure in the year of its introduction compared to a rise of
41.3% in expenditure on other drugs. They estimated that this policy saved £36092 per annum
which corresponded to a 42% reduction in expenditure. This was an uncontrolled study that
made a number of assumptions in the calculations of financial savings.
184. Dobrzanski S. Lawley DI, McDermott I, Selby M and Ausobysky JR. The impact of
guidelines on pen-operative antibiotic administration. J Clin Hosp Pharm 1991; 16:19-24.
Objectives:
To observe current surgical antibiotic prophylaxis, create a policy in this area and evaluate its
effect on the rationality of prescribing and the drug costs.
Method:
The use of peri-operative antibiotics was assessed, using pre-determined appropriateness
criteria, in a single general hospital on patients under the care of two consultants before and
after the introduction of guidelines. Patient outcome and cost factors were measured where
possible.
Results:
The indications for surgery in the 73 patients in the before phase and the 102 in the after phase
were similar. Before the guidelines, 17% of patients received appropriate therapy. The main
problem was failure to administer the drug. After the guidelines were implemented,
appropriateness increased to 60%. Cost/patient decreased from £38.13 to £16.93 due mainly to
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a reduction in the use of questionable therapy. Patient outcomes were not assessed for the
entire study.
Assessment (size of effect, design, generalisability):
The size of the effect was large but there are doubts regarding the methods used in assessing
the appropriateness of the costs. There was a risk of confounding and bias. The results are not
generalisable.
185. Upton DR. Antibiotic use review programmes - The duration of antibiotic therapy in a district
general hospital (conference presentation). Proceedings of the Guild 1989;26:84-7.
Objective:
To investigate the duration of antibiotic therapy in a large general hospital and to assess the
effectiveness of corrective measures.
Methods:
This was a prospective before/after study of antibiotic prescribing. The therapy of 200
consecutive patients (40 medical, 80 surgical and 80 orthopaedic) was examined in each phase.
A drug utilisation review process was used to examine the records and institute the intervention
to correct inappropriate prescribing. The intervention included a requirement for the prescriber
to specify a stop date, usually 5 days from the day of prescribing. Longer periods of therapy
could be specified. Where no date was specified, a pharmacist inserted a five day stop date but
therapy was monitored and the prescriber contacted to remind them of the stop date at least 24
hours before it became effective.
Results:
Patients in both phases were similar in terms of duration of admission (means were 15.8 days
in the before phase and 16.6 days in the after phase), number of antibiotic courses prescribed
and the number of episodes of infection or prophylaxis (244 before and 230 after). The
intervention increased the proportion of therapeutic courses that lasted for under 6 days from
31.7% to 53.8%; for prophylactic courses, the change was from 84.3% to 92.8%. A greater
effect was noted on wards where therapy had been less well-defined.
Assessment of study: (strength, size of effect, generalisability)
Insufficient data were provided on case mix, timing of the study and other potential
confounders. In addition, this study was open to bias due to pharmacists collecting the data.
The effect was moderate but is not generalisable.
186. Hughes J and Daly M. Guidelines for antibiotic prophylaxis prior to elective surgery. A
preliminary assessment. Hospital Pharmacy Practice 1991;1:41-4.
Objective:
To study the potential effectiveness of a guide to the use of prophylactic antibiotics drawn up
by clinicians and drug information pharmacists and to assess the potential savings that could
accrue from strict adherence to the guidelines prior to their formal introduction.
Methods:
The medical records of all patients admitted to three surgical wards in one hospital were
examined over a four week period. Details were obtained on the patient, their antibiotics
regimen, type of operation, stay and antibiotics given on discharge. The antibiotic courses were
determined to be either prophylactic or treatment by reference to the notes. All therapy was
costed and comparisons were made between the actual cost and the potential costs if the
antibiotic prescribing guidelines had been followed.
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Results:
Records of 261 patients were examined. Ninety two patients were monitored for their entire
stay. One hundred and sixty nine patients were lost to follow-up for the following reasons; no
antibiotic prescribed, patient transferred to another ward or antibiotics commenced before the
start of the study or completed after the end of the study. Forty seven patients received
prophylactic antibiotics; 35 went on to receive post-operative antibiotics. Forty five patients
received no prophylaxis; 42 of these received post-operative courses (gynaecological,
orthopaedic and urological surgery). There was a theoretical saving of 60% on the insertion of
prosthesis, 39% on hysterectomies and 89% or 99% for trans-urethral resection of the prostate
(depending on patient's tolerance of the drugs). The authors admitted, based on the
requirements for post-operative antibiotics that they found in their study, that the theoretical
savings that could be achieved were probably in excess of the realistic savings.
Assessment of study: (strength, size of effect, generalisability)
This was not an evaluation.
187. Smith JM. New drug evaluation. Pharm J 1985;235:369-72.
Opinion paper:
The author suggested that new drugs require evaluation before they are brought into general
use and that pharmacists can facilitate this process by evaluating the literature critically.
188. Bateman DN and Smith JM. A policy for laxatives (editorial). Br Med J 1988;297:1420-1.
Editorial:
The authors suggested that formularies and prescribing policies are useful but cannot be
implemented effectively without the support of consultants and ward or clinical pharmacists.
189. Wolfson DJ and Williamson PM. Prescribing restrictions: implications and reactions. DICP
1981; 15:594-7.
Descriptive study:
This paper described a prescribing policy, drawn up by a multidisciplinary committee, that
restricted doctor's freedom to prescribe antibiotics. A survey was carried out 21 months later
to ascertain opinions on the policy. A questionnaire was mailed to 104 hospital doctors. Forty
four usable responses were received, 37% were from surgeons and 57% were from physicians.
Fifty eight percent of the respondents were senior doctors and 36% were junior doctors. Only
2.3% used the policy daily, 6.8% once a week, 15.9% once a month and 47.7% less
frequently than that; 27.3% never used it. The policy was thought to be of most value to junior
doctors and general practitioners. It was felt to be a substantial infringement on the doctor's by
11.4% but no problem usually or at all by most of the rest; 25% saw it a positive contribution
to prescribing. Only 36.4% were in favour of extending the policy.
190. A report of the working party on the addition of drugs to intravenous fluids (Chair, A
Breckenridge). Department of Health and Social Security, HC(76)9. London, HMSO, 1976.
Govenunent Report:
The working party addressed issues concerning the safe preparation of intravenous infusions.
They highlighted the problems of microbial contamination and incompatibilities of the
constituents of intravenous infusions. They stated that those currently involved in intravenous
additions were untrained for the task. In addition, intravenous additions were carried out
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usually in an unsuitable area. They suggested that additions to intravenous fluids were aseptic
procedures that should take place under the supervision of a pharmacist in an appropriately
controlled area.
191. Daly M. Assessment of trainee nurses' perceptions of an intravenous drug administration
policy. Pharm J 1992;248:HS11-14.
Descriptive study:
This was a questionnaire survey, with 18 descriptive scenarios of situations where an
intravenous drug was to be administered. It was used to determine the extent to which nurses
found the intravenous drug policy at a single hospital met their needs. One hundred and sixty
seven trainees completed the questionnaires anonymously. Nurses were unsure often of when
they should refer to the policy document. The percentage of correct answers varied from 8 to
99% The results were used to create a more appropriate policy.
192. Goldberg LA. Drug use review. Br I Pharmaceutical Practice 1988;1O: 129
Opinion paper:
This paper described the process of drug use review. It provided opinions on the applicability
and usefulness of drug use review in informing drug policy in individual hospitals.
193. Griffiths J. Deciding priorities for drug usage review. Pharm J 1989;242:HS38-40.
Opinion paper:
This paper described in detail how drug use review can be applied to the rationalisation of drug
policy for the benefit of patients and institutions.
194. Kaye D. An investigation of the cost of drugs used on individual patients on an acute care of
the elderly ward. Hospital Pharmacy Practice 1991;1:281-5.
Descriptive study:
This paper described a costing system that takes individual patients' drug use and length of stay
into consideration. Used with re-admissions data, the authors expected that the system could
help target drug policy-making efforts, taking the quality of prescribing into account when
creating such policies.
195. Farrar K. Clinical directorates - How are they developing. Pharm I 1993;250:HS4O-41.
Opinion paper:
This paper described the development of clinical directorates and the nature of pharmacy
services provided to them. It indicated that pharmacists can more easily contribute to patient
care and the cost-effective use of medicines via the directorate structure.
196. O'Hare, JDG. The development and function of pharmaceutical services in psychiatric hospital
practice. PhD thesis. Belfast: Queen's University, Belfast 1989.
Descriptive study:
The thesis described the development of pharmaceutical services in a large psychiatric hospital.
Reasons were given for the latency in the development of services to psychiatric hospitals and
comparisons were drawn between psychiatric phannaceutical services in the United States and
Canada and the services in the United Kingdom. The thesis described the initiatives that were
taken to improve pharmaceutical services to the mentally ill at one hospital. The impact of the
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measures that were taken by the pharmaceutical staff to alter the prescribing of solid dose
potassium and iron preparations and the provision of a dedicated drug information service were
described. To alter prescribing habits, a list of recommended alternatives was created and
pharmacists reinforced the guidelines by consulting with prescnbers who ignored them. Over 9
years, a sustained large reduction in the use of the older preparations was seen and a rise in the
use of the recommended products. When the clinical pharmacy service was withdrawn in 1987,
adherence to the policy declined. Although there was a saving of 45% in expenditure on iron
therapy, the recommended potassium supplements were more expensive than the older ones.
The author concluded that it was difficult to assess the cost-effectiveness of the service. He
also ignored the cost of pharmacists' time in providing the service. Any changes in the
numbers and types of patients over time were not measured nor were other potential
confounders. An assessment of the queries that were directed at the drug information
department of the hospital revealed that most came from doctors (46/90) or nurses (39/90).
The effect of the provision of information actively by pharmacy staff was assessed when
certain vitamin preparations were "blacklisted". The provision of prescribing information
resulted in almost complete compliance with the recommended alternative resulting in a saving
of £2960 over the first year. Once again, this ignored potential confounders and the costs of
providing the information. Research undertaken into infection control had suggested a role for
the pharmacist in the psychiatric hospital. The development of a monitoring role for the
pharmacist and a novel system for maintaining therapeutic profiles were described. The
therapeutic profiles were compiled on paper first and then transferred to a spreadsheet since
their maintenance was time-consuming. Profiles were used to help monitor therapy, to help to
adjust stock levels to lower, more appropriate levels, and for teaching and audit purposes. A
section of the thesis considered research into the formulation and administration of alternative
therapy for psychiatric patients. Other areas that were covered included managerial issues, an
investigation into possible reasons for non-compliance (such as patients' inability to use child-
resistant closures), and a brief account of an unsuccessful attempt to develop a pharmacokinetic
service for phenytoin and digoxin. The thesis also considered the impact on therapeutic practice
of changes in pharmacy staff levels.
197. Upton DR, Holmes GKT, Fox PD, Cullen AMS and Poston JW. The long-term value of the
selected list as a method of controlling drug costs in a District General Hospital. Health Trends
1989;21:26-9.
Objective:
To determine the long term effects of the selected list on drug costs for affected drug classes in
a general hospital.
Methods:
Computensed drug use data were employed to measure the use of drugs in three periods of six
month each. These periods were the same six months of the year, before, after and one year
after the limited list was introduced. Costs were adjusted for inflation and for variations in
patient bed days.
Results:
Statistically significant reductions were observed in expenditure on several groups of drugs
namely, anxiolytics, hypnotics and sedatives, antacids, expectorants and mucolytic but not on
vitamins, laxatives, analgesics, and nasal preparations.
Assessment of study: (strength, size of effect, generalisability)
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The effect was fairly large but the results are not generalisable. In addition, there was no
information on variations in case mix over the time periods.
• 198.	 McCabe JC, Henry DA and Lawson DH. Drug information centres: a new role for
pharmacists? Scot Med J 1977;22:147-50.
Descriptive study:
This paper described the setting up and the facilities of the drug information services in
Glasgow. It also gave details on the workload in the first year. Over 85% of queries came
from hospital staff, mainly from pharmacists and doctors. Most questions concerned adverse
effects (21%), drug indications (20%) and availability (18%). The time taken to reply to
queries was less than an hour usually (65%). The centre also provided other services such as a
regular newsletter to update pharmacists on new drugs and other topics of interest.
199. McNulty H. Hospital pharmacy information centres and their role as suppliers of information.
Postgrad Med J 1977;53:556-8.
Descriptive study:
This paper described the development of drug information centres in the United States (USA)
and the United Kingdom (UK). It provided a summary of the services that were then currently
available in the National Health Service and their use. The service existed to inform
prescribing and to support the ward pharmacy service. The information service was especially
necessary given the rapid expansion in the numbers, and increasing complexity, of medicines
available. At the time, there were special information posts at regional level in 11 English
regions, in Scotland and one each in Wales and Northern Ireland. The Regional Drug
Information Phannacists' Group was established in 1975 to co-ordinate the services nationally,
especially the abstracting and specialised information services, and to develop a national
network and code of practice.
200. Rogers ML and Barrett CW. The drug information centre at the London Hospital. Pharm J
1972;209:37-9.
Descriptive study:
This paper described the planning, equipment and mode of operation of a drug information
centre at a large general hospital. The centre served to keep pharmacists abreast of current
developments, to answer questions from non-pharmacy health workers, to support the ward
pharmacy service and to compile selected information for distribution to health care
professionals.
201. Savage I. The information dispensers. Pharm J 1991;247:HS17-19.
Descriptive study:
This paper described the work of various drug information pharmacists and centres.
202. Maguire ME and D'Arey PF. Drug information services in four capital cities in the United
Kingdom. A tale of four cities - London (North East Thames), Cardiff, Belfast and Edinburgh.
J Chin Hosp Pharm 1988;13:207-12.
Descriptive report:
l'bis paper described the results of a survey of four drug information centres. Their facilities
included access to several journals and computer databases. Their staff included up to 5
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pharmacists, pre-registration students (2 centres), PhD students (one centre) and clerical
officers. The total cost of centres varied from £35,700 to £67,350 per annum. The
dissemination of information was wide. Published bulletins were distributed to several health
professionals. The centres handled between 1325 (Edinburgh) and 3491 (Cardiff) queries each
in 1985 at a cost per inquiry that varied from £5.36 (London) to £10.80 (Edinburgh). Most
queries were from pharmacists, followed by doctors and nurses.
203. Rodgers ML. Evaluation of some aspects of a drug information service. J Clin Hosp Pharm
1978;3: 189-202.
Descriptive study:
This paper described the North East Thames regional drug information service at the London
Hospital. The author compared and contrasted various models for the provision of drug
information within the region - a single centre, distributed services or a main centre with a
sub-centre network. The last model seemed appropriate but it was decided to measure activity
at the main centre and a sub-centre to inform the debate. A questionnaire was used to gather
information on queries received by the centres. In the study period, June 1975 to May 1976,
during which the main centre had 1.9 whole time equivalent (WTE) pharmacists and 0.8 WTE
students on average and the sub-centre had a pharmacist for 25 hours a week, the main centre
received 1611 queries and the sub-centre 519. In each case about 2/3 came from the base
hospital. A selection of 1456 main centre queries and all sub-centre queries were included in
the analysis. Results were provided on the nature of the queries, the time to answer them, the
proportion that were urgent, the daily distribution of queries, the source of queries and the time
by which answers were required. There were some differences between centres in these
factors. About half of all queries need immediate answers but they took longer to answer at the
sub-centre, probably due to part-time staff cover at the sub-centre. The main centre had a low
level of utilisation; a server would only be working on a query for only 'U) % of their time on
average. The comparable time for the sub-centre would be 15%. The author argued for
centralisation of the service on economic, but not on customer, grounds. He concluded by
recommending that centres should be staffed full-time. From the efficiency viewpoint, formal
services were thought to be best centralised but local representation was considered to be
important for optimal usage in the area served. The local representatives should have some
organisational link to the central service to allow filtering and referral of queries.
204. Maguire ME, D'Arcy PF and Smith AMJ. A decade of drug information experience in
Northern Ireland. J Clin Hosp Pharm 1985;10:297-302.
Descriptive report:
This paper described a drug information service provided at the Royal Victoria Hospital,
Belfast. It received 9,615 queries in the years 1975-84 inclusive, mostly from pharmacists
(46%), doctors (34%) and nurses (12%). The topics of the questions were mainly adverse drug
reactions (10%), availability or supply (18%), pharmaceutical issues (19%) or administration
or dosage (15%). The centre also produced bulletins. The authors described the likely future of
the centre as a source of support for clinical pharmacy and drug and therapeutic committees. It
was proposed that it would funetion within a collaborative relationship with the poisons
information centre.
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205. Brandoii M. A study of the inquiry workload in a regional drug information centre. 3 Cliii
Hosp Pharm 1984;9:127-31.
Descriptive study:
The author described a workload study carried out over 4 weeks (20 work days) at East Anglia
Drug Information Centre (DIC). Pharmacists recorded their activities for 30 minute periods.
During the study, 82 queries were received of which 45 (55%) were urgent. One hundred and
three queries were answered. On average, queries took 1.14 hours to answer. For urgent ones
this was 0.93 hours and for non-urgent queries it was 1.51 hours. Using 6 months of data, 554
queries had been received of which 358 (65%) were classed as urgent.
206. O'Hare JDG, McKee HA and D'Arcy PF. Analysis of drug information queries received by
the pharmacy in a long-stay psychiatric hospital. J Clin Hosp Pharm 1984;9: 139-42.
Descriptive study:
The article described the nature, source and number of queries received at one hospital. Over
10 weeks 90 queries were received. Thirty were on psychiatric drugs and the remainder on
general medical issues. Forty six queries were received from doctors and 38 from nurses. Most
were on drug use (39) or on therapy or therapeutics (28).
207. Morrow NC, D'Arcy PF and Pielou LW. Drug information inquiries - Who asks what and
where are the answers. 3 Clin Hosp Pharm 1984;9:322-31.
Descriptive study:
A survey of the workload of a drug information service over 5 years was reported. The
number of queries received varied from a low of 245 (1978) to a high of 357 (1980). On
average 43.9% emanated from medical staff (29.8% from junior and 12.2% from senior
hospital doctors and 1.9% from general practitioners), 30.6% from hospital pharmacists, 4%
from community pharmacists and 16.3% from nurses. Most queries were on drug
administration and dose (23.9%), choice and adverse reactions (14%), or pharmaceutical
problems (14.6%). To answer 26% of queries a primary reference source was used. The
average number of such sources used for these queries was 2.47. Six months of data were
considered in detail. Forty five percent of queries requiring the use of a primary reference
were from hospital doctors, 38% from pharmacists and 9% from nurses.
208. Adams PR. Evaluation of Welsh Drug Information Services. PhD Thesis. Cardiff: University
of Wales College at Cardiff, 1992.
Objectives:
To investigate how the information supplied by the drug information service in Wales was used
and the effect of information provision on patient outcome.
Method:
A prospective questionnaire survey of hospital and community doctors and pharmacists was
carried out to ascertain their perceptions of the usefulness of replies received to drug
information queries from one Regional and two District drug information centres (DICs) and
the use to which they put this information. The replies were validated using medical notes. In
addition, opinions were obtained from general practitioners (GPs) on their future drug
information requirements.
Results:
Two hundred and sixty three hospital doctors and 191 hospital pharmacists were sent
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questionnaires. The response rates were 89% and 97% respectively. There were few significant
differences in the replies that were given to questions by respondents who would have received
services from the two District and the Regional dnig information centres (DICs). The standard
of service in all three DICs was similar. Overall, for hospital-based respondents, the
information provided by DICs was found to be useful by 94% of respondents. In 66% of
cases, patients' therapy had changed as a result of the information received; usually a new
therapy was commenced. Information was used also to confirm existing therapy was correct or
to discontinue therapy, and for personal or peer education. Information in the medical notes of
a sample (20% approximately) of patients validated the results of the questionnaires. The use of
the information was mentioned directly in fewer than one fifth of medical notes but its use was
implicit in more than four fifths of the notes. Overall, for community-based respondents, 68%
of GPs and 37% of community pharmacists had used the information provided to influence
patient care directly. Four hundred and twenty one GPs in two districts had been asked to
provide opinions on the DIC services. Three quarters of them replied. Few GPs in one district
(23%), and more in the other (53%), had used the DIC. Utilisation of the DIC occurred mainly
as a result of the GPs' perceptions of the level of expertise of DIC pharmacy staff (83 in one
district and 61 % in the other) and personal unfamiliarity with the subject (54 in one district and
47% in the other). Those who never used DICs said that the main reasons were that they never
had a need to (55 and 37%, respectively, in the districts) or that they were unaware of the
existence of the DIC (19 and 39%, respectively, in the districts). Those that had used the DIC
found its services appropriate. Respondents defined various drug information needs that they
felt GPs had, such as the need for reviews of drug therapy for various diseases and for reviews
of new drug products.
Assessment (size of effect, design, generalisability):
The study was fairly large but was not a full evaluation since no comparisons were made.
There was an assumption that patients benefited if drug information was used although this was
not validated. The results are probably generalisable.
209.	 Taggiasco N, Sarrut B and Doreau CU. European survey of drug information centres. Ann
Pharmacother 1992;26:422-8.
Descriptive study:
This paper reported the results of a mail questionnaire of hospital drug information centres
(DICs) in 32 European countries. Two thousand and twenty six respondents were contacted and
267 questionnaires were sent. One hundred and ten (40%) questionnaires were received of
which 88 were analyzed. These replies included 47 from the UK. In general, DICs were
located in health care structures and run by doctors or pharmacists. The services of the DIC
were available usually to other health care professionals. Only the in the UK was a national
organised network maintained. The report provided details of the staff, opening hours,
resources and annual workload of the centres. Most employed specialist pharmacists and were
open during normal working hours. DICs used a variety of books, journals and databases and
most (72 centres) dealt with under 2000 queries per annum. DIC queries were often recorded.
Dics also produced bulletins and other information or educational material. Twenty DICs
implemented quality assurance programs. Of the 47 UK centres, only 2 were located in a
university; the remainder were located in a hospital. UK DICs were staffed by pharmacists
who specialised in drug information. Most DIC queries were received by telephone (in excess
of 80%). About two fifths were received from pharmacists and the same proportion from
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doctors.
210. Dhalla M. The National Poisons Unit. Pharm J 1991;247:HS22-3.
Descriptive study:
This paper described the work, staffing and facilities of the national poisons unit in New Cross
Hospital, London and number of inquiries received their each year. This unit was established
in 1963 following the publication of a report on the subject the previous year by the
Department of Health. No pharmacists were employed there. Its workload has increased
steadily and in 1990 the service had over 94,000 inquiries.
211. Herxheimer A. The drug information cascade. Pharm J 1993;250:412.
Opinion paper:
This paper provided opinions on the provision of information to prescribers, including that
provided by the industry, by specialised centres that provide evaluated information on drugs,
by drug information centres and by the creators of formularies. The author suggested that
future information initiatives should be directed towards making good quality information more
accessible and easier to use so prescribers, and ultimately the patient and the public, would
benefit. He suggested a national agenda to achieve this aim.
212. Anderson DA and Glare JG. VADIS - a drug information resource. Pharm J 1991;247:HS13-
16.
Descriptive study:
This paper described the view data drug information service, a computensed drug information
service that complements the British National Formulaxy.
213. Proudlove CR, Smith JC and Breckenridge AM. Medical awareness and usage of a regional
drug information service. Pharm J 1983;230:394-6.
Descriptive study:
The study reported the results of a postal questionnaire survey that elicited the opinions of 665
general practice (GP) and 566 hospital doctors on the Mersey drug information centre. Seventy
percent of the GPs and 62% of the hospital doctors replied. Forty six percent of the GPs were
aware of the service and 14% had contacted it for information. Forty five percent of hospital
doctors were aware of the service and 27% had used it. Doctors in a hospital with a drug
information centre were significantly more likely to be aware of its existence and to have used
it (p <0.01). Most (68.1%) of those in sites with a centre were aware of the centre (compared
to 41.3% who were not in such a site); 51.1% of doctors in sites with a centre had used drug
information services (compared to 23.8% who were not in such a site).
214. Morrow NC. Problem-orientated drug monographs developed for physicians in Northern
Ireland. Am J Hosp Pharm 1986;43:360-7.
Descriptive report:
This paper described the production of monographs on several drugs by a drug information
centre. The monographs were evaluated using a questionnaire survey of hospital and general
practice doctors. Self-completed questionnaires were sent, with the monographs, to 122
hospital and 67 general practice doctors. Fifty six (45.9%) hospital doctors and 26 (38.8%)
general practice doctors returned the questionnaires. There was a trend for junior hospital
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doctors, more than the more senior members of staff, to consider the rnonoraphs to be more
useful. Most doctors thought that the information was of moderate or substantial benefit
educationally or practically (88%), that it highlighted previous information (78%) or provided
new information (46%), that it was suitably pitched (86%) and that the range of data were
sufficient (66%). The majority of the doctors thought that the monographs were adequately
(55%) or well (43%) written, of a suitable length (90%) and a useful basis for peer review
discussion and therapeutic audit (77%), suitably designed (86%) and that their problem-
orientated approach was suitable (92%). Most (85%) would like to receive them again.
Important omissions were felt to be drug costs (25%). Respondents also said that information
on adverse effects, interactions, dosage and administration was of prime importance. The
authors claimed that the monographs were useful sources of information and could be used to
influence prescribing.
215. Lugg SC, Hudson SA and Golightly PW. An evaluation of response to specialist drug
information bulletins. Proceedings of the Guild 1980; 13:43-57.
Descriptive study:
The Trent Regional Drug Information Service (DIS) produced a specialist current awareness
bulletin for paediatrics and psychiatry which was sent to pharmacists, nurses and doctors.
Various hospital DISs in the region helped to produce these. A questionnaire survey was
distributed with the bulletins via the hospital DIS to two sample areas in the region and replies
were collected over 5 weeks. There was a 20% response rate to the questionnaire. Respondents
thought that the bulletins were readable, of the correct length and mostly (medical staff) or
usually (j)harmacists and nurses) relevant. Most respondents read all parts of the bulletins, kept
them for future reference, made them available to other staff and sometimes used them to
stimulate discussions with colleagues. There was general satisfaction with the format of the
bulletins; 45% of medical staff, 17% of nurses and 24% of pharmacists were completely
satisfied with them and only 5, 10 and 18%, respectively, were completely dissatisfied.
Problems were detected with the distribution of the bulletins and a there was a lack of
awareness of its existence. Personal interviews were conducted with a sample of responders by
a member of the DIS who was not involved in producing the bulletin. Thirty six nurses, 16
doctors and 10 pharmacists were interviewed. Interview and questionnaire data were in
agreement except with regard to what respondents did with bulletins after reading them. In the
interview survey, fewer medical (40%) and nursing staff (50%) said that they kept the bulletins
for future reference than had stated this in the questionnaire survey.
216. Hall T. The effect of drug bulletins on the prescribing of oral nitrates. Br J Pharmaceutical
Practice 1990;12: 122-8.
Objective:
To assess the effectiveness of a bulletin, which addressed the issue of nitrate tolerance, that
was produced by a hospital drug information department on nitrate prescribing.
Methods:
This was a prospective before/after study of oral nitrate prescribing at a single general hospital.
In the first phase, pharmacists collected prescribing information on all patients prescribed oral
nitrates in a two week period. The bulletin on oral nitrate therapy, prepared by the drug
information department in a manner similar to that employed in the past in the hospital, was
distributed to all medical and nursing staff. It made certain recommendations on nitrate
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therapy: to use the minimum effective dose, to give isosorbide dinitrate and mononitrate three
times a day and not at bedtime and to cover nitrate-free periods with other drugs for those at
high risk. After a two week washout period, data were collected again as in phase I.
Results:
The proportion of patients who had a nitrate-free period (of at least 10 hours) increased from
26.7% (8/30) in the before period to 62.8% (27/43) in the period following the distribution of
the bulletin. This increase of 36% was statistically significant. There was a trend to increase
the total dose of nitrate (2.3%) and to use isosorbide mononitrate. For in-patients, however,
the trend was to lower the average daily dose from 47.33 to 42.65 mg and to use the
mononitrate. The author said that no reasonable alternative explanation, other than the effect of
the bulletin, was found for the change in prescribing patterns.
Assessment of study: (strength, size of effect, generalisability)
The effect was moderate. There was a risk of bias in data collection but confounders are
probably not important in this short term study. The results are not generalisable.
217.	 Ross AJ. Quantifying ward pharmacy and its impact on patients. Br J Pharmaceutical Practice
1987;9:267-73.
Objective:
To quantify the ward pharmacy service provided in four hospitals and to measure the impact of
advice given by pharmacists on the treatment of patients.
Methods:
This was a prospective cross-sectional sample survey that counted and classified the type
(mechanical, pharmaceutical or clinical) and outcome (accepted or rejected) of queries raised
on prescriptions by pharmacists and non-pharmacists in four hospitals in 1985/6.
Results:
The number of queries raised was: Hospital A - 916 in 29 days; Hospital B - 1393 in 238
days; Hospital C - 1227 in 146 days; Hospital D - 596 in 145 days.The author found that the
sampling was representative. Of the total of 4132 queries, 1034 were mechanical, 1826
pharmaceutical and 807 clinical; there were 465 other queries. Most queries (94%) raised
solely during ward pharmacy (Hospital B) were raised by the pharmacist. In hospitals A,C and
D, 63%, 43% and 53%, respectively, of queries were raised by the pharmacist. In hospitals A-
D, 61%, 68%, 32% and 46%, respectively, of queries resulted in a change in the prescription;
31%, 12%, 635 and 47%, respectively, of queries were for information only. In total, 2177
(53%) of queries led to a change in a prescription.
Assessment of study: (strength, size of effect, generalisability)
This was a descriptive study not an evaluation. The author's claim, that a change in the
prescription was an indicator of pharmaceutical advice contributing to patient care, is dubious
since no information about patient care was provided. In essence this study showed that
pharmacists affect the prescribing process and may improve patient care. The problems of the
lack of a control group, no data on possible confounders (patient numbers, staff numbers and
changes etc), potential bias in data collection (by the pharmacists concerned), absence of
independent assessment of the value of the interventions and incompleteness of data collection
(author admitted this was a possibility) make it difficult to use these results. The
generalisability of the results is likely but would be assisted by the provision of more
information on the nature of the pharmacies and hospitals that were studied.
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218. Shaw P, Hollebon CE and Mason SK. An investigation into the role of pharmacists on
consultant ward rounds. Br J Pharmaceutical Practice 1980;2:13-17.
Descriptive study:
The aim of this study was to categorise and quantify the inquiries directed to three pharmacists
who regularly attended three consultant ward rounds at hospitals in one district. The
pharmacists had different amounts of time to spend in preparation for the rounds, differing
levels of experience of attending rounds and attended differing proportions of rounds. The
consultants were two general physicians and one rheumatologist. The pharmacists recorded
their inquiries and contributions at 64 ward rounds over 5 months. There were differences
between the results for each pharmacist, namely in the types and numbers of inquiries on the
rounds and in the number of times that they initiated therapy changes or gave advice. This may
reflect the differences between the pharmacists that have been mentioned. At the end of the
five month period the consultants completed a questionnaire; all though it was useful to have
the pharmacist on the round. The reasons give were that the pharmacists acted as a safety net
and provided information on dose, drug, formulation and interactions and helped control costs.
All would recommend the inclusion of a pharmacist on their colleagues' rounds.
219. Cairns CJ and Prior FGR. The clinical pharmacist: a study of his hospital involvement. Pharm
J 1983;230:16-8.
Descriptive study:
A survey was conducted of the contribution made by four pharmacists during ward pharmacist
and consultant rounds on units in a single hospital over six weeks. Three hundred and thirty
one queries were recorded by the pharmacists, about half of which were initiated by
pharmacists and half by doctors and nurses. Most queries concerned drug choice (30%), dose
(27%) or adverse effects (15%). Intervention by the pharmacist led to action in 75% of cases.
Another 13% of cases concerned queries by non-pharmacy staff requiring more information.
220. Gibson P and Freeborn SF. Are pharmacists effective on clinical rounds. Pharm J
1 985;234:201-2.
Descriptive study:
This paper described the results of a retrospective analysis of the contributions made on 75
ward rounds by four pharmacists over six months at a single hospital. These contributions were
those made in addition to contributions made during routine ward pharmacy visits. The study
was retrospective to reduce the potential for bias because of pharmacists' prior knowledge of
the study. Nine hundred patients were seen and 500 interventions were made. Most
interventions concerned medication choice (24%), actions and uses of drugs (23%) and dose
and frequency (17%). Forty one pereent of queries were initiated by the pharmacist, 58% by
the doctors and 1% by nurses. Only 9% of queries would have been detected by the ward
pharmacist if they had not been in attendance on ward rounds.
221. Cloete B and Heath PE. Pharmacist participation in a psychiatric consultant ward round. Pharm
J 1987;238;42-3.
Objective:
To determine the extent to which pharmacists attending psychiatric consultant ward rounds
were able to assist in reducing excessive drug usage.
Methods:
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A prospective time series study was conducted of the contribution made by a pharmacist on
ward rounds and the change in drug cost per patient over 12 months. The consultant was
unaware of the full extent of the study. Only data on patients present throughout the study were
used.
Results:
Thirty seven ward rounds were attended. l'his took a total of 103 pharmacist hours (706) and
resulted in 180 interventions. One hundred and fifty interventions resulted in changes in
treatment. Drug costs were reduced from £863.20 to £518.18. The number of items prescribed
per patient decreased from 3.75 to 2.66 (29%). The cumulative savings were £3,212.90 (based
on the supposition that patients' therapy would have remained unchanged in the absence of the
pharmacists' interventions). This was comparable to data obtained from four costing studies
that had been carried out during the year. The net saving was about £2,500 per annum.
Assessment of study: (strength, size of effect, generalisability)
The effect was large but the results are not generalisable. There was a risk of bias due to the
self-reported nature of the study. It was not a full economic evaluation and all costs and
consequences were not taken into account (drug administration costs, patient care effects).
Nevertheless, it was a reasonably sound study that took many costs and consequences into
account. The presence of a multidisciplinary team that monitored changes in therapy probably
protected against deleterious effects to the patient (long-stay wards with follow up of patients
over 12 months)
222.	 Trewin VF and Town R. Pharmacist effectiveness at case conferences. Br J Pharmaceutical
Practice 1986;8:298-304.
Objective:
Unclear. Probably to consider the effect of pharmacists in a case conference setting.
Methods:
A survey was performed of the self-recorded activities of three pharmacists at case conferences
in four wards in a geriatric department over 8 months. Records were made of all the questions
that were asked of the pharmacists and of the opinions offered by them, their replies and the
resultant action. The value of these interventions to the care of patients was elicited by the
consultants responsible for two wards and a junior doctor using a scoring system. All
interventions were scored (independently) by a pharmacist who was uninvolved in the study.
Results:
Doctors considered 18 of the 465 contributions made to be extremely helpful in the care of
patients, 166 definitely helpful and 175 of some help. One hundred and six had no immediate
benefit. In contrast, the pharmacists considered 2 to be extremely helpful, 39 definitely helpful,
279 to be of some help and 145 of no immediate benefit. The senior house officer was more
generous in his gradings than the consultants and was more in agreement with the pharmacist
than them. The commonest pharmacist interventions were drug discontinuation (86) and change
of dose or formulation (100); the most frequently asked questions concerned drug information
(62). Action was taken on 26% of the pharmacists' answers to questions asked of them and in
54% of instances where the pharmacist had offered an opinion. The more highly experienced
pharmacist made more contributions in the ward rounds.
Assessment of study: (strength, size of effect, generalisability)
This was an uncontrolled study and is subject to bias due to self recording. It provides some
evidence of phannacists' contribution to patient management. The use of doctors to review
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pharmacists' contribution helped to reduce the potential for bias. The assessments of
contribution were further strengthened by the relatively high level of agreement between
doctors' and pharmacists' judgements. The effect was moderate but not generalisable.
223. Ross AT. Evaluating the benefits of a clinical pharmacy service. Pharm J 1985;234:683-5.
Objective:
To quantify the ward pharmacy service provided in four hospitals and to measure the impact of
advice given by pharmacists on the treatment of patients.
Methods:
Prospective cross-sectional sample surveys were performed that counted and classified the
source (doctor, pharmacist, nurse or other), type and outcome (accepted or rejected) of queries
raised on prescriptions by pharmacists and non-pharmacists in four hospitals in 1985/6.
Results:
The number of queries raised was: Hospital A - 175 in 2 months; Hospital B - 164 in 3
months; Hospital C - 36 in 2 months; Hospital D - 96 in 3 months (Total 471). Sixty percent
of the pharmacists' recommendations were accepted of which 80% resulted in a change of
prescription; only 4% were rejected. Most queries were initiated by pharmacists (range 59-
94%) after therapy had started (range 29-63%).
Assessment of study: (strength, size of effect, generalisability)
This was a descriptive study not an evaluation. The criticisms of the study by Ross Al, 1987
(above) also apply here since this was an earlier report on the same study.
224. Tham PK. Outpatient counselling in a chest clinic. Br J Pharmaceutical Practice 1981;3(6): 12-
14.
Descriptive study:
The author described the activities of a single pharmacist at the chest medicine out-patient
clinic of a hospital. These activities aimed to increase the rationality and cost effectiveness of
drug use, patient compliance, patient education and the identification of potential adverse
reactions and interactions. The pharmacist reviewed the medical records of out-patients
attending the clinic and completed a medication profile for each one. This profile documented
any drug-related problems. These were subsequently discussed with the consultant. No data
were provided on patient numbers or workload.
225. Bishop SMJ, Gilchrist A, Kerr U and Donaldson S. A team approach to improving clinical
pharmacy services to psychogeriatric patients. Hospital Pharmacy Practice 1992;2:563-9.
Objective:
To improve the quality of clinical pharmacy services to a group of psychogeriatric patients
using a team approach.
Methods:
In a before/after study, patients in two wards (n=47) were actively monitored by two
pharmacists and those in two others (n=49) were not monitored for two periods during July to
September 1990 and 1991. The monitoring in the active group included assessment of therapy
using the notes and kardex. The pharmacists then met with the consultants and senior nurses
and made recommendations on therapy changes. The outcomes were noted and scored by the
pharmacists. In the control group basic patient information was collected but the notes were not
examined. Available expenditure and bed occupancy data were used to measure and compare
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changes in expenditure between the two wards.
Results:
Of the 102 interventions in the test group, 51 % were accepted. There was a reduction in the
mean number of routine drugs prescribed per patient in the test group from 3.48 to 3.23 (7%);
for as required drugs, the reduction was from 3.11 to 2.83 (9%). Using a process-driven,
external, pharmacy rating scale, the service to the test wards was considered to have improved.
Expenditure on medications, adjusted for bed occupancy, were reduced in the test wards from
£3.23 to £3.05 (for the control wards the figures were £3.01 increasing to £3.34).
Assessment of study: (strength, size of effect, generalisability)
This study measured the numbers of medications prescribed and interventions wade and
calculated savings crudely. It did not measure changes in patient care nor total drug costs
(including administration costs). In addition, there were few indications that the patients in the
control and intervention groups were similar and no data were collected on control patients in
the post intervention period. This gives rise to concerns about patient comparability. Self-
reporting and scoring of data results in concerns about bias. The size of the effect was small
and the results are not generalisable.
226. Pashley EM and Biggins CA. Prescribing trends in a hospital for mentally handicapped people
over a five to eight year period. Hospital Pharmacy Practice 1991; 1:115-7.
Objective:
To compare the medication received by the residents of a large hospital for the mentally
handicapped in 1983 and five years later.
Methods:
This study measured the effect of weekly drug reviews by a clinical pharmacist, which were
presented to a multidisciplinary team at one hospital, on the number and types of medications
that were prescribed for a stable population of in-patients before and 5 years after the
appointment of the pharmacist. A survey date was chosen in May 1988 and the medications
prescribed were recorded retrospectively then and, on as near a date as possible, 5 years earlier
(there were problems with data collection in 1983 and data more than 3 years from the 1983
date were not used).
Results:
Prescriptions for 296 patients were compared. The length of stay averaged 29.2 years (range 5-
68). Patients' handicap levels were mild (9), moderate (28), severe (228) and profound (28).
The proportion of patients receiving medication was reduced from 81% to 76%. The number
of epileptics and the proportion of patients that were receiving anticonvulsants remained stable
(although many more were on fewer anticonvulsants) but the proportion receiving any central
nervous system drugs fell from 69 to 56%.; The proportion receiving neuroleptics fell from 43
to 29% and the proportion receiving hypnotics from 18 to 10%. Greater numbers were
receiving as required medications in place of routine medications.
Assessment of study: (strength, size of effect, generalisability)
The size of the effect was moderate but the results are not generalisable. No data were
presented on patient care effects but it is unlikely that patient care would have been adversely
affected due to the long follow-up and the multidisciplinary nature of the therapy reviews.
There was a risk of bias in this study due to pharmacists' motivation to reduce therapy.
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227. Draper B and Freeborn S. Compilation of medical reports by pharmacists in a geriatric day
hospital. Br J Pharmaceutical Practice 1981;3(8):12-17.
Descriptive study:
The authors described the taking of drug histories and the creation of a medical report on
patients at a geriatric day hospital. These were discussed subsequently at a multidisciplinary
clinical meeting. Patients were interviewed, where necessary, to elicit information.
228. Taylor D. Changing prescribing habits within a mental health unit. Br J Pharmaceutical
Practice 1989;11:224-5.
Objective:
Unclear. The article provided a description of the prescribing problems identified at a mental
health unit as a result of the activities of a multidisciplinary working party. It also showed how
these decreased following the introduction of routine pharmacy input (attendance of a senior
pharmacist at monthly consultant management rounds, preparation of drug reviews,
contribution to registrar induction training and provision of advice on the correct use of the
drug chart).
Methods:
A survey was carried out by pharmacy staff. It consisted of a ut check' on all prescriptions
in the hospital (two acute wards and a day unit).
Results:
The initial survey ((March 1987) of 41 charts identified several problems, the most serious of
which were patients receiving depots not identified on the chart, concomitant prescribing of
medications from the same pharmacological group, absence of starting and termination dates
for therapy and the improper use of 'as required' prescriptions. Subsequent surveys took place
in June 1987 (45 charts) and a year later (49 charts), after pharmacists had become actively
involved in the unit. These showed a reduction in prescription problems in the period from
March 1987 to June 1988. These were reductions in the mean number of items per chart from
4.3 to 3.7, in the proportion of regular anticholinergics from 27 to 21 %, in the proportion of
day time benzodiazepines from 7 to 5% and in the proportion of night time benzodiazepines
from 12 to 5%, and in the proportion of charts with variable dose/route and no instructions
from 35% to 18%.
Assessment of study: (strength, size of effect, generalisability)
The study suggested that pharmacy activity was effective but the absence of data on medical
staff changes and patient changes leaves the results open to confounding. Collection of data by
pharmacists leaves them open to bias. The effect was moderate and not generalisable.
229. Hackitt K. Pharmacist participation in a geriatric out-patient clinic. Br J Pharmaceutical
Practice 1984;6:375-6.
Descriptive study:
This paper described the activities of a pharmacist who attended two consultant's outpatient
clinics at a single hospital. The consultants had invited the pharmacist to attend the clinic
following a successful period attending and contributing to ward rounds and counselling
patients. Patients were interviewed by the pharmacist on arrival at the clinic and, with an
awareness of the medical notes, the pharmacist reviewed their medications and prepared a
medication profile on each patient. This took an average of 5 minutes per patient. It highlighted
any potential side effects or drug interactions and assessed the need for patient counselling. The
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patient was counselled, usually for 3-5 minutes after he had seen the doctor, and was given a
medication chart describing the regimen and providing additional information if necessary. The
article enumerated the advantages and problems of the service but was not an evaluation.
230. Arnold JVH and Ross HM. Drug profiles and patient counselling as part of patient services for
elderly in-patients and patients attending a day hospital for the elderly. Br J Pharmaceutical
Practice 1981;3(2):11-14.
Descriptive study:
This article described the pharmacy service provided to geriatric in-patients at three hospitals
and to day patients at another facility. Pharmacists produced drug profiles on patients whilst
they were in hospital and maintained the profiles if the patients were transferred to the day
hospital. The profiles were used to solve drug supply problems, to clarify discharge medicine
requests (since pharmacists only visited the sites twice a week) and to aid in counselling
patients. Patients at the day care facility were provided with a medicines card that was updated
by the pharmacist. They were counselled there and, if social workers noted problems with
medications, they were counselled also at home.
231. Howards P. Pharmacist involvement with thromboprophylaxis policies. Pharm J
1993;250:HS51-2.
Descriptive study:
This paper described pharmacists' involvement with the creation and assessment of various
thromboprophylaxis policies in four general hospitals. The audit process and the directorates
were used to assist in increasing pharmacists' involvement in patient care
232. Ketley D and Godfrey B. Pharmacy and clinical directorates at Leicester Royal Infirmary.
Pharm J 1992;248:588-9.
Descriptive study:
This paper considered the pharmacy department's response to the introduction of clinical
directorates at a single general hospital. Pharmacy's role had changed to one where
pharmacists had become more involved in advising on drug policy and on the economic use of
medicines.
233. Hough JE, Martin P and Barrett CW. From ward to clinical pharmacy. Pharm J 1987;237:86-
7.
Descriptive study:
This paper described the problems of changing from ward to clinical pharmacy at two
hospitals. The authors discussed the training implications for pharmacists and the strengths and
weaknesses of the new system compared to the old one.
234. Anderson SC and Fletcher P. Hospital advisory services. Pharm J 1987;236:464-6.
Descriptive study:
This paper described a method of measuring pharmacists' performance when providing
advisory services in hospitals. It reported the results of a workshop sponsored by the
Department of Health in 1985. The paper concentrated on drug monitoring as a precursor to
the provision of advice on therapy. Services were described according to objectives, inputs,
outputs and outcomes. Although outcomes included changes in patient morbidity, the authors
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recognised the difficulty in measuring these.
235. Calder G. Aspects of the integration of the pharmacist into the ward therapeutic team
Hospital Pharmacy 1967;24:435-42.
Descriptive study:
This paper described several small uncontrolled studies that helped the pharmacy department
decide how its pharmacists might be most effective on the wards of a large general hospital and
at smaller long stay geriatric hospitals. It outlined the pharmacists' contribution to audit and
quality assurance of drug use and advocated their full integration into the therapeutic team.
236. Fitzpatrick RW. The pharmacist in a clinical area: a practical account. Br J Pharmaceutical
Practice 198 1;3(9): 18-27.
Descriptive study:
This study described the practice of clinical pharmacy by ward pharmacists and by pharmacists
who attended ward rounds in addition to providing ward pharmacy visits at two hospitals.
Those attending rounds did so about twice a week. All pharmacists recorded their
interventions. These included interventions on side effects, dose, deletion or addition of drugs,
drug selection, rationalisation of therapy and provision of information on pharmaceutical
aspects of drugs. Pharmacists who provided only ward pharmacy visits made similar, but
fewer, interventions than those who also attended ward rounds but no comparative figures were
provided to support this statement. The advantages of attending rounds were enumerated. The
interventions made by one pharmacist, who had attended rounds, were quantified for one
month. Eight rounds were attended and 23 interventions were made on these rounds. The
interventions were made on side effects (1), dose recommendations (6), drug deletion (4) or
addition (1), provision of information (3) and others (8). Seven patients were counselled. On
the ward visits made by this pharmacist 34 interventions were made. These were on side
effects (3), dose recommendations (6), drug deletion (10) or addition (2) of drugs, provision of
information (4), drug interactions (1) and others (8). No patients were counselled although this
activity was felt to be worthwhile by medical and nursing staff.
237. Walker R and Bussey RA. Assessment of a hospital based clinical pharmacy service. Pharm J
1986;237:558.
Objective:
To assess the quantity and quality of a clinical pharmacy services, particularly with respect to
its contribution to patient care.
Methods:
This was a prospective time series evaluation of the interventions made by a single pharmacist
on general medical and renal wards at a single general hospital. The ward pharmacist attended
the ward rounds of four consultants for 23 weeks (Phase I), attended the ward rounds of two
consultants and reviewed their patients' therapy for 38 weeks (Phase II) and attended the ward
rounds of the other two consultants and reviewed their patients' therapy for 31 weeks (Phase
111). The pharmacist recorded all interventions and classified them according to whether they
were rejected or accepted. Accepted interventions were subsequendy assessed by a panel of 4
hospital pharmacists and 3 general practitioners who were not based at the hospital.
Interventions were ranked on a visual analogue scale (VAS) according to whether they were
good (+ 3) or bad (-3) with respect to their contribution to patient care and to the optimisation
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of drug expenditure. Rejected interventions were graded similarly but according to whether the
pharmacist should or should not have made them.
Results:
Eighty five interventions were made in Phase 1, 457 in Phase II and 620 in Phase HI. Most
(82%) were made during ward rounds and the number of interventions significantly correlated
with the number of rounds attended. Of the 1162 interventions, 988 (85%) were accepted.
Interventions were made mainly on dose adjustment (23%), discontinuation of medicines
(19%), selection of medicines (12%) and side effects (9%). Doctor and pharmacist assessors
were in agreement on the grading of interventions. Of the 542 interventions that were made in
the first 2 phases, 461 (85%) were accepted. Of those that were accepted, 232 scored between
2.01 and 3 for contribution to patient care and 206 between 1.01 and 2; only one was given a
negative mark. In addition, 105 interventions scored 2.01-3 for their contribution to the
optimisation of drug expenditure and 216 scored 0.01-1; 15 scored a negative mark. This was
despite the pharmacist recording that only 7 interventions were made to optinuse drug
expenditure. Of the 81 rejected interventions, 74 were considered to be worth making.
Assessment of study: (strength, size of effect, generalisability)
The lack of proper controls in Phase I of this evaluation makes it difficult to draw conclusions
from the data. The effect was large when the number of interventions is considered but it is
impossible to say if patient throughput and medical and nursing staff factors were confounders.
The independent review of the interventions provided protection against bias in assessing the
contributions to care but bias remained a possibility due to data collection by the pharmacist
under study. The results are not generalisable.
238. Evans it. The pharmacist's role in improving the quality of life of patients receiving
chemotherapy. Proceedings of the Guild 1987;24:3-25.
Objective:
To evaluate the pharmacists' role, as part of an oncology team, in improving the quality of life
of oncology patients.
Methods:
This was a prospective 16 week controlled study of the effect of counselling by a pharmacist
on patients' quality of life and knowledge of therapy. All patients receiving parenteral
chemotherapy were asked to complete daily questionnaires about their symptoms. Patients were
allocated to two groups by sequential matching based on their symptom score, age, type of
cancer, chemotherapy, number of cycles received and karnofski index. All patients were
counselled initially but only those in Group A received follow-up counselling. Patients were
asked to complete an assessment form giving their views on their treatment and the
counselling. Counselling took place after consultation between the pharmacist and other
members of the oncology team to preserve a unified approach to therapy.
Results:
The 13 patients in the group that had been given additional counselling received 60 counselling
sessions lasting 1-1.5 hours each. A summaiy of these was recorded in the notes and reported
at team meetings by the pharmacist. All 24 of the pharmacists' interventions were acted upon
by doctors. At 49 counselling sessions information was given to patients about therapy.
Compliance with the questionnaire was 100% (although 2 patients in each group died during
the 16 week study). The average weekly symptom score in both groups was similar for
appetite, mouth care, activity, vomiting, mood, nausea, pain and indigestion. Anxiety and sleep
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scores were better in the group that had received additional counselling although this
improvement was not significant. Scores for information about treatment and overall feeling of
wellbeing were significantly better in the group that had received additional counselling. The
22 patients who were still alive at week 16 found the questionnaire useful in relaying
information about their treatment to the doctors. All in Group A commented on the helpfulness
of pharmacist counselling. The study suggested that pharmacists, acting as a member of a
multidisciplinary team, can improve the quality of care of patent receiving chemotherapy.
Assessment of study: (strength, size of effect, generalisability)
This study was carried out using an questionnaire which was not validated hence its results are
questionable. It appeared to have content validity. There was a risk of bias since the pharmacist
was collecting all the information and knew he was under study. The size of the effect was
moderate, although numbers were small. The results are not generalisable.
239. Cole R, Batson GA, Escritt A and Walker C. An integrated district-wide cancer care scheme.
Pharm J 1991;246:576-9.
Descriptive study:
This described the creation of a district-wide cancer care service, involving hospital and
community nurses, doctors and pharmacy staff, in South Humberside. The scheme was the end
result of a regional initiative on the use of chemotherapeutic agents. A multidisciplinary
working party met at intervals over four years to establish a system for the safe and economic
prescribing, and the supply and administration of these agents to improve the quality of
patients' lives. The working party created a cytotoxics record sheet, a district-wide
reconstitution facility serving hospitals and the community, a system for liaising between all
staff involved in the care of patients receiving cytotoxics and computerised records. Recently, a
clinical psychologist had become involved in the assessment of care. The pharmacy's
involvement was described in detail as were various problems and their solutions. The authors'
impressions were that medical and nursing staff appreciated pharmacists' assistance and the
system has benefited patients.
240. Branford D. Four years working with chronically disturbed mentally ill patients. Pharm J
1989;242:HS32-4.
Objective:
To assess the effect of a pharmacist on a new team (consultant, junior doctor, nurses,
pharmacist, occupational therapist and psychologist) that was set up to cater for the needs of
chronically disturbed mentally ill patients on two locked wards at one hospital.
Methods:
This was a prospective before/after 4 year study assessing the effects of the pharmacist on drug
treatment for patients on the two wards (nine males and nine females). The team met weekly to
discuss therapy. The pharmacists prepared dnig histories and rationalisation programs for
therapy. They recorded the outcomes of changes in therapy. Data were collected each month
on the drugs that had been used by each patient, additional doses of antipsychotics required and
drug costs. Patient well being was assessed subjectively due to lack of input by the
psychologist.
Results:
The female ward was converted from a locked to an open ward after one year but the male
ward remained locked due to problems with a single patient. The mean number of medicines
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prescribed fell from 3.6 (1-6 range) to 1.8 (1-3 range) for mates and 3.1 (1-5 range) to 2.3 (1-
4 range) for females. The mean dose of antipsychotic received also fell (converted to mg of
chlorpromazine); for males it fell from 1,367mg (range = 3000mg to 4000mg) to 567mg
(range = 100mg to 2100mg) and for females from 817mg (range 20mg to 2050mg) to 800mg
(range 0 to 2800mg). The cost of therapy (inflation adjusted) fell from £3411 to £2097 for
males and from £2484 to £1575 for females. The numbers of nursing staff remained unchanged
on the male ward but external changes (staff turnover, admittance of new severely disturbed
patients) affected staff on the female ward and may have affected the rationalisation program.
The number of 'as required' antipsychotics used also fell. Staff rated patients as being well,
more active and more responsive than they had been before. Many male patients were ready
for transfer to community care and 3 females had become day patients.
Assessment of study: (strength, size of effect, generalisability)
The effects were moderate to large although the group was small. The failure to measure
additional costs and benefits, such as the reduction in staff time associated with drug
administration, meant that some of the effects of the intervention were ignored. Phannacists'
and other team members' time was not measured either making it impossible to asses the true
effect of the intervention on costs. Bias was possible due to self-measurement but its effect was
likely to have been small in a long term study such as this. The results are not generalisable.
241. Cloete BG, Gomez C, Lyon R and Male BM. Costs and benefits of multi-disciplinary
medication review in a long stay psychiatric ward. Pharm J 1992;248: 102-3.
Objective:
To assess the effect of pharmacist participation in a multidisciplinary team on the use of drugs
and patients' well-being in a long-stay psychiatric ward. The team consisted of a consultant, a
junior doctor, a nurse and senior pharmacist. They met every 2 weeks for 2 hours. The
pharmacist took patient medication histories and participated in a review of patients' therapy.
Methods:
A 6 week time series study was performed on 19 patients. Seven days prior to the review on
the ward round, a nurse assessed the patients' mental state using an unpublished questionnaire.
This questionnaire appeared to be logical and informative (personal communication, B Cloete,
1993). The average monthly costs of drugs that were used on the ward was calculated from
hospital computer data, the doses of neuroleptics were converted to cblorpromazine equivalents
and compared before and after the study. The use of other drugs was also recorded.
Results:
The service reduced the incidence of polytherapy. The numbers of patients that were on more
than one antipsychotic dropped from 13 to 4, the number on an antidepressant plus an
antipsychotic from 8 to 1, the number on an antiparkinsonian agents plus an antipsychotic from
16 to 4, and the number on oral plus depot antipsychotics from 10 to 4. The mean number of
drugs per patient fell from 3.4 to 2.5 and the average daily chlorpromazine equivalent taken by
patients fell from 642mg to 434 mg. Monthly drug costs fell from £501 to £313 and this level
of expenditure had been maintained for a further 17 months. The pharmacy cost of the service
was £853 per annum. This compared with estimated drug savings of £2256 per annum (based
on the assumption that drug therapy would otherwise have continued unchanged). Patients'
global mental states improved by 62.5% on average and no patient deteriorated.
Assessment of study: (strength, size of effect, generalisability)
Only 19 patients on one unit in a single hospital and the efforts of one pharmacist were studied
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hence the results are not generalisable. The study was open to bias since the health care
professionals taking part were aware of the study and collected the data. The maintenance of
savings for an additional 17 months, however, lends credence to the figures for savings. In
addition, the assessment of patients' mental state six months after the end of the study showed
no deterioration (Personal conununicalion, Cloete 1993), thereby reducing anxieties regarding
bias. Most pharmacy costs were included but non-pharmacy costs were not and the moderate
effects that were produced by the service on costs were probably underestimated.
242. Ferguson BG and Weirs T. Are neuroleptics overused? Hospital Pharmacy Practice 1994;4:49-
50.
Objective:
To evaluate the pharmacists' role as a member of the clinical team looking after 12 long stay
psychiatric patients and to audit neuroleptic use over 3 years.
Methods:
A prospective before/after study was performed to assess the effect of pharmacists on drug use
over 3 years. The pharmacists took part in weekly multidisciplinary therapy review sessions.
Their input included an assessment of patients' therapy before the rounds, recommendations on
changes and provision of infomiation on adverse effects and therapies.
Results:
Daily chiorpromazine equivalent doses of neuroleptics fell for all patients, usually by 48%
(range 0-100%). Patients functioning was subjectively assessed, by other staff, and was
subjectively thought to have improved.
Assessment of study: (strength, size of effect, generailsability)
The effect was moderate to large. Failure to assess patients' functional status more rigorously,
and to provide data on the use of other medicines, makes it difficult to assess if patients'
functioning or therapy improved. Changes in costs were not measured. The study was open to
bias although the effects are unlikely to have been large in such a long term study. The results
are not generalisable.
243. Pilkington K. The role of the paediatric pharmacist. Hospital Pharmacist 1994;1:42-44.
Descriptive study:
This study described the role of the paediatric pharmacist in specialised hospitals. This role
includes the preparation, formulation and supply of medications in a form suitable for
individual paediatric patients, the provision of advice on therapy, adverse effects, specialised
doses, dosage forms and administration of drugs in intensive care facilities, the creation of
formularies and prescribing protocols, the contribution to financial control of paediatric
budgets, and the contribution to research. A day's work for a paediatric pharmacist was
described. This included the functions described above plus the provision of a formal drug
information service to the hospital and to other institutions and the provision of information and
counselling to the parents of patients. The expanding role of the pharmacist in this area
included the provision of intravenous additives and home total parenteral nutrition, and
participation in pain teams and in directorate services. Opinions were provided on the future
role of paediatric pharmacists and the need for specialist training in this area.
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244. Taylor DM and Heath ML. A disposable device for patient controlled analgesia compared to
intramuscular papaveretum. Hospital Pharmacy Practice 1992;2:623-8.
Descriptive study:
This paper described the results of a study of 16 patients receiving patient controlled analgesia
(PCA) and 16 receiving conventional pain relief using intramuscular opiates (controls).
Parameters compared were pain, opiate consumption and time to prepare the PCA devices.
Patients in both groups were similar in age, operation undergone (all hysterectomies) and
weight. There was no significant difference between groups in opiate consumption (78mg/48
hrs in the test group and 73mg/48 hrs in the controls). A questionnaire, completed by the
patients on discharge, showed that patients on PCA experienced significantly less pain than
control patients. The authors claimed that the study showed that PCA was useful and that
pharmacists and anaesthetists could collaborate successfully in providing PCA for patients.
245. Ashby N and Taylor DM. Patient-controlled analgesia and the hospital pharmacist. The
Hospital Pharmacist 1994;1:38-41.
Descriptive study:
This paper reviewed the development of patient controlled analgesia (PCA) and the extent of
phannacists' involvement in this area. The early devices, which nurses operated on the
patient's behalf, were described. So also were technical advances in the equipment that helped
to allay nurses' fears of overdosing patients. The range of currently available devices were
explained. The administration route is usually intravenous. The advantages and disadvantages
of PCA were described. Pain relief was thought to be more immediate but the preparation and
administration of PCA could be hazardous. Although PCA services have been run by
anaesthetists in the past, pharmacists were increasingly becoming involved in this service due
to the recognition, by a working party of the Royal Colleges, that a comprehensive
multidisciplinary team service offers advantages. Pharmacist involvement in PCA services have
included helping evaluate and select PCA devices, producing guidelines and protocols for PCA,
educating various staff involved in the service, producing pre-filled devices and programming
of the pumps, educating and counselling patients, monitoring to prevent adverse effects and
evaluating and assuring the quality of the service. Most references to these pharmacists' roles
were non-UK but there was some evidence that UK pharmacy departments were becoming
involved in several of these roles.
246. Cousins DH. The pharmacist on the resuscitation team - parts 1 & 2. Current Practice
1990;3:1-5 and 8-9.
Descriptive study:
This paper described the institution of pharmacists on cardiopulmonary resuscitation teams in
one English hospital, their activities and their potential contributions to care.
247. Cousins D and Tempest SM. The hospital pharmacist's role in cardiopulmonary resuscitation.
Pharm .1 1991;246:HS21-23.
Objective:
To assess the effectiveness of clinical pharmacists on the cardiopulmonary resuscitation (CPR)
team.
Methods:
A 10 statement questionnaire was used to ask 15 medical and 16 nursing staff their opinions on
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the pharmacy service on a 5 point scale ranging from strongly agree to strongly disagree.
Results:
All respondents agreed that the pharmacist contributed significantly to the organisation of
medication preparation and administration, that they provided expedient and accurate
preparation of medicines, and accurate labelling and record keeping, and that the service was
valuable and should be continued. Doctors agreed less strongly that the pharmacist helped with
dosage recommendations and calculations and provided pharmacological and therapeutic
information during the arrest although nurses agreed as strongly with these statements as they
did with other statements.
Assessment of study: (strength, size of effect, generalisability)
This evaluation was uncontrolled and based on opinions. It indicated that health professionals
thought that the service was worthwhile.
248. Hebron BS, Horton SW, Graham-Clarke EM and McGettigan AT. A pharmacy-based
parenteral nutrition service. Pharm J 1989;242:H520-22.
Objective:
Unclear. To evaluate the effects of a pharmacist-nm total parenteral nutrition (FPN) service.
Methods:
General data on patients, their biochemistry results and their outcomes were collected for three
successive 9 month periods during which pharmacists input in parenteral nutrition gradually
increased from simply supplying ampoules (Phase I), to more active intervention in therapy
choice plus the institution of a total parenteral nutrition (TPN) compounding service (Phase II)
to a full pharmacy service (Phase ill). Patients in the three phases had broadly comparable
diagnoses (although they were not matched on this factor) and the numbers treated remained
fairly constant.
Results:
When phases I and ifi were compared, during which 25 and 23 patients, respectively, were
treated, the mean duration of feeding increased from 6.88 to 16.1 days, the proportion of time
that serum electrolytes were outside the normal range decreased (significant for sodium and
potassium), the number of iatrogenic complications fell from 4 to 2 and the number of
iatrogenic complications per patient fell from 0.16 to 0.09, the number of unexplained pyrexias
fell from 10 to 5, the number of cases of sepsis increased from 6 to 12 but the percentage of
pyrexias per patient thy decreased from 3.5 to 1.6 (significant). The cost/patient/thy decreased
from £70 to £47 (adjusted for inflation). The proportion of patients alive at discharge increased
from 9/25 to 14/23. These mortality figures remained the same one month after discharge.
Assessment of study: (strength, size of effect, generalisability)
The effects were moderate but failure to match patients on the basis of diagnosis, changes in
general treatment and nutrition therapy over time, and lack of controls make it impossible to
assess the precise effect of the TPN service. It is likely that it contributed to some of the
improvements seen. The risk of bias was probably not high since many measurements were
carried Out by non-pharmacists. The results are not generalisable.
249. Goldberg LA. The pharmacist as a member of the nutritional support team. Irish Pharmacy
Journal 1983;61:421-3.
Opinion paper:
This paper provided an opinion on the pharmacists' role on the nutrition team, the contribution
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that would be made to the team as a result of the pharmacist being present, the use of
computers and of pharmacists' special skill in the production of parenteral nutrition and the
economic and patient safety benefits of the team service.
250. Farwell JA. Pharmaceutical factors in long-term parenteral nutrition. Proceedings of the Guild
1986;8:3-37.
Descriptive study:
This paper described the background to the development of total parenteral nutrition (TPN)
services in the UK and elsewhere. The team approach to service management was described
and advocated. Its benefits for patient (safety and quality of care), organisations (safety and
economy) and health care professionals (utilisation of skills and education) were enumerated.
Teams usually included doctors but may be led by nurses, doctors or pharmacists. The teams
may be organised in a variety of ways. Teamwork was felt to lead to the development of
protocols and better practice. Some units were said to undertake the provision of home
parenteral nutrition. The needs for staff training and regular updating, and patient training,
were emphasised and pharmacist were thought to have a role to play in providing this
education.
251. The report of the Working Party on pain after surgery. Joint Commission of the Royal College
of Surgeons and College of Anaesthetists. 1990.
Report:
This report recognised the deficiencies in current approaches to pain control and advocated the
provision of a comprehensive postoperative pain control service by multidisciplinary teams.
252. Cannon PJ, Bertch KE and Cousins DH. The introduction of a satellite pharmacy service for
the intensive care and coronary care units at a district general hospital. Pharm J 1990;244:36-
9.
Descriptive study:
This paper described the creation of a satellite pharmacy in a single hospital. The total time
that nurses spent on the preparation of intravenous injections was calculated and the costs of
setting up the satellite pharmacy were provided. Savings in nursing tune and in drugs, and the
increased pharmacy costs, were enumerated. The authors discussed how the satellite had
facilitated the development of clinical pharmacy services, such as advisory services on drug
administration, pharmacokinetic monitoring and product selection, education for health
professionals and assistance at medical emergencies. They also emphasised the role of satellite
pharmacy in increasing the integration of the pharmacist onto the health care team.
253. Anon. Role of the pharmacist in health education. Pharm J 1989;244:HS3O-31.
Opinion paper:
This paper described the views of the Guild of Hospital Pharmacists on the pharmacists' role in
educating patients and health professionals in primary and secondary care. In particular, it
mentioned their role in providing information leaflets for patients, providing advice on dealing
with drug abuse to health care workers and providing education for nurses, community
pharmacists and other community groups. They endorsed a co-operative approach between
pharmacists and other groups and professionals and enumerated various potential problems in
maldng full use of hospital pharmacists' skills, such as practical and ethical problems, the lack
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of remuneration and of time.
254. Report of the Royal Pharmaceutical Society working party on education and training, Part III
(Chair MR NL Wood). The feasibility of assessing competence to practice pharmacy. Pharm J
1990;247:496-9.
Report:
This document detailed the working party's assessment of the feasibility of introducing
competence assessment for practising pharmacists.
255. Royal Pharmaceutical Society of Great Britain. National continuing education syllabus for
pharmacy. Pharm J 1993;249:152-6.
Report:
This report set out the Society's position on postgraduate education. They endorsed continuing
education and suggested various methods of providing it.
256. Ashcroft CE and Hynam BM. An in-service clinical training program for hospital pharmacists.
Part ifi. Hospital activities. Pharmacy International 1982;3:254-6.
Report:
This paper described the activities in which the author thought hospital pharmacists should
receive training and the environment in which such training was considered to be possible,
such as on ward rounds and at clinical meetings, and via journal clubs and intra-departmental
meetings.
257. Flint J and Hancox D. Postgraduate education and training. Hospital Pharmacist 1994;1:31-3.
Review:
This report reviewed the means whereby hospital pharmacists were educated in the United
Kingdom in 1994. Mechanisms included the provision of education by hospital pharmacies
(ward pharmacists' meetings, review of interventions, journal clubs, induction training, reports
on study days and in-house programs), Schools of Pharmacy postgraduate diploma and Masters
courses, regional training, management training and the contribution made by professionals
organisations (Guild of hospital pharmacists, Hospital pharmacists group of the RPSGB,
UKCPA, College of Pharmacy Practice). Opinions were provided on future trends, such as the
use of distance learning.
258. Bentley A and Green R. A clinical pharmacy training program. Pharm J 198 1;227:247-9.
Report:
This paper described a course in clinical pharmacy that had been set up in 1981.
259. Clarke CM. Setting up a clinical pharmacy training programme on a medical professorial unit
in association with a university department of pharmacy. Proceedings of the Guild 1979;6:23-
7.
Report:
This paper described the setting up of a new course in clinical pharmacy, enumerated the aims
of the course, and described the teaching methods and learning situations used in the course.
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260. Noyce PR and Hibberd AR. Launch of the London MSc in Clinical Pharmacy. Pharm J
1980;225:4733-4.
Report:
This paper described a course in clinical pharmacy that had been set up at the time.
261. Veitch GBA. Postgraduate studies in clinical pharmacy at the University of Aston. J Clin
Pharm 1979;4:189-97.
Report:
This paper described the development and philosophy behind the 2 year MSc course in
Pharmaceutical Sciences that was founded in 1970 and its subsequent development into a
diploma course in the 1970s.
262. Florence AT. The Master's courses in clinical pharmacy at the University of Strathclyde. J
Clin Phann 1977;2:119-24.
Report:
This paper described the background to, and development of, a 2 year part time MSc course in
clinical pharmacy established in 1975.
263. Ashcroft C, Hynam BM and Rowland M. An in-service clinical training program for hospital
pharmacists. Part I. Historical developments. Pharmacy International 1982;3: 192-4.
Report:
This paper described the creation of the first in-service training program in clinical pharmacy
for hospital pharmacists in the UK in 1977. It was a joint development between the University
of Manchester and North Staffordshire Health Authority. The development of such programs
was in response to the needs of the newly developed clinical pharmacy service. MSc courses
were available but only for the select few hence a more widely-available course was required.
The article described the initiation of the course and the course activities in which hospital
pharmacists participated. The courses involved the co-operation of doctors, who allowed
pharmacists on ward rounds, and university staff, who held a one day meetings with the
participants each month to facilitate presentations of items such as case reports and drug
reviews. Nine and 16 pharmacists, respectively, participated in the first two groups that took
the course.
264. Fitzpatrick RW. An evaluation of a postgraduate training program in clinical pharmacokinetics.
Pharm J 1989;242:HS18-19.
Objective:
To evaluate a 60 hour clinical pharmacokinetics teaching programme for pharmacists.
Methods:
A before/after questionnaire was used to assess participants' understanding of the concepts and
knowledge covered in the course and their applications in practice. Participants were also asked
for their views on the course using another questionnaire.
Results:
l'hirty four pharmacists assessed the course, 10 in year 2, 15 in year 3 and 9 in year 4.
Overall, there was an improvement in understanding of concepts (mean change + 96%) and
equations (+ 157%). All participants were satisfied with the course and found it useful.
Assessment of study: (strength, size of effect, generalisability)
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The size of the effect was large but the results are not generalisable. The risk of bias was
reduced by assuring anonymity of assessment. The main problem with the study was that
competence, rather than performance, was assessed.
265. Mottraxn DR. A viable alternative in postgraduate continuing education. Pharm J
1991;245:E12-14.
Descriptive study:
This paper described the institution and evaluation of a video-loan scheme for postgraduate
education in Wales. Pharmacists in all branches of the profession, but mainly in community
pharmacy, used them. Over the years 1985/6 to '87/8 the proportion of hospital and industrial
pharmacists using the Mersey region scheme had increased whereas the proportion of
community pharmacists using it had decreased. In Wales the total number of users had
increased from 36 (1987) to 74 (June 1988). Pharmacists who replied to an assessment form
were positive about the scheme. The authors claimed that it was more economical and
convenient for the profession to use the schemes' videos than to organise evening courses.
266. Pugh J and Moss-Barclay C. Development of interactive computerised education for clinical
pharmacists. Pharm J 1991;246:327-9.
Descriptive study:
This paper described the development of an interactive computerised system for training
clinical pharmacists in nebuliser therapy. Pharmacists involved in testing the program (n= 12)
found it took 3 5-50 minutes to complete the cycle and their average score improved from 53%
(initial test) to 92% (re-test). They found it easy to use and liked training at their own pace.
The authors said that it was a valuable addition to existing training methods.
267. Verheul J. Computer-assisted learning (CAL) in pharmacy education and training. Pharm J
1992;249:467-9.
Descriptive report:
This paper described the development and applications of a computer assisted learning (CAL)
package in pharmacy. The author provided an appraisal of the currently-available packages,
most of which were more widely used by community pharmacists than their hospital
colleagues. He said that poorly designed software may have dampened initial enthusiasm for
CAL and he advocated the assurance of the quality of new CAL packages. He also commented
on new media that had become available such as hypermedia and videodisc.
268. Gerreti D. A postgraduate programme in social and administrative pharmacy by multimedia.
Pharm J 1994;252:88-9.
Descriptive report:
This paper described a new postgraduate course in social and administrative pharmacy that
utilised multimedia techniques.
269. Anon. Continuing education activities in Wales. Pharm J 1992;250:426.
Report:
This paper described the activities of the Welsh Centre for Postgraduate Phannaceutical
Education. Education was provided to community and hospital pharmacists using a network of
tutors who educate pharmacy staff using lectures and group discussions. Distance learning
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using videos and computer assisted learning were aiso available. Therapeutic teaching packages
had been developed specifically for hospital pharmacists. These could be used to supplement
in-house teaching material. In 1990-91, 63 % of hospital pharmacists in Wales took part in
some educational activities.
270. Davies G and Dodds L. The cascade method for clinical training. Pharm J 1992;248:120-2.
Objective:
To describe the use and assessment of a cascade system to provide training for hospital clinical
pharmacists in South East Thames.
Methods:
A description of the system was followed by the provision of results of before/after multiple
choice questionnaire assessments of trainee's knowledge. Trainees also completed a
questionnaire providing their views on the service.
Results:
This system allowed trainers to prepare material co-operatively thereby utilising all trainers'
expertise to produce better quality training packages. These could then be used by any trainer
in the region thereby optimising the use of resources. Pharmacists (n=7) who took a cardiac
failure cascade training session improved their score by 5.3 points (from an average of 18.6 to
23.9). In a broader sample of 6 districts (38 pharmacists) the average improvement in score
was 4.9 (range -4 to + 13). Trainees' comments were said to be generally positive. The authors
claimed that the method had not increased the cost of training in the region.
Assessment of study: (strength, size of effect, generalisability)
This was not a full evaluation since the only data provided were some data on improvements in
knowledge (rather than performance) after completion of a single course of the programme.
Costs and details of trainees' satisfaction with the course were not provided. Neither was the
scheme compared with other available training methods. The size of the effect was moderate
and is generalisable for that course only. Lack of information on the assessment method
precludes comments on bias or confounding.
271. Beswick DT, Cooper P and Elliot DN. Clinical pharmacy training in the South Western
region. PharmJ 1988;243:E7,E11.
Descriptive report:
l'his paper described the organisation of postgraduate clinical pharmacy education for
pharmacists in the South Western region.
272. Kay E. Training pharmacists and technicians in Leeds Western health authority. Pharm J
1990;245:524-5.
Descriptive report:
This paper described an approach to the provision of education for pharmacists and technicians
at a single hospital. Junior pharmacists received training in a planned rotation that involved a
combination of practical experience and formal training. Assessment was performed using an
appraisal interview with the pharmacists' departmental manager. Clinical training was
mandatory for these pharmacists. It was organised in blocks of 5 weeks. Participants received a
training manual which contained reading lists, a series of objectives, a selection of case
histories and examples of patient management problems. About 3 hours a week were devoted
to training for each participant. Trainees were assessed by a tutor using standard forms which
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allowed the tutee to give their opinions on the training received. Training initiatives for other
pharmacists included seminars, workshops and a journal club (which was shared with junior
medical staff). Technician training included weekly seminars on appropriate topics.
273. Clarke CM. The development of clinical pharmacy training programmes with special reference
to the development, structuring and assessment of an in-service training programme.
Proceedings of the Guild 1986;21:3-17.
Report:
This paper described the factors that had created a demand for clinical training, such as
pharmacists' increasing involvement in clinical pharmacy activities that demanded a new
perspective on their role. The aims and objectives of the course were listed and compared to
existing MSc and undergraduate courses at the local university. The aims of the different
courses were similar but the goals for, and the expectations of, the students were different. The
in-service training offered an intense period of exposure to patient-orientated activities. The
undergraduate teaching course involved 10 weeks of weekly three hour sessions at the hospital
in patient-orientated situations and weekly three hour tutorial. The article described the
teaching methods and learning situations used and tutor and trainee activities and
responsibilities. A survey was carried out three months after the in-service course to assess
participants' clinical pharmacy activities before and after completing the course. A random
sample of 30 was analyzed. There was an increase in pharmacist attendance on consultant ward
rounds from 15 to 20, in reading medical notes from 17 to 23, in taking drug histories from 2
to 7, in the provision of patient counselling from 12 to 17, in the provision of presentations to
colleaguesfromlotol2andinkeepingalogbookfromlto5;therewasnoincreasein
routine ward visits (26). Participants listed reading the notes, interpretation of biochemistry
results and haematology reports, intensive involvement on the ward, keeping a log book and
individual and group tutorials as the most useful aspects of the course.
274. Mitchell R and Veitch B. Continuing professional development - a role for the College of
Pharmacy Practice. Pharm J 1992;24:E8.
Report:
The College of Pharmacy Practice (CPP), in this paper, considered continuing education an
essential part of professional development. They described various college activities in the
educational sphere.
275. Gillow JL, Pratt JP and Banks R. Pharmacy involvement with registrar training in learning
disabilities. Pharm J 1994;252;370.
Descriptive study:
This paper described pharmacy input into training for a registrar using an audit cycle where the
doctor's training needs were assessed, efforts were made to meet them and the registrar's
needs were reassessed. A form was designed to allow the recording of clinical problems
encountered by the registrar, the action required and the outcome. The forms enabled the
provision of constructive targeted education by pharmacists for the registrar.
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276. Noyce PR. The role of the hospital pharmacist in the introduction of new medicines. Clinical
Trials. Pharm J 1985;235:367-69.
Opinion paper:
The author advocated a role for pharmacists in the design, ethics, organisation and
implementation of clinical trials.
277. Bramble P. The role of hospital pharmacists in clinical trials (letter). Pharm J 1992;248:6.
Descriptive study:
This paper reported the results of a pre-registration project which assessed what consultants and
pharmaceutical companies thought of the hospital pharmacists' role in trials. Although most
thought that pharmacists should be involved in organising the supply, recording and dispensing
of trial medicines, only half thought that they should be involved in the initial liaison with
companies and about 60% thought that they should be involved in the ethics committee.
278. Anon. Clinical trials. Pharm I 1992;248:766.
Report:
This paper reported a policy statement issued by the Guild of Hospital Pharmacists on the role
of hospital pharmacy in clinical trials. According to the Guild, pharmacists should be involved
in all aspects of trials. This included ethical committee involvement as well as the storage and
supply of drugs and the documentation of dispensing.
279. Ambler S. Pharmacy practice research and the Department of Health. Proceedings of a
conference on Pharmacy Practice Research hosted by the Department of Health and the Royal
Phannaceutical Society. London: The Royal Pharmaceutical Society, 1991:77-9.
Statement:
The author described Department of Health initiatives to increase pharmacy practice research.
Included was a description of the Enterprise Award scheme to fund pharmacists to undertake
research and research training in approved (non-pharmacy) institutions. The aim of the scheme
was to increase the pool of knowledge in pharmacy of social and behaviourial sciences
methods.
280. Anon. Practice Research Strategy for Britain. hit I Pharm Pract 1993;2: 188.
Statement:
This stated that a practice research strategy for pharmacy had been agreed by the Royal
Pharmaceutical Society of Great Britain and the College of Pharmacy Practice in consultation
with the Government health departments. The statement defined practice research and
underlined the Society's commitment to its development. It stated that the research would
advance knowledge, help in strategic developments and be applicable in practice. The Society
was to appoint a head of pharmacy practice research.
281. Jesson I, Jepson M, Kendall H and Pocock R. Multidisciplinary, commissioned research.
Pharm I 1991;247:8.
Opinion paper
This paper supported the use of multidisciplinary teams in practice research and discussed the
implications of commissioned work in pharmacy practice.
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282. Dingwall R. Pharmacy practice and the social sciences. Pharm J 1993;251:59-61.
Opinion paper:
This paper provided a view on how pharmacy practice research should develop. The author
argued that a partnership between various social sciences and pharmacy would benefit practice
research but the uncritical adoption of social science methods to pharmacy problems might lead
to poor quality research. He supported the idea (in the Enterprise Scheme) of training
pharmacists in non-pharmacy disciplines in non-pharmacy institutions. He examined the
arguments for applying social science methods to pharmacy problems as opposed to treating
pharmacy as a field in which social issues can be researched. He then explored a potential
research agenda for practice research that included research on pharmacy as a profession and
as an organisation, the effects on pharmacy of the changing division of labour in primary care,
and of changing health beliefs and the implications for medicine use. He also advocated the
consideration go the social process whereby new pharmaceutical entities enter the market place,
the impact of legislation on pharmacy, and the role of pharmacy in the social control of
medicines.
283. Report of a joint conference on Pharmacy Practice Research, Royal Pharmaceutical Society and
the Department of Health, 1991.
Report:
Many of the contributions in this publication reviewed the history of, and progress in,
pharmacy practice research in the UK and abroad, advantageous developments between
pharmacy and other health services researchers, and initiatives being undertaken by the
Department of Health and the Royal Pharmaceutical Society to promote pharmacy practice
research in the UK.
284. Savage I. Linking academic and pharmacy practice: the Brighton experience. Pharm J
1993 ;250: 158-9.
Descriptive report:
This paper described how the integration of research and practice can benefit both aspects of
pharmacy.
285. Savage I. Training for practice research. Pharm J 1992;248: 155-7.
Descriptive report:
This paper described the Enterprise scheme which funded and encouraged the development of
non-pharmacy research skills and hence further improved pharmacists' skills in practice
research.
286. Anon. Pharmacy practice research essential says Bill Darling. Pharm I 1994;252:411.
Opinion report:
This paper reported the opinion expressed by a senior pharmacy figure that practice research
was necessary to evaluate pharmacy services.
287. Greene R. Research methods in hospital pharmacy. Proceedings of the Guild 1983;16:3-6.
Descriptive report:
The author described research methods workshops that had been established at Chelsea School
of Pharmacy. The course was piloted in 1981 and run fully in subsequent years. It concentrated
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on teaching pharmacists research methods since the lack of research skills was thought to be
one of the main factors causing the poor quality of published pharmacy practice research.
Invited speakers, including sociologists and psychologists, taught on research theory and
methods that were applicable to pharmacy practice research. These courses placed research in
the context of the social situation. Teaching on the planning of research, sociological and
psychological methods of measurement, group work and other tasks filled the course. An
assessments of the course by 1981 participants rated it highly.
288. Branch CE, Bowden S, Roberts DE, Spencer MG and Luscombe DK. Is there a need for
unproved pharmacy services to the operating theatre. J Clin Pharm Ther 1993; 18:179-82.
Objective:
To determine the extent to which problems with stock control, accountability and wastage,
existed in theatres in a single hospital. To assess the need also for improved pharmacy services
to the operating theatre complex to improve drug control and patient safety and to assess the
feasibility of an operating theatre satellite.
Methods:
This study consisted of a review of the literature followed by an assessment of the cost of
drugs supplied to theatres in 1991/2 and the cost of usable and unusable (out of date, not in
usable condition) stock in theatres on a single day. Various options for the provision of
pharmacy services were costed.
Results:
In the financial year 1991/2 the value of stock supplied to theatre was £322056, which was
11% of the total drug budget for the hospital. Cost of stock in theatre was valued at £25574 of
which £887 (3.5%) was unusable. There was considerable duplication, poor storage and
organisation of stock in the theatres. The options for pharmacy services that were costed were
a satellite (too expensive at present since, unlike the US situation, no revenue could be
generated from the service), preparation of individual patient packs in the central pharmacy
(unacceptable because of possible delays in providing therapy and the cost of extra pharmacy
staff and porters) and expansion of the traditional distribution service plus clinical pharmacy
visits (the option chosen).
Assessment of study: (strength, size of effect, generalisability)
This was not an evaluation; it was an appraisal of the needs of a theatre complex for a
pharmacy service and the comparison of the costs of the various alternative strategies available
to solve the problems detected in a needs assessment. The study is representative of the better
studies on clinical pharmacy services in the UK, where many studies are designed to solve
problems rather than to evaluate services.
289. Mays N. Health Services Research in Pharmacy: A Critical Personal Review. Manchester:
Pharmacy Practice Research Resource Centre, 1994.
Descriptive Paper:
This was a personal review of some of the health services research literature in pharmacy
practice, particularly that relating to community pharmacy in the United Kingdom. Hand and
on-line search methods were used to locate literature. Three hundred abstracts of papers were
identified of which 130 were selected for complete reading. Selection was made subjectively on
the basis that the paper tackled important general health services research issues, that it tried to
assess costs, consequences or quality of services, that it tested hypotheses or tried to answer a
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research question, or that it drew on social science theory or methods. Mays found that the
pharmacy practice research literature mainly consisted of papers justifying the need for or
development of a service. This resulted in much useful descriptive research but little research
that was hypotheses driven, drew on social science theory or methods or involved collaboration
with other health care groups. The author focused mainly on community pharmacy. He
described the types of research that were commonly found, the limitations of this research and
the examples of sound pharmacy practice research. He created a list of his perceptions of the
current gaps in pharmacy practice research literature and indicated several methods that could
be used fruitfully by future researchers. The research gaps included the lack of large, multi-site
evaluations in primary care, studies of relations between pharmacists and other health
professionals and clients, studies of service quality, and studies of the influence of the
pharmaceutical industry and of health policy on phannacy.
290. Noyce PR. Information to patients and quality of life. Proceedings of the Guild 1986;22:35-8.
Opinion paper:
This paper set out the legal situation regarding patients' entitlement to information on
medications. It also discussed the impact and use of this information on patients' actions and
their quality of well-being and the complexities of the issues surrounding the provision of
appropriate information in a form that is useful to patients.
291. Kay EA, Moss IG and Rees JA. Patient information on antimalarial therapy for rheumatoid
patients. Pharm J 1987;239:19-20.
Objective:
To create and evaluate the effects on patients' knowledge of a patient information leaflet on
chioroquine.
Methods:
A prospective before/after survey was carried out to assess patients' knowledge of their
therapy. The study was performed at a single hospital. Knowledge was assessed using a
standardised questionnaires before, and one week, after patients had received the leaflet.
Results:
Informal discussions between a pharmacist and arthritic patients receiving chioroquine revealed
a need for additional information. The scores of 50 patients, who had not previously been
questioned about their therapy, improved significantly after receiving leaflets (p<0.001).
Improvements were found in knowledge of the reason for taking chioroquine with food (2%
increased to 50%), of the time lag for effects to be seen (48% increased to 84%), of the long
term nature of the therapy (32% increased to 76%) and awareness of various side effects other
than eye effects (such as skin rash, diarrhoea and nausea). Patients found the leaflet interesting.
Assessment of study: (strength, size of effect, generalisability)
This was a small study with moderate to large effect. There was a risk of confounding since
the interviewer could not be sure that patients were not reading from the leaflets in the after
phase of the telephone survey. The results are not generalisable. The results are limited also
since the study assessed only knowledge.
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292.	 Punchak SS and Kay EA. Educating arthritic patients about their drugs. Pharm J
1988;241:247-9.
Objective:
To describe an investigation into patients' knowledge of non-steroidal anti-inflammatory drugs
(NSAIDs) and intra-articular steroids (IACs). To write and test specific information leaflets.
Methods:
An assessment of patients' current knowledge of their therapy was conducted using a 30 minute
structured interview. The results were used to help create information leaflets. A prospective
randomised controlled trial was then undertaken to assess the effect of the information leaflets
on patients' knowledge of their therapy at a single hospital. Knowledge was assessed by a
standardised questionnaire, using a system that weighted the answers to important questions
more highly than those to less important questions. Assessment was carried out before, and one
week, after patients had received the leaflet.
Results:
Sixty eight outpatients and 32 inpatients were interviewed. Many showed that they knew little
about their therapy. The types of information requested by these patients included the purpose
of joint injections (24/59), the name of the preparation (14/59), the potential complications
(12/59), the expected duration of action (11/59), the frequency of repeat injections (7/59), the
side effects of NSAIDs and what to do about them (72/86), the problems with NSAID drug
interactions (61/86), how to recognise a response to NSAIDs (58/86), the purpose of the
NSAIDs (55/86), the name of the NSAID and the precautions to be taken whilst on NSAIDs
(49/86), when and how to take NSAIDs (47/86), and what to do if a dose is missed or how
long to continue the NSAID (46/86). Forty patients on NSAIDs and 40 on intra-articular
injections (IACs) were randomised to two test and control groups (n=20 in each). Those who
received patient information leaflets knew significantly more about their medicines than the
controls (p <0.001) and showed a significant improvement in their knowledge of their therapy
after receiving the leaflets. Control patients did not improve. The mean control group scores
were 5.8 in the before and 6.5 in the after phase; for the test group the scores were 6.7 before
and 14.8 after. For those on LACs, control group scores were 2.5 in the before and 2.8 in the
after phase; test JAC scores were 3.1 before and 8.5 after. After reading the leaflet patients
taking NSAIDS all took their drug after food and knew why this was necessary whereas before
receiving the leaflet 16 did so but only 9 knew why. All patients found the leaflets helpful.
Assessment of study: (strength, size of effect, generalisability)
This was a small study with moderate to large effect. There was a risk of confounding since
the interviewer could not be sure that patients were not reading from the leaflets in the after
phase of the telephone survey. The results are not generalisable. They are limited in that they
assessed no factors other than knowledge and the taking NSAIDs with food.
293.	 Catterall G and Littlewood A. Compliance with steroid treatment card advice. Pharm J
1989;242:R27-8.
Descriptive study:
One hundred patients (64 in-patients and 36 out-patients) aged 27-83 at a single hospital who
had been prescribed prednisolone for the maintenance of respiratory/rheumatological
conditions, were interviewed using a structured questionnaire to determine if they carried a
steroid card and to establish the extent of their knowledge of their therapy. Eighty four patients
claimed that they had a card but only 67 could produce one. Sixty three patients had a card and
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knew that abrupt discontinuation of therapy was undesirable; only 22 kept a supply of tablets in
reserve. Only one third knew what to do in the case of illness or knew that indigestion was a
side effect of therapy. Twenty percent knew what to do if they experienced indigestion. Half
would show the card to a doctor, 26% to a dentist, 21% to a nurse, and 8% to a pharmacist.
Of the 84 claiming that they had a card, 46 said that the dose recorded on the card was not up
to date and was different from that being taken. Only 47 patients knew that prednisolone was a
steroid and a only further 16 could relate it to their illness in some way.
294. Butler N, Skinner C and Graham NC. Asthmatics' attitudes to their condition and
understanding of their medication. Pharm J 1989;242:R25-7.
Descriptive study:
Eighty asthmatic patients, aged 16-77, at a single hospital (46 referrals to an asthma clinic and
34 who had been admitted with acute severe asthma) completed a structured questionnaire soon
after the first clinic visit or, for acute admissions, as soon as possible after recovery, to assess
their knowledge of and attitude to their disease and its treatment and prevention. Inhaler
technique was checked for 68 patients using a pre-determined method. Three quarters of young
smokers said that they had been advised to stop smoking by a doctor compared to 33% of older
smokers. Thirty seven (46%) patients thought that their asthma was sometimes or always
serious whereas 38 regarded it as just a nuisance. Of those taking prophylactic medication,
58% of young men, and 43% of the rest, thought that it prevented asthma. The majority (63%)
of patients scored the maximum for inhaler technique and many of the rest scored highly. Most
patients had been shown how to take their inhaler by a doctor, nurse or pharmacy technician.
Many young men would simply increase their medication if their asthma worsened suddenly. A
quarter of patients said they bad received helpful information on their asthma but none said that
it had been given by a pharmacist. Most patients (89%) would like more information on how to
prevent attacks (74%), on what the drugs do (66%), what to do when having an attack (59%),
what happens during an attack (57%) and how to take treatment properly (34%); the preferred
sources were hospital doctors or general practitioners.
295. Kay EA. Teaching patients about gold therapy. Pharm J 1985;235:545-6.
Objective:
To investigate patients' knowledge of gold therapy and to produce and assess a booklet
providing information on the topic.
Methods:
An interview study was conducted, using a standardised questionnaire to assess the knowledge
of patients attending out-patient clinics at one hospital. Based on the results, a booklet was
created and assessed by professionals prior to assessment by patients in a randomised trial.
Twenty six patients were randomly selected and divided into three groups as follows; group A
(n=12) got no additional information and groups B (n=7) and C (n=7) were given the
booklet. Group A were re-interviewed after 3 months. Group C were warned to expect an
interview after a week and Group B were not. Those in Groups B and C were matched for
age, sex and initial knowledge score but were not matched with Group A.
Results:
Ninety one patients were interviewed of which 70 considered the therapy to be effective, 42
said it reduced their pain and 38 said that it made them feel better. Seven patients were unable
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to recall any possible side effects. They said that the usual source of information on side effects
was the hospital doctor (48%) followed by the gold monitoring card (25%) and nurses (20%).
Only 45% could name a single monitoring test and 37% were dissatisfied with the information
that had been provided in the past. Group A's knowledge remained unchanged. All Group B
had read the booklet; 3 read it twice. Six of seven in Group C read all the booklet and 1 read
part of it. Reading the booklet took 15-30 minutes. Six patients in groups B and C who had
been dissatisfied with previous information were now satisfied. Patients in groups B and C
knew more about their therapy than those in group A but no data were provided on this; often
the increase was small and the score in group C was not different from that in group B
(showing that the promise of a re-interview had no effect).
Assessment of study: (strength, size of effect, generalisability)
This was a description since no evaluative information was presented.
296. Booth C. Would diabetic patients find talking to a pharmacist useful? Pharm J 1993;251:169-
70.
Descriptive study:
A self-completed questionnaire survey of 51 adults with diabetes mellitus (DM) (23 insulin-
dependent (IDDM) and 27 non-insulin dependent (N1DDM)) attending an out-patient clinic at a
single hospital showed that 78% of IDDM patients could correctly name their medication
regime compared to 54% of those with NIDDM. Most (71%) IDDM patients, and 58% of
NIDDM patients, said that they knew enough about their diabetes yet many indicated that they
would like to know more about specific areas (70% with IDDM and 50% with NTDDM),
including side effects of drugs, what to do about missed doses and information on the
complications of DM. Most claimed that they received the most useful information from
doctors (83% and 76% respectively for IDDM and NIDDM). None mentioned receiving
information from a pharmacist. More NIDDM (76%) than IDDM (40%) patients said that they
would find it useful to talk with a pharmacist about their medicines. Half of IDDM patients and
65% of NIDDM patients would find an information leaflet on their medicines useful.
297. Eagleton JM, Walker FS and Barber ND. An investigation into patient compliance with
hospital discharge medication. hit J Pharm Pract 1993;2: 107-10.
Descriptive study:
Using a structure attitudinal questionnaire, administered in an interview by a clinical
pharmacist and tablet counts, an assessment was made of 50 adult medical patients' knowledge
of their medicines and their compliance within 2 weeks of discharge from a single hospital.
Eleven patients deviated from their regimen. Fewer than 25% knew the name of their
medications or the purpose for which it was being taken and 70% knew no side effects. No
correlation was found between knowledge and compliance but the authors concluded that
patients on more than 4 medicines may be at a high risk of non-compliance. Half of the
patients felt they got insufficient information on their medicines.
298. Morrison J. Eye drop aids and counselling sessions for glaucoma patients. Hospital Pharmacy
Practice 1993;3:413-8.
Objective:
To find out any problems that glaucoma patients might have with eye drops, how to help them
overcome these problems and to discover the usefulness of certain eye drop aids.
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Methods:
This was a prospective cross-sectional and before/after study. A structured interview was used
to find out patients' knowledge of their condition and any problems they were experiencing
with their eye drops. A skill test was used to assess technique. Some patients were thereby
selected for follow-up. These received counselling and/or an installation aid and were followed-
up 5 weeks later by telephone or postal questionnaire.
Results:
Thirty five patients were recruited from an out-patient clinic in a single hospital. Thirty three
of these knew their diagnosis but only 3 could describe the cause of the glaucoma. The same
number knew the name of their medication but 21 did not know why it had been prescribed.
Three said that they did not understand or could not remember the directions that they had
been given. Sixteen patients were followed-up and 15 responded to the second questionnaire.
Of these 13 knew the cause of their glaucoma and felt more confident about using their eye
drops after the counselling session, and 12 fared better with their administration aid than they
had before.
Assessment of study: (strength, size of effect, generalisability)
The study was small, poorly controlled, subject to bias (clinical pharmacist, telephone
interview) and was carried out at a single site. Many measurements were subjective. The
results are not generalisable.
299. Kay EA, Bailie GR and Bernstein A. Patient knowledge of cardio-respiratory drugs. J Cliii
Pharm Ther 1988;13:263-8.
Descriptive study:
This paper described the results of a structured questionnaire interview study of 85 out patients
at a single hospital to ascertain their knowledge of their therapy. Most (85%) knew the reason
for their therapy, and the frequency of its use (73%) but few had been told of the duration of
use (16%) or of potential adverse effects (8%). Patients often changed the dose when they felt
like it (34%) and many (47%) felt that they had experienced side effects. Many (68%) asked
question about their treatment on topics such as indication (38%), side effects (26%), dose
(20%), and duration (18%).
300. O'Connor M, Malone M and Hambleton R. An investigation into information provided for
patients on home parenteral nutrition. J Clin Pharm Ther 1988; 13:403-9.
Descriptive study:
This paper described the results of a structured questionnaire interview of 76 randomly chosen
controls and the 34 patients receiving home parenteral nutrition from a single hospital to
ascertain their knowledge of therapy and to facilitate the production of an information booklet.
Patients and controls were similar in age, sex, education and marital status. The patients had an
adequate, but not significantly better, knowledge of nutrition (73% correct answers to
questions) than controls. Patients had significantly less understanding of parenteral nutrition and
the procedures used to monitor home nutrition than controls. Eighteen percent were unable to
name any components of feeding bags, 50% were aware they were receiving protein, only
15/29 knew why they were asked to breath into a metabolic cart (assesses basal metabolic rate)
and only 29% knew what brought about changes in their regimens. A booklet was created to
fill the knowledge gap based on the information that patients had said that they would find
useful. Thirty two patients completed an assessment questionnaire on the booklet. Most found
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it generally easy (53%) or very easy (44%) to understand, 28% said it contained information
that they did not know already but 72% said they learnt little from it and 19% said that they
would have appreciated getting the information at an earlier stage in therapy.
301. Horsley MG and Bailie GR. Risk factors for inadequate use of pressurised aerosol inhalers. J
Clin Pharm Ther 1988;13:139-43.
Objective:
To quantify the extent and nature of errors in pressurised aerosol inhalation (PM) technique in
asthmatics, to identify risk factors for poor technique and to assess the effect of structured
counselling by a phannacist.
Methods:
Eighty six asthmatics, in-patients and out-patients, were interviewed by a pharmacist and their
inhaler technique assessed using a structured assessment. If the score was less than a pre-set
figure, they were given instruction by a pharmacist using a standard technique. These patients
techniques were then reassessed directly after instruction.
Results:
Most patients were on one inhaler (56) and 24% had been using it for less than a week, 18%
foraperiodofaweekto6months, 17% for6monthsto2yearsand4l% formorethan2
years. There were 59 inadequate users. Inadequate use significantly correlated with increasing
age (p<0.02) and with the number of inhalers taken (p<O.O2) but not with duration of use.
Seventy five patients underwent reinstruction. This caused a significant improvement in score
(p <0.001); 54 were adequate users after instruction although older patients still fared worse.
Assessment of study: (strength, size of effect, generalisability)
This was a moderately-sized study. There were problems of potential bias, validity of
assessment and brevity of follow-up. The size of the result was moderate but the results were
not generalisable.
302. Cantrill JA. Discharge counselling by pharmacy - the need and the reality. Hospital Pharmacy
Practice 1992;2:429-33.
Descriptive study:
This article described an assessment of needs for discharge counselling that utilised changes in
therapy as a proxy for need. One hundred and twenty three patients medication was examined
over 12 weeks on one ward (93) and 4 weeks (30) on another. Sixty patients subsequently
received counselling from one of two pharmacists because they were being discharged on
medications. In total there were 544 changes in therapy in patients or an average of 4.8
medication changes/patient/admission (range 1-16). At the discharge counselling session, 52
problems were found in 37 patients. Some had received inadequate information (22), had an
inaccurate prescription (12) and had medication administration problems (9).
303. Aichtar R, Preece G and Sutciffe 1. A short drug history and identification service. Pharm I
1981;227:80-1.
Descriptive study:
This paper described the setting up of a drug history and identification service in a single
general hospital. The service was initially provided to two surgical wards with the aims of
identifying the drugs patients were taldng on admission, providing any relevant information on
drugs taken prior to admission and evaluating the feasibility of extending the service to all
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surgical wards as part of the ward pharmacy service. The pharmacist examined all the drugs
brought into the hospital by the patients, examined any general practitioners letters or other
relevant documents, and completed a drug identification form before talking informally with
the patient about their therapy and clarifying any other problems regarding medications. The
completed report was signed and left for the doctor's attention. During the 4 month trial period
188 forms were completed. In 19% of cases clarification of medicines being taken was
required but the pharmacy only had one request for this service from the other 12 wards in the
hospital. The authors claimed that this indicated a lack of nursing/medical awareness of these
issues. The service took a variable amount of time (2-45 minutes/day) and was continued with
a similar workload for the ensuing five months.
304.	 Dodds LI. An objective assessment of the role of the pharmacist in medication and compliance
history taking. Br J Pharmaceutical practice 1982;3: 12-24.
Objective:
To assess the impact of pharmacists taking medication histories by comparing those taken by
pharmacists and doctors and considering the interventions made as a result of the history-
taking.
Methods:
This project contained two studies.
Study I
Pharmacists took a medication history, separately from the doctor's normal history, on patients
admitted to gynaecological ward in a single hospital. Neither pharmacist nor doctor were to
look at the other's notes until both interviews were complete. Pharmacists used a questionnaire
designed for the purpose; doctors continued as normal. The content of doctor's and
pharmacist's interviews were compared for the second two months. The possible effects of the
history taking on patient counselling was assessed.
Study II
Interviews of GP admissions to a unit in another hospital were used to detect the number of
interventions that a pharmacist would make on the basis of medication histories. In this study
the pharmacist could consult the medical notes and nursing staff as required. Interviews took
place in the first 48 hours after admission.
Results:
Study I
Three hundred and two patients were interviewed over 4 months. Interviews occurred in the
first 24 hours of the admission and took 10 minutes on average. Forty one percent of the
entries in the pharmacists history in the first month of the comparison and 21 % in the second
were not recorded by the Senior House Officer (SHO). This difference was significant. Doctors
usually noted prescribed medicines but not those that were not prescribed. Fifty six percent
(month one) and 15% (month 2) of the adverse drug reactions (ADRs) detected by the
pharmacist were not reported by the SHO. Although 55% of ADRs reported by the pharmacist
were classed as drug allergies the physician had detected all except one ADR classified as an
allergy whereas the pharmacist often detected ADRs that seriously upset the patient or reduced
their quality of life and could affect compliance. About 20% of patients admitted to compliance
problems; 25% of these received discharge counselling as a result. Doctors, patients and nurses
were pleased with the service and reacted positively towards it.
Study II
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Interviews took about 15-30 minutes and 47 elderly patients were interviewed in 4 months.
There were 29 interventions directly resulting from the medication history taking service 16 of
which were directed at the prescriber. Therapy was adjusted in 13 cases. 8/16 interventions
were about drug side effects and 2 queried the need for the item. 10 of the 22 patients who
needed counselling would not have been selected for counselling in the absence of an
interview.
Assessment of study: (strength, size of effect, generalisability)
There was a risk of considerable bias in Study I since the doctor was aware of more
information at the time of drug history taking than the pharmacist. Other factors such as
learning curve and hawthorne effects were addressed. The size of the effect was moderate. The
lack of data on outcome makes it difficult to assess the pharmacists' contribution to care. The
process of care was, however, enhanced. The results are not generalisable. Bias might have
been a problem in study H but this was not an evaluation. It was a description and the results
are not generalisable.
305. Oakley JM and Perkins FF. A self-medication scheme for convalescent patients. Pharm J
1987;238:378-80.
Descriptive study:
This described the setting up of a self-medication program for rehabilitation and convalescent
patients in a small (60 bed) hospital. The aim was to increase patient's ability to care for
themselves following discharge. The scheme has been in operation since 1984 and over 1800
patients have been through it in this time. Nurses assessed the patient on admission and the
pharmacist assessed the medication regimen and discussed any changes with the doctor.
Patients who are very capable were given a week's supply in fully labelled containers and self-
medicated. Those who were less capable were started on daily supplies with nurse supervision
of self-administration. Gradually the supply was increased and the supervision decreased.
Patients who were initially judged incapable of self-medication were helped to cope better and
may eventually self-medicate. Patients were counselled as necessary by the pharmacist who
also answered any patient questions on drugs. Three cases were described to illustrate the
system.
306. Owen DS, James DW and Howard P. Self-medication schemes on the rheumatology ward. Br
J Pharmaceutical Practice 1987;9:386-90.
Descriptive study:
This paper described a self-medication scheme, started in 1984, for rheumatology patients at a
single hospital. The pharmacist took a medication history. After patients entered the scheme the
pharmacist counselled them and provided them with a card telling them how to take their
medicines. Of the 280 patients that had gone through the system, 91% were compliant with
their medications. The study claimed that patients knowledge of their therapy improved and
their satisfaction with the service was high but provided no data to substantiate these
statements.
307. Massey C. An evaluation of the benefits of pharmacist-acquired dnig histories. Proceedings of
the Guild 1987;25:80-1.
Objective:
To establish whether a pre-registration pharmacist takes more complete drug-histories than
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house officers and, if so, whether this is clinically important. To estimate the resource
implications of such a service.
Methods:
Newly admitted patients on 3 wards were identified by the pharmacist, their medical histories
read in the medical notes and their drug histories taken as soon as possible after admission.
The result of the medication histories were placed in the notes. Pharmacist drug histories were
compared with those taken by medical staff.
Results:
Sixty medication histories were taken by a pharmacist. This took 10 minutes per patient on
average. Compared with doctors' drug histories, those taken by the pharmacist were more
complete; doctors omitted 11.3% of prescription only medicines (POMs) taken regularly and
92.9% of those taken as required (pm), 35.9% of P category medicines taken regularly and
59.7% of those taken pm, and 100% of General Sales List (GSL) medicines taken regularly
and 75.6% of those taken pm. In total, doctors missed 40% of medicines being taken by
patients but only 8 omissions were thought to be clinically significant by the pharmacist. The
pharmacist noted 17 drug allergies and 13 adverse reactions; the doctor noted only 14 allergies.
Overall, 41.7% of the doctors' drug histories were inaccurate.
Assessment of study: (strength, size of effect, generalisability)
The effect was moderate. There was no estimation of the potential effect on patient outcomes
as a result of any omissions by the doctors that were detected by the pharmacist. The study
design was open to bias because the pharmacist knew of the study, looked at the doctors'
medical history prior to taking the medication history and judged the importance of the
omissions. The results are not generalisable.
308. Higham C. Drug history taking - a role for the ward pharmacist. Phann J 1982;22&302-6.
Descriptive study:
This paper described the establishment of a drug history taking service for rheumatology
patients at a single hospital. The history-taking method was described in detail and examples of
these provided. Histories taken by the pharmacist were entered in the case notes.
309. Corrigan MS. Primary pharmacy - a patients' self-help service. Pharm J 1989;243:458-60.
Descriptive study:
This paper described a self-medication scheme for medical patients at a single hospital. The
scheme ran alongside the primary nursing service. Patients used their own medicines in
hospital where possible and the pharmacy purchased special locked drug trolleys with
individual patient drawers, at a cost of £722 each, for the purpose of storing patients'
medications. Other costs were absorbed by the department of pharmacy but pharmacy staff
spent about double the amount of time that had been spent previously on the wards taking
medication histories and counselling patients. The article described the service and its
advantages and disadvantages. After six months 672 patients had been through the system.
Ward stocks had decreased by 20% and the health professionals involved had backed the
scheme enthusiastically.
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310. Baxendale C, Gourlay M and Gibson HiM. A self-medication retraining program. Br Med J
1978;ii: 1278-9.
Descriptive study:
This was a description of a self-medication program for geriatric patients in a single general
hospital in Glasgow. The consultant identified suitable patients at least 2 weeks prior to
discharge. The drug regimen was simplified if possible and a pharmacist interviewed the
patient, assessed their needs with respect to containers and labels and transferred the patients to
a self-medication system. Two days supply were given initially and nursing staff closely
supervised medication taking. After this the pharmacist checked with the patients on their
progress. If all was well, the scheme continued with reduced nursing supervision. The
pharmacist contacted the patient's own pharmacist prior to discharge to ensure that future
supplies were dispensed in suitable containers and contacted them again on the day of
discharge. They hoped to have patients followed up in the community by district nurses but this
has proved difficult. Overall, the scheme had progressed well.
311. Walker CA and Martin PC. In-patients self-medication in the elderly: a pilot scheme (abstract
of British Pharmaceutical Conference). Pharm I 1986;237:767-8.
Descriptive study:
This abstract described the setting up of a self-medication program for elderly patients in a
London hospital. Patients were selected for inclusion at a multidisciplinary ward meeting at
least two weeks before discharge. They were counselled by the pharmacist and given their own
drugs box. Patients' progressed through various stages during which nurse supervision
decreased and patient self-care increased. The supply of drugs given to patients' increased
gradually. Fifty patients have been through the scheme (21% of all discharges from the ward).
Seventy percent of those in the scheme derived some benefit from it. Of the remainder, 15%
would have managed without the scheme and 15% derived no benefit since they could not self-
medicate at all. The scheme took 50-60 minutes of pharmacist time per patient. Nursing staff
welcomed the scheme.
312. Trewin VF and Veitch GBA. Elderly patients at risk. Part 4:An assessment of self-medication
in the elderly. Br 3 Pharmaceutical Practice 1987;9:228-35.
Descriptive study:
This paper described the setting up of a self-medication program for elderly patients in one
hospital. Patients were selected at a multidisciplinary case conference. They were subsequently
counselled by pharmacists and had their medication-taking supervised by nurses. Nursing
supervision gradually decreased, and the quantity of drugs supplied to patients increased, as
patients become more self-caring. Patients receiving only one drug item had the best
compliance. Patients were re-counselled after 24 hours if necessary. This was found to improve
compliance for 31(26.2%) of patients, had no effect in 29 (24.6%) and reduced compliance
for 48.2% (58).
313. Simpson I and May LG. Self-administration in hospital - towards better compliance. Hospital
Pharmacy Practice 1992;2:30-33.
Descriptive study:
This paper described a self-medication scheme for use on acute medical wards at one hospital.
Any patient could be selected and assessed for self-medication. Doctors, nurse and pharmacists
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could assess patients but this was normally done by the doctors or nurses in the first 24 hours.
The paper described the scheme in detail.
314. Pratt JP and Dunnett NGM. A rehabilitation project for psychiatric patients. Pharm I
1985;234: 172-3.
Descriptive study:
This paper described a self-medication program for psychiatric patients to facilitate their
discharge to the community.
315. Wood SI, Calvert RT, Acomb C and Kay EA. A self-medication scheme for elderly patients
improves compliance with their medication regimens. mt I Pharm Pract 1992;! :240-1.
Objective:
To determine the effect of an in-patient self-medication programme on compliance post
discharge in elderly patients from 4 wards at two units of a single hospital.
Methods:
A prospective controlled trial was performed where patients were allocated to a control group
or a self-medication group depending on the unit of the hospital and the ward to which they
were admitted. Patients were similar as regards age, sex, mental test score and number of drug
taking events per day. Self-medicating patients graduated through a pm-set program whilst
controls received their discharge medication from nurses in the usual manner. The pharmacist
was involved in patient selection and in the creation of individualised self-medication regimens.
The pharmacist counselled selected patients on discharge. Compliance was assessed by tablet
count at 2 weeks and 3 months after discharge. Non-compliance could be 0 (full-compliance),
up to 15% (few errors) or in excess of 15% (many errors).
Results:
Of the 18 patients in the test group, 44% displayed full compliance and an additional 50% had
few errors at 2 weeks (compared to 13% and 40%, respectively, amongst the 15 patients in the
control group). At 3 months 7/11 test patients still being followed were fuliy compliant and a
further 1 had few errors. In contrast, 2/11 in the control group were fully compliant and a
further 1/1! made few errors. The differences between test and control groups in rates of non-
compliance in excess of 15% at 2 weeks and 3 months were significant (p<0.05).
Assessment of study: (strength, size of effect, generalisabiity)
The effect was moderate to large but the results are not generalisable. Due to the method of
assessing compliance (tablet count), however, there are concerns regarding the validity of the
results. One of the criteria for patients entry to the study was complete responsibility for their
own therapy so third party help was not formally assessed in this study. Yet 2/18 (11%) test
patients and 7/15 (47%) controls did receive some help from neighbours (Personal
communication, S Wood, 1993). This additional help did not improve medication taking in the
control group.
316. Snell M. Bristol's pharmacist for rheumatology and self-medication. Pharm I 1993;251:H518-
9.
Descriptive study:
This paper described the work of a rheumatology pharmacist who established and ran a scheme
to educate patients about their drugs. The self medication scheme was part of a
multidisciplinary patient education scheme. The article described the self-medication scheme in
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detail.
317. Sexton JA. Improvements in comprehension and other benefits to long stay psychiatric patients
following individualisation of medication. Proceedings of the Guild 1991 ;29: 59-63.
Objective:
To discover if individualisation of supply would increase psychiatric patients' comprehension of
their medicines at one hospital.
Methods:
Patients, selected by nurses as being representative, were allowed to handle their own drugs
under nursing supervision. Drugs were labelled individually and supplies were provided on a
fortnightly basis. Patients' comprehension of therapy was assessed on entry and at 10 weeks
after starting the program. Nurses' opinions were sought by questionnaire.
Results:
Sixteen patients completed the ten week study. Their comprehension scores improved
significantly (p<0.02). Twenty one nursing staff felt that the patients were more motivated not
to refuse medicines, that patient comprehension and compliance problems were now tackled
before discharge and patients gained an increased sense of responsibility, confidence insight,
self esteem, independence and decision-making capacity.
Assessment of study: (strength, size of effect, generalisability)
This study suffers from potential bias and small numbers. The results are not generalisable and
the effect was modest.
318. Baker D. An evaluation of drug information for cardiology patients. Proceedings of the Guild
1990;28:65-72. (Also published by Baker D, Roberts DE, Newcombe RG and Fox KAA in Br
J Clin Pharmac 1991;31:525-531).
Objective:
To establish if specially prepared drug information leaflets improves cardiology patients'
satisfaction with, and understanding of, their drug treatment.
Methods:
This was a prospective, randomised @atient allocation) trial. All patients over 18 years and
able to read who were admitted to a regional cardiology unit were invited to participate. On
discharge those agreeing to participate, and receiving drugs for which information leaflets had
been created, were randomised blindly to two groups; Group I (control) received the normal
verbal counselling about their medications and Group II (test) was given an individualised drug
information wallet. This wallet contained a leaflet giving general advice on medicines and
individual leaflets on each drug that the patient was receiving. Leaflets had been prepared on a
wide variety of drugs. Two weeks after discharge patients were asked to complete a postal
questionnaire to determine their satisfaction with the information provided and their
understanding of the use of the drug that they were receiving. This questionnaire was designed
in consultation with a clinical psychologist and had been piloted. Comparisons were made using
a Mann Whitney, Chi squared or Fischer exact test as appropriate.
Results:
One hundred and seventy of the 195 patients were receiving drugs for which leaflets were
available. Forty five patients were lost to follow-up due to their transfer to the surgery
department and 125 patients were randomised eventually. Questionnaires were returned from
101 (81 %) and there were 12 non-responders in each group. Group I (n=49) and Group II
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(n-52) patients were similar in age, sex and the number of drugs that they were receiving
(mean = 3.4, sd = 1.5). Patients receiving written information in addition to verbal information
showed significantly greater recall of information received and a greater knowledge of what to
do about missed doses, and of side effects and what to do about side effects (p cZO.001). These
patients were significantly more satisfied with the amount, quality, clarity and usefulness of
information given to them (p<O.001) and were less worried by it (p<O.OS) than were
controls. There was no significant difference between groups in the proportion of patients that
would continue the drug but tell the doctor if they experienced side effects for digoxin or beta
blockers. The findings suggested that the use of information leaflets in addition to verbal
counselling increased patients' understanding of their drug therapy and their satisfaction with
the information provided.
Assessment of study: (strength, size of effect, generalisability)
The size of the effect was moderate to large. This was a well-conducted study but there was a
risk that patients would have used the leaflets to answer questions related to recall of
information. This was not discussed in the paper. Nevertheless, patient satisfaction was higher
in the test group. Patients were comparable, the exclusion criteria were reasonable and bias in
assessment (by health professionals) was not an issue. The results are not generalisable.
319. MacDonald ET, MacDonald JB and Phoenix M. Improving drug compliance after hospital
discharge. Br Med J 1977;(ii):618-21.
Objective:
To assess the value of discharge counselling by a pharmacist and memory aids in improving
compliance in geriatric patients at one hospital.
Methods:
Patients were allocated, by rotation, to three groups. Sixty patients were counselled by a
pharmacist before discharge and their understanding of their therapy was checked. A formal
assessment was made of their understanding at the end of the session. About 15 minutes was
spent by the pharmacist in each session. Forty five patients were counselled before discharge in
the above manner but they were also issued with a memory aid, a pill wheel, an individual tear
off daily calender specifying the medication schedule, or a tablet identification card with a
sample of the tablets alongside the dosage schedule. Sixty patients acting as controls received
no extra counselling from the pharmacist but received only the usual brief description of tablet
types. No patient was excluded on the basis of mental frailty or visual acuity. All patients
completed the mental status questionnaire (MSQ). Where patients were illiterate, or had poor
vision, the tablet bottles were marked in a manner appropriate to their disability. All patients
were able to manage to take their tablets before leaving hospital. A week after discharge
patients were asked to detail their dosing schedule and to describe the purpose of the tablets.
Drug compliance was checked and the patient was given another weeks' supply. Patients
attended the day hospital twice a week and were formally assessed at 1,6 and 12 weeks after
discharge in addition to random "spot tests.
Results:
Patients in the three groups were similar in age, sex, MSQ score and number of tablets being
taken. Improved compliance was seen in the counselled groups at follow-up. The increase in
correct tablet taking was significant in those whose MSQ exceeded 12 (p<O.Ol) and in those
with an MSQ score of less than 12 (,p<O.05). Multiple errors were more common in patients
who had not received any counselling. The use of memory aids in addition to counselling did
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not improve compliance in general. At 12 weeks 14 60 patients who received no counselling
were making no errors in their medication (compared to 31/60 of those who had received
counselled and 18/45 of those counselled and given dosage aids). Forty two percent of those
who had received no counselling could remember their dosage regimen (compared to 68% of
those counselled and 67% of those counselled and given dosage aids).
Assessment of study: (strength, size of effect, generalisability)
The size of the effect was moderate. Problems with the compliance assessment method brings
the validity of the study into question. Tablet count may not give a reliable indication of the
number of tablets actually being taken and, additionally, does not measure when the tablets
were taken. The spot checks and the examination of patients' knowledge of their dosage
schedule reduced this potential problem in this study but the assessment of patients' knowledge
by the counsellor (pharmacist) may have biased the results. The results are not generalisable
since they involved a single pharmacist at one hospital.
320. Wandless I and Whitmore J. The effects of counselling by a pharmacist of drug compliance in
elderly patients. J Clin Hosp Pharm 1981;1:51-6.
Objective:
To assess the effect of counselling by a pharmacist on drug compliance in a group of elderly
patients (65 years or over) attending a day hospital.
Methods:
The study randomly allocated patients with a metal test score (MTS) of 20 or more to a control
or test group. Test patients were counselled by a pharmacist and controls received no
counselling. On attendance at the day hospital patients were asked to bring their tablets with
them. Compliance was assessed by tablet count. Initial knowledge was assessed, for the test
group, by the pharmacist having them disclose their dosage regimen. The patient was
counselled and then asked to recall the regimen to ensure understanding. Their knowledge was
assessed at the time using a 10 point scale. Interviews usually lasted 14.4 minutes (range 8-20).
Results:
Twenty three patients were allocated to the control group and 30 to the test group. Patients
were similar in age, MTS and number of prescribed medicines but their error rates at the
beginning of the study were significantly different. Test patients were counselled within 2-4
weeks of entry into the trial. Before counselling, 13 test patients were non-compliant; after
counselling 14 were non-compliant. The number of errors did not decrease significantly. The
initial difference between the test and control groups persisted past 4 weeks after counselling.
Verbal counselling did not improve compliance.
Assessment of study: (strength, size of effect, generalisability)
Differences in patients at baseline, the use of tablet counts as a method of assessing compliance
and the use of the counsellor to assess knowledge and errors, make the results subject to bias
and confounding and hence difficult to interpret. No effect was seen and the results are not
generalisable.
321. Palmer B. Patient education and drug therapy. Pharm J 1979;223:562-6.
Descriptive study:
This was a description of a number of efforts to provide more, and better quality, information
to general medical patients with chronic illnesses on four wards at one general hospital. The
activities undertaken were better labelling, patient counselling on discharge and the provision of
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an information sheet and a medication record card for each patient. Labelling increased
pharmacy costs by 20% for labour and about £4/month for labels but patients were pleased
with them and found them helpful. Over 4 weeks 436 patients were discharged of which 80%
(350) were counselled by the pharmacist. This took an average of 5-6 minutes per patient
(range 2-30 minutes). The ward sisters were very appreciative of the service since it saved
them time. Information sheets and record cards were prepared for 20 common classes of
medicines. These were sent to physicians for comment. The information provided included
drug name, use, action, advice on drug use and side effects and what to do if side effects
occurred. The record card, which contained a record of the medications being taken on
discharge, was given to patients and they could have their community pharmacist update the
card in the future. The information and record cards were welcomed by patients, doctors and
nurses and also patients' relatives. There was a subjective feeling of increased patient
knowledge. A questionnaire administered to patients the day before discharge ascertained the
type of information they would like to receive. The commonest types were how and when to
take the medicine (95%), what it was for (95%), its name (90%), the importance of taking it
regularly (83%) and side effects and what to do about them (74%). An additional pharmacist
would be required if the service were to be provided in the hospital.
322. Edwards M and Pathy MSJ. Drug counselling in the elderly and predicting compliance. The
Practitioner 1984;22&291-300.
Objective:
To compare the effect on patient compliance of the use of a standardised counselling protocol
by doctors, nurses and pharmacists.
Methods:
This was a prospective randomised controlled trial (single blind). Consecutive convalescent
elderly patients at a single hospital, who were over 65 years, living at home by themselves or
with their spouse, capable of being responsible for their own medication and taking at least one
oral preparation, were randomly allocated to one of four groups. These were no counselling
(n=20) or counselling by a nurse (n=25), doctor (n=19) or pharmacist (n=18). On the day of
discharge, patients were given a weeks' supply of drugs and counselling was carried out using
a standardised protocol. Patients who were unable to comprehend the instructions after three
attempts were withdrawn. This resulted in one withdrawal each in the doctor and nurse
groups. These patients were, however, included in the analyses as complete non-compliers.
Ten doctors, fifteen nurses and three pharmacists were involved in the study. Control patients
received a weeks' drug supply, which was given to them by the nurses in the usual manner.
All patients' mental status was assessed prior to discharge by nurses. Six days after returning
home a health visitor, who was unaware of the group to which the patient had been assigned,
visited the patient and assessed compliance by tablet count. Patients were asked to recall their
drug regimen. Inability to read the labels and any other problems were also noted. Results
were analyzed appropriately.
Results:
Patients in all groups were similar in age, sex and number of drugs/doses per day prescribed;
differences in home status had no effect on compliance. The mean mental test score was
significantly lower in the control group than in the test group. Improvement in compliance was
seen in the counselled group irrespective of who did the counselling (p<O.Ol). Doctors
(p <0.05) performed better than pharmacists or nurses (p <0.1). Counselled patients also
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showed better recall (p <0.02) and a greater awareness of how to obtain further supplies of
medicines. All counselled patients knew how to obtain more medicines compared with 3/20
controls (p <0.05) but counselling did not, however, lessen the taking of additional non-
prescription medications.
Assessment of study: (strength, size of effect, generalisability)
There was a possibility of bias in this study due to difference in mental score between
counselled and non-counselled groups. The size of the effect was moderate-large but the results
are not generalisable since the study was carried out at a single site. The involvement of
several practitioners makes the results more robust than those of other studies but the shortness
of follow-up limits the study.
323. Johnston M, Clarke A, Mundy K, Cromarty E and Ridout K. Facilitating comprehension of
discharge medication in elderly patients. Age and Aging 1986; 15:304-6.
Objective:
To assess the effect of counselling on compliance in elderly patients.
Methods:
A prospective randomised controlled trial was conducted in a single hospital. The control group
received the usual nurse counselling on discharge. Patients in the test group were given
additional standardised counselling (15 minutes) by a clinical pharmacist. Later on the day
when patients were counselled, a psychologist blindly assessed the patients' knowledge using a
standardised format and assessed their degree of orientation.
Results:
Thirteen controls and 14 test patients were recruited. Elderly patients' knowledge of medicines
was increased in the short term by pharmacy counselling. Test and control patients were
similar in age, sex, orientation score and the number of drugs being taken. Counselled patients
were significantly better informed about their medicines than controls (p <0.02).
Assessment of study: (strength, size of effect, generalisabiity)
A modest to large effect was seen but the assessment was not followed by a post-discharge
assessment making it difficult to estimate the true effects of the counselling. The results are
not generalisable.
324. Curtis CE. Pharmacist conducted patient discharge medication counselling. Pharm J
1988;241:HS33-4.
Descriptive study:
This paper assessed the feasibility of a pharmacist providing discharge counselling. Patient's
views on this service were assessed at a single hospital. Fifty eight general medical patients on
three or more medicines (22% of discharges) were counselled on discharge by one of the
pharmacists. This took an average of 11.4 minutes per patient or 60 minutes/week for the ward
studied. Fifty five of the 58 patients received questionnaires which they were asked to complete
at one week after discharge; 26(47%) returned the questionnaire. Twenty four found the
sessions useful. They could recall the names of 4 medicine on average (discharged on mean of
4.9), could recall many of the reasons for taking the medicines and fewer side effects. Ranked
in order of importance, 52% of patients thought that information on when to take medicines
was the most important followed by what the medicines are (29%), side effects (52%), drug
names (41%) and storage information (64%) (results from 17 patients).
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325. Colaluca A, Glet R, Smith D, Hunter G, Kinsman M and Purkiss R. In-patient counselling - a
technician's role. Br J Pharmaceutical Practice 1988; 10:334-40.
Descriptive study:
This paper reported on the setting up of a program to train technicians to counsel patients. An
eight week training program was set up. Suitable patients were selected for counselling at
discharge by pharmacists. The pharmacist provided the technician with information on the
patient and gave sufficient advance notice to allow the technician to prepare the counselling
material. In routine practice patient selection took 5-10 minutes per patient and technician
counselling took 30-60 minutes (including preparation time). The scheme was considered to be
worthwhile.
326. Sweeney SJ, Dixon JS and Sutcliffe I. The impact of the clinical pharmacist on compliance in a
geriatric population. Pharm J 1989;242:R4-6.
Objective:
To ascertain if a pharmacist could increase compliance by counselling elderly patients prior to
discharge using large print labels, compliance aids and information leaflets where appropriate.
To evaluate the effect on compliance of the number of medicines prescribed, the frequency of
administration and patients' social status.
Methods:
A prospective controlled study was carried out on 103 consecutive patients discharged from a
single hospital who were over 60, taking more than two medicines, responsible for self-
administration, and not receiving anticoagulants, chemotherapy or topical dermatological
preparations. Patients were allocated first to the control group (n=52) and then to the test
group (n=51). Patients were followed up at one and 6-7 weeks post discharge by the
pharmacist to asses their ability to cope with their medicines (by questioning) and to assess
their compliance (tablet count). Questions were asked also about other medicines that were
being taken. A re-supply of medicines was given (2 weeks supply initially and at 6-7 weeks an
8 weeks supply at the first visit). Patients were divided into those whose compliance was
excellent, those who made few errors and those who made sufficient errors to compromise
their well-being (>15% non-compliance as assessed by tablet count).
Results:
Patients were similar in age and sex. The mean number of medicines being taken by controls
was 3.7 (4.6 for test patients). Seventy percent of patients were followed up fully. Perfect
compliance was doubled in the test group and serious non-compliance reduced by 80% at 6-7
weeks. Counselling took 5-15 minutes. Many patients found the large print helpful; other aids
were also found to be helpful.
Assessment of study: (strength, size of effect, generailsability)
This study was open to bias, because the assessor was aware of the group to which patients
belonged, and confounding, due to compliance being assessed by tablet counting. In the
circumstances it was reasonable not to randomise but a larger number of medicines were being
taken by test patients at baseline which may have influenced the results. The effect was
moderate but not generalisable.
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327. Dodds U. Effects of information leaflets on compliance with antibiotic therapy. Pharm J 1986;
236:48-51.
Objective:
To evaluate the effect of antibiotic information leaflets on compliance by patients who had been
discharged from hospital.
Methods:
In a prospective single blind controlled study at a single hospital, patients were randomly
allocated to a control group or to receive a leaflet on one antibiotic. Nurses were requested not
to provide additional counselling; if the patient asked for it they were withdrawn. Compliance
was assessed, by a pharmacist who was aware of the group to which patients belonged, using
tablet count and an interview 3-5 days after discharge. The interview was standardised and was
scored by the pharmacist doing the visit and an independent assessor.
Results:
Over 3 months, 30 control and 31 test patients were recruited. They were similar at baseline in
age, sex, number of drugs prescribed, and the number and doses of antibiotics prescribed.
Compliance, knowledge and behavioral scores were significantly higher in the test group than
in the control group (p<0.01). Patients receiving two antibiotics (n=22) were given a leaflet
on one. Their scores for that antibiotic were significantly higher than for the other antibiotic
that they were taking and for which they had received no leaflet (p <0.05). There were no
differences between groups in the number of ADRs that patients reported. Patients receiving
the leaflets reacted favourably to them; 80% thought that they were useful and 70% thought
that they were necessary.
Assessment of study: (strength, size of effect, generalisability)
The study controlled for bias and confounding but it was conducted at a single site. The results
for study with an appropriately short follow-up period cannot be extended to other drugs that
may be taken for longer periods. The effect was modest to large but the results are not
generalisable.
328. Sandier DA, Mitchell JRA, Fellows A and Garner ST. Is an information booklet for patients
leaving hospital helpful and useful? Br Med J 1989;298;870-4.
Objective:
To determine if a booklet given to general medical patients on discharge, which included
details of their admission and treatment, increased their knowledge and recall at subsequent
outpatient clinics.
Methods:
A prospective trial was carried out with alternate allocation to test (n=65) and control (n=66)
groups. Patients were stratified by age (up to 65 years and over 65 years) and the number of
weeks between discharge and first outpatient visit (up to 3, 4, 5, 8 and over 8). The assessment
was made using a questionnaire adinimstered by the investigators at the first outpatient
attendance. Data were collected over nine months. Patients' educational status was noted and
also whether they used the booklet or other sources to answer questions on their treatment at
the assessment. Patients' general practitioners were asked to return an appraisal form on the
booklet.
Results:
Patients' knowledge of their medicines was increased by a joint pharmacy-physician booklet;
recall of drug name, frequency of dose and reason for taking the drug was better in the test
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(86%, 95% and 85% respectively) than in the control group (47%, 58% and 42% respectively)
(p<0.001). Many patients used the booklet as an aide memoir. Even if these patients' results
were excluded, a significant difference remained between test and control groups in their
ability to recall information about their therapy. Most (98%) test patients and 73% of control
patients would take the correct action when their supply ran out. Most patients (86%) had read
the booklet at least once. Seventy two percent of GPs replied to the appraisal forms. Of these
91 % thought it was a good idea, 81 % thought it would be helpful to them and to the patients,
and 72% though that it was an improvement on the old system.
Assessment of study: (strength, size of effect, generalisability)
A moderate to large effect was seen in this well-performed study but the results may he subject
to bias due to alternate rather than random allocation of patients. The results are not
generalisable since the study was conducted at a single site.
329. Raynor DK, Booth TO and Blenkinsopp A. Effects of a computer generated reminder chart on
patients' compliance with drug regimens. Br Med J 1993;306:1158-61.
Objective:
To investigate whether a reminder chart improved patients' compliance with their drug regimen
after discharge from hospital.
Methods:
A prospective randomised controlled trial was performed of patients being discharged from a
single general hospital who were regularly receiving two or more medications. Patients were
randomised to four groups. Two groups received the reminder chart (a computer generated
chart which listed details of the medicines being taken and when they were to be taken). One
of these two groups also received routine counselling from a nurse and the other group
received structured counselling from a pharmacist which included an explanation of the
reminder chart. The other two groups received only counselling, from either a nurse or a
pharmacist. Patients were visited 10 days later and questioned about their regimen to assess
their knowledge. Compliance was assessed by a pharmacist investigator using tablet count.
Results:
One hundred and ninety seven patients were involved. The statistical method was appropriate
and groups were similar at baseline with respect to age, sex and number of medicines being
taken. Patient compliance and knowledge of medicines were increased by a pharmacy-
generated reminder chart. Of those receiving it, 83% correctly described their drug regimen
(95% confidence interval =74-90 %) compared with 47% (95% CI=37-58%) of those without
the chart (p <0.001). Pharmacist counselling alone did not improve knowledge nor had it an
additional effect on knowledge over nurse counselling. The mean compliance score was 86%
(95% CI=81-91 %) in the two groups with no reminder chart compared to 91% (95% CI=87-
94%) in the group with a chart but no counselling and 95% (95% CI=93-98%) in the group
with the chart and counselling. A mean compliance score in excess of 85% was achieved by
63% (95% CI =53-73%) of those without a reminder chart and by 86% (95% CI =78-93%) by
those with it (p .czO.001). Most patients receiving the chart thought it was useful in helping
them take their medicines correctly (66/98) and had used it (86/98).
Assessment of study: (strength, size of effect, generalisability)
This was a well-conducted moderately-sized randomised trial. The effect was moderate to
large. Precautions were taken to optimise the validity of tablet counting as a method of
assessing compliance and to ensure that a note was made of patients who read the instructions
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from labels reminder chart. A small risk of bias remained due to the pharmacist assessing
patients' knowledge. It excluded patients with reading difficulties, the illiterate, and those with
visual impairment (among others), followed patients for only 10 days and was conducted at a
single site, hence the results are of limited generalisabiity.
330. Gibbs S, Waters WE and George CF. Prescription information leaflets: a national survey. J
Royal Society Medicine 1990;83:292-7.
Descriptive study:
This was an evaluative study of the effect of information leaflets (on penicillins, NSAIDs or
beta blockers) that were given to patients in community pharmacies on their knowledge of their
medicines and satisfaction with this information. The 1809 patients who received leaflets were
significantly more satisfied with the information received and knew more about their medicines
than the 1601 who had not been given them.
331. Furner M, Habing-Ridout H, Cross J, Wray L, DOCIdS L and Collins G. Patient information
leaflets. Pharm J 1994;252:7.
Opinion paper:
The view was expressed in this paper that patient information leaflets, which from 1/1/94 must
be provided as package inserts by the pharmaceutical industry, could be helpful in increasing
patient information on their medicines. Although there will be a need for the industry and
pharmacists to adjust to the new situation, they felt that pharmacists should take advantage of
the change in the law to optimise the provision of advice to patients.
332. Dodds L. Industry-produced patient infonnation leaflets; Are hospital phannacies making use
of them? Pharm J 1993;250:311-4.
Descriptive study:
As part of this study the attitudes of a systematic sample of 100 hospital pharmacies to
industry-produced patient information leaflets (PILs) were assessed. Sixty one percent (all
dispensary pharmacists) returned a postal questionnaire. Forty eight were providing verbal
andlor written information to some or all out-patients and 44 were providing this service to a
proportion of discharged patients. Most, however, greatly underestimated the number of
companies producing PIL. Few had read any PILs and many (70%) seldom or never (7%)
used them in counselling patients. Eighty five percent thought that hospital pharmacies should
distribute PILs and 84% said that they would use them if they were supplied by the industry.
Most (98%) thought that the provision of PILs should be accompanied by verbal counselling.
333. McEluay JC, Scott MG, Armstrong AP and Stanford CF. Audiovisual demonstration for
patient counselling in the use of pressurised aerosol bronchodilator inhalers. J Clin Pharm Ther
1989:14:135-44.
Descriptive study:
This paper described the development and use of a video tolp train asthmatics in the correct
use of their inhaler therapy. An assessment of the method using non-asthmatic volunteers found
that the video was as effective as personal counselling by a pharmacist and better than the use
of the package insert (p<Z0.05). An assessment of the acceptability of the video to community
(n=40) and hospital (n=68) patients found that 95% and 85%, respectively, found the video
useful. Two thirds of community patients and 50% of hospital patients identified an error in
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their technique as a result of seeing the video. Most thought that the video should be available
in all pharmacies (95 and 87% respectively). Almost all patients thought that the video
explained the inhaler technique well. This was not a service evaluation.
334. Freemantle N and Maynard A. Something rotten in the state of clinical and economic
evaluations. Health Economics 1994;3:63-7.
Opinion:
This paper described the lack of rigour in the currently available economic and clinical
evaluations of health interventions.
335. Mazzuca SA. Does patient education in chronic disease have therapeutic value? J Chronic Dis
1982;35:521-9.
This paper was a mets analysis of 30 controlled trials (24 of which used randomisation) on the
education of patients with chronic diseases. These papers were taken from the worldwide
literature on the topic. The results showed that programmes that tried to increase patient
knowledge alone were rarely successful; behaviourally-orientated programs were consistently
more successful in improving the clinical outcome of chronic disease. Patient education was
successful in improving compliance but knowledge and compliance may not be linked. There
were problems in this meta analysis due to variations in the definitions of counselling and
compliance.
336. Raynor DK. Patient compliance: the pharmacists' role. mt j Pharm Pract 1992;1:126-35.
Review:
The author based the review on work completed for his doctoral thesis (University of Bradford,
1991). He described a variety of methods used to improve patient compliance including
counselling, information leaflets, compliance aids, packaging, tailoring the regimen to the
patient's lifestyle, self-administration schemes and individualised leaflets. He said that no single
intervention on its own had been effective. The relatively high cost of providing many services
plus the present cost-conscious NHS environment meant that pharmacists, whom he felt had a
role in improving patient compliance by informing and educating patients, will have to direct
their efforts to developing cheap, effective programs that are generally applicable and
acceptable to patients and the medical profession. He stated that effective verbal counselling
improved knowledge but not necessarily compliance. He felt that the approach to patient
education should combine verbal information with written information that is easily understood.
Certain compliance aids, such as reminder charts, may improve compliance in sub-groups of
patients. Pharmacist's greatest effect would be to simplify regimens to reduce the number of
medicines being taken to four and dosing to twice a clay at most.
337. Goodyer U. Measurement of the effects of medication counselling given to elderly patients
with heart failure. (PhD thesis). London: University of London, 1992.
Objective:
To determine whether improved compliance, as a result of intensive medication counselling by
a pharmacist, in elderly patients with chronic stable heart failure can influence both objective
and subjective measures of heart failure.
Methods:
This was a prospective randomised controlled study of the effect of counselling on knowledge
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(measured by questionnaire), compliance (tablet Count), and outcome (sub-maximal 6 minute
exercise test, visual analogue scores (VAS) of breathlessness, the Nottingham Health Profile
(NPH) and chmcal signs of heart failure) of elderly patients with congestive heart failure.
These factors were measured at baseline and three months after patients had been receiving
counselling from a pharmacist.
Results:
Fifty patients were recmited to the test and control groups. Patients were similar at baseline.
Patients' knowledge of their medication increased in the test group. The proportion of test
patients able to name their medication increased from 25% to 83% (controls remained at 0%).
The proportion of test patients able to state the purpose of their medication increased from 83%
to 100% (increased from 87% to 91% for controls) and the proportion of test patients able to
state the dose of their medication remained at 100% for both groups. The proportion of test
patients able to name adverse drug reactions increased also. In all cases the difference was
statistically significant. Compliance increased by 32% in the test group (from 61 % to 93%)
whereas it increased only slightly, from 49% to 51 %, for control patients. Outcomes improved
for the test group: the six minute test increased by 20m and the distance travelled until
breathless increased by 26m (compared to reductions of 22m and 19m, respectively, for
controls). All changes were statistically significant (P <0.05). No correlation was found,
however, between changes in exercise tests and improved compliance. Peripheral and
pulmonary oedema scores improved for the test patients and remained unchanged for controls
but this was not statistically significant. The NPH score differences did not reach statistical
significance but changes in VAS did.
Assessment of study: (strength, size of effect, generalisability)
This was a moderately-sized, well-performed, study. Patients and researchers were aware of
the study and the designation of the patients hence there was a risk of bias. The use of several
assessors would have reduced this potential effect. The validity of tablet counts as a means of
assessing compliance is open to question. Patients' clinical conditions were said to have
remained stable since their prescriptions altered very little. Change in outcomes that were
observed were small. In addition, the absence of a correlation between changes in compliance
and outcome could have been due to confounding (tablet counts might have reflected
compliance poorly). The results were not generalisable.
338. Vincent CA Research into medical accidents: a case of negligence? Br Med J 1989;299:1150-3.
Report:
l'his paper described the systems that were available in the UK for studying and tracking the
incidence of medical error. These systems, which include the literature, confidential inquiries,
negligence cases, audits and studies of errors, were considered to be inadequate in providing
information about the causes and methods of preventing error.
339. Leape LL, Brennan TA, Laird N, Lawthers AG and Hiatt H. Adverse events and negligence in
hospitalised patients. Jatrogenics 1991;1:17-21.
Descriptive study:
A survey of a random sample of 30195 patients discharged from hospital in New York state in
1984 showed that 1133 (3.7%) had suffered disabling injuries due to medical treatment. In
27.6% of cases the injury was due to negligence. Drug complications were the commonest
form of adverse effect (19%) and antibiotics, anticoagulants and antiturnour drugs were most
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often implicated. Drug-related adverse events were responsible for 17.7% of all cases deemed
negligent and 14.1 % of events resulting in serious disability. The authors claimed that some
adverse events could have been prevented by redesigning the systems for processing medication
orders and administering medicines. They suggested the use of a computerised system with
patient-specific feedback to the prescriber.
340. Dubois RW and Brook RH. Preventable deaths: Who, how often, and why? Ann Intern Med
1988; 109:582-9.
Descriptive study:
l'his paper described the creation of a method that examines the issue of preventable deaths.
Summaries of the hospital course of 182 patients who died in 12 hospitaJs due to
cerebrovascular accident, pneumonia and myocardial infarction were reviewed by a panel of at
least three doctors. Using a majority rule criterion they found that 27% of deaths may have
been preventable; with unanimity rule this became 14%. They admitted that there was a need
to validate their methods but claimed that among the major causes of preventable death were
inadequate fluid management, control of arrhythmias, and treatment of angina, cerebral oedema
and sepsis, and improper use of antibiotics.
341. Einarson TR. Drug-related hospital admissions. Am J Hosp Pharm 1993;27:832-40.
Descriptive report:
This paper reviewed and summarised studies reporting drug-related hospital admissions
obtained by computerised and manual literature searches. Medline, Index Medicus and
International Pharmaceutical Abstracts were searched using the key words drug, drug-related or
latrogenic; admission, hospital admission, or hospitalisation; and ADR or adverse drug
reaction. References from the articles that were found were followed up. The studies that were
selected were in English. They reported the results of studies of humanc admitted to hospital
due to drug related adverse events resulting from drug use, non-compliance or unintentional
inappropriate drug use. Adverse events due to drug abuse, alcoholism, suicide attempts,
intoxication or inadequate prescribing were excluded. Between 1966-1989 the ADR rates at 49
hospitals or groups of hospitals in a variety of international settings, including the UK, were
published in 36 articles. Sample sizes ranged from 41-1 1891 patients (median=714, IQR=275-
1245; mean= 1412, sd=2233). The prevalence of reported admissions resulting from ADRs
ranged from 0.2-21.7%. The median was 4.9% (IQR = 2.9-6.7%). The mean was 5.5%
(sd=4.1 %). The weighted meta analytic estimate of ADR prevalence was 5.1% (95% CI =
4.4-5.8%). Of the ADR admissions, 71.5% were due to side effects, 16.8% were due to
excessive effects, 11.3% were hypersensitivity reactions and 0.4% were idiosyncratic. Of those
admitted with Al)Rs, 3.7% died. Eleven reports indicated that 22.7% of ADR hospitalisations
were induced by non-compliance. The results only apply to hospitalisations in developed
countries. No economic analyses of ADRs were found.
342. Hutcheon AW, Lawson DH and Jick H. Hospital admissions due to adverse drug reactions. J
Clin Pharm 1978;3:219-24.
Descriptive study:
The authors described the results of participation by two Scottish hospitals in the Boston
Collaborative Drug Surveillance Program. Of 2580 consecutive admissions to medical wards in
these hospitals, 85 (3.3%) were attributed to drugs taken at normal doses and 66 (2.6%) to
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overdoses. The proportions in the two hospitals were similar. The most frequently implicated
drugs at normal doses were aspirin, digoxin, warfarin, phenylbutazone and insulin. These
accounted for 51 % of all admissions due to adverse effects. The authors described the adverse
effects in detail. For overdoses, central nervous system drugs were the most frequently
implicated.
343. Alexander AM and Barnett JW. The Hereford Hospital prescribing study: Hospital activity
analysis as a source of adverse drug reaction data. J Clin Hosp Pharm 1983;9:45-50.
Descriptive study:
This paper described a study that assessed the usefulness of a hospital activity analysis (HAA)
system in recording adverse drug reactions (ADRs) at a single hospital. Five years of data
were examined for ADRs and the notes of those identified as potentially having experienced
ADRs were examined to obtain more information. ADRs were recorded as diagnoses for 126
(0.5%) of the 27,398 admissions. In 110(87%) of these cases, ADRs were the cause of
admission. Most ADRs were due to cardiovascular drugs (34.9%), primarily digoxin (28%).
Most (87%) ADRs occurred prior to admission. ADRs experienced during the hospital stay
were diagnoses for 0.03% of patients.
344. Lawson DH and Jick H. Drug surveillance for adverse drug effects. A study of medical
inpatients. J Clin Pharm 1978;3:203-10.
Descriptive study:
The authors described the results of participation by two Scottish hospitals in the Boston
Collaborative Drug Surveillance Program. Two thousand five hundred and eighty consecutive
admissions to 2 medical wards in each of these hospitals were studied over three years. On
average, patients received 4.6 drugs during admissions. The commonest adverse effects were
nausea (5.4%), vomiting (4.3%), elevated urea levels (3.7%) and drowsiness (3.4%). Serious
side effects were rare and included arrhythmias (1.5%), hypokalaemia (1.4%) and coagulation
abnormalities (0.9%). The reporting physician only expressed significant doubts regarding
causality in 7.1% of instances.
345. lnman WHW, Richards DJ and Rondel RK (eds). Monitoring by voluntary reporting at
national levels. Adverse Drug Reactions; their prediction, detection and assessment.
Edinburgh: Churchill Livingston 1972 page 86.
Descriptive report:
l'his paper stated that only 1-10% of adverse effects are reported to the Committee of Safety of
Medicine in the UK.
346. Veitch GBA and Talbot iCC. The pharmacist and adverse drug reaction reporting. Pharm J
1985;234: 107-9.
Descriptive study:
This paper described adverse reactions (ADR) reporting schemes in the UK and abroad and 10
years experience with such a scheme in the West Midlands. Ten percent of queries about
ADRs to a hospital in the region resulted in Committee of Safety of Medicines (CSM) reports
in the years 1976 to 1981. The paper provided opinions on ways of using ward and clinical
pharmacists to help detect and report ADRs.
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347. Spencer MG. Post marketing surveillance. Pharm J 1985;235:372-5.
Opinion paper:
This paper described the potential and actual contribution that pharmacists can make to post
marketing surveillance in hospital. The author described the Welsh voluntary reporting scheme
in detail and the contribution that drug information centres made in replying to adverse reaction
queries. He advocated an increased role for hospital pharmacists in reporting adverse reactions
to the Committee of Safety of Medicines.
348. Biddoiph A. The developing role of the hospital pharmacist in adverse drug reaction reporting.
Proceedings of the Guild 1983;17:21-43.
Descriptive study:
This paper examined the role that Australian hospital pharmacists played in adverse drug
reaction (ADR) monitoring and explored the potential for the development of this role in the
United Kingdom. It also described roles adopted in this area in the UK. In particular, it
described the work done in the Northern Region and Wales (in combination with their drug
information units) and in the West Midlands and Trent Regions.
349. Talbot ICC and Beeley L. Adverse drug reaction reporting in the West Midlands. I Clin Hosp
Pharm 1980;5:49-54.
Descriptive study:
This paper described the setting up and success of a voluntary adverse drug reaction (ADR)
reporting scheme in one region. Pharmacists were involved in assessing the ADR reports,
requesting additional information if necessary, and compiling bulletins for distribution to
pharmacists, doctors and others in the UK and abroad. Pharmacists were encouraged also to
help complete yellow cards.
350. Talbot iCC. The hospital pharmacists' contribution towards monitoring and reporting adverse
drug reactions. Proceedings of the Guild 1982; 12:11-33.
Descriptive study:
This paper described the West Midlands ADR reporting scheme, the roles played by the drug
information pharmacists, the ward pharmacists and others involved, and claims that the scheme
had increased reporting between 1976 and 1980. The change in the number of ADR reports
sent to the CSM was unknown hence the effectiveness of the scheme had not been evaluated.
351. Booth NJ, Luscombe DH, Smith CC, Veitch GBA and Grahame-Smith DG. Scheme to
promote, monitor and assess the reporting of adverse drug reactions. Pharm I 1988;241:R3.
Descriptive study:
This paper described an ADR scheme in one Oxfordshire hospital. Reports were collected,
followed-up and assessed by a team that included a pharmacist and a clinical pharmacologist.
The scheme was similar to that described by Irvine et al (1987). ADR reports were assessed
for causality, using an algorithm, and severity, using a five point scale. Where appropriate the
reporter was advised to send the report to the CSM. In 6 months 125 reports had been made
(2029 total admissions) of which 17 were sent to the CSM. The authors discussed how they
overcame several problems in ADR reporting schemes, such as doctors' ignorance of schemes,
doctors' lack of time to complete forms, the lack of provision of feedback to medical staff and
the lack of awareness amongst medical staff of the relationship between an ADR and drug use.
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352. Hardman C and Lloyd B. Adverse drug reaction monitoring by ward pharmacists. J Clin Hosp
Pharm 1982;7:71-3.
Descriptive study:
In 5 weeks, ward pharmacists at a 500 bed hospital detected 68 ADRs. Of these 71% were
definite, 9.7% probably, 12.9% doubtful and 6.4% unlikely using the West Midlands algorithm
form for assessing ADRs. One report was sent to the CSM.
353. Smith D. Prescription flagging to stimulate yellow card reporting. Hospital Pharmacy Practice
1992;2: 103-4.
Objective:
To assess a system to increase adverse drug reaction (ADR) reporting rates.
Methods:
A prospective before/after study was performed at a single large general hospital to assess the
effects of pharmacists using the CSM black triangle on drug charts to increase awareness of the
potential for an ADR occurring.
Results:
The number of reports sent to the CSM in the two years preceding the scheme were 3 and 5,
respectively, of which 1 in each year were on blank triangle drugs. Following the introduction
of the scheme these figures increased over the next two years to 7 and 10 reports were sent of
which 3 and 4, respectively, were on blank triangle drugs.
Assessment of study: (strength, size of effect, generalisability)
The size of the effect was small. The results were open to bias and confounding due to poor
implementation of the scheme and assumptions regarding the numbers of ADR reports to the
CSM. They are not generalisable.
354. Richardson J and Gibb C. Active adverse drug reaction reporting. A pilot study. Hospital
Pharmacy Practice 1992;2:247-8.
Objective:
To assess the effects of a system to increase ADR reporting rates.
Methods:
A prospective before/after study was performed at a single large general hospital to assess the
effects on adverse drug reaction (ADR) reporting rates of pharmacists using the CSM black
triangle on drug charts, in addition to labelling the medication container with a yellow warning
sticker and increasing awareness by a campaign sponsored by the Drug and Therapeutics
Committee. The number of ADRs reported was counted.
Results:
The scheme had increased the monthly number of ADR reports from 4 to 12 in the first three
months.
Assessment of study: (strength, size of effect, generalisabiity)
The size of the effect was moderate to large. The results were open to bias and confounding
since it was an uncontrolled study. They are not generalisable.
355. Spencer MG. Adverse reactions - monitoring side effects. The Welsh adverse drug reaction
scheme. Proceedings of the Guild 1986;21:58-61.
Descriptive report:
This paper described the setting up and success of a voluntary adverse drug reaction (ADR)
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reporting scheme in Wales. The scheme was similar to that established in the West Midlands.
Before the scheme was instituted, the average annual number of adverse events reported in
Wales (to the Committee of Safety of Medicines) was lower than the UK average. One
pharmacist helped to co-ordinate the scheme. The scheme has improved reporting from 385 to
520 ADR reports in the first year (37%).
356. Anon. Hospital pharmacists "should be involved in ADR reporting". Pharm J 1988;241:656.
Report:
It was advocated in this report that the Committee of Safety of Medicines should allow
pharmacists to participate in their yellow card scheme. The West Midlands scheme encouraged
pharmacist participation and had achieved a higher rate of reporting than elsewhere.
357. Anon. Hospital pharmacists seek involvement in ADR monitoring. Pharm J 1989;242:433-4.
Report:
Some clinical pharmacologists supported hospital pharmacists' involvement in ADR reporting
although there was debate about the cost-effectiveness, and benefit, to patients from such a
system.
358. Committee of Safety of Medicines. Report of the adverse reactions working party. London:
Department of Health and Social Security, 1985.
Report:
The working party accepted that hospitals pharmacists had a role in investigating and assessing
ADR reports but they recommended that pharmacists should not report ADRs to the CSM
independently.
359. Anon. Hospital pharmacists to use yellow cards in proposed CSM study. Pharm J
1990;244:330.
Report:
This report stated that the CSM had started a trial that allowed hospital pharmacist in the
Northern Region to report ADRs to them using specifically labelled yellow cards. Reports from
a pharmacist could only follow from a discussion between the pharmacist and the patient's
doctor about the ADR.
360. Randhawa IlK, Smith JC and Irvin LE. Hospital doctors' attitudes to adverse dnig reactions
and their reporting. Pharm J 1987;238:793-5.
Descriptive study:
The authors described the results of an interview survey of 60 randomly-chosen hospital
doctors to determine their attitudes towards adverse drug reaction (ADR) reporting (one year
after the local scheme had started). The survey was carried out by a pharmacy student. Twenty
seven doctors had reported an ADR previously. There were 17 consultants, 13 senior
registrars/registrars and 10 senior and 20 junior house officers. Most (85%) doctors thought
that there was a low level of ADR reporting. This perception was similar for reporters and
non-reporters although reporters perceived a higher incidence of ADRs causing admissions that
non-reporters. Only 26% knew what the new product awareness sign meant. Seventy two
percent felt they would be able to identify ADRs if they occurred. The problems in identifying
ADRs were establishing which drug was causing the ADR when patients were on multiple
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drugs (34%) and difficulty in distinguishing between organic disease and ADRs (30%). Seventy
percent said that would report ADRs but only those that were significant ADRs. Reasons for
under-reporting were complacency (2%), fear of litigation/breach of confidentiality (2%), guilt
that harm had been caused (2%), ambition to publish case reports (5%), ignorance of how
(5%) and what (32%) to report, difficulty in reporting suspected ADRs (39%) and
lethargy/lack of time (13%). Eighty two percent were aware of the local ADR scheme (95%
for reporters and 68% for non-reporters). Seventy one percent felt that there were advantages
in a local ADR scheme such as simplicity in completion of reports (29%) and encouragement
of discussion and feedback (22%). Forty seven percent said that greater involvement of the
pharmacist would be an advantage. When asked if pharmacists should be involved in actual
reporting 70% agreed that they should report in conjunction with doctors, 10% thought that
they should report directly and 20% felt they should not report at all.
361. The NHS Management Executive. Clinical Audit. Meeting and improving standards in
healthcare. London: Department of Health, 1993.
Policy:
This described the Department's policy on, and commitment to, clinical audit.
362. Pruce D. Professional audit in hospital pharmacy. Pharm J 1993;251:151.
Opinion paper:
This paper outlined the Royal Pharmaceutical Society audit development fellow for England's
opinions on hospital pharmacy audit. He concluded that there was evidence that UK
pharmacists were participating in professionals audit and quality assurance.
363. Shaw R. Quality assurance of hospital pharmacy services. Pharm J 1993;251:HS45-6.
Descriptive study:
This article outlined the use of quality assurance in measuring performance in hospital
pharmacy services and in improving their quality. It addressed standard setting, performance
measurement and customer care and provided a view on future initiatives in the quality
assurance of hospital clinical pharmacy services.
364. Pruce D. Professional audit. Audit activities within English hospitals. Pharm J 1993;251:HS4O-
1.
Report:
The Royal Pharmaceutical Society audit development fellow for England reported on the extent
and depth of interest in audit in hospital pharmacy. His advertisement in the Pharmaceutical
Journal asking for information on audits led to 50 replies. In addition, there were 23 bids for
audit money from a Society fund. Several hospitals had adopted standards documents for
services but there was variation in the conduct of audit. Some pharmacies had also used
external audit to asses their services. Many audits concentrated on intervention monitoring,
waiting times, patient satisfaction, national schemes (drug information, radiopharmacy and
community services pharmacy) and focused audits (problem areas). Pharmacists were also
taking part in clinical audit.
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365. Kelly CA and Mason-Duff J. Two years on the audit trail in Scotland. Pharm J
1993;251:HS42-3.
Descriptive study:
This paper described the national audit structures and the local ones in Scotland. It also
described education and training initiatives to support audit and various audit projects in clinical
pharmacy, drug information and other areas of service provision.
366. Roberts DE. Professional audit in Wales. Pharm J 1993;251:HS44-5.
Descriptive study:
This paper described the progress that had been made in Wales to increase pharmacists'
participation in pharmacy and clinical audit. A survey of 8 hospitals showed that audits were
being performed. The topics that had been addressed included interventions, waiting times,
dispensing errors, efficiency of drug purchasing systems and complaints.
367. Audit in pharmacy. A report of a working party of the Royal Pharmaceutical Society (Chair; N
Wood). Pharm J 1992;248:505-9.
Report:
This report described audit, the types of audit, the audit structure and process, the training
implications for pharmacists and the case for audit. The potential interaction between pharmacy
audit and the audits being undertaken by other professions was briefly covered. This document
outlined the Society's support for audit in the profession and the efforts that they intend to
make to develop audit.
368. Cole SE, Hebron B and Scott D. The quality of the pharmacy supply service to wards. Pharm
I 1988;241:R8.
Descriptive study:
This paper described a system that assess nurse satisfaction with pharmacy supply services.
Over a 6 week period, less than 1 % of the 27740 doses that would have been administered to
patients were missed. Half of all missed doses were first doses. The system was seen as a step
towards improving the quality of service.
369. Cox H and Mounsey C. Pharmacy quality circles. Pharm I 1989;245:HS34-5.
Descriptive study:
This study described the setting-up of a quality circle in a single general hospital. Most staff
were interested in the idea and 11/30 went on to receive training after initial introduction to the
idea. The article described the training given (techniques used were brainstorming, flow charts,
cause and effect analysis, pareto analysis and paired comparisons), the selection of the problem
for analysis (inaccuracies in computer stock levels) and the process of solving the problem.
There was a 70% reduction in the number of visits made to stores by dispensary staff as a
result of implementing a corrective system.
370. Godfrey B, Smith El, Williams MA, Burberry PN and Farrar KT. Using workload audit to
enhance the quality of pharmacy services. Phann J 1990;246:R1-3.
Objectives:
To assess the effects of various strategies to improve workflow in the dispensary in a large
general hospital.
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Method:
A prospective cross-sectional survey of dispensary workload, waiting times, processing times,
and dispensing times was carried out before and after the sequential introduction of various
changes in work practices. The changes were designation of a specific checking area (1987-8)
and of a professional checker to check prescriptions on arrival and a technician to check final
products (1988-9). The surveys took place over one week periods in October 1987 (before) and
October 1988 (after 1) and in March 1989 (after 2) for the in-patient dispensary and in October
1987 (before) and March 1988 (after) for outpatients. Staffing factors were also noted.
Results:
There was no change in overall staffing levels but the ratio of pharmacists to technicians and
pre-registration pharmacists fell from 1.16 (1987) to 0.99 (1988) and 0.71 (1989). Despite an
8% increase in workload from 1987 to 1988,and a further 16% increase between 1988 and
1989, queuing, dispensing and checking times fell in successive years in the main dispensary.
Waiting times in excess of 140 minutes fell and those less than 140 minutes rose. There was a
reduction in the percentage of prescriptions with waiting times of more than 60 minutes from
36 to 30%. Despite a 7% increase in workload in the out-patients dispensary, most
prescriptions were completed within 20 minutes (84%) after the changes compared to 31%
completed in 20 minutes before the changes.
Assessment (size of effect, design, generalisability):
The size of the effect was moderate. The study was well-conducted but may be subject to bias.
The results are not generalisable.
371. Hayes P, Kayne S, Martin T and McMurdo A. Use of professional self audit in pharmacy
practice. Phaim J 1992;249:650-2.
Report:
The paper provided a practical interpretation of the Pharmaceutical Society's guide to self-
audit. It drew on experience of audit in New Zealand to do this.
372. Hynam B. Pharmaceutical audit in practice. Pharm J 1993;250:844-5.
Descriptive report:
The author reported on the external audit activities of a group of pharmacists from the West
Midlands region. They piloted an audit process in several hospital in the region with much
success. The process included a visit to a hospital pharmacy by 3 senior pharmacists from
other districts. The team-members rotated. In the first year they concentrated on ward
pharmacy and distribution systems. The visiting team audited the service in the hospital in co-
operation with the pharmacists there and reported their findings back to the hospital pharmacy.
The team did not follow-up sites to complete the audit cycle. The author claimed that the
system had been well-accepted and that there was support for creating a permanent team to
perform this function.
373. (un J, Hubbard N and Pickup JF. Intervention reporting on the South Western Region
computer system. Pharm J 1993;251:HS24-6.
Descriptive study:
This paper described the background to the development of a region-wide computer system for
recording and monitoring interventions. The system was based on standards set for the
prescription monitoring service by clinical pharmacy managers in the region over a number of
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years. The system, which had been developed at one site, allowed the routine collection of
data. These data had been used to provide continuous management and clinical information, to
record clinical pharmacy advice, to provide data for audit, to highlight recurrent problems, to
provide material for continuous education and peer-review, and to reduce duplication of effort
when pharmacists provided services to the same patients. The original system was upgraded
and was found to reduce the number of queries from dispensary staff to clinical pharmacists
but further adaptations were subsequently made to increase the comprehensiveness of the data
set. The main modifications were to permit the recording of the clinical significance of
interventions and their cost avoidance, and to log patient counselling and therapeutic drug
monitoring advice. This new system was currently being piloted and it was envisaged that it
might have applications in community pharmacy.
374. Hubbard CN and Elliott DN. Clinical pharmacy standards and audit: the South Western RHA
approach. Pharm J 1994;252:61-2.
Descriptive report:
The authors discussed the approach taken to quality assurance of clinical pharmacy services in
their region. A core document was created by one of the authors and refined by the clinical
pharmacy managers group. This contained standards and criteria in a number of areas of
activity. Standards were set for patient related services (ward pharmacy, provision of drugs and
clinical pharmacy interventions), policy related clinical pharmacy (drug policy maldng
committee work, drug use evaluation, written guidelines for drug use and formularies) and
education and training (in-house and external courses, induction training and performance
review). Criteria and object parameters were set and performance was being assessed in 13
provider units in the region as part of routine internal audit.
375. Davies G and Lewis L. Clinical audit - a new development? Phann J 1989;245:HS3O-1.
Descriptive study:
The conduct of clinical audit at a single general hospital was outlined in this paper. Pharmacists
were initially invited to participate in a review of drug therapy for audit purposes by a hospital
consultant. More recently their input had increased to two audits per month. The article
described the audit process from the pharmacy perspective (aims, patient selection, preparation
and presentation) and proposed certain benefits to patient and the hospital staff from their
involvement. Benefits included an increase in pharmacists' ability to influence prescribing, an
improved perception of pharmacy as a source of information, an increase in doctors' awareness
of costs and prescribing trends, the subjection of prescribing to peer review, the optimisation
and rationalisation of therapy and an increased awareness of issues such as compliance.
376. Ridley-Siegert D, van Kan E and Anthistle J. Audit of benzodiazepine prescriptions in hospital
admissions. Hospital Pharmacy Practice 1991;1:311-3.
Descriptive study:
This paper described the results of a 3 month audit of all prescription charts of patients
admitted to one ward in each of four areas (general medicine, general surgery, psychiatry and
care of the elderly) in a general hospital. Doctors were unaware of the drug classes being
studied, and in some cases, of the whole study. Details of patients and prescriptions were
obtained by the pharmacists and recorded on special audit cards. Seven hundred and five
patients were admitted, of which 344 were prescribed benzodiazepines. Three hundred and
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ninety six prescriptions for the drugs under study were recorded; 41 patients were given more
than one benzodiazepine or given them on more than one occasion. Most patients (328) were
prescribed the drugs 'as required', usually for sleep (95%). At least 69% of prescriptions were
initiated during the admission but few (4.7%) were continued on discharge. Forty one of 101
prescriptions for benzodiazepines started prior to admission were discontinued. Information was
also gathered on prescriber and patient factors that influenced prescribing. The study showed
that current prescribing guidelines at the hospital were being followed. The authors identified
some areas for improvement which could be taken forward in the audit cycle.
377. Eccles S, Barber N, Frater A and Wilson P. A better pill to swallow. The Health Services
Journal 1992;102:22-3.
Descriptive report:
This paper described efforts being made by pharmacists to become more involved in medical
audit at four hospitals in a London Region.
378. Harris SK, Smith FJ and Moss F. The pharmacist's contribution to medical audit: Perceptions
of doctors and pharmacists in the North West Thames Regional Health Authority. J Soc Admin
Pharm 1993;10:36-41.
Descriptive study:
A random sample of 45 doctors and 15 pharmacists were selected for interview to obtain their
views on pharmacists' potential contribution to medical audit. Forty two of the forty five
doctors and all 15 pharmacists agreed to the interview. In general, doctors were positive in
their attitude to pharmacist participation in audit. Although 10 had attended audits where
pharmacists had participated, most (73%) would not have thought of inviting a pharmacist to
their audits. On reflection 10 thought that it would be a good idea. Doctors suggested several
areas where pharmacists could contribute such as the provision of drug usage and expenditure
data (18/42), the provision of advice on drug choice during case presentation audits and the
performance of drug use review reports (4/42), and the provision of drug information (5/42).
When doctors were presented with 6 scenarios of pharmacist involvement in audit most would
accept pharmacist involvement (acceptance ranged from 79 to 100%). Pharmacists thought that
the doctors would accept their involvement also when presented with these scenarios but, in
general, they were more negative and thought that there were medical and pharmacy barriers to
pharmacists' participation in audit, such as conflict with medical staff and resource issues.
379. Bussey RA and Martin AM. Adverse drug reaction monitoring and the pharmacist. Pharm J
1985;235:593.
Objective:
To investigate how a clinical pharmacist working in close collaboration with clinicians could
stimulate, complete and improve adverse drug reaction (ADR) reporting.
Methods:
This was an uncontmlled before/after study of the number of ADR reports made by medical
and renal physicians in a single hospital.
Results:
The pharmacist assisted in collecting information and interviewing patients with suspected
ADRs. Evidence was assessed by the pharmacist and the relevant clinician. If the result was a
decision to report the ADR to the CSM then the pharmacist completed the form. It was then
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signed by the doctor and forwarded it to the Northern Region reporting centre. For the 12
months before the study 2 ADRs were reported from the unit. In the 21 months of the study 79
ADRs were investigated of which 44 were decided to be true ADRs (39 reported by doctors
and 5 by the pharmacist). These were forwarded to the CSM. The pharmacist interviewed 28
patients in hospital and a further 14 at outpatient clinic to gather evidence for the assessments.
The pharmacist helped to establish the lack of evidence in support of 35 ADRs thereby
improving the quality of reporting.
Assessment of study: (strength, size of effect, generalisability)
The effect was large. There was a risk of bias due to pharmacist collection of data and lack of
controls. The results are not generalisable.
380.	 Irvin LE, Grimmer SFM and Smith JC. Adverse drug reaction reporting. Br J Pharmaceutical
Practice 1987;9:316-21.
Objective:
To investigate ways in which the pharmacy department could encourage the identification and
reporting of ADRs.
Mcthods:
A multidisciplinary team was set up to investigate problems associated with ADR reporting in a
hospital. The numbers of ADR reports before and after setting up the team ADR reporting
service were counted.
Results:
The multidisciplinaiy team (doctors and pharmacists) found that the lack of availability of CSM
cards, the lack of tune to fill them in and the lack of feedback on the reports were the main
problems in ADR reporting. The team made changes. They monitored the ADRs reported and
co-ordinated a reporting scheme. Clinical pharmacists became more involved in stimulating
interest in the scheme in their daily work. A simple initial report card, which was collected
twice daily by pharmacists and completed by them, was provided. An easily identifiable ADR
card holder was placed on the wards. Feedback was given to doctors and others on the ADRs
that had been reported by the medical and nursing staff and a regular bulletin on ADRs was
published. In the year prior to the scheme the annual number of CSM reports/1000 acute beds
was 18 (93% of reports); in the year following, this had increased to 74 (69%). In the first
half of 1986, 47 reports were made per 1000 beds (56%). The proportion of ADR reports that
were subsequently reported to the CSM (shown as a percentage in brackets) fell. The highest
relative proportion of reports came from clinical pharmacology beds. Most cards were
completed by doctors (58%) and pharmacists (40%). Subjectively, the authors thought that the
service was improving the ease with which ADR reports were made. They felt also that
patients had benefited from the earlier reporting of their ADRs, pharmacists' help in this area
was more obvious to others and had become better appreciated and that the service had
improved inter-disciplinary relationships.
Assessment of study: (strength, size of effect, generalisability)
The effect was large but the results were open to bias and confounding and are not
generalisable.
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381. Alexander AM, Barnett JW and Veitch GBA. The Hereford Hospital prescribing study.
Investigation of methods to identify patients with adverse drug reactions. J Clin Hosp Phann
198 1;6:20-6.
Descriptive study:
This paper described a study that assessed the effectiveness of four methods of detecting
adverse drug reactions (ADRs) at a single hospital that had a computerised patient data
collection system called HAA. Patients receiving indomethacin were used to test the four
methods. These were, firstly, diagnostic summaries were examined for references to ADRs,
secondly, HAA data were searched for referral/transfer to an additional consultant, thirdly,
prescribing data were searched for discontinuation of indomethacin and, fourthly, prescribing
data were searched for evidence of the use of drugs that counteract the adverse effects of
indomethacin. Of 2852 admissions in 1977, 120 were receiving indomethacin. Thirty seven
percent were on it prior to admission, 82% received it during their stay and 38% received it on
discharge. Diagnostic summaries revealed 3 ADRs and transfer data revealed none. Prescribing
data revealed 19 discontinuations of indomethacin on admission of which 8 were ADRs. There
were also 21 discontinuations of indomethacin for those who had been started on it during their
stay of which 4 were ADRs. Prescribing data revealed also that 23 patients received antacids, 3
received anti-ulcer drugs, 12 received iron and 5 received antidepressants (drugs which were
thought might potentially be prescribed for ADRs). No ADRs were investigated for validity or
causality but the authors stated that routine monitoring of prescriptions was helpful in
identifying ADRs.
382. Everden AJ. Adverse drug reactions. Br J Pharmaceutical Practice 198 1;3(8)6-8.
Descriptive study:
The author reported a method of detecting adverse drug reactions (ADRs) based on examining
the prescriptions for and-diarrhoeals and antihistamines at a single hospital. Patients' notes
were then reviewed and the probability of an ADR having occurred ascertained. Twenty eight
patients received one, and 1 received two, anti-diarrhoeals. An ADR was a possible cause in
10 instances. Fourteen patients received antihistamines of which 10 were possible ADRs.
383. Robb J, McEvoy J, Greenwood E, Hollands R and Kopleman P. Blood glucose monitoring;
completing the audit cycle. Phann J 1990;248:590-1.
Objectives:
To review the effects of the audit process on the use of diabetic monitoring.
Method:
A time series study was carried out. It consisted of a questionnaire survey of nursing staff and
ward pharmacists. Nursing staff were asked about the ward's use of glucose monitoring strips
daily during two separate assessment weeks. In addition, ward pharmacists were surveyed daily
and asked more specific questions about the use of glucose monitoring strips. The survey was
conducted during the same months of 1987, 1988 and 1991 on the medical wards of two
hospitals.
Results:
Pharmacy involvement in multidisciplinaiy audit in two UK District General Hospitals (DGHs)
increased the appropriateness of the use of blood glucose monitoring in diabetics between 1987
(before) and 1988 (after 1). It also showed that the lack of a continuous involvement by
pharmacy resulted in the ward staff reverting to their original pattern of practice (after 2,
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1991). This indicated a continuing need for reinforcement of training via the audit cycle. The
numbers of patients surveyed and the proportion of insulin-dependent diabetics were similar on
all three occasions.
Assessment (size of effect, design, generalisability):
The study design suffers from time-related non-comparability; staff and other factors may have
changed and influenced the result. The effect was moderate and generalisable although the
numbers were small.
384. Cavell GF and Taylor KA. Prescription endorsing standards. An audit of clinical pharmacy
practice. Hospital Pharmacy Practice 1993 ;3: 3 67-72.
Objectives:
To develop an agreed list of prescription monitoring standards and to measure performance
against them.
Method:
Two pharmacists developed the standards. An audit was carried out of the prescription
monitoring activities of pharmacists before and 5 weeks after introducing the standards at
hospitals in a healthcare district. Ten medication charts were selected at random on each ward
on the same weekday and the pharmacists' endorsements were compared, by the two senior
clinical pharmacists, with those recommended in the standards document. A seminar was held
after the first audit to educate pharmacists and to allow them to put their ideas forward on
prescription monitoring. The numbers of omissions were calculated for each phase of the
study.
Results:
In the first audit 380 drug charts monitored by 17 pharmacists on 44 wards were audited (2276
items). In the second 391 drug charts monitored by 15 pharmacists on 44 wards were audited
(2492 items). Twelve pharmacists took part in both audits. For these pharmacists, there was a
significant (J) <0.0001) improvement in performance. On average the improvement was 63%.
The proportion of omissions decreased from 20.6% on average (range = 6-41 %) to 11.3%
(range = 3.2-20.5). There was no correlation between workload and omission rate.
Assessment (size of effect, design, generailsability):
This study was well-conducted. The effect was large and the results are generalisable although
the numbers were fairly small.
385. Bond CM, Williams A, Taylor RJ, Grimshaw J, Maitland J and MacLeod N. An introduction
to audit in Grampian: a basic course for pharmacists. Pharm J 1993;250:645-7.
Objectives:
An introductory course in audit, run for community and hospital pharmacists in a single
Scottish Health Board by a multidisciplinary group, was evaluated for its effects on
pharmacists' attitudes to audit.
Method:
This was a prospective before/after attitudinal survey.
Results:
Sixteen community and hospital pharmacists attended the one day course. They all found it
useful and enjoyable. Attitudes to audit tended to improve as did participants' perceptions of
their ability to conduct audit.
Assessment (size of effect, design, generalisability):
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The study used a survey which did not seem to have been validated. The numbers were small.
The attitudinal changes were small and are not generalisable.
386. Cousins D. From CIVA to DIVA. Pharm J 1994;252:198-9.
Opinion paper:
The author provided an opinion on the importance of supplying intravenous additives (IVAs) in
the 1 990s. The former centralised service (CIVAs) was giving way to a de-centralised service
(DIVAs), mainly due to the need for a patient-focused responsive service, the creation of the
clinical directorate structure within hospitals, and the institution of internal contracts. It was
envisaged that the industry would provide high use items and de-centralised pharmacy units
would provide specialist items. The advantages of this new model, and its implications for the
practice of pharmacy in the United Kingdom, were outlined.
387. Anon. CIVA services come of age. Pharm J 1993;250:882-3.
Report:
This article reported on a joint meeting of the Royal Pharmaceutical Society's Hospital
Pharmacists Group and the National CIVAs (central intravenous additives) Group. Issues
discussed included the stability of products, special licensing requirements, medical devices,
quality assurance and clinical pharmacy implications. A few sites that reported customer
satisfaction data found that the service was appreciated.
388. Anon. CIVAS - The cost-effective service customers want. Pharm J 1990;246:HS32-3.
Report:
This article reported on CIVA (central intravenous additive) services provided at a number of
hospitals. At one site a service of some sort had been provided since the 1950s. Pharmacists at
several sites reported a high level of customer satisfaction with the service and claimed that it
was cost-effective.
389. Goldberg LA. The preparation of cytotoxic drugs. Pharm J 1983;230:224-5.
Descriptive study:
This paper described the setting up of an aseptic unit for the preparation of cytotoxic drugs in
one hospital.
390. Hatton I and Barrett CW. A trial 24-hour pharmacy intravenous additive service in a London
teaching hospital. J din Pharm 1979;4:71-86.
Descriptive study:
This paper described the introduction of a trial 24 hour intravenous additive service (IVAs).
The introduction of the service was preceded by a survey of prescribing to determine
commonly-used IVAs. This provided an idea of workload (150 items per 24 hours). Some
items were purchased commercially thereby reducing the expected demand to 28 items per 24
hours. The survey also showed that few WAs were required after 22.00 and before 08.00
hours. Nursing and medical staff were surveyed to establish the acceptability of the commercial
solutions three months after their introduction. Most were satisfied and the service went ahead
for 11 weeks. The paper described the service in detail. Two thousand one hundred and fifty
two IVAs were provided (195 IVAs per week). Before the service was introduced an average
of 1071 were made each week. Excluding cytotoxics, 37 drugs were used. Only 3% of calls
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were made after 22.00. The questionnaire survey of junior medical staff had a 65% response
rate. Most (99%) had used the service and were satisfied with it (97%). One fifth considered it
to be an essential service, 50% thought it was a valuable service and 25% thought that it saved
time. Only 6 doctors thought that it was too expensive.
391. Mounsey A, Bell D and Fahey M. Resident pharmacist services - An overview. Pharm J
1993;250:HS9-1 1.
Descriptive report:
The authors described the residency service at a large general hospital. They also reported the
results of their telephone survey of activities performed by 31 hospitals that provided a
residency service. Resident phannacists represented 133 of the estimated 5000 hospital
pharmacists in the UK. The types of rotas worked by resident pharmacists varied and all were
backed up by more senior pharmacists at home. The level of activity also varied from so low
that no time off in lieu was given on weekdays to very busy rotas. Hospital pharmacy opening
hours affected the rotas and workload as did the availability of casualty pre-packs, emergency
drug cupboard stocks, the size of the hospital, the length of time for which the residency had
been established, the appropriateness of ward stocks to case mix and restrictions on the
type/grade of staff who could bleep the pharmacist. The residents' major tasks were to provide
drugs and drug information but some provided more advanced services such as ward visits,
poisons information, cardiac arrest team services and aseptic dispensing. The advantages and
disadvantages of a residency services were enumerated and a computer system for monitoring
workload was mentioned.
392. Talbot JCC. A survey of the 24-hour pharmaceutical service at Nottingham City Hospital.
Proceedings of the Guild 1977;1:41-4.
Descriptive study:
This paper described the residency service at a single hospital. The workload for 15 months
(25 12 calls) was analyzed and showed that 59.1% of calls were for new prescription items,
14.4% for drug information, 11.1% for stock items, 6.3% for to discharge drugs, 4.4% were
outside calls, 3.5% were for controlled drugs and 1.2% for manufacturing items. The
proportion of calls that resulted in the prescriber being contacted was 4.3% on average, rising
to 6.9% when new house officers started. Few (5.6%) calls were received after midnight and
only 7.5% of calls were urgent. The cost of the service was £2700 per annum. The benefits of
the service included the rapid and reliable provision of drugs and drug information, lower drug
stocks on wards, greater training and experience for pharmacists and increased medical-
pharmacy contact.
393. Cullen AMS, Norman AJ and Sandwich N. Identification of a demand for an out of hours
service at a district general hospital. Br J Pharmaceutical Practice 1980;2(3): 10-13.
Descriptive study:
l'his was a needs assessment for residency services at a large general hospital. Calls to the on-
call pharmacist over one year were examined. Eighty two calls were for drug supply, 11 were
for information only and 16 were for both supply and information. There were 10 other calls
of which one was a drug recall. This hospital also had an emergency drug cupboard and calls
to the on-call pharmacist were discouraged and could only be made by senior staff. Ninety
eight items were borrowed from the emergency cupboard over the same period but, during a
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one month survey, wards borrowed 68 items from each other (wards were asked to make
records of borrowings). Of these 68 borrowed items, 41 were non-stock items. An earlier
study had shown that only 10 intravenous additions were made to each week that could not
have been kept as stock items. The annual total number of items that could have been dealt
with by a resident was estimated to be 1553 items. This was thought to indicate a need for a
residency service.
394. O'Kane MK and Barrett CW. Problems of determining and meeting the requirements for
providing an effective pharmacy service during evenings, nights and weekends at a London
teaching hospital. J Clin Phann 1979;4:59-70.
Descriptive study:
The current method of providing out-of-hours pharmacy services at one hospital was to contact
any pharmacist named on a call-out list. The service depended on pharmacist's goodwill. This
was found to be unsatisfactory and a series of surveys were conducted to determine the true
demand for out-of-hours pharmacy services. A five month survey of calls to pharmacy staff
showed that the average number of calls was one per week. A survey was also conducted
during a 3 week period, in which the old system was used and a further 3 weeks in which only
pharmacist who lived near the hospital were named on the call-out list. In the first 3 weeks the
number of calls was similar to that in the first study but, in the second 3 weeks, it had
increased to 9/week. A third survey was conducted whilst a trial intravenous additive (IVA)
service was in operation and the list of call-out pharmacist included only those who lived close
to the hospital. During this survey the average number of calls rose from 8/week to a
maximum of 44/week. The call out rate dropped off again when the trial WA service stopped.
The nature and timing of calls was analyzed also. One hundred and ninety four calls (62%)
were for supply only, 66 (21%) for information leading to supply, 61(19%) would have
required a pharmacist to come in and 54 (17%) were for information only. The authors said
that it was not easy to determine the need for an on-call service. They said that they would
need additional information if maldng a case for funding a residency service but felt that there
was a need to improve out-of-hours pharmacy services.
395. Chrystyn H and Mulley BA. Therapeutic drug monitoring: the way ahead. Br J Pharmaceutical
Practice 1984;6:282-7.
Descriptive study:
The authors described the development of therapeutic drug monitoring services for
anticonvulsants, theophylline and aminoglycosides in a general hospital. The service was a co-
operative venture involving the pharmacy, biochemistry and microbiology departments and the
medical staff. Most of the article was devoted to describing pharmacokinetic calculations using
a programmable calculator.
396. Brown AM. Establishment of a pharmacy-run TDM service. Br J Pharmaceutical Practice
1986;8: 154-9.
Descriptive study:
This paper described the institution of pharmacy TDM services at a Birmingham hospital.
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397. Bourne JG, Farrar KT and Fitzpatrick RW. Practical involvement in therapeutic drug
monitoring. Pharm J 1985;234:530-31.
Descriptive study:
This paper described the use of ward pharmacists to interpret aminoglycoside levels. They used
two case studies to illustrate the service.
398. Betts A, Huppler C, Hookway J and McCluckie J An investigation of the potential for
pharmacy involvement in drug monitoring. Proceedings of the Guild 1980;8:51-7.
Descriptive study:
This paper described the results of four projects used to investigate the application of drug
monitoring for four drugs at a Manchester hospital. The projects involved interpreting the
levels, providing the results to doctors and assessing pharmacists' contribution to patient care.
Samples were assayed at a hospital or regional facility for 9 patients receiving digoxin, 22
receiving phenytoin, 9 receiving theophylline and 3 receiving lithium. The authors concluded
by questioning the usefulness of monitoring digoxin levels routinely and assay services that take
10 days to provide a result for theophylline and 14 for digoxin. Clinicians were sceptical about
the usefulness of the services.
399. Henley HE. Gentamicin in neonates. Is there a need for a therapeutic drug monitoring service.
Hospital Phannacy Practice 1993:3:149-57.
Descriptive study:
The aims of this study were to evaluate the use of gentamicin in a neonatal unit in a general
hospital, to assess the need for a TDM service, and if a need was identified, to investigate
methods for its introduction. Over a five month period data on neonates receiving gentamicin
was collected daily by the author or, for her, by the unit's staff. The information collected
included age, gestational age, sex, weight, dosage regimen, serum level monitoring data, and
results. Individual patient levels were predicted using population data and a computer program
and were compared to the actual levels. Fifty neonates were studied. Only 56% received a dose
that maintained correct trough and peak levels. Forty percent had toxic trough concentrations
and 4.2% had subtherapeutic or toxic peak concentrations. The computer program was
significantly more accurate in its predictions than population data. There was a perceived need
for a TDM service. It was thought that the computer program could assist in its provision.
400. Elfellak M, Doran iF and Grieve MS. Audit of digoxin monitoring in Tayside. Pharm J
1990;244:726-8.
Descriptive study:
The authors considered the appropriateness of general practice and hospital requests for serum
digoxin levels in a one week period in a Scottish health board where pharmacists involvement
with the service was variable. The requester was contacted 1-2 days after the results were
made available by the laboratory. This allowed judgement of the appropriateness of the request,
sampling and dosage adjustment. Fifty nine requests were made in one week, 18 of which were
from general practice. The remainder were from 8 different hospitals. Data were obtained from
the requester in 56 cases (15 GPs only). Thirty of these 56 (54%) requests were for
appropriate indications. For hospital requests, this was 20/4 1 (49%). Forty eight percent of
samples (27/56) were drawn less than 6 hours from the last dose and 20% were drawn prior to
reaching steady state; for the hospital requests these percentages were 44% and 22%,
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respectively. Forty three percent of samples were taken at the appropriate time (49% for
hospital-derived ones). Seventy three percent of patients had their dose adjusted/maintained to
achieve therapeutic levels (28/4 1 for hospital requests). In the remainder, doses were not
changed despite levels outside the therapeutic range. In 18 cases the doctor adjusted the dose
despite the level having been taken at the incorrect time. Only 15 (27%) requests were
appropriate (correct timing of sample and indication for assay); in hospitals the figure was 12
(29%). No formal TDM services appear to have been available in the board. The authors
claimed that the results were likely to have been representative and that the misuse represented
£4,500 per annum in assay material costs.
401. Brodie MJ. Overuse of monitoring blood concentrations on antiepileptic drugs (letter). Br Med
J 1987;294: 1097-8.
Correspondence:
The author said that only 24 (43%) therapeutic drug monitoring requests were appropriate at
his hospital. He claimed that the service was misused and that doctors used it because it was
available (the Everest factor). He also raised the issue that therapeutic ranges have been
derived from population values and that there may be problems in adjusting therapy for
individuals on that basis. In an ongoing prospective evaluation of the anticonvulsant monitoring
service at his hospital one third of the 700 assays over the year showed a plasma concentration
that surprised the requester. Twenty percent of patients had had their dose adjusted as a result
showing that the service was useful.
402. Gibb I, Campbell Cowan JC, Parnham AJ and Thomas TH. Use and misuse of a digoxin assay
service. Br Med J 1986;293:678-80.
Descriptive study:
The authors audited the serum digoxin assay service over 12 weeks to assess the clinical
indication for assay requests and the role of assays in clinical management. On requesting a
level doctors were asked to complete a form giving patient details, dosage regimen, time from
last dose to sample, reasons for using digoxin and for the sample, and any changes that would
be made in therapy whilst awaiting the results of the assay. A second form was then sent which
included assay result reports. This asked the requester to indicate the use to which the assay
result had been put in patient management. Six hundred and twenty three assays were
performed; 358 were from within the hospital and were included in the results. Both
questionnaire were returned for 285 (80%) of requests. For 67 (24%) requests there was no
clear indication for the request. For 225 (79%) assays, the timing of the samples were given
but these were inappropriate because they were within 6 hours of the last dose for 80. Of these
incorrectly timed samples, 15 of 69 led to a reduction in dose, compared to 10/116 of those
taken at the correct time (p<0.05) thereby demonstrating that inappropriate clinical decisions
may be made due to incorrect sampling. Therapy was changed for 44 patients in the time
whilst the results were awaited and for 55 after getting them. Twenty four changes appeared to
have been related solely to assay results. They concluded that about 75% of assays were
justified but admitted that awareness of the audit may have influenced the results. In addition,
wasteful use of assays resulted in about a £6000 loss to the hospital per annum.
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403. Doran JF. Requests for digoxin assays (letter). Lancet 1986;i:321-2.
Correspondence:
Two thousand nine hundred and two requests for digoxin levels made in one year were
analyzed. Those made in one week were analyzed in detail (n=55). Only 20 (36%) were
appropriate; most (64%) were requested because the service existed. The process of requesting
the levels was poor. Thirty six (64%) samples were taken within 6 hours of the last dose
(incorrect time) and only 14 samples were taken at the correct time. Requests were
accompanied by a reason for them and an appropriately taken sample in only 8 (14%) cases.
404. Purkiss R. Development of a pharmacokinetic service - experience after one year. Pharm J
1982;229:61-3.
Descriptive study:
This paper described the setting up of a therapeutic drug monitoring (TDM) service and the
methods used to monitor anticonvulsant therapy in a Birmingham hospital. Four hundred and
thirty patients' levels were monitored in the first year.
405. Copeland RJ, Thorpe H and Kay EA. Inappropriate digoxin monitoring. J Clin Pharm Ther
1992; 17:172-4.
Descriptive study:
The authors evaluated the use of the digoxin assay services for in-patients at a single general
hospital over a seven week period. The requester was contacted within 48 hours of the request
and interviewed using a structured questionnaire to ascertain the appropriateness of the request,
sampling and dosage adjustment. One hundred and thirteen requests were made over seven
weeks. Data were obtained from the requester in 88 cases. In 22(25%) cases, requests were
considered to have met all the criteria for appropriateness and action (timing of sample,
indication and appropriate action). Sixty six requests were considered wasteful. Of these, 48
(55%) were for appropriate indications. In 24 (48.5%) cases the samples were drawn at the
correct time. Thirteen requests were drawn less than 6 hours from the last dose and, of these,
2 patients had their dose adjusted on the result. Six samples were drawn prior to reaching
steady state. A further 7 of the appropriate requests (that had been taken at the correct time)
were considered to have been wasteful since inappropriate action was taken after receipt of the
results. The authors found also that doctors' actions showed no improvement during the study
despite repeat interviewing. They claimed that the results indicated potential danger to patients
from inappropriate adjustment of dose based on results from inappropriately-taken samples and
represented £3,777 per annum in assay costs. They suggested increased education and
intervention by health care professionals to improve the situation.
406. Horsley MG and Bailie GR. Effectiveness of theophylline monitoring by the use of serum
assays. J Clin Hosp Pharm 1988; 13:359-64.
Descriptive study:
Criteria were created on indications for assay and sampling, and documentation of therapeutic
drug monitoring requests. Data from 10 male and 10 female out-patients receiving theophylline
were studied to determine the effectiveness of the use of serum levels in their therapy. There
were definite indications for drawing levels in 9, none in 3 and a contraindication in 8 patients.
Adequate records, permitting interpretation of levels, were made for 6 patients. The daily dose
was stated incorrectly for 7 patients and other information was often incorrect. Interpretation of
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levels was appropriate for 12 patients. Reports were sent to 10 of the patients' general
practitioners of which only 4 stated the result. A number of recommendations were made for
improvement, including the compilation of a list of indications for drawing levels, the
redesigning of the request and report forms, and the education of personnel.
407. Roberts JE and Hughes DK. Audit of anticonvulsant plasma level assays. Br J Pharmaceutical
Practice 1990; 12:298-305.
Descriptive study:
The authors considered the appropriateness of general practice and hospital requests for serum
anticonvulsant levels at a single general hospital using a self-completed questionnaire survey.
Information from the request form and the questionnaires was used by the authors to judge
appropriateness of requests. Ninety six of the 149 (64%) questionnaires were returned from 50
hospital (52%) and 44 (48%) general practice doctors. Assays were carried out to investigate
poor control (26%), check compliance (24%) and as a routine investigation (30%). Many
doctors stated that they would not request routine levels despite having done so. Sixty two
percent of requests were from house officers or registrars and 38% from consultants. Many
assays were performed prior to steady state (phenytoin 15% and carbamazepine 14%) and
several of these patients had their dose changed as a result (phenytoin 8% and carbamazepine
4%). Of the hospital doctors, 38% thought that there was no need for an advisory service for
interpreting levels, 36% thought there was a need for such a service and 26% were unsure.
The corresponding figures for general practitioners were 11 %, 74% and 15%, respectively.
The authors felt that there was a need for pharmacy input in drug level monitoring.
408. Taylor D. Therapeutic drug monitoring - another way forward. Pharm J 1991;247:34.
Opinion paper:
The perceived inadequacies of the current drug monitoring system were described. These
included inappropriate requests for levels using samples drawn incorrectly and provision of
inadequate information on the meaning of the results of assays by laboratory staff. The author
advocated a pharmacy-run interpretation service to counter the current problems. Pharmacists
could also take on the analytical aspects of the service and even take blood samples.
409. Thomson AH. Meeting the challenges of therapeutic drug monitoring. Pharm J 1993;251:
HS2O-2.
Opinion paper:
The author advocated a multidisciplinary approach to therapeutic drug monitoring (TDM) but
recognised that this may be difficult in the light of interprofessional conflicts and economic
constraints. She believed that pharmacists have specific knowledge that better suits them to
interpret drug level data than other groups. Where necessary, training should be provided to
enable pharmacists to fulfil this role. Increasing computerisation of hospital departments may,
she thought, facilitate pharmacy involvement in this service. Drugs monitored in the future may
be different from those monitored in the past.
410. Duxbury B. Control of anticoagulant therapy (letter). Lancet 1981;i:l001.
Correspondence:
It was claimed that anticoagulant therapy control is poor in the United Kingdom despite
advances in testing methods.
564
411. Harries AD, Birthwell AJ and Jones DB. Anticoagulant control (letter). Lancet l981;i: 1320.
Correspondence:
In a retrospective study of 157 patients who had attended three medical wards for anticoagulant
therapy on a total of 3216 occasions over periods of up to 7 years, it was found that 34% of
levels were outside the therapeutic range. Fifty five patients, who had visited more than 20
times each, had levels outside the therapeutic range on 26% of occasions. Fifty two of these 55
were in the therapeutic range for more than 50% of the time and 35 were in the therapeutic
range for more than 70% of the time. Under therapy was the commonest problem.
412. Kemp CC and Carrington DW. Pharmacists as members of clinical team. Pharm J
1978;222:564.
Descriptive study:
This paper described the development of the pharmacists' role in anticoagulation control as a
member of the clinical team in a single hospital. Pharmacists were seconded to an
anticoagulation clinic and assisted doctors there in running the clinic by seeing the patient at the
same time as the doctor, by providing advice and information on interactions and by making
records of dose changes in patients' personal therapy books.
413. Pegg M, Bourne J, MacKay AD, Lawton WA and Cole RB. The role of the pharmacist in the
anticoagulant clinic. J Royal Coil Physicians 1985; 19:39-44.
Objective:
To describe the management and organisation of an anticoagulation clinic, jointly run by
doctors and pharmacists, and to retrospectively compare their results with those obtained by
standard (doctor only) clinics.
Mhods:
A retrospective study was carried out on 116 randomly-selected patients records, 62 of whom
had attended the jointly-run clinic and 54 who had attended the doctor-only clinic. Data (notes
and records) were examined to elicit information on patient's age, sex, weight, smoking
history, alcohol consumption, indication for anticoagulation, biochemical results, dose and
duration of heparin and warfarin therapy, loading dose of warfarin, length of stay after
commencement of warfarin, use of dnigs known to interact with warfarin, evidence of bleeding
or other side effects, and of non-compliance or intercurrent illness. Anticoagulant control was
assessed by the average interval between appointments, the proportion of visits on which the
levels were in the therapeutic range and the degree of level fluctuation from visit to visit.
Results:
The pharmacists' role was to counsel the patient and to adjust doses where necessary, to decide
on the patient's next appointment date and to dispense a supply of tablets. Guidelines were
created to ensure good practice. The doctor's could be called upon if the pharmacist thought it
was required. Referral to a doctor was otherwise only every three months for those on short-
term therapy and twice yearly for others. Patients in both groups were similar in age, sex,
renal and hepatic function, and indication for therapy. Anticoagulation control was also similar;
the mean (range) interval between appointments was 1.82 (0.3-4.0) weeks for the jointly-run
clinic and 1.81 (0.3-13.0) weeks for the doctor-only clinics. The figures for the proportion of
levels that were above the therapeutic range were 19 and 26%, respectively. For the proportion
of levels that were below the therapeutic range, the figures were 11 and 7%, respectively. The
mean (range) difference in levels between clinic visits were 9.93 (0-58) and 9.88 (0-59),
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respectively. The number and type of unwanted effects were similar for doctor and pharmacist-
run services. No significant cost benefit was obtained by substituting a pharmacist for a doctor.
Assessment of' study: (strength, size of effect, generalisability)
This was a moderately-sized retrospective study. It avoided introducing bias by retrospective
evaluation and by random selection of charts for evaluation. Pharmacists managing
anticoagulation with supervision by doctors in a outpatient setting performed as well as doctors
managing anticoagulation alone. Although it was a retrospective study, there were no data
availability problems. The results are not generalisable.
414. Radley AS and Hall J. The establishment and evaluation of a pharmacist-developed
anticoagulation clinic. Pharm J 1994;252:91-2.
Descriptive study:
The authors described the setting up of a pharmacy-run anticoagulant clinic at a single general
hospital. Protocols were developed and the idea was sold to the doctors in the hospital. Doctors
were involved in the initial assessment of patients and then their continuing care was the
responsibility of the pharmacist. The authors described several practical issues, such as
organisational and phlebotomy issues. They undertook an audit of the clinic at the end of the
first year during which 1492 JNRs (international normalised ratios) had been performed on 241
patients. This represented an average of 6.2 INR/patient and a visit interval of 1.9 months. The
INR achieved by the pharmacist was compared to that in the standards; 6.8% were above the
range and 7.2% below it, 1.2% were in the toxic range and 2% were below the accepted lower
end of the therapeutic range. None of the results that were in the toxic level were due to
inappropriate dosage changes in the clinic and only one case of grossly subtherapeutic dosing
was attributable to a pharmacist. An audit of the counselling program was conducted using a
knowledge-based questionnaire that was completed by an interviewer speaking with 100
patients. Most patients had a basic understanding of their therapy. Patients usually knew the
name of the drug (98%), the dose (82%), the action of the drug (95%), the time of dosing
(93%), the diagnosis requiring warfarin (78%), actions on side effects or missed doses (89%)
and the effects of alcohol (80%), diet (73%) and other drugs (69%) but few knew the meaning
of INR (39%). The authors advocated the involvement of pharmacists in anticoagulation clinics
and suggested standards for use in these clinics. The clinic's success had been reinforced by a
request for a similar service at a nearby hospital.
415. Oakley PA and Reeves E. The value of a centralised reconstitution service. Pharm J
1984;232:391-2.
Descriptive study:
This described the value of a centralised service for cytotoxic reconstitution in a district health
authority. The service could reduce wastage of expensive products and increase safety for staff
and patients. A one year study was carried out at two hospitals in the district. Problems with
the current system, where specific nurses reconstituted cytotoxics, were elicited from medical
and nursing staff and a range of literature and other sources were drawn upon to provide
information on stability and safety issues. Subsequently a pharmacy reconstitution service was
set up for 4 weeks at one site and 10 weeks at another. The nurse reconstitution service was
only used outside of pharmacy opening hours. The pharmacy reconstitution service was
described. The average weekly workload was 179 dose units at one hospital and 48 at the other
and, on average, three doses were reconstituted by nurses each week. They estimated that
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annual savings on drugs would be £17,000. Greater pharmacy control of stocks would provide
an additional saving of £16,000 per annum. These savings were stated to exceed the cost of
providing the service (staff, drugs and equipment) but the method of calculating savings and
costs was not given.
416. Anderson M, Brassington D and Bolger J. Development and operation of a pharmacy-based
intravenous cytotoxic reconstitution service. Br Med J 1983;286:32-6.
Descriptive study:
The background to, and development of, an intravenous cytotoxic therapy reconstitution service
at the London Hospital was described. The preparation facilities and methods were described.
The authors claimed that the hazards to patients and staff, and the wastage of drugs, had been
reduced since the pharmacy took over responsibility for the reconstitution of cytotoxic therapy
from medical staff. This was not an evaluation but the authors estimated that £5000 (from an
annual bill of £47500) had been saved due to the more efficient dispensing method.
417. Clark CM, Baffle GR, Whitaker AM and Goldberg LA. Parenteral drug delivery - value for
money? Pharm I 1986;236:453-5.
Descriptive study:
The authors set out to evaluate the quality and cost of the hospital's current parenteral drug
delivery system. They quantified the potential for error in drug and dose, and rate method and
timing of administration, and the cost of the service. At the outset, a pharmacist interviewed
nursing and medical staff on each ward and department to elicit current practice for preparing
parenteral drugs. Two representative wards were then chosen and, for seven days, every
parenteral drug preparation was observed by a member of the multidisciplinary project team.
The observer noted 27 items of quality or cost information for each reconstitution that was
observed. Average staff, drug and consumable costs were calculated. Two hundred and twenty
four parenteral doses were observed. These included 83 intravenous (IV), 124 intramuscular
(IM) and 17 subcutaneous (SC) administrations. Most (81%) were prepared by nurses and the
remainder by doctors. From the quality perspective, 7% of IV prescriptions had to be checked
for clarity with the prescriber prior to reconstitution. In 22% of cases the nurse or doctor was
disturbed during the reconstitution process and in 28% of cases the preparation was not
checked prior to administration. Seven errors were made (3.1%) in drug selection and dose, 2
of which were detected by the pharmacist. Errors on IV drug were highest (6%). Overall, 13
errors were made in drug, dose, route, diluent or (failure of) administration; most (11, 13.3%)
were on IV drugs. Eighty two percent of all errors were not picked up in the normal checking
processes. Forty nine percent of drugs were administered more than one hour before, or after,
the correct time; 19% were administered more than two hours from the prescribed time.
Aseptic procedures were deficient in many cases. The annual cost to the district health
authority (overheads, pharmacy labour, consumables, nursing and medical labour, dose error,
drug waste and drugs) for IV, IM and SC drug administration was £1.27m, £O.38m and
£0. lOm respectively with the greatest cost per dose being attributed to IV drugs (f4.94/dose).
The team suggested that a pharmacy-run central intravenous additives service might be safer
and more cost-effective than the current reconstitution practices.
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418. Cousins DH, Lee M, Stanaway M and Neary C. Implementation and evaluation of a
centralised IV additive service for antibiotic injection. Pharm J 1989;242:HS14-16.
Descriptive study:
The study compared the cost and quality of a pharmacy-based IVA service with those of a
traditional service (investigated by Clarke CM et al, 1986). The hospital produced 70-80% of
all regular intravenous therapy in a centralised pharmacy facility. This facility and the service
were described. Using the costing method of Clarke and co-workers (1986), independent
researchers costed the provision of intravenous doses at this hospital. The administration of 100
IV doses was observed on 9 wards over 10 days and the reconstitution of 320 doses and 9
batches of drugs was observed in the pharmacy. The costing included staff time, drugs,
disposables, waste and error data but excluded overheads (taken to be fixed and difficult to
measure) and quality assurance (which would continue in any case due to the provision of
parenteral nutrition and cytotoxic services). The costs from the study by Clarke CM et al
(1986) were adjusted to present day costs and were adjusted for differences in medical and
nursing practices that affected IV administration at the author's hospital. From the quality
perspective, the provision of CIVAs permitted all doses to be administered according to the
manufacturers instructions of administration over three minutes compared to 78% being
administered in one minute in the Salford study. Most (90%) doses were administered within I
hour of the prescribed time compare to 51% in the Salford study. The error rate in drug
selection and administration fell from 9.7% to 1 %. Drug wastage fell from 7.9% to 4%.
Nursing time per dose fell from 10.5 minutes (assumed 3 minutes administration time) to 5.3
minutes. The average cost per dose was £5.17 for the traditional system (Salford) and £5.13
for the C1VAs system. This was a partial evaluation that ignored several important costs. The
authors validated the Salford data to a very limited extent (15 non-CIVAs doses on 2 wards and
presentation of Salford data to ward staff). The study indicated that quality factors were
improved by the CIVAs service (although this was mainly compared to another hospital's
practices).
419. Wilson M. An evaluation of the cost effectiveness of a centralised intravenous admixture
service. Proceedings of the Guild 1990;27:3-11.
Objective:
To assess the effect of a central intravenous additives service (CIVAs) on the quality of
medication provision, workload and costs compared to a traditional nurse-reconstitution service
at a large general hospital.
Methods:
Work sampling methods were used to measure IV preparation time. Every IV dose preparation
and administration was observed and timed for one week on two wards. An additional week
was spent in the pharmacy carrying out the time measurements for preparation there. The
potential for microbial contamination of solutions was assessed by judging adherence to aseptic
technique. Other quality indicators were administration time in relation to prescription time,
accuracy in drug, dose diluent and route selection, rate of administration and the performance
of expiry data checks. Costs were calculated from workload data, consumables and drug
wastage. A work study specialist, a pharmacist and a nurse were involved in the
measurements.
Results:
Observations were made of the preparation of 68 CIVAs doses in the pharmacy, 11 nurse
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preparations of doses that could have been prepared by pharmacy, and 84 other doses (non-
CIVAs). The 83 ward administration observations from the Salford study were also used
(Clarke CM et a!, 1986). Differences between the Salford data and the data gathered at the
hospital on nurse preparation and administration were large and the Salford data, although
presented by the author, will not be reported here. Quality of service was higher for the
CIVAs service. When CIVAs were used there was greater adherence to handwashing (90%)
and correct aseptic technique in preparing (100%) and administering (75%) the drugs than
when nurses (91 %, 82% and 36% respectively) or other groups (81 %, 87% and 61 %,
respectively) prepared them. When nurses prepared IVs they were more likely to check the
expiry dates (85%) than when CIVAs were used (78%) or when others prepared the IV (47%).
Differences in errors in selecting the correct drug, dose, diluent and route and in the number of
interruptions were small. The mean difference in administration time (with respect to
prescription time) was 46 minutes for CIVAs, 84 minutes for nurse-prepared IVs and 51
minutes for those prepared by others. Seventy seven percent of CIVAs were administered
within 1 hour of the prescription tune compared with 45% of nurse-prepared IVs and 73% of
those prepared by others. CIVAs were administered in a mean of 17.9 minutes (all
administered in more than 3 minutes); other IVs were administered in a mean of 1.6 minutes
(only 13% administered in more than 3 minutes). There was a mean saving of 3.96 minutes of
nursing time per dose when CIVAs were used but the total cost of preparing a CIVAs dose
was more (f2.l0) than nurse-prepared IVs (f 1.41), mainly due to the higher cost of minibags
for CIVAs products.
Assessment of study: (strength, size of effect, generalisability)
Although this could have been a cost-effectiveness evaluation., several components of a sound
economic evaluation were absent. The main problem was that this was a partial evaluation;
capital investment costs were not included nor were the benefits of the increased quality of
service. In addition, no link was established between the quality improvements in the CIVAs
service and improved patient care. The study was carried out at one hospital and was otherwise
well-performed but the results are not generalisable (as amply shown by comparison with the
Salford data).
420. Whiting B, Kelinan AW, Bryson SM, Derkx FilM, Thompson All, Fotheringhani GH and
Joel SE. Clinical pharmacokinetics: a comprehensive system for therapeutic drug monitoring
and prescribing. Br Med J 1984;288:541-5.
Descriptive study:
The authors described the setting up and impact of a laboratory service to monitor drug levels
of several drugs, including digoxin, theophylline and phenytoin, in a Scottish hospital. The
service was available to other hospitals and general practitioners in the area. Extensive details
of the assay methods were provided and the service used nomographic and computer
predictions of levels. On average, 330 requests for assay measurements were received each
month. Of 235 samples for digoxin levels, 88 (35%) were in the therapeutic range. Repeat
samples for digoxin levels, obtained 2-4 weeks after issuing a laboratory report that included
interpretation of the level obtained and, where necessary, recommendations for dose change,
were more often in the therapeutic range (66%) than initial samples. A similar improvement
was seen for theophylline levels (n = 145); 29% were in the therapeutic range initially and 70%
were in the therapeutic range following the provision of interpretations of the levels and
recommendations for changes in doses. The results for phenytoin (n= 107) followed a similar
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pattern; 19% were in the therapeutic range initially and this increased to 45% following
monitoring and interpretation. The authors claimed that the service improved the use of these
drugs but the study was not an evaluation. Although the change in output (proportion of
patients whose drug levels were in the therapeutic range) was likely to have been associated
with the service, the study was uncontrolled and insufficient data were presented on causality.
In addition, no data were presented on patient outcome or economic factors.
421. Cope JH, Farrell JP, Hetzel MR and Noyce PR. No TDM...No comment. Pharm I
1985;235:599.
Descriptive study:
The authors described a pharmacy-run TDM service for theophylline. In five months 108
patients levels were reported. Twenty two levels were performed on those receiving the drug
intravenously. Forty one percent were in the therapeutic range. Of the 32 and 44 drug levels
that were measured for patients with chronic obstructive airways disease and asthma, 47% and
36%, respectively, were in the therapeutic range. Of the 22 patients on whom reports were
made, only two remained outside the therapeutic range on rechecking levels. Case vignettes
were cited in support of the value of the service.
422. Lowen NP, Moxliam I, Bunn RJ and Hodges M. A "rapid result" pharmacy-based theophylline
monitoring service. Pharm J 1987;239:45-8.
Descriptive study:
The authors described a therapeutic drug monitoring (TDM) service for theophylline at a
general hospital and discussed its impact on patient care. 250 in-patients, under the care of a
chest physician and receiving theophylline or aminophylline products, were monitored over 18
months. Pharmacists carried out the drug level analyses and the interpretation of levels was
facilitated by a computer program. Of the 250 initial levels, which were measured 6-12 hours
post-dose, 103 were in the therapeutic range, 18 were toxic and 129 were subtherapeutic. The
computer program was used to predict a 24 hour theophylline profile for each patient. Of the
250 patients, 42 of the 103 with measured levels in the therapeutic range had profiles where
the level fell outside that range for some time. Dose recommendations were made for all
patients whose predicted 24 hour profile was inadequate. The 18 patients with toxic measured
levels were brought within the therapeutic range. Of the 171 patients with computer predicted
subtherapeutic profiles, 87 had their levels re-measured after dose changes and the re-measured
levels were in the therapeutic range (the remainder were discharged and not followed up or
stopped receiving theophylline). Four case studies were provided to illustrate the dose
adjustment methods. The authors claimed that the service increased the proportion of patients
whose levels were in the therapeutic range. This study was not an evaluation. It was
uncontrolled, open to confounding and many patients were lost to follow-up (about 50%). No
economic or patient outcome data were provided.
423. Fitzpatrick RW and Moss-Barclay C. The effectiveness of drug level monitoring and
pharmacokinetics in individualising theophylline therapy. J Clin Hosp Pharm 1985;10:279-87.
Objective:
To evaluate a service that adjusts theophylline levels based on pharmacokinetic monitoring.
Methods:
A randomised controlled trial was performed on 56 patients. Equal numbers (n=29) were
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allocated to control and test groups. In the test group drug levels were taken and
pharmacokinetic calculations were performed to individualise the dose. Controls were selected
randomly prior to the setting up the study from patients in the hospital receiving slow-release
preparations of theophylline or aininophylline. Levels were taken and analyzed retrospectively
so as not to affect the prescribing patterns of doctors. Test patients were selected from those
admitted to hospital with respiratory problems and identified by their doctor as needing
theophylline or aminophylline therapy. Patients had a pre-dose blood sample taken and were
commenced on therapy. Phannacokinetic calculations guided therapy for each test patient.
Levels were re-measured at steady state.
Results:
Patients in the control and test groups were similar in terms of age, weight, sex and severity of
congestive cardiac failure. The mean steady state theophylline level was well within the
therapeutic range with a narrow standard deviation in the test group (mean 13.44, sd 3.3 mg/l).
In the control group the mean level was 10.7 (sd=7.9 mgfl). The difference between the
groups was not statistically significant. Most (88%) test patients had levels in the therapeutic
range whilst only 34% of controls had levels in the therapeutic range. No test patient, but 14%
of controls, had toxic levels.
Assessment of study: (strength, size of effect, generalisability)
This study was small but well-performed. Precautions were taken to reduce the risk of bias and
confounding. The size of the effect was small and the results are not generalisable. In addition,
only output was measured; economic factors and patient outcomes were not measured.
424. Barlow TJG, Gralmm P, Harris JM, Hartley JPR and Turton CWG. A double-blind, placebo
controlled comparison of the efficacy of standard and individually titrated doses of theophylline
in patients with chronic asthma. Br J Dis Chest 1988;82:251-61.
Objective:
To compare the effect of giving theophylline as a standard or as an individually-titrated dose to
assess the value of dose titration for patient function.
Methods:
This was a three months prospective double blind placebo controlled trial with a crossover
phase. Fifty four patients with chronic asthma were recruited. They were given placebo,
standard therapy (300 mg of a theophylline preparation twice daily), or had their dose adjusted
individually. The study was preceded by a run-in phase to determine the exact dose that each
patient needed to achieve levels in the therapeutic range. Levels were taken at steady state and
patients were not permitted to take drugs that can interfere with theophylline levels. In the
study, patients recorded their peak flow rates and symptom control each day and were seen
monthly to assess their lung function, to check serum theophylline levels and to change
treatments (which were given in random order). The investigators and patients were unaware
of the randomisation. Precautions were taken to maintain blinding. Only results in weeks 3 and
4 were used to reduce andy potential carry-over effects of each phase.
Results:
Forty patients completed the trial; 7 were rejected in the run in phase due to side effects(6) or
uncontrolled asthma (1), 5 withdrew during the study due to side effects (1), because of the
demands of the study (2) and due to a severe asthmatic attack (3) and two died (asthma-related;
subsequently found that they had been on placebo). After the run-in phase, the mean dose of
theophylline required to maintain 21/40 patients in the therapeutic range was 479 mg twice
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daily. This exceeded the standard dose recommended by the manufacturer (300 mg bd).
Patients whose theophylline dosage was controlled using TDM had improved asthmatic control
in comparison with controls and those on standard therapy. FEy ' was significantly higher for
patients after standard (2.11 litres), titrated (2.15 litres) in comparison to and placebo (1.89
litres), but in the sub-group who needed more than the standard 300 mg bd dose FEy,
improved only upon dose titration. The results for PEFR, FVC and home peak flow
measurements showed similar differences. Other factors, such as the use of inhaled
bronchodilators, wheeze and cough and subjective physician assessment, showed a consistent
trend supporting the argument that the use of titrated doses significantly improved patients'
lung function.
Assessment of study: (strength, size of effect, generalisability)
This was a small, well-performed, medium tenn study that showed a moderate effect of
titrating theophylline dosing using TDM. It was carried Out using out-patients hence compliance
cannot be assumed. Nevertheless it successfully linked use of titrated doses to patient health
status measures. Its results are likely to be generalisable to patients who are similar to those in
the study,that is adult, non-smoking, chronic asthmatics of both sexes who do not have
uncontrolled cardiac failure, abnormal liver function tests or peptic ulcer and are not pregnant.
425. Sewell GJ, Bradford E and Rowlands CG. Home-based cancer therapy by continuous infusion.
Pharm J 1989;243:139-41.
Descriptive study:
This paper described a cytotoxic therapy programme that allowed suitable patients to receive
their chemotherapy at home by continuous intravenous infusion. This was felt to reduce side
effects and may improve quality of life. The relative costs of the service were thought to be
less than those associated with in-hospital therapy.
426. Rowland CG. Home continuous infusion chemotherapy. Practitioner 1985;229:889-92.
Descriptive study:
This paper described the creation and implementation of a policy for providing patients with
home chemotherapy.
427. Haines J and Bradley M. Pharmaceutical services to residential homes: present and future. Br J
Pharmaceutical Practice 1990; 12:326-8,334.
Descriptive study:
An interview survey of residential home owners or managers in 4 health authorities was
undertaken by a community services pharmacist. In the 30 homes surveyed (17 privately-owned
and 13 local authority) a variety of services were provided by community pharmacists. Of the
homes that expressed an interest in regular visits from their supplying pharmacist, the main
services requested were staff training, explanation of drug use and side effects, and information
on drug colour changes when generics were used. When the interviewer directly asked
interviewees about specific services, many owners requested advice on drug storage (19),
checks for drug interactions or overdose (18), a delivery service (18), the destruction of
unwanted medicines (15), medication profiles and records (14) and assessment of residents for
self-medication (4).
572
428. Narula N, Shulnian S and Sheridan J. Medication related problems in residential homes for the
elderly. Pharm J 1992;248:623-5.
Descriptive study:
A community services pharmacists assessed clinical pharmacy needs in two residential homes
in a health district in London by analysis of the problems that were encountered during
monthly visits to these institutions over 16 months. The number of problems encountered
fluctuated greatly during the first 9 months but decreased rapidly thereafter. The study
identified several needs, including the need for the provision of specific educational and
information to staff in such homes. The results were used to create forms that a community
pharmacist could use in subsequent visits but the pharmacy service was not evaluated.
429. Humfress A and Timbrell H. Home choice - A care scheme with a domiciliary pharmacy
service. Pharm J 1992;249:686-7.
Descriptive study:
This paper described a project involving several professionals that attempted to evaluate the
feasibility of caring for elderly people in their homes as opposed to in a nursing home or in
community hospital care. The community services pharmacist co-ordinated pharmaceutical
services for the scheme and liaised with the care and training managers, nurses and other
professionals involved. The role of the community services pharmacist was to perform a
medicines assessment. This consisted of taking a drug history and assessing the client's ability
to handle and administer their medication. Compliance aids were considered where necessary.
Arrangements for the supply of medicines by the local community pharmacist were then made
and the local GP was visited to ensure that he had complete records of the medication.
Training was provided also for carers to enable them to help in medicine administration. At a
later stage medication review might be performed by the pharmacist. It was thought that much
of this work could be devolved to community pharmacists in the future.
430. Barber L and Taylor B. Community services pharmacy - a developing role. Br J
Pharmaceutical Practice 1988;10:368-71.
Descriptive paper:
This paper described the role of the community services pharmacist. This role included the
provision of drug information to health professionals and institutions in primary care and the
creation of networks for the safe transfer of patients from secondary care institutions to
primary care.
431. Taylor E. CSPs - What of the future? Pharm J 1990;245:HS1.
Opinion paper:
This paper provided a view of the future role of the community services pharmacist after the
NHS changes. This role would depend on customer demand and the results of reorganisation of
responsibilities for community care. It was thought that the role could include the development
and monitoring of policies for medicine use, the provision of clinical advice to nursing and
medical staff, staff training (particularly of support staff) and liaison with community
pharmacists. It was thought that services may, in future, be provided within contracts which
may be sold to service managers, social services inspectorates, commissioning units and others.
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432. Welsby P. Pharmaceutical advisers. Pharm J 1992;249:490.
Opinion paper:
This paper described the role of pharmaceutical advisors to Family Health Service Authorities
(FHSAs). Some held joint FHSAlhospital appointments. Joint appointments were thought to
enhance the links between primary and secondary care, to facilitate the creation of joint
prescribing protocols and to help provide community care to patients. It was thought that
establishing joint formularies could help reduce differences in the use of drugs in primary and
secondary care. Pharmaceutical advisors provided several services, such as helping to reduce
prescribing costs, providing pharmaceutical advice and advice on drug therapy, and acting as
facilitators between various agencies in primary care. The changing role of the FHSA
pharmaceutical advisor had prompted them to establish training and self-help groups to ensure
a consistent approach was maintained in addressing community drug use issues.
433. Ascough G and Stanford D. The community services pharmacist: a varied role. Pharm J
1990;245:11S21.
Descriptive report:
This paper described the varied duties of community services pharmacists (CSPs). Their roles
varied depending on the local situation and involved contact with several other professionals
such as chiropodists, nurses, midwives, child health specialists and dentists. CSPs may carry
out hospital pharmacy tasks also. The services that could be provided included the provision of
pharmaceutical services to health centres and their staff. This entailed liaison between hospitals
and the community staff to ensure the correct, safe and economic use of medicines, the
provision of chug information and advice on chug use in a variety of situations, the provision
of education both formally and informally, the development of drug use policies, the supply of
stock items to health centres and clinics, the supply of vaccines and other products, and the
inspection and monitoring of premises and drug handling in the community care centres where
drugs are stored. Wider roles included health promotion, the provision of support to carers in
the community, and liaison with drug abuse teams and community psychiatric nurses.
434. Cochrane RA, Mandal AR, Ledger-Scott M and Walker R. Changes in drug treatment after
discharge from hospital in geriatric patients. Br Med J 1990;305:694-6.
Descriptive study:
This paper examined the changes in the drug regimens of 50 elderly patients who were
followed up for 12 months after discharge from a general hospital. At 6 to 14 days, 45/50
patients had had their regimen changed; 11 were taking a different dose, 10 had stopped the
drugs and 20 were taking new drugs. Forty six patients did not remember being told when to
take their drugs on discharge. Many changes were potentially detrimental to the patients. The
authors claimed that the lack of communication between hospital and community health care
staff, including pharmacists, may be contributing to unnecessary and potentially harmful
alterations in patients' drug regimens soon after discharge from UK hospitals.
435. Oborne A and Dodds L. Pharmacy care for medical patients at discharge: which way forward?
Pharm J 1993;251:HS14-5.
Descriptive study:
This paper described an investigation into the contribution that a pharmacist can make in the
discharge process for acute general medical patients. A questionnaire survey of patients'
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satisfaction with the amount and quality of medicine-related information found that there were
few problems with labels or containers. Patients often did not ask for more information because
they felt that they would be unnecessarily bothering very busy staff. The authors felt that ward
pharmacists could circumvent this problem by pro-actively offering information. GPs' and
community pharmacists' opinions were elicited using a postal questionnaire survey. Both
groups felt that a weeks' supply of take home medicines did not permit sufficient time to
organise a re-supply in primary care and recommended the provision of 14 days therapy on
discharge. A representative group of patients were interviewed at home one week after
discharge to investigate unintentional changes to therapy, compliance and other drug-related
problems. It was found that patients frequently forgot the information provided to them. To
counteract this, a written instruction card could be issued with the medicines. Since patients
often (68%) used different community pharmacies, phannaceutical discharge as advocated by
the Pharmaceutical Society would not necessarily work. The authors said that they would now
investigate various methods of improving the discharge process.
436.	 Dobrzanski S and Reidy F. The pharmacist as a discharge medication planner in surgical
patients. Pharm J 1993;250:HS53-6.
Descriptive study:
This paper described the organisation and benefits of a system where patients' own medicines
are used, where possible, in hospital. The pharmacist on a surgical unit interviewed patients,
took a medication history and examined the quality of any of the patients' medicines that had
been brought into the hospital. The enabled the pharmacist to explore the patients' information
needs, the appropriateness of the prescription written by the surgical junior doctors (taking the
information provided by the patient into account) and the medication supply needs of the
patient. Attendance, by the pharmacist, on the surgical ward rounds and the use of protocols
enabled the pharmacist to predict patients' medication needs whilst in hospital and at discharge
as well as the expected discharge date. Patients' own drug supplies could be used, new supplies
organised, self-medication organised, patient counselling provided on an ongoing basis rather
than as a single session at discharge, and pharmacy staff time could be used more effectively.
Over one month, 240 patients were seen by the pharmacist. Forty percent of patients were
unsure about taking routine medication prior to admission or surgery and many had missed
doses of necessary medicines as a result. Most (90%) patients thought that self-medication
using their own drug supplies would be desirable. One hundred and forty one patients brought
their own medicines into hospital; 21 left all their medicines at home and 78 were not taking
any medicines. Of the 442 items brought into hospital by patients (worth £714) 73 were not
used or discarded and supplies of a further 32 items had almost run out. Excluding inhalers,
159 items were not held as stock on the wards. Of these, 63 were suitable for use. One
hundred and seventy six discharge medication lists were written by the pharmacist (for
signature by the doctor). For 23 patients, nothing new needed to be dispensed. Three hundred
and thirty seven items were returned to patients on discharge resulting in drug cost savings of
£616 in addition to uncosted dispensary pharmacist time. The clinical pharmacist spent 37
minutes/week on average interviewing patients, an unspecified amount of time counselling them
and 45 minutes/30 beds/day on ward rounds (uncosted). The cost for pharmacy provision of
the service was not supplied.
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437. Anon. Society produces checklist for hospital admission and discharge. Pharm J 1993;250: 145.
Descriptive report:
This paper reported the production of a form that could facilitate the movement of patients
between primary and secondary care. It would be used by pharmacist in both care settings to
facilitate the provision of seamless pharmaceutical care. It was thought to be especially useful
for the elderly, mentally-ill, those with learning difficulties, and those with complex medication
needs.
438. Jackson C, Rowe P and Lea R. Pharmaceutical discharge - A professional necessity of the
1990s. Pharm J 1993;250;58-9.
Descriptive study:
This report introduced the concept of pharmaceutical discharge of patients when they move
from one health care environment to another. It was designed to ensure that all pharmaceutical
requirements, including information, could be communicated easily and safely between
practitioners in different health care sectors. It was seen as a useful contribution that
pharmacists could make to patient care following the introduction of the purchaser/provider
split and the increasing emphasis on the provision of care in the community.
439. Bennett E. Prescribing at the hospital community interface; the role of the pharmacist
facilitator. Pharm J 1994;252:443-8.
Descriptive study:
This paper described the efforts of a pharmaceutical facilitator at a general hospital to resolve
prescribing problems at the hospital/community interface. Inquiries were made of all
consultants and GPs in the authority regarding such problems. Eleven of 33 consultants replied
and 24/100 GPs. Nine consultants and 23 GPs reported problems; further problems were
highlighted during the first year of the facilitator's job. Many problems concerned consultants
requesting GPs to prescribe expensive unfamiliar drugs (3 consultants and 11 GPs), and the
initiation of therapy using drugs that were cheap in the hospital but expensive in the community
(9 GPs). Other problems were the supply of insufficient quantities of drugs on discharge or at
outpatient clinics (3 consultants and GPs). Various recommendation were made, such as the
supply of 14 days therapy where a specialist felt that this was necessary and, for outpatients,
the provision of 7 days' therapy on A&E prescriptions or a full course of antibiotics, and the
provision of 10 days' therapy on discharge. Patients' own drugs were to be returned to them.
An improvement in communications between the hospital and community pharmacists was
identified as remaining a target.
440. Malone M. Evaluation of an information booklet for general practitioners with patients on
home parenteral nutrition. J Clin Pharm Ther 1988;13:391-4.
Descriptive study:
This paper described the development and assessment of an information package on home total
parenteral nutrition (HTPN) for general practitioners (GPs). The information booklet included a
background information section plus sections on HTPN training, complications, arrangements
for supply and hospital management. Thirty booklets were distributed to GPs who had patients
that were initially started on HTPN in a single hospital. A questionnaire was sent also to these
GPs to assess their views on the booklet. Twenty three questionnaires were returned (76.7%).
Most GPs found the booklet easy to read and about the right length (21), interesting (16) and
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provided some useful information (22). There were criticisms of the printing and presentation
(4) styles. The personalised section on each patient was found to be of some help (11) or very
helpful (12). Fewer GPs whose patients had been on TPN for more than a year found the
information very useful (36%) in comparison with those GPs whose patients were on TPN for
less than one year (78%).
441. Mawhinney WM, McMullen AT and Muigrew PJ. Pharmaceutical input to CAPD service =
safety, efficiency and economy. Proceedings of the Guild 1990;27:60-4.
Objective:
To provide a CAPD (continuous ambulatory peritoneal dialysis) fluid delivery service and to
assess patients' and health professionals' satisfaction with the pharmacy managed CAPD supply
service to patients in their homes. The service included pharmacy purchase of fluids. Pharmacy
also made the arrangements for the delivery of the fluids (by a contractor), counselled patients,
provided information to doctors and nurses, and monitored expenditure on CAPD fluids.
Mhods:
Satisfaction surveys were sent to patients and professionals. The questionnaire asked about their
satisfaction with the new, as opposed to the old, service. An analysis of costs was carried Out
over 12 months.
Results:
All patients responded to the survey. Patients were more satisfied with the pharmacy-run
service than they had been with the previous non-pharmacy service. Fifty six percent of
patients found the monthly meetings with the pharmacist beneficial or essential, 61 % found the
home visits beneficial, 66% thought that the service had increased their knowledge of their
drug regimen and 70% thought that the service had increased their knowledge of why they
should be taking their drugs. Health professionals (3 consultants, 5 junior doctors, 10 nurses, 1
social worker and 1 dietician) found the service very satisfactory and the pharmacist was
considered to be a source of information and advice, and they were thought to be of help with
research. The service resulted in savings of £52,300 in 1988/89. This far exceeded the cost of
the pharmacist employed and the expense of providing the service (15,200).
Assessment of study: (strength, size of effect, generalisability)
The design of this study did not preclude bias since survey respondents were not blinded. In
addition, some results may be inaccurate since some costings relied on nurses' opinions of time
saved. The service now employs a second pharmacist, however, which may suggest that
savings had been made and have been sustained (Personal communication, WM Mawhinney
1993). Most costings were carried out appropriately hence the savings made are probably real.
It was not a full economic analysis. It proved that the service saved money by improving the
process of care but only suggested that patients and health care professionals benefited as a
result. The results are not generalisable.
442. Pattinson S and Garforth H. Re-issue of patients' own medicines on discharge from hospital.
Proceedings of the Guild 1979;6:30-36.
Descriptive study:
This paper described a scheme where patients own drugs (PODs) that were brought into
hospital were re-issued to them on discharge if they were suitable for re-issue. The study was
carried out in two hospitals over three months and was well-accepted by patients and
professionals. At one hospital the scheme resulted in the re-issue of 3% of PODs. There was a
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large variation in the proportion of PODs that were re-issued depending on the type of ward
under study. The savings per patient, of £1.08 for males and £0.75 for females, were felt to be
disappointingly low. The potential problems in running such a scheme were discussed. These
included small amounts of drugs arriving in pharmacy, possibly because of a lack of nurse and
patient awareness of the scheme, problems with record-keeping and failure of the ward
pharmacists to mark the discharge prescription appropriately.
443. Macmanus E and Marshall NM. Patients own medicines (letter). Pharm J 1988;240:325.
Descriptive report:
This letter described a scheme where patients' own drugs (PODs) were re-issued to them on
discharge from hospital if they were suitable. The system had been in operation for 6 years in
a single hospital and the estimated savings were £8,000 per annum in 1981.
444. Cutts C and Athey S. The control of medicines brought into hospital by patients. Pharm J
1992;249:HS 10-11.
Descriptive report:
This paper described a scheme where patients' own drugs (PODs) were re-issued to them on
discharge from hospital if they were suitable for re-issue. The system had been in operation in
a single hospital for 8 years. A 4 week survey was carried out on 20 wards to assess the
scheme. Seven hundred and forty seven items of PODs were received of which 27% were
returned, 30% destroyed at discharge and 43% destroyed in error by ward (40%) or pharmacy
(3%) staff. PODs formed 15.6% of the total discharge items. Fifty seven percent of PODs
were handled correctly. To improve the effectiveness if the system, the policy was changed and
staff were re-educated. The estimated annual savings were £7,400 and pharmacy costs were
about £1,000.
445. Cotter S, McKee M and Barber N. Pharmacists and prescribing: an unrecorded influence
(editorial). Quality in Health Care 1993;2:75-6.
Opinion paper:
The authors suggested that hospital pharmacists frequently influence therapeutic decisions but
their input was rarely recorded where it could be seen clearly by others, such as in the medical
notes. They postulated that the absence of records of pharmacists' influence (from the medical
notes) had several negative consequences for the processes that examined the quality of care.
Given the evidence that doctors would not object to pharmacists' records in the notes, they
proposed that immediate action should be taken to ensure that all those who influence therapy
record their input in the medical notes. This, they said, would establish accountability and help
in the assurance of the quality of medical care.
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Survey of clinical pharmacy services in United
Kingdom National Health Service hospitals
SIOBHAN M. COTFER, NicHolAs D. BARBER, AND MARTIN MCKEE
Abstract: The extent to
which clinical pharmacy ser-
vices are provided in National
Health Service (NHS) hospi-
tals in the United Kingdom
was studied by means of a
questionnaire.
Questionnaires inquiring
whether and to what extent
certain clinical pharmacy ser-
vices were provided were
mailed to all NHS hospital
pharmacies in 1992. The
questionnaires also requested
information about the hospi-
tal and the number and qual-
ifications of pharmacists
employed. The results were
compared with those of a sur-
vey of pharmaceutical servic-
es in the United States.
Of 508 questionnaires
mailed, 416 usable responses
were returned. Services com-
monly provided were inpa-
tient drug therapy
monitoring (96%), clinical
trials support (92%), formu-
lary management (89%), par-
ticipation in drug and
therapeutic committees
(9 7%), and an on-site drug
information center (60%).
Services infrequently provid-
ed were therapeutic drug
monitoring (21%), medica-
tion history-taking (16%),
and a 24-hour on-site phar-
macist (10%). Several services
were associated with pharma-
cies that employed many
pharmacists, pharmacists
with advanced education, or
specialist clinical pharmacists
and pharmacies located in
medical school teaching hos-
pitals. U.K. hospital pharma-
cies provided fewer
patient-oriented services and
more drug information, ther-
apy monitoring, and pharma-
cist education services than
U.S. hospital pharmacies.
Provision of clinical phar-
macy services in the United
Kingdom was associated with
employment of many phar-
macists, pharmacy clinical
specialists, and pharmacists
with advanced education.
Index ternis: Administra-
tion; Clinical pharmacy;
Clinical studies; Data collec-
tion; Drug information cen-
ters; Formularies; National
Health Service (Great Britain);
Patient education; Pharma-
ceutical services; Pharmacists,
hospital; Pharmacy and ther-
apeutics committee; Pharma-
cy, institutional, hospital;
United Kingdom
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I
n the United Kingdom (U.K.), clinical pharmacy
has developed over the past 25 years, primarily in
National Health Service (NHS) hospitals. These are
publicly funded, account for most U.K. hospitals, and
provide health services for their local population with-
in broad contracts. In 1988 the Department of Health
recommended (but did not require) that hospitals pro-
vide clinical pharmacy services, such as monitoring and
modification of drug therapy, discharge counseling,
and clinical trials support.' Similar recommendations
were made by several pharmacy organizations and in
an independent report in [9862.3,a,b The effect of these
recommendations on the provision of clinical pharma-
cy services is unknown.
We conducted a survey to determine the nature and
extent of clinical pharmacy services in U.K. NHS hospi-
tals and to examine the effects of resources and hospital
and staffing factors on those services. The survey was
carried out during the NHS reforms, which were intend-
ed to encourage greater accountability and efficiency in
the health service by creating a managed health care
market.4
Before 1989 all NHS hospitals were directly managed
units in a vertical management structure. Hospitals
were the lowest of several tiers and provided services
according to decisions reached at higher tiers, namely
District Health Authorities (which are responsible for
the health care of residents in their geographical area),
Regional Health Authorities, and the Department of
Health in England. There were slight variations in this
structure in Wales, Scotland, and Northern Ireland, and
a small number of Special Health Authorities were
directly responsible to the Department of Health. The
1989 NHS reforms allowed the hospitals to become self-
governing NHS trusts, which sell services to purchasers
of health care, namely primary care physicians and
district health authorities. Although the hospitals re-
main in the NHS, they now have greater autonomy in
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providing and developmg services within government
health policy. In this marketplace, hospitals changed
from directly managed units to self-governing NHS
trusts. Health care resources are being redirected toward
primary and ambulatory care. 5 These changes have
implications for existing hospital clinical pharmacy
services and for the development of new services.
This report provides the first comprehensive mea-
sure of clinical pharmacy services in the United King-
dom. It provides a baseline for planning and monitoring
future service developments and allows for internation-
al comparison of clinical pharmacy services. Before
reporting the survey, we will briefly describe a typical
NHS hospital pharmacy service and the nature of phar-
macy education in the United Kingdom.
U.K. NHS hospital pharmacies usually provide all
services from a single location, although they may serve
more than one site or hospital. Pharmacies supply
medicines to wards using stock and nonstock dispens-
ing. Stock drugs (those in frequent use) are provided by
distribution services, often staffed by technicians and
assistants.' Ward pharmacists usually visit the wards
daily on weekdays to initiate the supply of nonstock
drugs. Several days' supply of these drugs are provided
for individual inpatients, following the ward pharma-
cist's visit or on production of the patient's medication
chart in the pharmacy. Patients have individual medi-
cation charts containing prescriptions and records of
drug administration. Pharmacies in some parts of the
United Kingdom dispense drugs for ambulatory care
patients. Computers are widely used for stock control
and labeling and, increasingly, for creating financial
and drug-use reports. In the past, the drug budget has
been held by the chief pharmacist, but clinical direc-
tors now hold it in some hospitals. All pharmacy staff
are managed by the chief pharmacist, who is usually
responsible to a hospital manager.
Membership in the Royal Pharmaceutical Society of
Great Britain, a prerequisite for practice as a pharmacist
in the United Kingdom, is gained after a three-year
degree course and one year's preregistration training.
Postgraduate education is voluntary. Most formal courses
result in an M.Sc. degree or a diploma, generally in
clinical or hospital pharmacy or in clinical pharmacol-
ogy.6 An M.Sc. degree typically requires one year of full-
time study or the equivalent and is similar to a Pharm.D.
degree. A diploma requires about half the time that an
M.Sc. requires. M.Phil. and Ph.D. degrees are attained
after a period of research on a specialized topic.
Methods
Data collection. In May 1992, 508 questionnaires
were mailed to all U.K. NHS hospital pharmacies that
provided comprehensive pharmacy services. To be in-
cluded, a pharmacist had to be present in the pharmacy
during usual working hours, and services beyond drug
supply had to be provided. We excluded hospitals that
did not have an on-site pharmacy (receiving a visiting
pharmacy service or operating as a satellite) and those
served by a pharmacy located at a site already included
in the survey. Respondents had been identified by all
District Pharmaceutical Officers in England and their
equivalents in the rest of the United Kingdom; these
individuals are responsible for services in their geo-
graphical areas, which may contain several hospitals.
Where apparent gaps were noted, these individuals
were asked to clarify the number of hospital pharmacies
that existed in their area and the source of pharmaceu-
tical services for hospitals without a pharmacy. These
were usually institutions providing long-term care for
elderly, mentally ill, or mentally handicapped patients
but retaining the title "hospital" for historical reasons.
The questionnaire was pretested among a panel of
clinical pharmacists throughout England and Wales. It
inquired about all aspects of hospital clinical pharmacy
services, the hospital (size, medical school affiliation,
management), and the pharmacy (number and qualifi-
cations of pharmacists). Most questions had a closed
section, with a choice of two (yes or no) or four respons-
es (none, very little, a moderate amount, or lots), and an
open section. With regard to provision of a clinical
service,"lots" was defined as two or more hours per
week, on average, over the year. Open questions were
used where appropriate. Nonrespondents were mailed
reminders after six weeks and telephoned one month
later.
Data analysis. Data were entered on a dBaselV
database (Borland Inc., Scotts Valley, CA) and analyzed
by using the Statistical Package for the Social Sciences
(SPSS/PC+, SPSS Inc., Gornichem, Netherlands) and Epi
Info (version 5, Centers for Disease Control and Preven-
tion, Atlanta, GA7). Information from ordinal categori-
cal variables was collapsed to form binary data ("none"
and "very little" were changed to "not provided," and a
"moderate amount" and "lots" were changed to "pro-
vided") and described by using frequencies. A priori
hypotheses exploring the relationship between clinical
pharmacy services (dependent variables) and demo-
graphic and resource variables (independent variables)
were tested. For this purpose, data on service provision
were grouped according to the value of the indepen-
dent variable, and the proportions of pharmacies pro-
viding service in these groups were compared. We
report between-group differences greater than 20% or a
factor of 3.
Historically, hospital pharmacy services have been
managed differently in each of the five NHS sections
(England, Scotland, Wales, Northern Ireland and the
Special Health Authorities). Special Health Authorities
are highly specialized national referral centers with
separate funding arrangements and are linked to post-
graduate medical schools. Preliminary research suggest-
ed that this division influenced the development of
clinical pharmacy services because of variations in the
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nature and implementation of Department of Health
policy. Hypotheses were created to examine the effects
of the Department of Health1 and Nuffield Report3
recommendations to develop clinical pharmacy servic-
es; preliminary research indicated that some pharma-
cists thought these documents had aided the develop-
ment of services. We inquired if pharmacists thought
that either document had resulted in increased resourc-
es for clinical pharmacy services.
Data on clinical pharmacy services were then exam-
ined for associations with perceived increased resourc-
es. We hypothesized that location of pharmacies in
trust and teaching hospitals could affect the provision
of clinical pharmacy services. The attainment of trust
status might be associated with a more proactive style
of hospital management, and the greater demands
made on pharmacies in teaching hospitals may have
stimulated clinical pharmacy service development. It
was thought that the presence of specialist clinical
pharmacists (who spend 50% or more of their time on
a clinical pharmacy specialty), pharmacists with higher
qualifications (diploma, M.Sc., M.Phil., or Ph.D.), or
larger numbers of pharmacists would facilitate the pro-
vision of clinical pharmacy services. The results were
census data; hence most statistical tests were inappro-
priate, but data were treated as a sample in time (as
pharmacist numbers may change over time) to test for
associations between number of pharmacists and the
provision of services. The number of pharmacists em-
ployed was categorized into ranges and a chi-square test
for trend8 (a priori level of significance, 0.05) was used
to establish if the proportion of pharmacies providing a
clinical service varied with increasing numbers of phar-
macists. The null hypothesis was that there was no
difference in provision of clinical services among groups
(1-3, 4-6, 7-9, 10-12, 13-15, or ^16 pharmacists).
Results
Response rate. Of the 508 questionnaires mailed,
45 responses were excluded: 30 from ineligible sites and
15 from sites that had received two questionnaires. Of
the corrected initial sample (463), 416 (90%) question-
naires were returned. The response rate varied from
61% (14/23) in Northern Ireland to 96% (23/24) in
Wales. There had been total coverage of eligible phar-
macies and a high response rate, and the results were
treated as census data. Nonresponding and responding
pharmacies were similar in terms of location in teach-
ing hospitals (24% and 23%, respectively). All four
nonresponders in Scotland and six of the nine nonre-
sponders in Northern Ireland were located in nonteach-
ing hospitals.
Validity and reliability. Face and content valid-
ity were ensured by pretesting. The nature of the ques-
tionnaire precluded testing for criterion-related and
construct validity. It was impossible to check for test—
retest reliability in a single mailed questionnaire but we
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tested for inter-rater and parallel-forms reliability. At 15
sites, two questionnaires were completed by different
pharmacists and were returned separately at intervals in
excess of two weeks, so it was assumed that they had
been completed independently. Within-site replies to
closed questions were identical, demonstrating inter-
rater reliability. Our data on staffing were comparable
to contemporaneous data collected by an English re-
gional health authority, which showed parallel-forms
reliability.e
Demographics, staffing, and operating hours.
Few responding pharmacies (105/389, 27%) were locat-
ed in teaching hospitals in the United Kingdom as a
whole, but a higher proportion were located in such
hospitals in Scotland (19/41, 46%) and Northern Ire-
land (7/14, 5 0%). This is consistent with the presence of
relatively high numbers of medical schools in Scotland
and a bias toward responders being located at such sites
in both parts. Some pharmacies (118/402, 29%) were in
self-governing NHS trusts.
The median number of hospital beds served was 545
(n = 409). The interquartile range (IQR) was large (522
beds), and the frequency distribution was highly skewed,
with a long right tail. The median numbers of beds
served by pharmacies in Special Health Authorities
(174) and Northern Ireland (308) were lower.
The median number of pharmacists employed was
seven (IQR = 9 pharmacists, n = 389). The median
number of full-time equivalents (FTEs) was also seven
(IQR = 8.5 FTE, n = 375), indicating that most pharma-
cists held full-time positions. Both frequency distribu-
tions were skewed to the left. The Special Health
Authorities employed relatively more pharmacists (3.5/
100 beds), and Northern Ireland relatively fewer (1.2/
100 beds), compared with the United Kingdom (1.5/
100 beds), with similar results for FI'E-adjusted figures.
Many pharmacies (185/410, 45%) employed special-
ist clinical pharmacists, with a median of two (IQR = 2
pharmacists). Pharmacists with advanced pharmacy
education were employed in 305 (74%) of 410 hospi-
tals; 45% of the 410 hospitals had pharmacists with a
diploma, 53% had pharmacists with an M.Sc. degree,
6% had pharmacists with an M.Phil. degree, and 15%
had pharmacists with a Ph.D. degree. Hospitals em-
ployed a median of two pharmacists with advanced
education (IQR = 3 pharmacists). The employment of
pharmacists with M.Sc. degrees by more Scottish hospi-
tals (29/44, 66%) and pharmacists with diplomas by
more Welsh hospitals (14/23, 61%) probably reflects
the availability of the courses in 1992.
Pharmacies operated for a median of 8.5 hours daily
(IQR = 0.5 hour) on weekdays. Most opened on Satur-
days and public holidays (305/4 14, 74%) and remained
closed on Sundays (374/414, 90%). Hours were restrict-
ed to a median of three on Saturdays, Sundays, and
bank holidays (IQR = 0.5, 2, and 1 hours, respectively).
When closed, pharmaceutical services typically consist-
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ed of a pharmacist on call from home, providing advice
and available to arrange drug supply; more rarely, a
residency service was provided, where a sole on-site
pharmacist provided emergency pharmacy supply and
advisory services (Table 1). Residency service was more
common in teaching hospitals (Table 2) and where
specialist clinical pharmacists were employed (Table 3).
Drug therapy monitoring. Monitoring therapy
for short-term (acute) patients involves a pharmacist
looking at the prescription and considering whether
the therapy is appropriate. Most pharmacies monitored
short-term (acute) and long-term inpatient drug thera-
py on the ward (367/393, 93%), confirming that ward
pharmacy was standard practice. Monitoring was typi-
cally provided for short-term patients daily on week-
days (351/392, 90%) but rarely on weekends (51/393,
13%); for long-term patients it was at least weekly (245/
335, 73%) in most hospitals that served these patients.
Drug therapy monitoring was associated with increas-
ing numbers of pharmacists (Table 4). The median
number of pharmacists working on the wards in each
hospital was six (IQR = 7 pharmacists), which, in com-
parison with the median number employed (eight),
indicates that most pharmacists worked on the wards.
Partidpation in ward rounds. Pharmacists par-
ticipated in ward rounds conducted by medical staff and
contributed to treatment decisions in many hospitals,
especially in those with more pharmacists (Table 4),
clinical pharmacy specialists (Table 3), or pharmacists
with advanced qualifications (Table 5). In most hospitals
(288) some pharmacists attended ward rounds, but all
pharmacists attended rounds in few hospitals (33).
Table 1.
Clinical Pharmacy Services in United Kingdom National Health Service Hospitals
Service
Monitoring drug therapy for acute inpatients
Monitoring drug therapy for long-term patientsa
After-hours service
Pharmacist in-house (residency)b
Pharmacist on call from home
Participating in medical ward rounds
Participating on drug and therapeutic committee
Enforcement of formulary systemc
Providing advice to clinical directorates
Providing financial information on drug use
Providing information used in creating prescribing policies
Providing information used in making formulary decisions
Providing information used in new product evaluations
Participating in infection control servicesd
On-site drug information center
Providing education for pharmacy staff
Providing education for nurses and student nurses
Providing education for physicians
Providing education for medical students
Providing education for other hospital health professionals
Conducting practice research
Contributing to medical audite
Performing pharmacy audite
Participating in clinical audite
Providing support for clinical trials
Participating on total parenteral nutrition teams
Participating on cytotoxic chemotherapy teams
Participating on patient-controlled analgesia teams
Therapeutic drug monitoring
Anticoagulation control
Providing advice on wound care
Taking patients' medication history
Helping patients with self-medication schemes
Counseling patients about their medication
Providing patient education for all patients
Operating CSM ADR monitoring scheme
Operating an additional ADR monitoring scheme
No. (%) of Pharmacies Providing Service
394/409(96)
313/335(93)
39/412
363/412
321/414
329/341
295/333
181/279
360/397
296/397
288/397
237/397
24/391
245/411
28 1/413
267/416
27/416
17/416
64/416
170/412
204/410
108/404
29/404
380/413
147/401
92/399
60/388
83/394
18/377
66/404
67/409
204/407
245 406
102/401
187407
46/367
allot all hospitals had long-term patients.
bResident pharmacists usually provide on-site emergency pharmacy supply and advisory service. They work alone but may be supported and advised
by pharmacy staff at home.
342/415(82%) of hospitals had a formulaiy. Enforcement of the formulary meant that fewer than 100% of requests for nonformulary products were ac-
ceded to by pharmacy.
dThese would be understood by respondents to include assistance with the creat on of infection control policies and provis on of advice about them.
eQual ty assurance activity led by and predominantly involving, doctors (medical audit), pharmacists (pharmacy aud t), or multiple discip ines (clinical au-
dt
Also known as self-administration schemes.
CSM = Committee of Safety of Medicines. ADA adverse drug react on.
Vol 51 Nov 1 1994 AmJ Hosp Pharm 2679
Service
In-house after-hours pharmacy servicesa (n = 387)
Practce research (n 385,
Participation on TPN teams (n = 374)
Participation on cytotoxic-therapy teams (n = 372)
Reports United Kingdom clinical pharmacy services
Table 2.
Variation in Provision of Selected Pharmacy Services in United Kingdom National Health Service Hospitals with
Location in Medical School Teaching Hospitals
No. (%) Pharmacies Providing Service
Nonteaching Hospitals 	 Teaching Hospitals
	
9282(3)	 29/105(28)
	
91/281 (32)	 68/104(65)
	
83/270(31)	 58/104(56)
	
47268(18)	 40104(38)
3Catled' residency services in the United Kingdom. Res dent pharmacists usually provide on-site emergency pharmacy supply and adv sory service They
work alone but may be supported and advised by pharmacy staff at home
bTPN = Tota parenteral nutrition.
Table 3.
Variation in Provision of Selected Pharmaceutical Services in United Kingdom National Health Service Hospitals with
the Presence of Specialist Clinical Pharmacistsa
Service
In-house after-hours pharmacy servicesb (n = 409)
Partidpating in medical ward rounds (n = 409)
Providing education for pharmacists (n = 408)
Providing education for nurses (n = 410)
Conducting practice research (n = 407)
Contributing to medical auditc (n 405)
Participating on TPN teamsd (n = 396)
Participating on cytotoxic therapy teams (n = 394)
Taking medication histones (n = 404)
Operating additional ADR schemee (n 35)
No. (%) Pharmacies Providing Service
Specialist Clinical Pharmacists	 Specialist Clinical Pharmacists
Not Present	 Present
	
11/225(5)	 28/184(15)
	
146/224(65)	 171 185(92)
	
131/224(58)	 146/184(80)
	
125/225(56)	 140/185(76)
	
60/222(27)	 110/185(59)
	
90/221(41)	 112/184(61)
	
55/215(26)	 91/181 (50)
	
25214(12)	 66/180(37)
	
19 221 (9)	 48/183(26)
	
10/194 (5)	 36/168(21)
apharmacists who spend 50% or more of their time on a clinical pharmacy specialty.
bCalled "residency services" in the United Kingdom. Resident pharmacists usually provide on-site emergency pharmacy supply and advisory service. They
work alone but may be supported and advised by pharmacy staff at home.
CA quality assurance activity led by, and predominantly involving, physicians.
dTPN total parenteral nutrition.
ADR = adverse drug reaction. Additional" means in addition to the Committee of Safety of Medicines ADR monitoring scheme.
Participation in hospital policymaking
groups. Drug and therapeutic committees (DTCs) ex-
isted in 87% of hospitals.d Pharmacists typically partic-
ipated in DTC meetings, more so in hospitals with
greater numbers of pharmacists. Formularies existed in
82% of U.K. hospitals and were enforced to some degree
(i.e., some nonformulary requests were not approved)
in most of these. Some Special Health Authorities (3/9)
had a formulary, but only one enforced it. This may
reflect the high proportion of senior specialist medical
staff in Special Health Authorities, impeding agreement
on drug policies. Formulary enforcement was associat-
ed with increasing numbers of pharmacists. Few phar-
macies were involved in infection control, including
creating and providing advice on infection control
policies, possibly because of increasing involvement of
nurses in this area.
Inmost hospitals with clinical directorates (279/4 16,
67%), advice on drug use was provided to the clinical
directorate by pharmacy. This service was associated
with increasing numbers of pharmacists and employ-
ment of pharmacists with advanced education. Irre-
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spective of the existence of the directorate structure,
most pharmacies provided financial information on
drug use and information used in the creation of pre-
scribing policies, in making formulary decisions, and in
evaluating new medicinal products.
Drug information and educational services.
Many hospitals (245) had an on-site pharmacy drug
information center, and 236 (96%) of these contained
designated pharmacists. On-site drug information cen-
ters were associated with increasing numbers of phar-
macists and pharmacists with advanced education. In
the absence of an on-site drug information center,
information was often obtained from other drug infor-
mation centers.
Education was provided for pharmacists in 281 hos-
pitals, often as part of an M.Sc. (31% of providing
hospitals) or diploma (77% of providing hospitals)
course. Most such courses in 199 1-92 focused on clini-
cal pharmacy6; this is consistent with our observation
that more hospitals in Northern Ireland (3/7, 43%) and
Scotland (18/27, 67%) provided education for M.Sc.
courses (compared with 31% in the United Kingdom)
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Table 4.
Variation in Provision of Selected Pharmaceutical Services in United Kingdom National Health Service Hospitals with
the Number of Pharmacists Employed
4-6
2.55
3.42
5.29
4.45
1.29
2.37
2.56
5.58
5.21
1.26
1.82
1.72
2.16
2.30
3.14
1.25
2.66
0.76
1.73
1.95
5.30
1.18
servicea
Monitoring acute inpatients
Monitonng k)ng-term patient therapy
Participat ng in medical ward rounds
Participating in DT(Y
Enforcing formulary system0
Providing advice to clinical directorates
On-site drug information center
Providing education for pharmacists
Providing education for nurses and nursing students
Providing education for health professionalst
Conducting pharmacy practice research
Participating in medical audit9
Participating in pharmacy audith
Participating on TPNI teams
Participating on cytotoxic therapy teams
Participating on PCA teams
Therapeutic drug monitoring
Taking medication histories
Helping patients with self-medication scheme&'
Patient counseling
Providing patient education
Assisting with CSM ADR schem&
Odds Ratios for Number of Pharmacistsb
7-9	 10-12	 13-15	 16+
	
4.30
	 NDC	 340
	
ND
	
1.93
	
4.10
	
2.02
	
2.64
	
8.69
	
7.12
	
22.42
	
25.85
	
4.19
	
6.98
	
8.37
	
14.30
	
1.30
	
1.68
	
3.54
	
3.21
	
4.08
	
4.45
	
538
	
17.44
	
9.15
	
11.93
	
12.11
	
111.3
	
13.56
	
13.54
	
31.80
	
ND
	
6.86
	
7.25
	
7.18
	
50.76
	
1.27
	
2.18
	
3.85
	
4.32
	
6.29
	
8.53
	
10.22
	
36.57
	
2.72
	
3.06
	
4.08
	
4.71
	
4.16
	
422
	
3.70
	
10.84
	
6.09
	
5.02
	
18.28
	
15.17
	
14.78
	
7.97
	
6.02
	
24.44
	
6.75
	
5.19
	
5.10
	
12.50
	
2.42
	
2.10
	
3.25
	
7.46
	
0.94
	
1.10
	
064
	
3.02
	
1.32
	
1.72
	
3.07
	
5.59
	
2.70
	
3.20
	
3.65
	
4.73
	
6.48
	
4.19
	
5.58
	
5.98
	
1.31
	
1.44
	
2.31
	
2.71
an = 318 for each service.
bpr i lity of service provision in each range compared with a probability of 1 when 1-3 pharmacists are employed. Chi-square analysis showed sig-
nificant differences (<0.05) among odds ratios for all services.CND = no data.
dDrug and therapeutics committee.
L0
 than 100% of nonformulary requests were acceded to by pharmacy.
tOther than doctors, nurses, medical students, and pharmacy staff.
SQuality assurance activity led by. and predominantly involving, physicians.houal ity assurance activity led by, and predominantly involving, pharmacists.
'TPN = total parenteral nutntion.
iPCA = patient-controlled analgesia.
kAlse called self-administration schemes.
iCSM = Committee of Safety of Medicines, ADR = adverse drug reaction.
and more hospitals in Wales (16/17, 94%) and Special
Health Authorities (5/5, 100%) provided education for
diplomas (compared with 77% in the United King-
dom). Provision of education was associated with in-
creasing numbers of pharmacists, specialist clinical
pharmacists, and pharmacists with advanced educa-
tion. Education was more frequently provided where
pharmacy resources were thought to have increased as
a result of the Department of Health recommendation
HC(88)54 1
 (148/1 73, 86%) or the Nuffield Report3
 (68/
77, 88%) than where resources were thought to have
been unaffected (124/227, 55%, and 188/302, 62%,
respectively).
Many pharmacies provided education for hospital
nurses; few provided it for physicians, medical stu-
dents, or other groups of nonpharmacist health care
professionals and workers. Education of nurses was
associated with the presence of specialist clinical phar-
macists or pharmacists with advanced education. For
nurses and other health care professionals, training was
associated with increasing numbers of pharmacists.
Involvement in research, audit, and clinical
trials. Some pharmacies undertook practice research
and 127 of 155 (82%) indicated that researchers were
performing it as part of advanced education, mainly
toward master's degrees (68) and diplomas (64). Prac-
tice research was associated with location in teaching
hospitals, increasing numbers of pharmacists, specialist
clinical pharmacists (Table 3), and pharmacists with
advanced education. It was more common where re-
sources were thought to have increased because of
HC(88)54 (94/174, 54%) than at other sites (71/225,
32%). Pharmacies typically provided support services
for in-house and pharmaceutical company-sponsored
clinical trials.
Some pharmacies participated in medical audit, but
fewer were involved in pharmacy or clinical audit (Ta-
ble 1). Contributions to medical audits included provi-
sion of financial information on drug use (169/197,
86%), help with devising prescribing policies (134/188,
71%), feedback on adherence to policies (115/186, 62%)
and information on prescribing problems (86/180,48%).
Pharmacy audits examined interventions, specific clin
-
ical pharmacy services, errors, and response time. Clin-
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Table 5.
Variation in Provision of Selected Pharmacy Services in United Kingdom National Health Service Hospitals with the
Presence of Pharmacists with Advanced Qualifications
Service
Participating in medical ward rounds (n = 409)
Advising chnical directorates (n = 276)
On-site drug information center (n = 406)
Providing education for pharmacists (n = 408)
Providing education for nurses (n = 410)
Conducting practice research (n = 407)
Performing pharmacy auditb (n = 4fJ)
Participating on TPN teamsc (n = 396)
Patient counseling (n = 401)
No. (%) Pharmacies Providing Service
Pharmacists with Advanced	 Pharmacists with Advanced
Qualifications Not Present	 Qualifications Present
	
63/105(60)	 254/304(84)
	
2965(45)	 150/211(71)
	
36/104(35)	 206/302(69)
	
52/104(50)	 227/304(75)
	
52/105(50)	 213/305(70)
	
18/103(17)	 152/304(50)
	
13/1 02 (1 3)	 95/298(32)
	
18/97(19)	 128299(43)
	
44/99(44)	 206/302(66)
aPharmaosts who possess a diploma, M.Sc., M Phil or Ph D
bQual i ty assurance activity led by, and predominantly involving pharmacists.
9FN = total parenteral nutntion.
ical audits included multidisciplinary audit of depart-
ments and of other hospitals or their departments.
Contribution to medical audits was associated with the
presence of specialist clinical pharmacists, and contri-
bution to pharmacy audits was associated with the
presence of pharmacists with advanced education. In-
volvement in both activities increased with increasing
pharmacist numbers.
Specialist clinical pharmacy services. Many
pharmacies contributed to multidisciplinary teams. Par-
ticipation on total parenteral nutrition (TPN), cytotoxic
therapy, and patient-controlled analgesia (PCA) teams
was associated with increasing numbers of pharmacists.
Participation on TPN and cytotoxic-therapy teams was
associated with location in teaching hospitals and the
presence of specialist clinical pharmacists, and partici-
pation on TPN teams was associated with pharmacists
with advanced education. Provision of a therapeutic
drug monitoring service was associated with increasing
numbers of pharmacists. Anticoagulation services and
wound care advice were rarely provided by pharma-
cists.
Services provided directly to patients. Few
pharmacies took patients' medication histories, except
in Scotland (16/45, 36%). This was done mainly for
inpatients (56/66, 85%). Assistance in formal programs
enabling patients to self-administer medications was
provided in 50% of all pharmacies; this service was
provided less frequently in Northern Ireland (4/13,
31%) and Special Health Authorities (3/9, 33%). Patient
counseling was frequently provided for both inpatients
(167/238, 70%) and outpatients (151/238, 63%). t Coun-
seling was provided least frequently in Special Health
Authorities (3/9, 33%) and most frequently in Scotland
(32/43, 74%) and Wales (16/22, 73%). Patient educa-
tion was provided less often in Northern Ireland (1/13,
7%) than elsewhere. Throughout the United Kingdom,
patient education was provided mainly for outpatients
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(59/98, 60%). The provision of these services was asso-
ciated with increasing numbers of pharmacists. Medi-
cation history-taking was associated with specialist
clinical pharmacists, and patient counseling was associ-
ated with pharmacists with advanced education.
Adverse drug reaction (ADR) monitoring.
Some pharmacies assisted in the operation of the Com-
mittee of Safety of Medicines ADR monitoring scheme.
(The Committee of Safety of Medicines advises the
Licensing Authority on questions of the safety, quality,
and efficacy of new medicines for human use. It is also
responsible for encouraging the collection and investi-
ation of reports of suspected ADRs.) Provision of addi-
tional ADR monitoring schemes was associated with
specialist clinical pharmacists. Both services were avail-
able to all inpatients and to about half of all day
patients and outpatients.
Discussion
This study reports the extent of clinical pharmacy
services in U.K. NHS hospitals in 1992. Some services
were frequently provided, such as drug therapy moni-
toring on wards (ward pharmacy), drug-use control
(financial information and formulary and DTC activi-
ties), and clinical trials support. Others were rare, such
as education for some health professionals, advice about
wound care and infection control, participation in
clinical audit and PCA teams, pharmacist-run anticoag-
ulation control, medication history-taking, some ADR
monitoring, and after-hours residency services.
The results strongly support the existence of associ-
ations between the provision of services and increased
numbers of pharmacists, specialist clinical pharmacists,
and those with advanced education. Weaker associa-
tions were noted with location in teaching hospitals,
location in certain parts of the United Kingdom, and
perceptions of increased resources. Increased clinical
pharmacy services in teaching hospitals may be
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attributable to greater innovation and development of
all services and a greater need for pharmacy support
services. The failure of Special Health Authority phar-
macies to provide some services may be related to a
dominant medical profession inhibiting clinical phar-
macy development, and the greater development of
patient-oriented services in Scotland may be a regional
factor. Associations with increasing numbers of phar-
macists may illustrate the need for a critical mass of
pharmacists to provide many services. Pharmacists with
advanced education or specialists may have greater
confidence and expertise, facilitating service develop-
ment. Service provision in 1992 seemed to have been
unaffected by the creation of NHS trusts, but most
hospitals were not yet trusts. Increasing attainment of
trust status and market forces in the NHS may reduce
the number of pharmacists employed or adversely af-
fect education, with potentially negative effects on
clinical pharmacy services.
Comparison of services provided In the Unit-
ed Kingdom and the United States. We recognize
that there are dissimilarities in the nature of clinical
pharmacy services provided in U.S. and U.K. hospitals,
partly because of different definitions of clinical phar-
macy. We also recognize that there are differences in
the health care systems and in survey methods. Still,
broad comparisons of hospital pharmacy services in the
United Kingdom and the United States remain possible.
Data were compared with those cited for U.S. commu-
nity hospitals in 1992. The case mix in the hospitals in
both surveys was broadly comparable. We cannot ex-
plain the differences that we noted, but standards re-
quired by the Joint Commission on Accreditation of
Healthcare Organizations may have influenced the pro-
vision of certain services in the United States. No such
organization exists in the United Kingdom.
Hospital pharmacies in the United States are open
longer on weekdays (15 hours/day) and weekends (13
hours/day) than those in the United Kingdom. The
number of pharmacist FTEs per 100 occupied beds was
much lower in the United Kingdom (1.4) than in the
United States (6.7). This may be related to the needs of
unit dose distribution systems in the United States and
the use of well-trained nonpharmacist support staff in
U.K. hospitals. Our survey did not examine this topic in
detail.
Information and education services were more fre-
quent in the United Kingdom than in the United States,
where 12.7% of hospital pharmacies had a drug infor-
mation center and about one quarter had a formal
pharmacist development program. U.S. and U.K. phar-
macies were involved to a similar extent in drug policy-
making mechanisms. Most U.S. hospitals had a phar-
macy and therapeutics committee with pharmacist
representation, but data were unavailable on the extent
of pharmacist activity on these; fewer U.S. hospitals
had a well-controlled formulary. Patient education or
counseling was provided for inpatients by more (69%)
U.S. than U.K. pharmacies, but similar proportions
provided ADR detection and monitoring programs,
took patient medication histories, and provided drug
therapy monitoring. There may, however, be substan-
tial differences in the provision of drug therapy moni-
toring in the two countries; all U.K. patients received
the service, albeit not on a daily basis, but it was
provided for more than half of all inpatients by only
47% of U.S. pharmacies. Pharmacokinetic consulta-
tions for inpatients or ambulatory care patients (57%)
were provided by more pharmacies in the United States,
but provision of nutritional support consultations was
similar (37% in the United States) to that in the United
Kingdom. Comparison of quality improvement servic-
es was difficult. Pharmacy audit of clinical and nonclin-
ical services was infrequent in the United Kingdom, but
contributions were often made to medical audit; in the
United States, quality assurance for clinical services was
performed in about 30% of hospitals, but data were
unavailable on contributions to multidisciplinary au-
dits or quality assurance.
Conclusion
There are a number of differences in the extent of
clinical pharmacy services in the United Kingdom and
the United States, most notably the greater develop-
ment of patient-oriented services in the United States
and of drug information, therapy monitoring, and phar-
macist education in the United Kingdom. Strongly
positive associations were found between the provision
of clinical pharmacy services and increasing numbers of
pharmacists, pharmacy specialists, and pharmacists with
advanced education in U.K. NHS hospitals.
aHaron P1, Standing VF, Watling JJ. Clinical pharmacy. A
statement from the Regional Pharmaceutical Officers' Committee.
U.K. National Health Service; 1988.
bEuropean Society of Clinical Pharmacy, United Kingdom
Clinical Pharmacy Association, and Societe Francaise de Pharma-
cie Clinique. Clinical pharmacy education and training for phar-
macists in the European Economic Community. Netherlands;
1989.
cpharmacy technicians undergo specific vocational training
and provide services such as compounding and dispensing. Assis-
tants usually hold less substantial qualifications.
dClinical directors, often physicians, manage organizational
sections (clinical directorates), usually grouped according to med-
ical specialty, in NHS hospitals.
eWilson P. Personal communication. 1993.
Drug and therapeutic committees usually include medical,
pharmacy, and other staff. They determine hospital drug policy in
consultation with pertinent staff.
gAudit is a quality assurance activity. It may be led by, and
predominantly involve, physicians (medical audit), pharmacists
(pharmacy audit), or multiple disciplines (clinical audit).
hpaflents receiving noninvasive diagnosis or review of treat-
ment are referred to as outpatients; those undergoing a procedure
or other treatment who are not typically admitted are referred to
as day patients.
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Establishment of a 900 telephone number
at a university-based drug information service
PHILIP 0. ANDERSON
Abstract: Effects of convert-
ing a free drug information
service at a university medi-
cal center to a 900 telephone
number are described.
Calls to a university medi-
cal center drug information
service had increased beyond
the capacity of staff. A tele-
phone survey to recent users
of the service indicated that
callers outside the institution
would be willing to pay a fee
for the service, so a 900 num-
ber was instituted for outside
calls in January 1993. Staff re-
corded data on all questions
they answered; data for 1993
were compared with those
from 1992.
Question volume decreased
by 48% after the 900 number
was instituted, with questions
from outside the institution
dropping by 55%, questions
from outside health care pro-
fessionals dropping by 72%,
and questions from the lay
public increasing slightly.
One severe impediment to
callers from local hospitals
was that many hospitals
block access to 900 numbers
from their telephone systems.
The average length of a call
was three minutes and the
average cost per call was $6.
Net income during the first
year of operation was $6698.
The 900 number provided
some income, but it did not
completely offset operating
costs.
A 900 telephone number is
a workable, but imperfect,
method of providing drug in-
formation to outside callers.
Early notification of users be-
fore implementing a 900
number is essential to allow
time for them to arrange tele-
phone access.
Index terms: Administra-
tion; Costs; Data collection;
Drug information centers;
Pharmacy, institutional, hos-
pital; Telephone
Am J Hosp Pharm. 1994;
51:2684-7
S
everal methods of charging for hospital- and
university-based drug information services have
been reported in the literature, including fixed-
or variable-priced contractual arrangements and fee-
for-service methods. 14 Although commercial drug in-
formation services provide information to the lay public
via 900 access, 56 a literature review revealed no reports
of such services being provided to health professionals
via a 900 telephone number from a drug information
service based at a university medical center.
The University of California San Diego (UCSD) Drug
Information Service (DIS) was established in 1978. The
DIS was made available to a11 community health profes-
PHILIP 0. ANDERSON, Pauu1.D., FASHP, is Director, Drug Informa-
tion Service, Department of Pharmacy, University of California
San Diego Medical Center, 200 West Arbor Drive, San Diego, CA
92103-8925.
Presented at the 28th Annual ASHP Midyear Clinical Meeting,
2684 AmJ Hosp Pharm Vol 51 Nov 1 1994
sionals at no charge from the outset. It also handles
questions from the lay public regarding the use of
medications during breastfeeding. Staffing has varied
between 1 and 1.2 pharmacist full-time equivalents
(FTEs) plus some pharmacy resident coverage, with one
full-time pharmacist (the director) providing most of
the staffing. During 1992 and 1993, DIS staffing consist-
ed of 1.2 FTE pharmacists; pharmacy residents account-
ed for an additional 0.2 FTE in 1992 and 0.3 FTE in 1993.
From the first full year of operation in 1980, the number
of calls received by the DIS increased almost every year
from 1019 in fiscal year 1980 to 3622 in fiscal year 1992
(the university's fiscal year is July to June).
Atlanta, GA, December 6, 1993.
Copyright © 1994, American Society of Hospital Pharmacists,
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Abstract
Objective—To investigate systematically
participation in audit of NHS hospital
pharmacists in the United Kingdom.
Design—Questionnaire census survey.
Setting—All NIIS hospital pharmacies in
the UK providing clinical pharmacy
services.
Subjects-462 hospital pharmacies.
Main measures—Extent and nature of
participation in medical, clinical, and
pharmacy audits according to hospital
management and teaching status, educa-
tional level and specialisation of phar-
macists, and perceived availability of
resources.
Results-4 1 6 questionnaires were re-
turned (response rate 90¼). Pharmacists
contributed to medical audit in 50¼
(204/410) of hospitals, pharmacy audit in
27'/. (108/404), and clinical audit in only
7'/. (29/404). Many pharmacies (59'!.
(235/399)) were involved in one or more
types of audit but few (4'!., (151399)) in all
three. Participation increased in medical
and pharmacy audits with trust status
(medical audit: 57°!, (65/115) trust hospital
v 47'!. (132/281) non-trust hospital;
pharmacy audit: 34'!. (39/114) v 24°!.
(65/276)) and teaching status (medical
audin 58'!. (60/104) teaching hospital v
47'!. (130/279) non-teaching hospital;
pharmacy audit 30'!. (31/104) v 25%
(68/273)) and similarly for highly qualified
pharmacists (MPhil or PhD, MSc,
diplomas) (medical audit: 54'!, (163/302)
with these qualifications v 38'!. (39/103)
without; pharmacy audit: 32'!. (95/298) v
13'!, (13/102)) and specialist pharmacists
(medical audit: 61'!. (1 12/184) specialist v
41'!. (90/221) non-specialist; pharmacy
audit: 37'/. (67/182) v 19'!. (411218)).
Pharmacies contributing to medical audit
commonly provided financial Information
on drug use (86% 169/197). Pharmacy
audits often concentrated on audit of
clinical pharmacy services.
Conclusion—Pharmacists are beginning
to participate in the critical evaluation of
health care, mainly in medical audit.
(Qua/nv in HeoJ:h Carc 1993,2 228-231)
This is changing: there is a growing emphasis
on audit carried out by other professional
groups, either alone or with others. Phar-
macists have much to contribute to the audit
process, not least because they frequently
maintain records of their contributions to
good prescribing practices.' Also involving
experts on medicines in audit of a health
care process that includes the use of drugs
has obvious benefits, such as help in impro-
ving prescribing and drug administration
processes.
A few papers have reported the experiences
of pharmacists auditing their own activities1'
or participating with others in audit,°"' but
one study suggests that the extent to which
this is happening is limited.' Until now the
extent to which pharmacists throughout the
UK are involved in audit has not been
systematically investigated. We report the
results of a study that examined the nature and
extent of hospital pharmacists' participation in
medical, pharmacy, and clinical audit activities
Within the NHS. This information identifies
examples of current audit activities, explores
the determinants of involvement in audit,
provides a baseline against which future
initiatives can be evaluated, and suggests areas
where such initiatives might be directed.
Methods
In March 1992 a postal questionnaire was sent
to all NHS hospital pharmacies that provided
clinical pharmacy services (that is, pharmacies
where a pharmacist was present during normal
working hours and where services in addition
to supplying drugs were provided). These
pharmacies had been identified by prior
communication with district pharmaceutical
officers in England, chief administrative
pharmaceutical officers in Scotland and Wales,
directors of pharmaceutical services in
Northern Ireland, and chief pharmacists in
special health authorities. The questionnaire
had previously been tested among a panel of
clinical pharmacists from throughout England
and Wales. It inquired about all aspects of
hospital clinical pharmacy services and
included a section on pharmacists' partici-
pation in audit; their contribution to medical
audit, and their involvement in clinical audit
(question phrased to exclude contribution to
Introductionmedical audit) and pharmacy audit. The box
Since the 1989 NHS review t
 medical audit, shows the definitions of these terms, as used in
with doctors assessing the quality of their own the questionnaire. Each question had a pre-
work, has been the major focus of attenti coded section asking if pharmac y staff
and funding in the United Kingdom (U )8 Li windy participated in the audit activity and
I
Definitions of audit
.\kdiLJI audit	 audit of tIlL practices iii
d,,ctir..
Clinical audit
	
	 - audit of the practices of
health care professionals
Pharmac audit - audit of the practices of
pharmacists
an open section inviting respondents to specify
these activities. The question on medical audit
additionally requested information on the
extent of provision of different types of help
and information for the audit process. Postal
reminders were sent after six weeks, and
further non-responders were followed up b
telephone.
Data were analysed with the statistical
package for the social sciences (SPSSIPC+).
Information from ordinal categorical variables
was collapsed to form binary data (none and
very little = not provided; a moderate amount
and lots (on average two hours a week or
more) = provided) and described using
frequencies. Comments volunteered by
respondents to open sections of questions
were coded with key words.
A priori hypotheses, on relations between
participation in audit (dependent variables)
and demographic, staffing, and other (mdc-
pendent variables), were tested. Among the
independent variables tested were pharma-
cists' perceptions of increased availability of
resources for clinical pharmacy services owing
to a Department of Health policy document,
HC(88)54° and the Nuffield repon, both of
which recommended the development of
clinical pharmacy in the hospital sector in the
UK. Although the documents pre-date audit,
they may have increased pharmacists'
involvement in wider aspects of health care,
including audit. The data set was a census
because of total coverage of UK NHS hospital
Tabk I Percentage (nu,,,kr) of pharmacies parnciparss,g in audit in KHS hospszahf
in thc UK, according to hospital managuient and rcaching status
1c of audit	 Mo,ssgeu,.ou status	 Teaching szatis4
,san in
XHS in..,	 D,rccth ii.anaped in,,:	 Non-teaching	 Teadn,,g
Medical audit
	 57(65/115)	 47 (i32/281)	 47 (130/279) 58(60/104)
PharTnacv audit
	 34 (39/114)	 24 (65/276)	 25 (68/273)	 30 (31/104)
Clinical audit
	 ii (i3/il5)	 5(15/275)	 5 (i3/275)	 13(13/102)
Percentages vary
 slighik from orerail recuhs owing to missing data.
f Pharmacies us which a pharmacist was present dunng normal working hours and services us
addiuon;o supplying drugs were pros ided.
$Lticanon us medical school teaching hospitals.
Table 2 Perce,,,agc' (nun,bcr) of pharniacics participating in audit in NHS hospiralsf
in the UK, according to educational level and specsahsarion of pharmacists
Ttpc a/audit	 EmphivMciw a/phanuacuts junk kjhcr
	
Emphiwuiciw of spec*ahst dimcai
acut uy	qi.aisjicancws4	 plwnuau,su%
.'%Of .s,s$n.J	 hrn$.s5J	 Nor cnsplossd	 Ernplov.d
Mcdical audi,
	
38 (39 103)	 54 (163/302)	 4i (90/221)	 61(112/184)
Pharmacs audit
	
13 (13/102)	 32 (95 29'S	 14 (41/218)	 37 (67/182
Clinical audit
	 3 (3/lOt	 9 (26/297)	 4 (0/217	 Ii (20/183)
Pcrcentagcc sar'. stightis ouinc to missing d.iis
tPharmacics in ishich a pharmacts, uas present during normal working hours and sri-i..c'. in
add tion to suppl y ing drugs v.erc prusidd
;\tPhil or Phi). .MSc, or d,pic.mas
Spcnding 50' • or more of th ir time norking in a sptciatici area of pharmac'. for example.
an oncologs specialist pharmacist
Jli['iial p/i iris,.), 5(1' p.irii. ,p,,Ii,,,s is,	 229
pharmacies and a high response rate (see
results below), ibis made most statistical tests
inappropnatc. To assess the effects of staffing
on participation in audit activities, however.
the data were treated as a sample in time and
tests for trend were conducted.
Results
GENERAl. RESULIS
The response rate to the questionnaire was
90% (416/462). Within the UK the response
rates varied from 61% (14/23) in Northern
Ireland to 96'Vn (23/24) in Wales. Except for
Scotland, where all non-responders were non-
teaching hospital pharmacies, and Northern
Ireland, where 67% (six) were non-teaching
hospital pharmacies, similar proportions of
responding and non-responding pharmacies
were located in teaching hospitals (27%, 112
and 23%, 11 respectively).
Pharmacists reported contributing to
medical in 50% (204/410) of hospitals,
undertaking pharmacy audit in 27% (108/404)
and participating in clinical audit in only 7%
(29/404). Many pharmacies (59%, 235/399)
were involved in one or more types of audit
but few (4%, 15/399) in all three types.
EFFECT OF HOSPITAL TYPE
Although half of all pharmacies surveyed
reported participation in the medical audit
process, a higher proportion of those in NHS
trust hospitals and medical school teaching
hospitals contributed than those in directly
managed units or non-teaching hospitals
(table 1). The same observation applied to
pharmacies' participation in pharmacy audit;
small numbers precluded comments on
variations in participation in clinical audit.
EFFECT OF STAFFING FACTORS
The likelihood of pharmacists' participation in
medical and pharmacy audit increased signiii-
cantly with increasing numbers of pharmacy
staff (x2 = 20-8 and 25-2 respectively,
p < 0-001). The odds ratio for conduct of
pharmacy audit increased twofold when four
to six pharmacists were employed and fourfold
when more than 10 were employed; the
corresponding odds ratios for contribution to
medical audit were 1-7 and 3 1 respectively.
The presence of pharmacists with higher
qualifications (MPhil or PhD, MSc, or
diplomas) or specialist clinical pharmacists
(who spend half of their time or more in a
clinical pharmacy specialty) was associated
with pharmacists' participation in all types of
audit (table 2). When pharmacists with higher
degrees were employed the proportion of
pharmacies conducting pharmacy audit more
than doubled, and when specialist clinical
pharmacists were present the proportion of
pharmacies contributing to medical audit
increased by 20° o, from 41% (90 pharmacies)
to 6P'/o (112).
EFFFCT OF PERCEIVIT) RI SOCRCF SHIF'i S
Some respondents indicated that the health
circular HC(88)54° and the Nuffield report'
had increased resources for hospital clinical
Financial infurmjti.'n on drug use
Help in crejtion 01 pre'...nbing polu.ics
Information on adherence ii' agreed pres..nt'ing p*.Iicies
information on problems in presenhing pr,'sess
'Perccntagcs vary
 slighik owing u' missing djia.
fNumbcr of respondents to individuji quesii..ns iaiwd slightly.
lit, jb01I07)
7i 134/IS'!
ui2 (uS/Iso!
414 (Sn/ISO)
230
	 ( nit.'. .thk.. 1/ails,
Tab/c ? Pcric,,iag. (,,,i,,iM) i'/ pisarsisa.. sc paris. ,p.jlui &. in .vsj,, us XHS #nr,p,:aif
so ,h. LK. a. • us J,,u so p/sailii.s.s i . p.r. .pu.u. / in.'. a'..! a; a,/,s!',/u, .1 r. 'us,.
chnha/ pisarnia,	 i: ,,,. 1.' hf '('0. 4 ,sn,/ \ ss'O. hi s. p. ii
lie'. 'I an)?!	 !i(	 ' '4	 5	 I r f5i
.1.1st sh
	
i5.I&'.	 bi.j. •i..i	 4.,.,	 I,,, r.a'. .1 a,,,. n
MediaI audit	 44 tIl li' 227	 5" li i i I2	 47 iI .12/iiI	 ut 17/75j
I'harmcs judn	 I') .4 221	 t	 I' I l7'	 24 '2f'.IMI	 35' (25'175)
Chnical audit	 7 (i1i1222	 II II7i	 7 (20'2'5"s	 14 (u/75)
*percta van slighils on ung i, missing djlj
f Pharmacies in which a pharmacist was present dunni normal s..,.rking hours and services in
addition to supplying drugs ere provided.
TaNc 4 N..uur.. ,'f i/sc ,.usinhssi,. ii, i i! I,s..'cp,iai ph,an,,ac:e.c is' ,n,d,i,,j audit us \7-fS
lunpitahs' in i/h' tK
Ir,,-,g,ag. (25.;.)
pharmacy services. An association was
observed between preceived increases in
resources, consequent on these reports, and
participation in medical and pharmacy audit
(table 3). Pharmacies in which resources were
considered to have increased as a result of the
health circular were more commonly partici-
pating in medical audit (59%, 101/172) and
pharmacy audit (38%, 64/170) than those in
which resources were considered to have been
unaffected (44%, 100/227 and 19%, 43/224
respectively). Similarly, pharmacies were more
commonly participating in medical audit
(63°.6, 47/75) and pharmacy audit (38%,
28/75) in hospitals in which it was thought
that clinical pharmacy
 resources had increased
as a result of the Nuffield report than in those
where no effect had been perceived (47%,
142/303 and 24%, 72/300 respectively).
SPECIFIC CONTRIBUTIONS TO AUDIT
Of pharmacists' contributions to medical
audit, the commonest was providing financial
information on drug use (86%, 169/1 97)
(table 4). Many pharmacies helped to create
prescribing policies (710/n, 134/188) and fed
information on adherence to such policies
back to the audit group (62%, 115/186). A
smaller proportion (48%, 86/180) supplied
information on problems experienced by
pharmacists with the process of doctor's
prescribing. Some pharmacies volunteered
additional information on contributions to
medical audit. Of these, 36 stated that they
were involved in directly auditing prescribing.
Examples given included audit of the
prescribing of antibiotics, anti-emetics, and
depot neuroleptics.
Those pharmacists who specified the
pharmacy audits carried out indicated that
activities pursued included the audit of
interventions (54 pharmacies), when
pharmacists make inquiries (often of a doctor)
to satisfy
 themselves that a prescription is
appropriate, often resulting in alteration of the
prescription, and audit of specific clinical
pharmacy services such as therapeutic drug
monitoring, central intravenous additives
sei-vuces, and drug information services (41)
pharmacies), errors in pharmac processes
such as dispensing (16), and service response
time (16).
The clinical audit activities pursued varied
from multidisciplinary audit of whole depart-
ments (25) and of medicine usage (17) to
auditing other hospitals or their departments
(three). Specific examples included audit of
physiotherapy and dietetics departments,
audit of laxative and antacid use, and audit of
drug supply and distribution at other
hospitals.
Discussion
The results of this census survey suggest that
pharmacists are beginning to become involved
in audit activities, particularl y in medical
audit. They are starting to evaluate their own
activities and services but have rarel y, as yet,
become involved with other health care
professionals in clinical audit. This picture is
true for most parts of the UK.
EXPlANATIONS FOR PRESENT LEVEl. OF
PARTICIPATION IN AUDIT
Pharmacists' involvement in medical audit
tended to be based on providing information.
This is a traditional and, perhaps, more easily
assumed role for pharmacists than that of
direct involvement in the prescribing arena
and in creating prescribing policies. Phar-
macists were less involved in using medical
audit as a means of alerting doctors to
prescribing problems; fewer than a quarter of
pharmacies surveyed did this. Prescribing
problems are usually addressed in one to one
doctor-pharmacist discussion in the ward or
through hospitalwide policies, often linked to
formulary management. Yet prescribing prob-
lems are common, and research has shown
that pharmacy has a unique insight into
individual problems in particular medical
specialties through its system of ward
pharmacy' 3 and because of its use of
computerised records of drug usage. Medical
audit enables systematic review of prescribing
problems and the development of strategies
for their ftiture avoidance, all as part of an
educational process.
The most common pharmacy audit
activities were audit of the ward pharmacy
service, of prescription monitoring, and of
more specialised services such as therapeutic
drug monitoring. The existence of these
programmes is encouraging and signifies a
desire among some pharmacists to evaluate
critically their clinical services. These internal,
professional audits also complement external
audits currently performed on some sections
of pharmacy departments, such as manufac-
turing units.
The virtual absence of pharmacists' activity
in clinical audit may not indicate their lack of
interest. Rather, it may simply reflect the
limited extent to which clinical audit was
performed in NHS hospitals at the time of the
survey. The nature of the audits in which
pharms. s .i in olt ed nus signit, to snie
extent, the expansion of the pharmacy
manager\ responsibilities to encompass
mana gerial responsibilit y for paramedical
groups v. ithin hopitls.
Pharmacies in teaching hospitals p.irtici-
pated more lrequcntiv in all audit activities.
From evidence gathered in this survey the
most hkdv reason is their greater development
of clinical pharmacy
 services with more highly
qualified pharmacists. The same pattern of
greater participation was seen in trust hospitals
and in hospitals that employed pharmacists
with higher degrees and specialist clinical
pharmacists; it is not immediately obvious why
this should be so. The association between
perceived increases in resources for clinical
pharmacy services and increased participation
in audit may mean that pharmacy managers
committed to developing clinical pharmacy
used documents such as HC(88)54° and the
Nuffield report' 2
 to support their efforts. Since
neither of these resulted in additional direct
government funding the association may be a
proxy for a high level of commitment by
pharmacy managers and general managers to
make services more appropriate.
NEXT STEPS
The variation in the extent to which phar-
macists have become involved in audit demon-
strates considerable scope for development. By
providing examples of what is being done this
survey suggests ways in which pharmacies not
yet involved in audit might start.
Several factors could contribute to
increasing pharmacists involvement in audit.
Pharmacists have yet to optimise their
contribution to medical audit, becoming team
workers not simply providers of information.
Doctors would welcome greater involvement
by pharmacists in audit, 14
 and pharmacists
may be raising artificial barriers that limit their
participation. The difficulty
 of undertaking
audit in hospital pharmacies with only one or
two pharmacists may be overcome by
organising programmes with nearby hospitals,
possibly using pharmacists with higher degrees
to lead the process. This model of audit may
also be applicable to community pharmacy
where, currently, pharmacists often practice
alone. The new regional offices could provide
useful leadership and coordination for such
schemes. Although audit must be led locally,
academic pharmacy practice units could
accelerate its development by providing
training and by disseminating information on
audit methods. This would be an appropriate
use of funds for clinical audit. The medical
royal colleges have had a key role in promoting
medical audit and disseminating guidance on
good practice. Similar activity
 is needed in
pharmacy . The Pharmaceutical Society should
assume this initiative. Its recent appointment
of an audit fellow, in association with the
Department of Health, is but a first step; it is
essential that the resulting work is not
conhncd to pharmacy
 audit but seeks to
integrate pharmacists into clinical audit.
Clinical audit has much to gain from greater
participation by pharmacists. Hospital
pharmacies routinely gather information on
several aspects of the process of drug use that
could be usefully incorporated into audit
cycles. This should facilitate linking health
care processes with outcomes and help to
enhance both. Such a scenario will necessitate
research into aspects of service provision,
which audit should stimulate by providing the
research questions. 1t
 With increasing emphasis
on multidisciplinary audit, these questions will
be addressed by multidisciplinary health
services research, to which pharmacists can
contribute by promoting increased commu-
nication and collaboration between pharmacy
and mainstream health services research
centres.
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Hospital clinical pharmacy services
provided to primary care
SIOBHAN M. COTTER, NICHOLAS D. BARBER and MARTIN McKEE
Recent changes in the LTmted Kingdom national health service (NHS) have
increase(l the need for pharmacy services in primary care. Government documents
have advocated a role for hospital pharmacists in the provision of clinical
pharmacy services to primary care. A census survey was carried out to establish the
extent to which hospital pharmacists have become involved in the provision of
clinical pharmacy services to primary care patients and health professionals.
Questionnaires were sent to district pharmaceutical officers in England (and their
equivalents in the rest of the UK). One hundred and mnety.three questionnaires
were returned (92 per cent). Hospital pharmacists provided few advisory,
educational or information services to patients and primary care health
professionals, with the exception of primary care nurses. Pronounced variations in
service provision were observed in different parts of the UK. Respondents gave
reasons for their limited involvement and indicated that the provision of services is
increasing.
The survey shows that government policy on the provision of hospital clinical
pharmacy services to patients and health professionals in primary care has not
been implemented. The provision of such service is, however, increasing, mainly as
a consequence of the NHS reforms and the movement of resources to primary
care.
RECENT shifts in the provision of health care to
the community' have posed challenges for phar-
maci,ts who, in common with other health profes-
,ionals, increasingly seek to provide a "seamless
serb ice". Historically, pharmacy service provi..
slOn in primary and secondary care has been
segregated but there are suggestions that this is
changing. 3 A goernInent health circular,t and
other repprts.' 6 advocate that hospital clinical
pharmacists deelop advisory roles in primary
care. Although this has many perceived benefits,
the extent to which it has happened is unknown.
Clinical pharmacy has been defined by the
Department of Health as the application of phar-
maceutical skills to "medicine usage both at the
policy making level and in the treatment of
individual patients". t The aim of this study was to
examine and quantify the extent to which hospital
pharmacists hae become involved in the provi-
sion of clinical pharmacy services to health pro-
fessionals, institutions and patients in the prima.
ry care sector. Data were examined for the
existence of links between service provision and
perceived changes in hospital pharmacy
resources.
Methods
En 1992, a postal questionnaire was sent to the
professional managers of pharmacy services in
each district (or equivalent) 5 in the UK NHS,
namely, district pharmaceutical officers (DPhOs)
in England. chief administrative pharmaceutical
officers (CAPOs) in Scotland and Wales. direc-
tors of pharmaceutical serb ices (DPSs) in North-
ern Ireland and chief pharmacists in special
health authorities (SHAs. providers of specialist
health services). The questionnaire had pre iously
been pre.tested among DPhOs in one English
region and by a panel of clinical pharmacists from
England and Wales. It explored the extent to which
selected advisory, information and educational
services were provided, at the time, by hospital
pharmacists (including community services phar-
macists) to health professionals. institutions and
patients in the community. These services had
been selected following initial questionnaire pre-
tests. Most questions consisted of a closed section.
providing a choice of two (yes/no) or four respons-
es (none, very little, a moderate amount and lots).
followed by an open section. Postal reminders
were sent after six weeks and further non-
responders were followed-up by telephone.
Data were entered on dBase IV (Borland Inc.
Scotts Valley, California) and analysed using the
Statistical Package for the Social Sciences (SPSS
PC+, SPSS Inc. Gornichem, The Netherlands).
Information from ordinal categorical sariables
was collapsed to form binary data (none and very
little = not provided; a moderate amount and lots
= provided) and described using frequencies.
These frequencies represent the number of dis-
tricts in which services were provided by hospital
pharmacists to various recipients in primary
care. Hypotheses were tested exploring the rela-
tionship between the proision of clinical pharma-
cy services (dependent variable) and percei%ed
changes in hospital pharmacy resources as a
consequence of health circular HC(88)54.' the
Nuffield Report 6 and attainment of trust status
* Distnct a used to refer also to health boards cutIand and
Northern Ireland) and health authorities tales and ,pecial 	 £
health authorities)
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Table 4: Provision of clInical pharmacy services by hospital pharma-
cies in the UK national health service to community pharmacists
Service	 Number %) of d stricts' prov d ng each serv ce
Al UK Eng and N Ire land Scot and Wa es SlAst
(n=193) (n=165	 n=3) (n=12	 (n=8	 n=5)
Adv ce on ana ges a
equ pment used n pat ent
contro edanagesa 	 7 4) 5 (3) 0 (0) 0 0) 2 25) 0 0)
Advice on parenteral
nutrit on equipment used
in total parenteral
nutrition	 4 (2) 4 (2) 0 0)
	
0 (0) 0 0) 0 0)
Advice on discharge of
patients with specific drug
needs	 42(22) 32(19) 1(33) 3(25) 4 50) 2(40)
Drug nforrnation from drug
information centres
	 80(42) 63(38) 1(33) 7(58) 8(100) 1(20)
Educational services	 30(16) 23(14) 1(33) 4(33)	 1(13) 1(20)
• Includes district health authorities (England), hea th boards (Scotland and Northern
Ireland) and health authorities (Wales and special health authorit es)
t Special health authorities
Table 5: Provision of clinical pharmacy services by hospital pharma-
cies in the UK national health service to other primary care health
professionals
Service	 Number (%) of d str ctst prov d ng each serv cc
All UK England N Ireland Scot and Wa es 	 SHAs
(n=192)(n=164) (n=3) (n=12) (n=8) 	 (n=5)
Information on general
drug-related matters 	 70(36) 61(37) 1(33) 4(33) 4(50)	 0(0)
Drug information from drug
information centres	 64(33) 54(33) 1(33) 4(33) 5(63)	 0 0)
Educational services	 33(17) 28(17) 1(33) 2 (17) 2(25) 	 0 0)
* Not including GP5, primary care nurses or community pharmacists
t Includes district health authorities (England), health boards (Scot and and Northern
Ireland) and health authorities (Wales and special hea th authorit es)
Special health authorities
Table 6: Provision of clinical pharmacy services by hospital pharma-
cies in the UK national health service to primary care institutions*
Service	 Number (%) of distr ctst providing each serv cc
All UK England N re and Scotland Wales 	 SHAs
(n=193)(n=165) n=3) (n=12) In=8)	 n=5)
	
Advice on wound care 	 58(30) 48(29) 0 0) 5(42) 5(63) 	 0 0)
Advice on sedation policies 	 29(15) 26(16) 0 0) 2(17) 1(13) 	 0(0)
Advice on analgesial
equipment used in patient
	
controlled analgesia	 35(18) 32(19) 0 (0) 1 8) 2(25) 0 0)
Informat on on general
	
drug-related matters 	 92(48) 80(49) 2 67) 5(42) 5(63) 0 0)
Drug nformatlon from drug
	
information centres	 52 (27) 43(26 0 (0) 4 33) 5(63) 	 0(0
	
Educational services	 61(32) 52 32) 2 67) 3 25) 4 50) 0 0)
• Includes residential homes, hospices and nurs ng homes
t Includes district health authorities (Eng and) flea th boards (Scot and and Northern
Ireland) and health authorit es (Wales and spec al flea th author t es)
f Spec al health authorities
pro%ided (Table 4). Communication between hos-
pital pharmacists and their colleagues in the
community about patients with specific drug-
related needs being discharged from hospital was
uncommon (22 per cent) and community pharma-
cists rarely recei%ed educational services from
hospital pharmacies (16 per cent).
Primary care health professionals (other than
doctors, nurses and community pharmacists),
were provided with information on drugs in about
a third of districts and with educational services
in under one fifth (Table 5). Service provision in
Wales was higher than in the rest of the UK.
Ser% ices were not provided in SHAs (Table 5).
Information on general drug-related matters
was often (48 per cent) provided to primary care
institutions. This included residential homes, hos-
pices and nursing homes. Many districts provided
education for staff in these institutions (32 per
cent) and advice on wound care (30 per cent) but
few provided advice on sedation (15 per cent) and
PCA (18 per cent). No services were provided in
S HAs. Health boards in Northern Ireland provid-
ed only general drug information and education.
Advice on wound care was provided more com-
monly in Scotland and Wales than in England
(Table 6).
Changes in resources Respondents were asked
about the effects of certain documents on hospital
pharmacy resources. HC(88)543 was considered
to have increased pharmacy resources by 49 per
cent (94 192) of respondents overall in the UK,
but by more respondents in Scotland (9/11) and
Wales (6 8). Although few UK respondents overall
(16 per cent, 30/185) thought that the Nuffield
report6 had increased pharmacy resources, four
of seven Welsh respondents thought that it had
done so.
Trust status had been attained by one or more
hospitals in 58 per cent (106/183) of districts. No
SHA, and fewer Scottish (2/10) and Welsh (3/8)
than English (100/158) districts contained trust
hospitals. In the 106 districts where trust hospi-
tals existed, 22 (21 per cent) of respondents
thought that pharmacy resources had altered as a
result.
Possible explanationa for levels of service provi-
sion It had been hypothesised that positive shifts
in hospital pharmacy resources would increase
the provision of clinical pharmacy services to
primary care. Increased resources as a result of
HC(88)544 or the Nuffield report' had a greater
effect on the provision of clinical pharmacy
services to primary care than trust status. The
provision of 20 of the 27 services inquired about
in the questionnaire was higher (by 10 per cent
or, for infrequently provided services, by a factor
of two) in districts where resources were thought
to have increased as a result of HC(88)54. where
the Nuffield report was thought to have increased
resources, 21 services were more commonly pro-
'tided. Three services were more frequently pro-
%ided, and one less frequently provided, where
hospitals had attained trust status. Perceptions of
changes in resources due to attainment of trust
status were associated with the increased provi-
sion of nine services.
The comments volunteered (by 133 respondents)
provided useful additional information. In 22
districts, hospital pharmacy departments were
increasing their activities in primary care. Some-
times the input was via family health services
authority (FHSA) pharmaceutical advisers, who
were often hospital pharmacists on a part-time or
sessional basis (12 cases).
Twenty-nine respondents provided etamples of
specific services that were not inquired about in
the closed questions, or gave further details of
answers to the closed questions. These included
the provision of newsletters outlining changes in
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(Iepite the existence of several facilitating fac-
tors. These include the remo%al of barriers be-
teen primary and secondary
 care that has led to
a need for hospital pharmacy input into the care
of patients in the community, rising expenditure
on drugs in primar y
 care that has created a need
for increased controls on drug use, and ad%ocacy
of the use of hospital pharmacy expertise in the
pro%ision of ad%ice on better prescribing. Not-
withstanding these factors, the implementation of
go%ernment policv4 on hospital pharmacists'
in'. ol '.ement in the provision of clinical services to
primary care has been incomplete.
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LI ROAD SPECTRUM1
How FAR FORWARD?
By SIOBHAN COTFER, MARTIN McKEE and NICHOLAS BARBER
Way Forward for Hospital Pharniaceu-
Services (HC(88)54 in England and
s and similar documents in Scotland
Northern Ireland) were the first govern-
(policy documents supporting the de-
pment of clinical pharmacy in United
;dom National Health Service hospitals.
assumed that some clinical pharmacy
ices were provided in most hospitals and
e specific recommendations on the pro-
ci of others.
SURVEY
The Way Forward was effective for live
years and has recently been extended, It is
appropriate, therefore, to consider if it has
achieved its aims and whether its recom-
mendations are still relevant in the changed
NI-IS of 1994. We do so here, on the basis of
a major survey that we have carried out into
the work of NHS hospital pharmacies (AmJ
Hosp Pharm 1994;51:2676).
The creators of the Way Forward assumed
some clinical phannacy services were well-
developed in 1988 although there were few
published data to hand. The services con-
cerned were the routine review of prescrip-
tions, drug information, guidance and prep-
aration of products requiring assembly for
specific patients, and systems to encourage
rational and economic use of medicines.
Our survey, which quantified the provision
of an extensive range of clinical pharmacy
services provided in UK NHS hospitals in
mid-1992, found that most of the assump-
tions were correct.
The survey found that almost all UK NHS
hospital pharmacies routinely reviewed in-
patient prescriptions. Although an on-site
drug information centre was to be found in
just two thirds of hospitals, all pharmacies
provided drug information. Most hospitals
(87 per cent) had drug and therapeutics
committees and pharmacists were active in
almost all of these. Hospitals usually (82 per
cent) had a formulary; in most it was actively
used to control drug use.
The predominant message in the Way
Forward was a recommendation to develop
clinical pharmacy services. The 1992 survey
quantified the provision of many of these
services and showed that several, but not all,
services have been developed (see Table).
From these results we conclude that
services which were assumed to be already
well-developed in 1988 were extensively
provided by 1992 but recommendations for
service development have not been imple-
mented universally. We found that 43 per
cent of respondents thought that circular
Siobhan M Cotter is a Phi) student in the
health sen'ices research unit, London School of
Hygiene and Tropical Medicine. London. Dr
McKee is senior lecturer in public health
medicine in the same unit Nicholas 8arber is
professor of the practjce of pharmacy. School of
Pharmacy. Universi(y of London
1
HC(88)54 or its equivalent had increased
resources for clinical pharmacy. The survey
also showed that provision of clinical phar-
macy services was associated with a percep-
tion of increased resources for clinical phar-
macy as a result of the Way Forward.
Although the absence of comprehensive data
on service provision prior to the publication
of the Way Forward makes it difficult to
comment on its effect in furthering the
development of clinical pharmacy our re-
sults suggest that its publication was an
important facilitator in this process.
Since the publication of the circular there
have been significant changes in the NEtS.
Although its aim is still pertinent today the
system for the management and provision of
health care has changed. Resource manage-
ment has been implemented widely and
there is an internal market for health care.
Hospital pharmacies now provide services to
clinical directorates. Some do so within
contracts, with directorates defining the
services they wish to purchase. This, rather
than the Way Forward, may increasingly be
determining the services that are provided.
The NHS changes have also provided phar-
macy with further opportunities to promote
the rational use of medicines. Pharmacies in
two thirds of hospitals with clinical director-
ates had availed themselves of these by
providing directorates with advice and fi-
nancial information on drug use and materi-
al for the creation of prescribing policies.
SHARING
Government policy has emphasised the
provision of health care in the pnmary
sector. This has several implications for
hospital pharmacy. There is a pressing need
to share hospital clinical pharmacy expertise
with community pharmacists since increas-
ing numbers of patients are being treated in
primacy care. Reductions in the length of
hospital stay and the greater use of day care
has created a need for hospital pharmacists
to extend their traditional clinical activites to
facilitate the provision of seamless care.
Primary care is also receiving increased
resources, financed in part by reallocation of
resources from secondary care. Consequent-
ly, pharmacy departments have to contend
with annual cost improvements with ramifi-
cations for staff and services. Furthermore
hospital services are competing to secure
contracts with purchasers in primacy care.
This has increased the emphasis on the
provision of cost-efficient, high quality
pharmaceutical care by hospital pharmacies.
As contracts increase in specificity it is likely
that pharmacy departments will adjust ser-
vice provision to meet the expectations and
needs of the pnmary care customer.
Since 1988, there have been other signifi-
cant developments in hospital clinical har-
macy Numerous clinical pharma srv
not mentioned in the Way Fo
been developed_and many hospi I pha',iia
cy departments have large numbers of staff
with valuable expertise and skills. Most
hospital pharmacists now receive further
education, frequently acquiring a higher
qualification. A core of highly educated
hospital pharmacists exists who can poten-
tially provide a vanety of clinical pharmacy
services. But which services?
CUSTOMERS
In the past the answer might have been
guided by the recommendations of the Way
Forward or of other clinical pharmacy docu-
ments. Now the answer is more likely to be
provided by hospital pharmacy's customers,
both within and outside the hospital. Some
of the basic services are likely to be secure,
such as those that help ensure safe prescrib-
ing and efficient utilisation of expensive
drugs. Quality and cost-effectiveness of pa-
tient care is now paramount and services
that contribute to these goals are welcomed.
Questions may, however, be asked about the
manner in which services are provided and
pharmacists may be required to show how
their services are contributing to effective
patient care.
The problem with the Way Forward is
that it did not anwer such questions. It was a
policy document. It made recommendations
but did not require compliance with them. It
provided guidance on the provision of clini-
cal pharmacy services but not proof that
they were necessaiy or effective.
Pharmacists and their representative
bodies must now take a major role, linked
closely with the NHS research and develop-
ment strategy, to review systematically the
current state of knowledge on the efficiency,
effectiveness and acceptability of their clini-
cal pharmacy seTvices, develop programmes
of research to fill the gaps and disseminate
the results. They will then be in a position to
answer the key questions that will be posed
in local negotiations. This must be the new
way forward.
Table: Provision of clinical pharmacy services
in UK NHS hospitals related to recomnienda-
tions made in the Way Forward (HC188 J54)
Medication histoiy-taking	 16%
Operation of Conunlltae of Satetyof
Medicines a
	
dn reaction
mon.todng scheme:	 46%
(I) ensured the doctors got the
yellow card	 75%
(Ii) ensured the yellow term
was completed 	 55%
Operation of an additional ADR scheme 13%
Contilbubon to ug therapy decisions
on ward rounds	 78%
Formal therapeutic drug monitoring
service	 21%
Discharge counselling	 42%
Support for clinical inals	 92%
Practice research activity 	 41%
Note: 508 questionnaires were mailed and 416 usable
responses returned
Tiii l'iIARMA(illllCAI JO(JRNAi (Vet 253)	 17 1OOA
